COMVENTION ISSUE

INNOVATION

CONNECT THE WORLD

BIOHK2026

香港國際生物科技論壇暨展覽

SEPTEMBER九月 9 WED - 12 SAT

香港會議展覽中心

HONG KONG CONVENTION AND EXHIBITION CENTRE

PROGRAM GUIDE

BIOHK IS KALEIDOSCOPE OF GLOBAL BIOTECH INDUSTRY

INFINITE POSSIBILITIES

生物科技誌 BIOTECHGAZINE

SEPTEMBER 2026

中信证券
CITIC SECURITIES

Connecting Healthcare Innovation with Capital Markets

Insight ▸ **Industry** ▸ **Capital** ▸ **Wealth**

From industry insight to growth, capital formation and wealth creation



CITICS Platform

Leveraging CITIC Securities's integrated ecosystem to connect innovation, industry and capital

Investment Banking

Advisory and execution across IPOs, refinancing, M&A and strategic transactions

Wealth Management

Serving entrepreneurs and investors through diversified wealth solutions and connectivity

Research

Deep sector insight and institutional research support for the healthcare industry

Disclaimers: This advertisement is produced by CITIC Securities. This advertisement has not been reviewed by the Securities and Futures Commission ("SFC") or any other regulatory authority in Hong Kong.

Connect with CITICS Healthcare

BIOTECHGAZINE 生物科技誌

SEPTEMBER 2026

編輯委員會

總編輯 Chief Editor

于常海 YU Cheung Hoi, Albert

梁傳昕 LEUNG Chuen Yan

副總編輯 Deputy Chief Editor

馮子陽 FENG Ziyang

劉雨瀟 LIU Yuxiao

編輯 Editors

張安業 ZHANG Anye

殷志慧 YIN Zhihui

鄧昕愷 DENG Xinkai

魏國剛 NGAI Kwok Kwong

出版社 Publisher

海康生命出版社有限公司 H. K. Life Publishing Limited

電話 Tel: (852) 2111 2123 傳真 Fax: (852) 2111 0782

電郵 Email: editorial@hkbio.org.hk

地址 香港新界沙田石門安耀街3號 匯達大廈1615-18室
Units 15-18, 16/F South Wing Delta House, 3 On Yiu Street, Shatin, N.T. Hong Kong

電郵 Email: editorial@hkbio.org.hk

廣告查詢 Advertising

電郵 Email: editorial@hkbio.org.hk

出版日期 Publishing Date 2026年9月 SEPT 2026

版權所有，未經本會及作者同意，不得翻印 All reproduction requests are subject to the approval of HKBIO and authors

CONTENTS

About 1

Welcome Note 05

About BIOHK 06

Organizational Structure 07

Event Information 11

Sponsor and Exhibitor list 12

Day 1 Agenda & Speakers Biographies 19

Day 2 Agenda & Speakers Biographies 67

Day 3 Agenda & Speakers Biographies 151

Day 4 Agenda & Speakers Biographies 227

Resources 2

Exhibitor & Sponsor Advertisement 249

WELCOME NOTE

We are pleased to announce the 5th edition of BIOHK — BIOHK2026, which will take place at the Hong Kong Convention and Exhibition Centre from September 9 to 12, 2026.

Hong Kong, the globally acclaimed "super-connector" linking China and international markets, is a world leader in finance, scientific research, and talent attraction. As the world's 3rd largest financial center, Hong Kong reclaimed the global IPO crown in 2025, outpacing the New York Stock Exchange. Complementing this, the Hang Seng Biotechnology Index has surged over 100% year-to-date — a clear sign of strong investor confidence in the city's biotech sector. This financial momentum directly fuels biotech innovation, cementing Hong Kong's status as a premier nexus for global biotech collaboration.

Riding the momentum of BIOHK2025's extraordinary success — which gathered over 250 speakers,10,000 participants from 20+ countries, and 100+ outstanding exhibitors — BIOHK2026 is poised for unprecedented growth! We will focus on a broad spectrum of cutting-edge themes, including regulatory policies, biotech investment, AI, innovative drugs, cell and gene therapies, cancer research, anti-aging, synthetic biology, Traditional Chinese Medicine, medical devices and other pivotal areas shaping the global biotech landscape, bringing together stakeholders from government, industry, academia, research, investment, hospitals and end-users.

BIOHK2026 is more than a convention — it is a strategic gateway for international enterprises entering East Asia and a vital springboard for Chinese companies going global. It is also a pivotal platform for fostering collaborations, spanning research partnerships, inter-enterprise cooperation, and corporate-capital alliances.

Don't miss the next wave of biotech transformation! We cordially invite you to Hong Kong from September 9 to 12, 2026, to experience the energy, contribute your expertise, and seize boundless opportunities.

Let's unite to shape the future of biotechnology — and redefine what's possible, together!



Professor Albert Cheung Hoi YU, PhD, JP
Co-President of BIOHK2026
Professor at Peking University
Chairman of Hong Kong Biotechnology Organization
Chairman of Guangdong-Hong Kong-Macao Greater Bay Area Biotechnology Alliance



Dr. Chuen Yan LEUNG, PhD
Co-President of BIOHK2026
Co-founder, Silver Dart Capital
Partner Healthcare Investments, Value Partners Group

ABOUT BIOHK2026

BIOHK2026, the Hong Kong International Biotechnology Conference and Exhibition, is hosted by the Hong Kong Biotechnology Organization (HKBIO). It is the premier biotechnology conference and exhibition in Asia that brings together global biotech leaders, innovators, and stakeholders. Dive into the world of groundbreaking advancements, connect with industry experts, and explore new frontiers in biotechnology.

BIOHK2026 offers a unique opportunity to delve into world-class, cutting-edge biotechnology research. It encompasses a vast spectrum of key elements, including academic innovation, policy trends, industrialisation pathways and investment dynamics. These core themes combine to create a holistic, all-round ecosystem for comprehensive exchange across the biotech sector.

A DRIVER OF GLOBAL COLLABORATION

Launched in 2022, BIOHK has successfully held four editions so far. Leveraging Hong Kong's unique advantages as an international innovation hub, BIOHK has rapidly emerged as one of the most influential biotech industry events across Asia, gaining widespread recognition in the sector.

Our unwavering vision is to build a world-class, collaboration-driven platform that leverages Hong Kong's unique strengths, connects global research, industry and capital, and propels the biotech sector toward cross-border innovation and tangible progress.

A KALEIDOSCOPE OF BIOTECHNOLOGY

BIOHK2026 serves as a vibrant kaleidoscope of biotechnology, bringing together diverse stakeholders spanning government, academia, research institutions, industry, investment, and end-users.

Its thematic scope covers the entire biotech value chain, including policy interpretation and analysis, cutting-edge research, clinical applications, achievement transformation, industry development, investment and financing, among others.

WHERE BIOTECH FROM AROUND THE WORLD CONVERGES

ORGANIZATIONAL STRUCTURE

CO-PRESIDENT



PROFESSOR ALBERT CHEUNG HOI YU, PHD, JP

Professor, Peking University:Chairman, Hong Kong Biotechnology Organization (HKBIO) ;Chairman, Guangdong-Hong Kong-Macau Greater Bay Area Biotechnology Alliance (GBABA)



DR. CHUEN YAN LEUNG, PHD

Co-founder, Silver Dart Capital; Partner Healthcare Investments, Value Partners Group

HONORARY PRESIDENT



MR. FOK CHUN YUE BENJAMIN

Director of the Fok Ying Tung Foundation



AMBASSADOR GEORGE HARA

Honorary Professor of Medicine, The University of Hong Kong

DR. KENNEDY Y H WONG, BBS, LLD, DCL, JP

Managing Partner, Philip K H Wong, Kennedy Y H Wong & Co



PROFESSOR HERMAN HU, GBS, JP

Chairman of Ryoden Development Limited



ORGANIZATIONAL STRUCTURE



MR. CHRANK CHEN

Partner, Ausvic Capital Limited Investment

MR. GORDON CHENG

Chief Executive Officer, Cameron Pace China Limited





DR. CHUN YUAN CHIANG

Vice-Chair & Deputy Secretary-General, CCG Hong Kong; Council Founder, IHDpay Group; Director, Anti-Inflammatory Professional Committee

MS. LAN FENG

Vice President,
China Pharmaceutical Innovation and Research Development Association





DR. XIAOYAN HE, PHD

Vice President, Arton Economic Institute; Deputy Director, Special Committee of the Guangdong-Hong Kong-Macao Greater Bay Area Biotechnology Alliance; Endocrinologist, Boao Super Hospital

DR. CHARLES HU, PHD

Founder & CEO, Ryoden Medical Holdings & Incando Therapeutics Group



ORGANIZATIONAL STRUCTURE



DR. CHRISTINE HUANG, MD, PHD

Founder & CEO, Quantum Life Limited; Managing Director, HK Longevity Medical Centre

MR. SIMON JE

Chairman of the Board, Galaxy Treasure Group, Founder and Chairman, Hong Kong International Blockchain and Financial Association (HKIBFA)





DR. SHAN LI, PHD

Co-founder, XcellGene

MR. DA LIU

Managing Director, CR CP Life Science Fund





MR. ANDREW NG

Managing Director and Head of Healthcare, VMS Group; Investment Partner, Panacea Venture

MR. MING TANG

Chief Executive Officer, YNBY International Limited



ORGANIZATIONAL STRUCTURE



MR. HUA TIAN

Innovation and Entrepreneurship Mentor, HSBC Business School, Peking University; Senior Research Fellow, Zhongyuan Development Research Institute, Henan University; Specially Appointed Consultant, Shenzhen Fortune Venture Capital Co., Ltd.

DR. MAKI WAN, PHD

Former President, Rotary Club Kowloon Golden Mile





MR. ALISTER WONG

Associate, Philip K.H. Wong, Kennedy Y.H. Wong & Co; Deputy Secretary, Hong Kong United Youth Association (30th Board)

DR. JASON YAO, PHD

Vice President, Transfar Group





DR. BEN YU, PHD


Business Director, Nan Hai Corporation Limited; Director, HK01

EVENT INFORMATION

BIOHK2026

Organizers:	Hong Kong Biotechnology Organization Reed Sinopharm Exhibitions Co. Ltd.
Academic Advisory Committee & Joint Organizers:	Hong Kong Biotechnology Organization China Pharmaceutical Innovation and Research Development Association Chinese Society of Biotechnology(CSBT)
Date:	9-12 September 2026
Venue:	Hong Kong Convention and Exhibition Centre, Hall 3C - 3E
Website:	https://bio-hk.com

Floor Plan 平面圖



SPONSOR LIST

IN ALPHABETICAL ORDER

AetherBio

Asia Pacific M&A Digital Exchange Limited

Asian Fund for Cancer Research Limited

Bai Dao Data

Beijing Exshine Biopharm Technology Co., Ltd

BGI Group

Biocytogen Pharmaceuticals (Beijing) Co., Ltd.

Centre for Innovation and Entrepreneurship at the University of Macau

China Securities Co.,Ltd.

CLSA Limited

DCH Auriga

DEFTA Limited

Delonix Bioworks

DIP（Deep Intelligent Pharma）

Fiman (Changchun) Biotechnology Co., Ltd.

Founton Capital Ltd. HK

GBA (HK) MEDICINE & LIFE SCIENCE INNOVATION THINK TANK

GlaxoSmithKline

GLOBAL BRAND RESEARCH INSTITUTE LIMITED (City University of Hong Kong)

GTJA Investment Group

Guangzhou Development Zone Low-Altitude Industry Development Co., Ltd.

Guangzhou Dongyuan Pharmaceutical Technology Co., Ltd.

Hong Kong Applied Science and Technology Research Institute

HONG KONG FOOD PROFESSIONALS ASSOCIATION LIMITED

HONG KONG INTERNATIONAL FOOD TECHNOLOGY AND INNOVATION LIMITED

Hong Kong-Shenzhen Innovation and Technology Park Ltd.

Hony Capital

SPONSOR LIST

IN ALPHABETICAL ORDER

Hua Medicine (Shanghai) Ltd.

LKS Faculty of Medicine, The University of Hong Kong

NANJING CHIHEAL BIO MEDICINE TECHNOLOGY CO.,LTD

Pulnovo Medical Limited

Reed Sinopharm Exhibitions

Shenzhen Biopharmaceutial Industry Alliance

Shuimu BioSciences Ltd.

Sidley Austin

Susheng Biotech (Hainan) Co., Ltd. Fuyao Xingmei (Hainan) Technology Co., Ltd.

The Hong Kong Polytechnic University

TOURSUN GROUP HK LIMITED

Transfar Innocity·Overseas Returnees Town

YUNNAN BAIYAO GROUP CO.,LTD

EXHIBITOR LIST

SOTT BY BOOTH NO

Booth No.	Exhibitor
T01	Centre for Innovation and Entrepreneurship at the University of Macau
T02	Transfar Innocity · Overseas Returnees Town
T03	Hong Kong-Shenzhen Innovation and Technology Park Ltd.
T07	City University of Hong Kong
T09	Shenzhen Biopharmaceutial Industry Alliance
	China Medical System Holdings Limited (CMS)
	China Resources Sanjiu Medical & Pharmaceutical Co., Ltd.
	Joincare Pharmaceutical Group Industry Co., Ltd.
	Kexing Biopharm Co., Ltd.
	Shenzhen NuoShadow Biotechnology Co., Ltd.
	Shenzhen Salubris Pharmaceuticals Co., Ltd.
	Shenzhen Wanze Pharmaceutical Co., Ltd. / Wanze Co., Ltd.
	Shenzhen Xiangen Pharmaceutical Co., Ltd.
	Signet Therapeutics (Shenzhen) Co., Ltd.
	XtalPi Inc. (Shenzhen XtalPi Technology Co., Ltd.)
T10	Guangzhou Development Zone Low-Altitude Industry Development Co., Ltd.
	Akeso Biopharma Co., Ltd.
	Biosyngen Co., Ltd.
	Guangdong Shuimu Medical Technology Co., Ltd.
	Guangzhou Communications Investment Group Co., Ltd.
	Guangzhou Daguang Pharmaceutical Co., Ltd.
	Guangzhou Dongyuan Pharmaceutical Technology Co., Ltd.
	Guangzhou High-tech Zone Investment Group Co., Ltd.
	Guangzhou Huajin Pharmaceutical Technology Co., Ltd.
	Guangzhou Royal Lee Cancer Hospital Co., Ltd.
	Juventas Cell Therapy Ltd.
	Yipinhong Pharmaceutical Group Co., Ltd.

EXHIBITOR LIST

SOTT BY BOOTH NO

Booth No.	Exhibitor
T11	**DIP（Deep Intelligent Pharma）**
T12	**Hainan Pavilion**
	FuyaoXingmei (HaiNan) Technology Co., Ltd.
	Hainan Demei Pharmaceutical Co., Ltd.
	Hainan Haikang Nuode Medical Devices Co., Ltd.
	Hainan Huayan Collagen Technology Co., Ltd.
	Hainan JinXiong Pharmaceutical Co., Ltd.
	Hainan Susheng Biotechnology Co., Ltd.
	Micropeptide Biotechnology Co., Ltd.
T13	**Nordic Future Health Pavilion**
	Anocca AB
	Cirio Advokatbyrå AB
	ExpreS2ion Biotechnologies ApS
	ImmuneBiotech AB
	Keeada Health
	NextCell Pharma AB
	Softmed Medical Solutions
	Uveo Sverige AB (Uveo Europe)
	Veltio Pharma AB
T14	**Yunnan Baiyao Group Co., Ltd.**
T15	**CITIC Group Corporation**
	CHINA CITIC BANK INTERNATIONAL LIMITED
	China Securities Co.,Ltd.
	CITIC Medical & Heath Group Co.Ltd
	CITIC Pacific Limited - DCH Auriga
	CITIC Securities Company Limited

EXHIBITOR LIST

SOTT BY BOOTH NO

Booth No.	Exhibitor
T16	**Shanghai Pufa Shangcheng Enterprise Development Co., Ltd.**
T17	**LKS Faculty of Medicine, The University of Hong Kong**
T18	**Biocytogen Pharmaceuticals (Beijing) Co., Ltd.**
3E-A01	**Limu International Decoration Engineering Co.,Ltd**
3E-A02	**Limu International Decoration Engineering Co.,Ltd**
3E-A03	**First Aid**
3E-A04	**First Aid**
3E-A05	**Persatuan PJ Lestari**
3E-A06	**The Chinese University of Hong Kong**
3E-A07	**ScienCare Pharma**
3E-A08	**Consulate General of the Philippines**
3E-A09	**NANJING CHIHEAL BIOMEDICINE TECHNOLOGY CO., LTD.**
3E-A10	**SHUIMU SCIENTIFIC LIMITED**
3E-B01	**BOC LIFE**
3E-B02	**Biometas Group**
3E-B03	**Baidao Data**
3E-B04	**The Hong Kong Polytechnic University**
3E-B05	**Airdoc Technology (HK) Limited**
3E-B06	**Hong Kong Council for Testing and Certification**
3E-B07	**Shanghai InnoStar Bio-tech Co., Ltd.**
3E-B08	**OPIS Research**
3E-B09	**Original Cells (HK) Biotechnology Research Institute Limited**
3E-B10	**Beike Biotechnology**
3E-B11	**Hinton AI**
3E-B12	**Taimei Intelligence R & D Co.,Ltd.**
3E-B13	**Fiman (Changchun) Biotechnology Co., Ltd.**

EXHIBITOR LIST

SOTT BY BOOTH NO

Booth No.	Exhibitor
3E-B14	**GeneMind Biosciences Co., Ltd.**
3E-B15	**BGI Group**
3E-B16	**Chinese Peptide Company**
3E-B17	**Chinese Peptide Company**
3E-B18	**THEDERMA SHANGHAI CO.,LTD.**
3E-C01	**Asymchem Laboratories (Tianjin) Co., Ltd.**
3E-C02	**Science/AAAS**
3E-C03	**Jiangsu Medphoenix Medical&Technology Co.,Ltd**
3E-C04	**Novotech Clinical Research (Hong Kong) Limited**
3E-C05	**Highthink Medical Technology (HK) Limited**
3E-C06	**Toursynbio**
3E-D01	**KingMyLab**
3E-D02	**Sichuansheng, Dazhoushi, Dazhuxian**
3E-D03	**Sichuansheng, Dazhoushi, Dazhuxian**
3E-D04	**Global Incubator Network Austria**
3E-D05	**HUAMEDICINE**
3E-D10	**HUAMEDICINE**
3E-D06	**Syneos Health**
3E-D07	**BIOSYN (HONG KONG) COMPANY LIMITED**
3E-D08	**Hong Kong Science & Technology Parks Corporation (HKSTP)**
3E-D09	**Hong Kong Science & Technology Parks Corporation (HKSTP)**
3E-D11	**HONG KONG INTERNATIONAL FOOD TECHNOLOGY AND INNOVATION LIMITED**
3E-D12	**HONG KONG INTERNATIONAL FOOD TECHNOLOGY AND INNOVATION LIMITED**
3E-D13	**HONG KONG INTERNATIONAL FOOD TECHNOLOGY AND INNOVATION LIMITED**
3E-D14	**HONG KONG INTERNATIONAL FOOD TECHNOLOGY AND INNOVATION LIMITED**
3E-E01	**Reed Sinopharm Exhibitions**

EXHIBITOR LIST

SOTT BY BOOTH NO

Booth No.	Exhibitor
3E-E02	Hong Kong Biotechnology Organization
3E-E03	Guangzhou Weimi Bio-Tech Co.,Ltd.
3E-E04	Omics Empower
3D-A01	Hong Kong Food Professional Association
3D-A02	Hong Kong Food Professional Association
3D-A03	Hong Kong Food Professional Association
3D-A04	Hong Kong Food Professional Association
3D-B01	GenChim Testing (Shanghai) Co., Ltd.
3D-B02	Hong Kong International Food Technology And Innovation Limited
3D-B03	Nanjian Hongyun Walnut Processing and Sales Co., Ltd., Yunnan Province
3D-B04	Daido Group - Premium One-stop Fresh Food Supply Chain & Distribution Hub in Hong Kong
3D-C01	Kunming Guimeixuan Food Production Co., Ltd.
3D-C02	HONG KONG ANDA LIFE TECHNOLOGY LIMITED
3D-C03	Shanghai Haojinwei Food Technology Co., Ltd.
3D-C04	Gansu Xinyuan Group
3D-C05	Kings (HK) Health Food Limited
3D-C06	Jin Jia Zhuang (Huizhou) Health Food Limited
3D-C07	Origin Quantum Computing Technology (Hefei) Co., Ltd.
3D-C08	CNI Corporation Sdn Bhd
3E-S01	Consulate General of Hungary in Hong Kong
3E-S02	Consulate General of the Republic of Belarus in the Hong Kong SAR
3E-S03	PR Newswire
3E-S04	Shk Cultural Development Association Limited
3E-S05	Consulate-General of Uruguay in Hong Kong
3E-S06	Wallonia Export-Investment Agency Shenzhen Office
3E-S07	Selesta Partners Limited
3E-S08	Guangzhou Zhiyi Biotechnology Co., Ltd.

AGENDA+ SPEAKERS BIOGRAPHIES

DAY ONE

09 September, WED



09 September 2026 (WED), Day 1

09:00 – 10:30 — Main Stage

Opening Ceremony

10:30 – 13:00 — Main Stage

Keynote Session

13:20 – 16:00 — Theater 2

The Hong Kong Centre for Medical Products Regulation (CMPR) and Global Regulatory Collaboration (Co-organized by Department of Health)

14:00 – 17:00 — Theater 5

CITIC · Hong Kong Main Forum: Global Biotech Leaders Summit

14:00 – 18:00 — Theater 1

AI Forum 1:
AI-Driven Life Sciences & Drug Discovery: From Foundation Models to Paradigm Shifts

14:00 – 15:30 — Theater 3

Global Cooperation Forum 1:
Hainan Special Session: From Hainan Free Trade Port to the World – Hainan-Global Healthcare Integration Forum
(Co-organized by Haikou National High- tech Zone)

14:00 – 18:00 — Theater 6

Future Food Tech International Collaboration Summit

14:30 – 18:00 — Theater 5

Shenzhen–Hong Kong Biotech Cross-Border Collaboration & Innovation Summit
(Co-organized by Shenzhen Biopharmaceutical Industry Alliance)

15:30 – 18:00 — Theater 3

Global Cooperation Forum 2:
Across the Pacific: China-US Biotechnology Competition and Cooperation

16:00 – 18:00 — Theater 2

Hong Kong's "1+" Policy Empowering the Globalization of China's Innovative Drugs Seminar

09:00 - 10:30 (MAIN STAGE)

Opening Ceremony

Speakers:

Albert Cheung Hoi YU
Chairman of Hong Kong Biotechnology Organization

Chun-Ying LEUNG
Vice-Chairman of the National Committee of the Chinese People's Political Consultative Conference (CPPCC); Former Chief Executive of the Hong Kong Special Administrative Region (HKSAR)

Chung-Mau LO
Secretary for Health, The Government of the Hong Kong SAR

Chuwen LIU
Member of the Party Leadership Group and Deputy Director-General, Shenzhen Municipal Development and Reform Commission

Dong SUN
Secretary for Innovation, Technology and Industry, The Government of the Hong Kong SAR

Xu CHEN
Deputy Director of the Guangzhou Greater Bay Area Office; Member of the Leadership Group & Deputy Director of the Guangzhou Development and Reform Commission

10:30 - 13:00 (MAIN STAGE)

Keynote Speech

Speakers:

Victor DZAU
Past President, U.S. National Academy of Medicine; Chancellor Emeritus and James B. Duke Distinguished Professor of Medicine of Duke University; Past CEO of Duke Health
Speech Title: Harnessing the Transformative Power of Biotechnology for Global Health

Jonathan SYMONDS
Chair of GlaxoSmithKline (GSK)
Speech Title: Prevention as the best medicine: Harnessing innovation and data for healthier societies and stronger economies

Yuk Ming Dennis LO
Vice-Chancellor and President, The Chinese University of Hong Kong
Speech Title: Biology and Applications of the Emerging Field of Cell-free DNA Fragmentomics

Sven Peter Emanuel NOBEL
Chairman of the Nobel Sustainability Trust
Speech Title: A World in Balance: Transforming Life Science Innovation into Sustainable Prosperity

Ruilin SONG
Chief Expert of China Pharmaceutical Innovation and Research Development Association (PhIRDA)
Speech Title: Reflections on China's Pharmaceutical Innovation Advancing Toward an Emerging Pillar Industry under the New International Situation

Tao XU
Member of the Chinese Academy of Sciences, Fellow of The World Academy of Sciences for the Advancement of Science in Developing Countries; Executive Deputy Director of Guangzhou National Laboratory, Director of Bioisland Laboratory
Speech Title: Cohort Big Data and Autonomous Labs: Driving Innovation in Next-generation Biotherapeutics

Yan ZHAO
Chairperson and President, Bloomage Biotechnology
Speech Title: AI+BT, the Global Value of China's Biomanufacturing: Technology Making Life and Health Accessible to All

13:30 - 16:00 (THEATER 2)

The Hong Kong Centre for Medical Products Regulation (CMPR) and Global Regulatory Collaboration (Co-organized by Department of Health, HKSAR)

Opening Remarks:

Representative of the Department of Health, Government of the Hong Kong Special Administrative Region

Moderator:

Charles HU
Founder & CEO, Ryoden Medical Holdings & Incando Therapeutics Group

Speakers:

Lot CHAN
Assistant Director (Preparatory Office for Centre of Medical Products Regulation), Department of Health, the Government of HKSAR
Speech Title: CMPR: Future of Hong Kong's Medical Products Regulation

Mohd Nasrul MOHAMAD NOOR
Senior Principal Assistant Director, National Pharmaceutical Regulatory Agency (NPRA), Ministry of Health Malaysia
Speech Title: The Malaysia Model: Advancing Pharmaceutical Quality through Specialized Regulatory Frameworks and Regional Collaboration in ASEAN

13:30 - 16:00 (THEATER 2)

Speakers:

Raymond Swee Boon CHUA
the Deputy Director-General of Health (Health Regulation) at Singapore's Ministry of Health (MoH) and the Chief Executive Officer of the Health Sciences Authority (HSA)
Speech Title: Building Trust Across Borders: Singapore's Approach to Regional Regulatory Synergy

Obaidullah MALIK
Chief Executive Officer, Drug Regulatory Authority of Pakistan
Speech Title: Enabling Pharmaceutical & Biotechnology Innovation: Pakistan's Regulatory Pathway for Global Collaboration and Investment

Taruna IKRAR
Professor, Chairperson of Indonesian FDA
Speech Title: TBC

Panel: Building Trust and Connecting China Innovation to Global Patients: Asia-Pacific Collaboration and Hong Kong's Role as a Catalyst

Moderator: Zili LI
Panelist: Jinhua ZHANG, Li CHEN, Lot CHAN, Mohd Nasrul MOHAMAD NOOR, Nisa LEUNG, Raymond Swee Boon CHUA, Taruna IKRAR

14:00 - 17:30 (MAIN STAGE)

CITIC · Hong Kong Main Forum: Global Biotech Leaders Summit

Panel: Towards a New Global Health Governance: Advancing Equity and Access in Biotech Innovation

Moderator: Richard STONE
Panelist: Chaksing LAU, Jian Kang ZHU, Michael LU, Victor DZAU

Panel: The New Wave of AI Pharma: Dialogue Among Cross-Industry Leaders(Co-organized by China Securities)

Moderator: Helen HE
Panelist: Crystal QIN, Feng REN, Lianjie LIU, Tim RUAN, Tony HE, Wei LIU

Panel: International Medical Cooperation: Dialogue Among Hospital Leaders(Co-organized by CITIC Medical & Health)

Moderator: Hua CAI
Panelist: Abdulrazaq AL-JAZAIRI, Chengyu ZHANG, Ge LIN, Kenneth TSANG, Zhaoxiang BIAN

14:00 - 18:00 (THEATER 1)

AI Forum 1: AI-Driven Life Sciences & Drug Discovery: From Foundation Models to Paradigm Shifts

Moderator:

Xinzhu WANG
Co-Founder of Potentiam Biosciences

Speakers (Part 1):

Karen AKINSANYA
President, Head of Therapeutics R&D and Chief Strategy Officer, Partnerships at Schrödinger, Inc.
Speech Title: Molecules that Matter: AI, Physics & Medicine Discovery

Feng REN
Co-CEO and CSO of Insilico Medicine
Speech Title: TBC

Wei LIU
Co-Founder & CEO, BioMap
Speech Title: TBC

Yuguang WANG
CEO, Shanghai Toursynbio SAI Technology Co., Ltd.
Speech Title: Biologic R&D Powered by Scientific Superintelligence

Speakers (Part 2):

Yuanyuan SUN
Founder, Chairman, Zhihe Yuanchuang AI Pharma
Speech Title: TBC

Dong LI
Professor, School of Life Sciences, Tsinghua University
Speech Title: Pushing the envelope of super-resolution microscopy for sustained live imaging of rapid subcellular processes

Yann GASTON-MATHÉ
IKTOS CO-FOUNDER & CEO
Speech Title: Breaking Screening Barriers: GenAI and Robotics Powering Next-Generation Molecule Discovery

Defang OUYANG
Associate Professor of Faculty of Medicine, University of Macau
Speech Title: AI-Driven Drug Discovery and Development

14:00 - 18:00 (THEATER 1)

Panel: Software, Platform, or Pipeline: How Do TechBio Companies Choose Their Business Models?

Moderator: Michelle CHEN

Panelist: Edward LI, Fei GU, Karen AKINSANYA, Yann GASTON-MATHÉ, Yuguang WANG

Panel: What AI Can and Cannot Do — The Real Boundaries of Life Science Translation

Moderator: Mark TANG

Panelist: Allen GUO, Chunyi WEN, Stanley SHEN, Yang HUANG

14:00 - 15:30 (THEATER 3)

Global Cooperation Forum 1: Hainan Special Session: From Hainan Free Trade Port to the World – Hainan-Global Healthcare Integration Forum (Co-organized by Haikou National High-tech Zone)

Speakers:

Yunfei WANG

Investment Promotion Manager at Haikou National Hi-Tech Zone International Investment Development Co., Ltd.

Speech Title: Biopharmaceutical Industry Cooperation Opportunities at the Haikou National High-Tech Zone

Sheng ZENG

CEO, Susheng Biotech (Hainan) Co,. Ltd.

Speech Title: Cell Therapy in Hainan Free Trade Port, the Case of Susheng Biotech

Fang ZONG

Hainan Dermavon Pharmaceutical Technology Co., Ltd., Deputy General Manager

Speech Title: TBC

Hongbin JIAO

Partner, KING & WOOD

Speech Title: TBC

14:00 - 18:00 (THEATER 6)

Future Food Tech International Collaboration Summit

Congratulatory Message from former UN Secretary-General Ban Ki-moon

Presented by Chunsheng MIAO (Special Envoy of former UN Secretary-General Ban Ki-moon)

Speakers (Part 1):

Zhidong MIN

President, Hong Kong International Food Science & Technology Innovation Development Co., Ltd.; Chairman, Hong Kong Food Professionals Association

Yuk Lam LO

President of HK Bio-Med Innotech Association

Ye TIAN

Secretary-General of China Good Agri-products Development & Service Association

Speakers (Part 2):

Yi ZHANG

Deputy Director General, Bureau of Technology Transfer, Chinese Academy of Agricultural Science

Jay D. KEASLING

Department of Chemical & Biomolecular Engineering and Department of Bioengineering, University of California, Berkeley Biological Systems & Engineering Division, Lawrence Berkeley National Laboratory Joint BioEnergy Institute (JBEI)

Guangwei LIU

President, World Eatology Forum

Speakers (Part 3):

Fu GAO

Vice President, China Council for the Promotion of Ethnic Trade

Thematic Forum: International Food Science and Technology Innovation & Cooperation

Moderator: Carmen MAN

Panelist: Hidekazu CHAYAMA, Jiuchi LAO, Kuei-Nan KAO, Paul-Éric JARRY, Wenrui ZHOU

Panel: Precision Nutrition and Genomics

Panelist: Elaine Lai Han LEUNG, Fengzhong WANG, Lai-Ying FONG, Simon LEE, Yaping ZHANG, Yu FENG

Moderator: Danyu ZHAO

Panel: Sustainable Protein and Nutrition Health Translation

Panelist: Carmen MAN, Fuqing WU, Jay D. KEASLING, Rongrong LIU, Wei WEI

13:30 - 18:00 (THEATER 5)

Shenzhen–Hong Kong Biotech Cross-Border Collaboration & Innovation Summit (Co-organized by Shenzhen Biopharmaceutical Industry Alliance)

Opening Remarks:

Chuwen LIU
Member of the Party Leadership Group and Deputy Director-General, Shenzhen Municipal Development and Reform Commission

Representative of the Government of the Hong Kong Special Administrative Region,

Speakers:

Hongjie DAI
Chair Professor, Department of Chemistry, the University of Hong Kong
Speech Title: TBC

Philip Wai Yan CHIU
Dean, Faculty of Medicine, The Chinese University of Hong Kong
Speech Title: TBC

Panel: Breaking Cross-Border Barriers, Energizing the Greater Bay Area's Innovation Core

Moderator: Yichong LI

Panelist: Duncan CHIU, Kenneth Man Chee CHEUNG, Philip Wai Yan CHIU, Vincent MA, Yinxiao WU

Panel: Competing Globally — Capital Empowering Industrial Expansion Overseas

Moderator: Andrew NG

Panelist: Jian MA, Jian LIU, Jian ZHANG, King-shun YAN, Meng DING

15:30 - 18:00 (THEATER 3)

Global Cooperation Forum 2: Across the Pacific: China-US Biotechnology Competition and Cooperation

Moderator: **Holly MENG**
CEO, Exin BioPharma Inc.; CEO, Global BioPharma Partnerships LLC.

Speakers:

Jimmy ZHANG
Executive Mentor, QB3/Bakar Labs, UC Berkeley
Speech Title: TBC

Louis P. KASSA
President and Chief Executive Officer of the Pennsylvania Biotechnology Center, the Baruch S. Blumberg Institute, the Hepatitis B Foundation, and B+Labs, University City
Speech Title: Pennsylvania's life sciences ecosystem and our collaboration with PABC and the Blumberg Institute

Panel: China–U.S. Forum 1: Contrasting the Globalization Strategies of Chinese and U.S. Biotech Companies

Moderator: Holly MENG

Panelist: Fiona YU, Jimmy ZHANG, Louis P. KASSA, Masatomo SAKAIRI, Simon HUA

Panel: China–U.S. Forum 2: Hong Kong's Role as the Biotech Bridge

Moderator: Jiawei TANG

Panelist: Helen CHEN, Johan H. FABER, Kelvin SHAO, Raju KUCHERLAPATI, Sherman K.W. FUNG, Thomas FUNG

16:00 - 18:00 (THEATER 2)

Hong Kong's "1+" Policy Empowering the Globalization of China's Innovative Drugs Seminar

Opening Remarks:

Dalong ZHU
Professor of Endocrinology; Director, Endocrine and Metabolic Disease Medical Center, Nanjing Drum Tower Hospital, the Affiliated Hospital of Nanjing University Medical School; Former President, Chinese Diabetes Society (CDS), Chinese Medical Association.

Ruilin SONG
Chief Expert of China Pharmaceutical Innovation and Research Development Association (PhIRDA)

Wenying YANG
National Distinguished Physician; Former Chair, Chinese Diabetes Society (CDS), Chinese Medical Association; Vice President, Asian Association for the Study of Diabetes (AASD)

Speakers:

Li CHEN
Founder and CEO of Hua Medicine
Speech Title: Glucose Homeostasis from Concept to Medicine

Panel: The Path to Globalization for Chinese Innovative Pharmaceuticals: A Perspective from the First Beneficiaries of the "1+" Initiative

Moderator: Qing DONG

Panelist: Juliana CHAN, Michael YIM, Xiaoying LI, Zhiyi HE

KEYNOTE SPEAKERS - MAINSTAGE



Victor DZAU

Past President, U.S. National Academy of Medicine; Chancellor Emeritus and James B. Duke Distinguished Professor of Medicine of Duke University; Past CEO of Duke Health

Victor J. DZAU, MD, was born in China and grew up in Hong Kong. He is one of the most influential leaders in health and is recognized globally for a highly decorated career as a physician scientist, administrator, and leader. He is past and inaugural president of the U.S. National Academy of Medicine (NAM), having led its transition from the Institute of Medicine. He is chancellor emeritus of Duke University, past CEO of Duke Health, and served as chair of departments of medicine at Harvard and Stanford. Dzau's seminal research laid the foundation for the class of lifesaving heart drugs known as ACE inhibitor. He pioneered gene therapy for vascular disease. As President of the NAM, Dzau led the Commission on a Global Health Risk Framework, the Healthy Longevity Global Grand Challenge, and the International Human Gene Editing Initiative, the Grand Challenge in Healthy Longevity and the Action Collaborative on Translating Emerging Science, Technology, and Innovation in Health and Medicine. In 2018, Dzau launched the NAM's International Health Policy Fellowship Program, which enables scholars from Chinese University of Hong Kong (CUHK) to gain experience in global health policy. This endowed fellowship is now named the Cheng Dzau Fellowship at CUHK. This was followed by establishing a similar fellowship with Hong Kong University (HKU) in 2019. Dzau has served in leadership and advisory roles for US and international governments, WHO, World Bank, World Economic Forum and Universities. He co-chairs the G20 High-Level Independent Panel on pandemic financing, the World Economic Forum Regional Vaccine Manufacturing Collaborative, and the International Pandemic Preparedness Science and Technology Expert Panel. He serves on the Global Preparedness Monitoring Board, co-chaired the G20 Scientific Panel on Global Health Security, and advised the G7 Hiroshima Health Task Force. He chairs the International Advisory Board of McGill's School of Population and Global Health, the Tsinghua Medicine Advisory Council, and . the International Advisory Board of the Hong Kong University of Science and Technology School of Medicine. He chairs the Singapore International Advisory Council of Human Health and Potential, serves on the Singapore Research Innovation and Enterprise Council, and chairs Singapore's precision medicine initiative, PRECISE. He chairs the International Scientific Advisory Committee of the Qatar Precision Medicine Institute. Dzau brings more than 35 years of experience in biomedical research and biopharmaceutical industry. He has served on the Scientific Advisory Board of United Therapeutics, Board of Directors of Medtronic, Alnylam, Genzyme and PepsiCo. His deep expertise in biomedical research, innovation strategy, regulatory science, and health system transformation provides substantial value to organizations operating at the intersection of science, medicine, and industry. Dzau's many honors include the Gustav Nylin Medal (Sweden), Max Delbrück Medal (Germany), the Ellis Island Medal of Honor (US), and the Henry Friesen International Prize (Canada). In 2019, he was named an Honorary Citizen of Singapore, the country's highest recognition for a foreign national. In 2025, he received the Order of the Rising Sun from Japan. He holds a Doctor of Science Honoris Causa from the University of Hong Kong (2016) and from the Chinese University of Hong Kong (2024), and received an honorary professorship from Tsinghua University in 2025, among 24 honorary doctorates from US and international universities.



Yuk Ming Dennis LO

Vice-Chancellor and President, The Chinese University of Hong Kong

Professor Dennis Lo is the ninth Vice-Chancellor and President and the Li Ka Shing Professor of Medicine of The Chinese University of Hong Kong (CUHK). He is also the President of the Hong Kong Academy of Sciences. His research interests focus on the biology and diagnostic applications of cell-free nucleic acids in plasma. In particular, he discovered the presence of cell-free fetal DNA in maternal plasma in 1997 and has since then been pioneering non-invasive prenatal diagnosis using this technology. This technology has been adopted globally and has created a paradigm shift in prenatal medicine. He has also made many innovations using circulating nucleic acids for cancer detection, including the screening of early stage nasopharyngeal cancer. In recognition of his research, Professor Lo has been elected as Member of the Chinese Academy of Sciences (CAS), Founding Member of the Hong Kong Academy of Sciences, Fellow of the Royal Society, Foreign Associate of the US National Academy of Sciences and Foreign member of the Academia Europaea. Professor Lo has won numerous awards, including the 2014 King Faisal International Prize in Medicine, the 2016 Future Science Prize in Life Science, the 2019 Fudan-Zhongzhi Science Award, the 2021 Breakthrough Prize in Life Sciences, the 2021 Royal Medal, the 2021 ESHG Mendel Award, the 2022 ISPD Pioneer Award, the 2022 Lasker~DeBakey Clinical Medical Research Award, the 2023 inaugural Tengchong Science Prize, the 2024 Jiménez Díaz Lecture Award and the 2025 Richard B. Johnston, Jr., MD Prize in Developmental Biology by March of Dimes.

KEYNOTE SPEAKERS - MAINSTAGE



Sven Peter Emanuel NOBEL

Chairman of the Nobel Sustainability Trust

Peter Nobel Chairman, Nobel Sustainability Trust Chairman of Swedish clean-tech company Nobel Aquatech AB Peter Nobel graduated from the Royal Institute of Technology in Stockholm with a degree of Master of Science in Material Science and Engineering. Nobel has extensive experience positioning companies for successful market share growth in various international industrial markets including the global HVAC industry, and has taken up CEO roles across different industries. He has experience in executive positions in sales and marketing, R&D and manufacturing at global companies such as Alfa Laval and SWEP International. Nobel co-founded and led start-ups companies in the clean-tech sector, with expertise on compact and efficient heat cells as well as developments on new water purification technologies. Nobel holds listed patents in heat exchanger technology and international pending patents for water purification technology. He now works actively as advisory consultant to company boards in Japan, Hong Kong, and beyond.



Ruilin SONG

Chief Expert of China Pharmaceutical Innovation and Research Development Association (PhIRDA)

Mr. Song Ruilin, Chief Expert of China Pharmaceutical Innovation and Research Development Association (PhIRDA), Expert of Talent Pool for State Affairs of Chinese People's Political Consultative Conference (CPPCC), Advisor on Participation in and Deliberation of State Affairs for the Central Committee of Chinese Peasants and Workers Democratic Party. He is also L.L.B. of China University of Political Science and Law, EMBA of China Europe International Business School, Doctor of Social and Administrative Pharmacy of China Pharmaceutical University and Visiting Scholar of the University of Sydney. Mr. Song had served in the Legislative Affairs Office at State Council of China for a long time, engaging in health and drug policy, legal studies and in charge of law making and reviewing in the areas of pharmaceutical and healthcare industry. In recent years, he mainly engages in the research on China's pharmaceutical innovation policy.



Jonathan SYMONDS

Chair of GlaxoSmithKline (GSK)

Jon was appointed to the Board as Chair of the Board of GSK on 1 September 2019. Jon has extensive international financial, life sciences and governance experience. Jon served as a Non-Executive Director of Genomics England from October 2013 to October 2025. From April 2014 until February 2020, he was an Independent Non-Executive Director of HSBC Holdings plc where he also served as Chairman of the Group Audit Committee and as Deputy Group Chairman from August 2018. Jon was previously Chairman of HSBC Bank plc, Chief Financial Officer of Novartis AG, Partner and Managing Director of Goldman Sachs, Chief Financial Officer of AstraZeneca plc, and a Partner at KPMG. He was also a Senior Advisor to Chatham House. Jon is a Fellow of the Institute of Chartered Accountants in England and Wales, an Honorary Fellow of the Oxford School of Pharmacology, and an Honorary Fellow of the Academy of Medical Sciences. External appointments: -Non-Executive Chair, Energy Aspects -Chair, European Round Table for Industry -Member, Investor & Issuer Forum (I&IF) Steering Committee

KEYNOTE SPEAKERS - MAINSTAGE



Tao XU

Member of the Chinese Academy of Sciences, Fellow of The World Academy of Sciences for the Advancement of Science in Developing Countries; Executive Deputy Director of Guangzhou National Laboratory, Director of Bioisland Laboratory

He has long been dedicated to research on super-resolution imaging technology and ultra sensitive detection methods, and has achieved a series of innovative outcomes in high-end scientific instruments, bio-manufacturing and intelligent equipment. He has published multiple academic papers in top-tier journals such as Cell, Nature Cell Biology, etc. He has undertaken key projects from the National Natural Science Foundation of China and multiple projects from the Ministry of Science and Technology, including the 973 Program. He is a recipient of the Chang Jiang Scholar Professorship, the National Science Fund for Distinguished Young Scholars, and the Recruitment Program of Global Experts (the Ten Thousand Talents Program). He has won the National Natural Science Second Prize, He Liang He Li Science and Technology Progress Award, Tan Jiazhen Life Science Innovation Award, National Innovation Excellence Award, and so on.



Yan ZHAO

Chairperson and President, Bloomage Biotechnology

Zhao Yan founded and leads Bloomage International and Bloomage Biotech (688363.SH). Bloomage Biotech is a global leader in the glycoscience industry, pioneering advances in biotechnology and biomanufacturing. Since its inception in 2000, the company has been dedicated to addressing one of the most pressing challenges in life sciences: aging. The foundation of Bloomage Biotech was built upon the biomanufacturing of hyaluronic acid—an essential molecule that has regulated cell fate since the emergence of multicellular life. In 2007, Bloomage became the world's largest supplier of HA with a current global market share of 44%. Building on this foundation, Bloomage pioneered the precision control of hyaluronic acid's biochemical properties through synthetic biology and enzymatic degradation. These innovations have driven global research breakthroughs on the role of hyaluronic acid in aging intervention and tissue regeneration, highlighted by publications in Nature in 2013 and 2023. With deeper insights into cellular aging, Zhao expanded the company's focus to a broader range of bioactive compounds, builting the world's largest synthetic biology and biomanufacturing platform to accelerate the translation of scientific discoveries into scalable solutions, bridging the gap from the lab to industry. Today, Bloomage Biotech delivers integrated solutions across four sectors: bioactive materials, pharmaceuticals and medical aesthetics, skin science, and nutritional science. Fostered a distinguished portfolio of brands: Biohyalux, Quadha, MedRepair, Bio-meso, Aqualuna, and Bloomage Health. Beyond business, Zhao also supports cultural, sports, and social initiatives, and her leadership has been recognized with honors such as Forbes China Top 100 Outstanding Businesswomen (2024) and the Golden Roundtable Award for Entrepreneurial Spirit.

OPENING CEREMONY SPEAKERS - MAINSTAGE



Chun-Ying LEUNG

Vice-Chairman of the National Committee of the Chinese People's Political Consultative Conference (CPPCC); Former Chief Executive of the Hong Kong Special Administrative Region (HKSAR)



Chung-Mau LO

Secretary for Health, The Government of the Hong Kong SAR



Dong SUN

Secretary for Innovation, Technology and Industry, The Government of the Hong Kong SAR



Albert Cheung Hoi YU

Chairman of Hong Kong Biotechnology Organization



Chuwen LIU

Member of the Party Leadership Group and Deputy Director- General, Shenzhen Municipal Development and Reform Commission



Xu CHEN

Deputy Director of the Guangzhou Greater Bay Area Office; Member of the Leadership Group & Deputy Director of the Guangzhou Development and Reform Commission

SPEAKERS - MAINSTAGE



Abdulrazaq AL-JAZAIRI

Director, Clinical Trials Transformation Division King Faisal Specialist Hospital & Research Center
Riyadh, Saudi Arabia

Dr. Al-Jazairi is a Clinical Pharmacy Consultant in the field of Cardiovascular Pharmacotherapy and the Director, Clinical Trials Transformation Division at the prestigious King Faisal Specialist Hospital and Research Center (KFSH&RC), Riyadh Saudi Arabia. He received his Doctor of Pharmacy degree from Campbell University at Buies Creek, North Carolina, USA, and a general Pharmacy Practice Residency at Duke University Medical Center (DUMC), Durham, NC. In 2000, Dr. Al-Jazairi completed a two-year Specialty Residency in Cardiovascular Pharmacotherapy from Philadelphia College of Pharmacy (PCP), University of the Sciences in Philadelphia in conjunction with the Hospital University of Pennsylvania (HUP), Philadelphia, Pennsylvania. More recently, 2014, Dr. Al-Jazairi earned a Master degree in Pharmaceutical and Healthcare Business from Mayes College, University of the Sciences in Philadelphia. Dr. Al-Jazairi is a board certified pharmacotherapy specialist with Cardiology added-qualification. Dr. Al-Jazairi has more than 60 original research publications, and delivered many national and international presentations. Dr. Al-Jazairi is the Founder of the Saudi Clinical Pharmacy Society, 2018. He is an editorial board member of prime journals, including Annals of Pharmacotherapy and the Annals of Saudi Medicine, for more than 25 years. He sets in several committees in Saudi-FDA, Saudi Commission for Health Specialties and Saudi Health Council. He is a member of the International Accreditation Commission, ASHP. Dr. Al-Jazairi enjoys training students and residents in Cardiology, Clinical Research and Evidence-based Medicine. Dr. Al-Jazairi is the Director of the first and only Cardiology Residency Program accredited by ASHP outside the States, at King Faisal Specialist Hospital and Research Center (KFSH&RC). He also serves as an Associate Professor, School of Pharmacy and School of Medicine in Alfaisal University, Qassim University, and adjunct Assistant Professor in Princess Nora University and member of the Advisory Board for College of Pharmacy.



Zhaoxiang BIAN

Hospital Chief Executive, The Chinese Medicine Hospital of Hong Kong

Professor BIAN Zhaoxiang Hospital Chief Executive The Chinese Medicine Hospital of Hong King Professor Bian Zhaoxiang is a leading expert in Chinese Medicine clinical studies, a highly regarded Chinese Medicine research scientist in the field of gut dysbiosis, and a passionate advocate for the integration of Chinese Medicine into holistic healthcare system. Professor Bian's academic pursuit at Nanjing University of Chinese Medicine, where he obtained a degree in Chinese Medicine. He then pursued a Master of Philosophy in Chinese Medicine from Beijing University of Chinese Medicine, followed by a Doctor of Philosophy in Integrative Medicine from Guangzhou University of Chinese Medicine. Since joining HKBU in 2001, Professor Bian has held various positions, including the Tsang Shiu Tim Endowed Professor in Chinese Medicine Clinical Studies, Director and Chair Professor of the Clinical Division, Director of the Centre for Chinese Herbal Medicine Drug Development, Director of the Chinese EQUATOR Centre, and Director of the Vincent VC Woo Chinese Medicine Clinical Research Institute. As the CMHHK's Hospital Chief Executive, Professor Bian is leading the Core Management Team, healthcare professionals, and all other hospital staff to pursue the preparatory work for the hospital's commissioning, with a view to commencing services in phases from December 2025 onwards.

SPEAKERS - MAINSTAGE



Hua CAI

General Manager, CITIC MED FUNDS

Cai Hua, General Manager, CITIC Medical Fund. His key concurrent appointments include: Expert, CITIC Think Tank; Senior Research Fellow, CITIC Foundation for Reform and Development Studies; Vice President, China Medical Pharmaceutical Material Association; Deputy Director, Internet Medical Health Working Committee, Internet Society of China; Council Member, Chinese Association of Geriatric Research; and Standing Committee Member, Pharmacoeconomics and Drug Evaluation Special Committee, China Association for Research and Promotion of Traditional Chinese Medicine. He holds dual bachelor's degrees in Pharmacy and Law from Shandong University, an Executive MBA from CEIBS, and is currently pursuing a doctorate in Pharmacoeconomics at China Pharmaceutical University. He formerly served as Regional General Manager at MSD (China) and Managing Director at China eCapital Corporation.



Victor DZAU

Past President, U.S. National Academy of Medicine; Chancellor Emeritus and James B. Duke Distinguished Professor of Medicine of Duke University; Past CEO of Duke Health

Victor J. DZAU, MD, was born in China and grew up in Hong Kong. He is one of the most influential leaders in health and is recognized globally for a highly decorated career as a physician scientist, administrator, and leader. He is past and inaugural president of the U.S. National Academy of Medicine (NAM), having led its transition from the Institute of Medicine. He is chancellor emeritus of Duke University, past CEO of Duke Health, and served as chair of departments of medicine at Harvard and Stanford. Dzau's seminal research laid the foundation for the class of lifesaving heart drugs known as ACE inhibitor. He pioneered gene therapy for vascular disease.

As President of the NAM, Dzau led the Commission on a Global Health Risk Framework, the Healthy Longevity Global Grand Challenge, and the International Human Gene Editing Initiative, the Grand Challenge in Healthy Longevity and the Action Collaborative on Translating Emerging Science, Technology, and Innovation in Health and Medicine. In 2018, Dzau launched the NAM's International Health Policy Fellowship Program, which enables scholars from Chinese University of Hong Kong (CUHK) to gain experience in global health policy. This endowed fellowship is now named the Cheng Dzau Fellowship at CUHK. This was followed by establishing a similar fellowship with Hong Kong University (HKU) in 2019.

Dzau has served in leadership and advisory roles for US and international governments, WHO, World Bank, World Economic Forum and Universities. He co-chairs the G20 High-Level Independent Panel on pandemic financing, the World Economic Forum Regional Vaccine Manufacturing Collaborative, and the International Pandemic Preparedness Science and Technology Expert Panel. He serves on the Global Preparedness Monitoring Board, co-chaired the G20 Scientific Panel on Global Health Security, and advised the G7 Hiroshima Health Task Force. He chairs the International Advisory Board of McGill's School of Population and Global Health, the Tsinghua Medicine Advisory Council, and . the International Advisory Board of the Hong Kong University of Science and Technology School of Medicine. He chairs the Singapore International Advisory Council of Human Health and Potential, serves on the Singapore Research Innovation and Enterprise Council, and chairs Singapore's precision medicine initiative, PRECISE. He chairs the International Scientific Advisory Committee of the Qatar Precision Medicine Institute.

Dzau brings more than 35 years of experience in biomedical research and biopharmaceutical industry. He has served on the Scientific Advisory Board of United Therapeutics, Board of Directors of Medtronic, Alnylam, Genzyme and PepsiCo. His deep expertise in biomedical research, innovation strategy, regulatory science, and health system transformation provides substantial value to organizations operating at the intersection of science, medicine, and industry.

Dzau's many honors include the Gustav Nylin Medal (Sweden), Max Delbrück Medal (Germany), the Ellis Island Medal of Honor (US), and the Henry Friesen International Prize (Canada). In 2019, he was named an Honorary Citizen of Singapore, the country's highest recognition for a foreign national. In 2025, he received the Order of the Rising Sun from Japan. He holds a Doctor of Science Honoris Causa from the University of Hong Kong (2016) and from the Chinese University of Hong Kong (2024), and received an honorary professorship from Tsinghua University in 2025, among 24 honorary doctorates from US and international universities.

SPEAKERS - MAINSTAGE



Helen HE

Co-Head, R&D Department at China Securities Co., Ltd

Ms. Juying He is Co-Head of the R&D Department at China Securities Co., Ltd., and Chief Analyst for Global Health and Industry. She holds a Master of Management from Fudan University and has many years of experience in healthcare sell-side research. She has led her team to win multiple prestigious awards for Best Healthcare Analysts, including those from New Fortune, Shanghai Securities News, the Golden Bull Award, and Sina Finance's Golden Unicorn Awards.



Chaksing LAU

Vice-President & Pro-Vice-Chancellor (Health), Dean of Medicine, The University of Hong Kong

Professor Chak-sing Lau is currently Vice-President & Pro-Vice-Chancellor (Health) and Dean of Medicine at The University of Hong Kong. He is meanwhile Chair and Daniel CK Yu Professor in Rheumatology and Clinical Immunology of the University's Li Ka Shing Faculty of Medicine (HKUMed).
He presided over the Hong Kong Academy of Medicine (2016 – 2020), a statutory body for medical and dental specialist training in Hong Kong which is also a key advisory body to the HKSAR Government on health-related policies. Today, he sits on numerous strategic committees/ working groups of the Health Bureau, Hospital Authority and Department of Health. He is also a member of the Research Council under the Health Bureau.
Professor Lau is known as a pioneer for establishing and advancing rheumatology in Hong Kong, Asia and beyond. In 2022, he was selected as an Honorary Member of the European Alliance of Associations for Rheumatology (EULAR), and elected as Member of Academia Europaea in 2023, and conferred the degree of Doctor of Science honoris causa by the University of Glasgow in 2024. He is Honorary Fellow of the American College of Physicians; the Academy of Medicine, Singapore; Singapore College of Physicians; Royal College of Physicians of Thailand; Academy of Medicine of Malaysia; the Royal College of Physicians of Ireland; and the Hong Kong Academy of Medicine.



Ge LIN

President, Reproductive & Genetic Hospital CITIC-Xiangya

Lin Ge, a member of the Communist Party of China, is a research professor and doctoral supervisor who receives the Special Government Allowance of the State Council. He currently serves as President of Reproductive & Genetic Hospital CITIC-Xiangya , Director of the Institute of Reproductive and Stem Cell Engineering at Central South University, Director of the Key Laboratory of Human Stem Cells and Reproductive Engineering under the National Health Commission, and Deputy Director of the National Engineering Research Center for Human Stem Cells. He also holds multiple positions including member of the 13th Hunan Provincial CPPCC and standing committee member of the Reproductive Medicine Committee of the Chinese Medical Doctor Association. He has led his team to achieve a series of original breakthroughs in stem cell and reproductive medicine: establishing China's first human embryonic stem cell line in 2001 and building the world's largest embryonic stem cell bank; inventing a novel somatic cell nuclear transfer method and obtaining the world's first human therapeutic cloning embryo; establishing a platform for differentiating stem cells into functional cells, with the world's first successful clinical application of stem cell derived hepatocytes in treating liver failure. In assisted reproduction, his team established blastocyst biopsy and PGT platforms, delivered China's first "cancer free baby," and developed the MicroSeq technology to exclude chromosomal translocations. To date, over 260,000 healthy infants have been born through assisted reproduction under his leadership. He has presided over 16 major projects including the 863 Program and the National Science Fund for Excellent Young Scholars, published 96 SCI papers, been granted 57 patents, and participated in formulating 4 industry standards. He has been selected for the National Hundred Thousand and Ten Thousand Talent Project and received honors such as National Young and Middle Aged Expert with Outstanding Contributions and the Hunan Provincial May Day Labor Medal. He also initiated the "Changsha Model" for integrated prevention and control of rare diseases, generating significant social benefits.

SPEAKERS - MAINSTAGE



Lianjie LIU

Managing Director, Investment Banking Management Committee, China Securities

Mr. Liu Lianjie holds a Master's degree from Tsinghua University PBC School of Finance and an EMBA from China Europe International Business School (CEIBS). He joined China Securities Co., Ltd in 2006 and has over 20 years of experience in investment banking. He currently oversees the Global Capital Markets business under the Investment Banking Management Committee. Mr. Liu founded and leads the investment banking team that focuses on the biopharmaceutical and healthcare sector, which ranks among the top tier in the industry.



Wei LIU

Co-Founder & CEO, BioMap

Former CEO of Baidu Ventures and Group VP of Baidu, Mr. Liu has led investments and incubation of more than 200 innovative companies in the AI sector over his approximately 20-year venture capital career.



Michael LU

Dean, School of Public Health, University of California Berkeley

Dr. Michael C. Lu, MD, MS, MPH is the Dean of the School of Public Health at the University of California, Berkeley. Prior to coming to Berkeley, Lu served as Director of the federal Maternal and Child Health Bureau. During his tenure, he transformed key federal programs in maternal and child health, and launched major initiatives to reduce maternal, infant, and child mortality across the nation. For his leadership, he was awarded the prestigious U.S. Department of Health and Human Services' Hubert H. Humphrey Service to America Award in 2013. Prior to his government service, Lu was a professor of obstetrics-gynecology and public health at UCLA, where his research focused on racial-ethnic disparities in birth outcomes from a life-course perspective. As a practicing obstetrician for nearly two decades, he attended more than 1000 births, and was voted one of the Best Doctors in America. Lu is a member of the National Academy of Medicine. Lu received his bachelor's degrees in political science and human biology from Stanford University, master's degrees in health and medical sciences and public health from UC Berkeley, medical degree from UC San Francisco, and residency training in obstetrics and gynecology from UC Irvine.

SPEAKERS - MAINSTAGE



Crystal QIN

Founder & CEO, LaNova Medicines

Dr. Crystal Qin, Founder & CEO of LaNova MedicinesDr. Crystal Qin graduated from Shanghai Jiaotong University School of Medicine and obtained her PhD in Cancer Immunology in Belgium. She worked at Dr. L. Williems Institute in Belgium, Baylor College of Medicine in US, Chinese Academy of Sciences, GSK and SciClone Pharmaceuticals. She founded LaNova Medicines in 2019, a clinical stage biotech company focus on discovering novel biologic therapies in the fields of ADC and Immuno- Oncology, and currently serve as CEO of the company.



Feng REN

Co-CEO & CSO of Insilico Medicine

Dr. Feng Ren is the Co-CEO and CSO of Insilico Medicine, He earned his Ph.D. in Chemistry from Harvard University in 2007 and embarked on a distinguished career in biopharmaceutical innovation. He began at GlaxoSmithKline (GSK), where he spent a decade advancing drug discovery and development. In 2018, Dr. Ren joined Medicilon, a global contract research organization (CRO), as Senior Vice President and Head of Drug R&D Services, overseeing operations in both the Chemistry and Biology Departments with a team of over 600 chemists and biologists. Dr. Ren transitioned to Insilico Medicine in 2021 as Chief Scientific Officer (CSO), where he assumed responsibility for advancing internal pipelines and fostering external collaborations in drug discovery and development. His exceptional contributions and leadership were recognized with a promotion to Co-CEO in June 2022. Under his guidance, Insilico R&D team successfully developed 22 pre-clinical candidate compounds, with 10 molecules received IND clearance in therapeutic areas including fibrosis, inflammation, oncology, and anti-viral treatments. Dr. Ren also played a pivotal role in driving four out-licensing agreements for proprietary pipelines as well as forging numerous strategic R&D collaborations, collectively valued at more than $3.5 billion. Dr. Ren publishes over 70 peer-reviewed papers and over 100 patents.



Richard STONE

Senior International Correspondent, Science Magazine (AAAS)

Richard Stone is the senior international correspondent for the weekly journal Science. He also serves as Special Advisor, Science Diplomacy and Engagement, for the international Human Frontier Science Program organization in Strasbourg, France. His overseas experience includes stints as a Fulbright Scholar at Rostov State University in Rostov-on-Don, Russia in 1995-96 and at Kazakh National University in Almaty, Kazakhstan in 2004 - 05. Stone opened the Beijing bureau of Science in 2007 and spent 5 years in China. Among many highlights, he and Bruce Alberts, President Emeritus of the U.S. National Academy of Sciences, interviewed former Premier Wen Jiabao for Science in 2008.

SPEAKERS - MAINSTAGE



Kenneth TSANG

Regional Chief Executive Officer, IHH Healthcare North Asia

Dr. Joseph Tsang Kit- lim leads the business development of IHH Healthcare in North- Asia, covering general hospitals, a network of primary- care, specialist and surgical clinics, day- care medical centres in Hong Kong and a large flagship medical centre in Shanghai. He drives operational excellence and clinical quality for the Group across the region. His strategic leadership has been instrumental in delivering sustainable, long- term growth for IHH Healthcare's integrated healthcare business in Mainland China. Concurrently, Dr. Tsang serves as Chief Executive Officer of Gleneagles Hospital Hong Kong. He oversees the hospital's Hong Kong operations, and spearheads the development of service portfolios under Gleneagles Healthcare Network, Gleneagles Day- Centres and Parkway- Lab. He also heads the Gleneagles Hospital Hong Kong Clinical Trials Centre, contributing to medical innovation and advancement in Hong Kong and its neighbouring regions. Prior to joining IHH Healthcare, Dr. Tsang worked for over 25 years with the Hospital Authority of Hong Kong. He began his career as a practicing physician in the Department of Medicine at Queen Elizabeth Hospital, before transitioning into full- time healthcare administration at the Hospital Authority Head- Office. He held senior management responsibilities spanning patient safety, strategy and service planning, infection control and cluster- wide services. Dr. Tsang is a Fellow of the Hong Kong Academy of Medicine (Community Medicine), Fellow of the Hong Kong College of Community Medicine and Fellow of the Royal Australasian College of Medical Administrators. He is also an Honorary Clinical Associate Professor at the School of Public Health, Li Ka Shing Faculty of Medicine, The University of Hong Kong.



Jian Kang ZHU

President, Macau University of Science and Technology

Professor Jian-Kang Zhu is a world-renowned molecular geneticist and plant biologist, elected to the U.S. National Academy of Sciences, and currently President and Chair Professor at Macau University of Science and Technology. He earned his Ph.D. in Plant Physiology from Purdue in 1993. He has held professorships at Arizona, UC Riverside (where he directed the Institute for Integrative Genome Biology and held the Jane Johnson Chair), KAUST as Center Director, and Purdue as Distinguished Professor. He also served as Director of the Shanghai Center for Plant Stress Biology, CAS, from 2012–2021, and since 2022 as Director of the Institute for Advanced Biotechnology at Southern University of Science and Technology.

His research spans plant stress biology, epigenetics, and gene-editing technology. He pioneered the SOS pathway for salt tolerance, uncovered mechanisms of drought and cold stress, and developed highly efficient gene-editing tools used in crop breeding and cell/gene therapy. He also discovered DNA demethylation, enabling methylation editing for disease treatment and anti-aging.

With hundreds of publications, his work has garnered over 185,000 citations and an h-index of 204. He is a perennial Highly Cited Researcher and serves on editorial boards of leading journals, exerting global influence in stress biology, epigenetics, and biotechnology.

SPEAKERS - THEATER 1



Karen AKINSANYA

President, Head of Therapeutics R&D and Chief Strategy Officer, Partnerships at Schrödinger, Inc.

Karen Akinsanya, Ph.D.
President, Head of Therapeutics R&D and Chief Strategy Officer, Partnerships at Schrödinger, Inc.

Karen leads the company's therapeutics research and development organization. Karen is also responsible for therapeutics business development, ventures strategy, outreach, and growth initiatives that leverage synergies between the company's therapeutics and software businesses. She has more than 30 years of experience spanning academia, pharmaceutical R&D, and business development. Karen joined Merck Research Labs in 2005 and held positions of increasing responsibility in clinical pharmacology, development team leadership in early clinical development, as a therapeutic area head, and search and evaluation lead in business development. Karen received her Ph.D. from the Royal Postgraduate Medical School at Imperial College in London in endocrine physiology. After post-doctoral training at Imperial and the Ludwig Institute for Cancer Research (UCL), Karen held several R&D roles at Ferring Pharmaceuticals in the UK and US.



Michelle CHEN

CEO, Form Bio

Michelle Chen, Ph.D., is President, CEO, and Board Member of Form Bio, the first spin-off from Colossal Biosciences, where she leads the company's efforts to apply AI to genetic medicine design, scale up, and genome engineering applications.
Previously, she served as Chief Business Officer at Insilico Medicine, where she built and led strategic partnerships that translated AI-driven drug discovery into major platform and pipeline deals with biopharma.
Michelle brings cross-functional leadership experience spanning R&D, product, operations, and commercial strategy. She has held leadership roles at WuXi Biologics, BioMarin, Roche, Merck, and Agilent Technologies, and has advised venture capital firms and biotech startups. Over her career, she has led company formations, executed numerous M&A, licensing, collaboration transactions, and worked with investors across the U.S., Europe, and Asia.
Michelle earned her Ph.D. in Biochemistry from the University of Washington, completed postdoctoral research at UC San Francisco, and trained in bioinformatics at Stanford University.



Yann GASTON-MATHÉ

IKTOS CO-FOUNDER & CEO

Yann is a seasoned R&D professional, strategy consultant and biotech entrepreneur with 20+ years of experience in pharma (Servier, Ipsen), molecular diagnostics (IntegraGen) and strategy consulting (Capgemini Consulting, BearingPoint, Cepton). He is also a skilled data scientist with several patents and publications in the field of biostatistics and biomarkers discovery and validation. Yann is Co-founder and CEO of Iktos, a global leader in artificial intelligence and robotics for drug discovery. Its generative AI technology designs molecules in silico, optimized to meet all key success criteria of a discovery project. Through software and strategic collaborations with pharmaceutical companies, Iktos combines AI-driven molecular design with robotic synthesis and biological testing, to accelerate drug discovery.

SPEAKERS - THEATER 1



Fei GU

Head of genomics lab, Alibaba DAMO Academy

With 15 years of dedicated experience in bioinformatics and computational biology, Dr. Gu lead the AI for Life Science research at Alibaba DAMO Academy, focusing on intelligent modeling of DNA, RNA, and multi-omics data, as well as the application of AI to cell perturbation analysis and cell therapy.
Dr. Gu have authored more than 40 peer-reviewed publications, accumulating over 3,000 citations.



Allen GUO

Founder and CEO of Shuimu Future; Founding CEO of Baihe.com (Heyou.com); Founding Partner of 2048 Capital

Allen Chunlong Guo holds a Bachelor's degree in Engineering Physics from Tsinghua University and pursued doctoral studies at UC Berkeley EECS as Hitachi Fellow and Haas School of Business as Mayfield Fellow. Prior to founding Shuimu with Prof. Hongwei Wang, he built a distinguished career as a serial entrepreneur and technology investor. He co-founded Baihe.com, one of China's leading online matchmaking platforms, and subsequently founded 2048 Capital. He also worked at Accenture Technology Labs in Palo Alto, where he led research in wireless sensor networks and data mining.Drawing on his cross-disciplinary experience spanning nuclear physics, semiconductor, internet technology, and life sciences, Mr. Guo has guided Shuimu Biosciences through three core strategic pillars: cryo-EM structural determination services, AI driven TOTEM 300kv and 400kv CyroEM and SMART platform development, and building future AI4S data infrustructure. The company recently achieved a world-first high-resolution cryo-EM structure of the obesity drug target GPR75, demonstrating the platform's capability to accelerate small-molecule drug discovery and to shape the next-generation structural data foundation to power AI models in life sciences.



Christine HUANG

Founder & CEO, Quantum Life Limited; Managing Director, HK Longevity Medical Centre

Dr.Christine Yuan HUANG is the Founder and CEO of QuantumLife. Dr. Huang is also the Technology Transfer Director of Hong Kong Quantum AI Lab, and Managing Director of HK Longevity Medical Centre, focusing on providing end-to-end precision longevity medical technology solutions to improve health-span. Dr. Huang has vast experience in the biotechnology and longevity field and shares her professional insights as a Venture Partner of LongeVC. Dr. Huang was selected as one of Forbes China 2020 “30 Under 30 (Healthcare and Science)” for her development of cancer liquid biopsy technology, and she was awarded as the “Pioneer of Genome Technology ”in 2025. In 2022, she was elected as a Fellow of the Royal Society of Medicine in the UK, and in 2024, she became a Fellow of the European Society of Preventive Medicine. She is also a member of the Advisory Board of Wing Wah Charity Foundation Hong Kong, and a columnist of Forbes China. Dr. Huang was elected as a Fellow of Guangzhou Youth Federation in November 2022. Dr. Huang obtained Doctor of Medicine from the Southern Medical University and Master of Public Health from the University of Hong Kong, Li Ka Shing Faculty of Medicine. Now she is also an Honorary Senior Research Associate at the University of Hong Kong.

SPEAKERS - THEATER 1



Yang HUANG

Head of Greater China Healthcare Research, JPMorgan

Yang Huang, PhD, is the Head of JPMorgan's China Healthcare Equity Research team. During his career, his team has been Aisa Institutional Investor Runner-up. Before joining JPMorgan, Yang was the lead China Healthcare analyst at Bank of America Merrill Lynch and Credit Suisse. He started working in equity research in the US in 2014, and later at Citi focused on US Biotech stocks. His PhD thesis and postdoctoral research at the NIH studied computational biology. Yang is also a CFA chartholder.



Dong LI

Professor, School of Life Sciences, Tsinghua University

Dr. Dong Li is Xinghua chair professor and New Cornerstone investigator at school of life science, Tsinghua University. He received B.E. in optical engineering at Zhejiang University in 2006, and Ph.D. in electronic and computer engineering at Hong Kong University of Science and Technology in 2011. Then he spent four years for postdoctoral research of developing super-resolution microscopy at Janelia Research Campus, Howard Hughes Medical Institute. Dr. Dong Li's group focuses on developing super-resolution microscopy (SIM) for high-speed and long-term live imaging, and exploring their applications in biological research. Dong Li's research synergizes the developments in both microscope hardware and algorithmic software to push the boundary of super-resolution live-cell imaging.



Edward LI

Principal Architect, Life Sciences Google Cloud APAC

Edward Li is the Principal Life Science Architect at Google Cloud APAC, where he leverages cutting-edge technology to design and scale innovative AI solutions for the life sciences sector. His career spans over a decade of leadership across top-tier pharmaceutical companies, global research institutes, and clinical hospitals, including pivotal roles at BeOne Medicine, Global Health Drug Discovery Institute (GHDDI) and the Chinese PLA General Hospital. Edward specializes in the intersection of AI-driven drug discovery, clinical informatics, and wearable technology. A recognized expert in his field, Edward is a member of the China 50 Forum on Health and Medical Big Data. Edward graduated from Washington University in St. Louis. His research is widely published in prestigious journals and conferences, including JCIM and ICLR.

SPEAKERS - THEATER 1



Wei LIU

Co-Founder & CEO, BioMap

Former CEO of Baidu Ventures and Group VP of Baidu, Mr. Liu has led investments and incubation of more than 200 innovative companies in the AI sector over his approximately 20-year venture capital career.



Defang OUYANG

Associate Professor of Faculty of Medicine, University of Macau

Prof. Ouyang is the pioneer and internationally-recognized scientists in computational pharmaceutics and AI drug delivery area. Since 2011, he has pioneered the integration of multi-scale modeling, artificial intelligence and big data techniques in the field of drug delivery – "computational pharmaceutics". He has published 2 books, 5 book chapters and over 150 refereed SCI journal papers, along with more than 150 invited talks. He held over 10 approved patents, which had been used in medicinal products. He edited the first book in this research domain <Exploring Computational Pharmaceutics – AI and Modeling in Pharma 4.0> (Wiley, 1st Edition in 2015 & 2nd edition in 2024). He has developed the crucial "Rule of 5" for effective AI drug delivery models and successfully built the first global artificial intelligence (AI)-based formulation platform "FormulationAI"D.
He serves as the associate editor of <Drug Delivery and Translational Research>, the editorial board or scientific advisor of <Advanced Drug Delivery Review>, <Asian Journal of Pharmaceutical Sciences>, <Pharmaceutical Research>, and <Journal of Pharmaceutical Sciences>. He successfully trained 8 PhD and over 30 master students. He has been recognized as "World's Top 2% Scientists" from 2020 to 2025.



Feng REN

Co-CEO and CSO of Insilico Medicine

Dr. Feng Ren is the Co-CEO and CSO of Insilico Medicine, He earned his Ph.D. in Chemistry from Harvard University in 2007 and embarked on a distinguished career in biopharmaceutical innovation.
He began at GlaxoSmithKline (GSK), where he spent a decade advancing drug discovery and development. In 2018, Dr. Ren joined Medicilon, a global contract research organization (CRO), as Senior Vice President and Head of Drug R&D Services, overseeing operations in both the Chemistry and Biology Departments with a team of over 600 chemists and biologists.
Dr. Ren transitioned to Insilico Medicine in 2021 as Chief Scientific Officer (CSO), where he assumed responsibility for advancing internal pipelines and fostering external collaborations in drug discovery and development. His exceptional contributions and leadership were recognized with a promotion to Co-CEO in June 2022. Under his guidance, Insilico R&D team successfully developed 22 pre-clinical candidate compounds, with 10 molecules received IND clearance in therapeutic areas including fibrosis, inflammation, oncology, and anti-viral treatments. Dr. Ren also played a pivotal role in driving four out-licensing agreements for proprietary pipelines as well as forging numerous strategic R&D collaborations, collectively valued at more than $3.5 billion. Dr. Ren publishes over 70 peer-reviewed papers and over 100 patents.

SPEAKERS - THEATER 1



Stanley SHEN

Co-Head of Pharmaceuticals and Biotechnology Research, China Securities

Stanley Shen is Co-Head of Pharmaceuticals and Biotechnology Equity Research at China Securities, with a focus on innovative and generic pharmaceuticals. He has more than 10 years of combined industry and equity research experience, having previously worked at Hengrui Pharmaceuticals and AstraZeneca, where he received the President's Award. He holds a master's degree from The Chinese University of Hong Kong.



Yuanyuan SUN

Founder, Chairman, Zhihe Yuanchuang AI Pharma

Graduated from Nanjing University with 17 years of experience in omics industry and traditional drug screening platform development, providing genomic/proteomic research products and technical services for domestic universities, government agencies, hospitals, and third-party research institutions. In 2015, assembled a team to pioneer AI applications in novel target discovery and lead compound identification, subsequently developing a proprietary AI drug discovery platform based on logical algorithms, currently advancing drug pipelines targeting disease areas with unmet clinical needs including multiple sclerosis (MS), inflammatory bowel disease (IBD), Parkinson's disease (PD), etc.



Mark TANG

Founder, 111 Longevity LLC; Founder, Phagionics Inc.; Founding Partner, Good Health Capital, New York

Mark Tang is the Managing Director of Good Health Capital, a healthcare PEVC firm with offices in New York and Shanghai, and Chairperson of World Biotech Capital LLC, a cross-border venture capital, M&A, licensing, and IPO advisory firm. Mark is also a co-founder of 111 Longevity LLC and Phagionics Inc. Originally from mainland China and educated in the US, Mark is a veteran Chinese biotech investor with over two decades of experience in the field of biotechnology as an entrepreneur, educator, advisor, and investor. He served as the biotech director at Rutgers Business School and as a lecturer at Rockefeller University. Mark has worked at investment banks, including Morgan Stanley Dean Witter and UBS PaineWebber. He is the author of "The Essential Biotech Investment Handbook," which is published in both English and Chinese. Mark has co-founded three tech startups that have achieved successful exits. He holds degrees from NYU Stern School of Business and the Harvard T.H. Chan School of Public Health.

SPEAKERS - THEATER 1



Yuguang WANG

CEO, Shanghai Toursynbio SAI Technology Co., Ltd.

Wang Yuguang, Associate Professor at Monash University and UNSW, and Founder & CEO of Toursynbio. He obtained his Ph.D. in Mathematics from the University of New South Wales and previously served as a Research Scientist at the Max Planck Institute, Germany. His long-term research covers computational mathematics, large-language models, artificial intelligence and AI for Science. He has more than ten years of in-depth research experience at the interdisciplinary intersection of artificial intelligence, applied mathematics and computational biology. He has published over 100 academic papers in top-tier international conferences and journals including ICML, NeurIPS, ICLR, Nature Communications, Cell Reports Medicine, and has been awarded MegaRobo Engineer Award (Top Medal) in 2025.



Xinzhu WANG

Co-Founder of Potentiam Biosciences

Xinzhu Wang is a Co-Founder of Potentiam Biosciences, a drug discovery company developing novel therapeutics against targets identified through AI-powered platforms. She also serves as Secretary General of HKBIO, Hong Kong's biotechnology industry organization.



Chunyi WEN

Associate Professor, Department of Biomedical Engineering, The Hong Kong Polytechnic University

Dr. Chunyi WEN is an Associate Professor at The Hong Kong Polytechnic University (PolyU) with over 15 years of experience in clinical and basic osteoarthritis (OA) and skeletal ageing research. He serves on the Board of Directors for the Osteoarthritis Research Society International (OARSI). Since joining PolyU, Dr. WEN has secured substantial competitive external research funding as Principal Investigator (PI) from major bodies including RGC, HMRF, and ITF. He has published over 100 peer-reviewed articles in high-impact journals, such as Nature Microbiology, Nature Medicine, Nature Reviews Rheumatology, Annals of the Rheumatic Diseases, PNAS, and ACS Nano. Dr. WEN developed pioneering imaging and diagnostic approaches to evaluate OA progression in humans (Ultrasound Med Biol.) and animal models (ACS Nano, Prog Biophys Mol Biol.). His research contributions have earned international recognition, including the U.S. NAM Healthy Longevity Catalyst Award (2022), TechConnect Global Innovation Award (2020), Young Investigator Award of Endothelins (2013), AOSpine East Asia Research Grant Award (2013), and the Oldendorf Award (2011).

SPEAKERS - THEATER 2



Cynthia CAO

General Manager, Hua Medicine Technology (Hong Kong) Limited

Cynthia Cao, General Manager of Hua Medicine Technology (Hongkong) Ltd., VP of the Department of Corporate Operations and Great Bay Development in Hua Medicine. Boasting over a decade of professional experience in pharmaceutical operational management, Ms. Cao oversees the company's daily operational management and commercial advancement strategies. Joining Hua Medicine in 2012, she has led the operations team to support the full-cycle R&D and launch preparation of dorzagliatin, the company's first innovative drug candidate. During the project advancement, Ms. Cao coordinated cross-departmental resources and established a standardized operational management system to ensure efficient collaboration and seamless connection across research and development, manufacturing, regulatory registration and other core links. In preparation for the product launch, she took charge of key foundational work including supply chain system construction and market access layout, laying a solid groundwork for the commercialization of dorzagliatin after its approval. Focused on team collaboration and process optimization, Ms. Cao consistently delivers pragmatic and efficient work outcomes, effectively supporting the steady implementation of the company's overall development strategy.



Lot CHAN

Assistant Director (Preparatory Office for Centre of Medical Products Regulation), Department of Health, the Government of HKSAR

Mr Lot Chan studied pharmacy in UK and public health in Hong Kong. He has joined the Department of Health of the Government of Hong Kong Special Administrative Region for 30 years. For may years he has been involved in the approval of pharmaceutical products registration and clinical trials, import/export control of medicines, licensing and inspection of pharmaceutical traders, and enforcement of drug-related laws. During his service in the Department of Health, Mr Lot Chan has led the application for the accession to the Pharmaceutical Inspection Co-operation Scheme and the statutory regulation of advanced therapy products.

Currently, Mr Lot Chan is the Assistant Director of Health, responsible for the preparatory work of the establishment of the Centre for Medical Products Regulation (CMPR).



Juliana CHAN

Professor, Department of Medicine & Therapeutics, Faculty of Medicine, The Chinese University of Hong Kong (CUHK); Director, Hong Kong Institute of Diabetes and Obesity, CUHK; Head, Division of Clinical Pharmacology, Department of Medicine & Therapeutics, CUHK

Professor Juliana C.N. Chan is an internationally renowned clinician-scientist specializing in diabetes, endocrinology, and precision medicine. She is Professor of Medicine and Therapeutics at the Faculty of Medicine, The Chinese University of Hong Kong (CUHK), and Director of the Hong Kong Institute of Diabetes and Obesity. Professor Chan has led pioneering research in diabetes epidemiology, genetics, complications, and personalized care among Asian populations. She established the Hong Kong Diabetes Registry and founded the Joint Asia Diabetes Evaluation (JADE) Program, which has advanced diabetes care across Asia. She has authored more than 500 peer-reviewed publications and received numerous international honors, including the American Diabetes Association's Harold Rifkin Award and the Kelly West Award.

SPEAKERS - THEATER 2



Li CHEN

Founder and CEO of Hua Medicine

Dr. Li Chen, Founder, Chairman and Chief Executive Officer of Hua Medicine, former Chief Scientific Officer of Roche R&D Center (China) Co., Ltd., has over 30 years of experience in innovative drug R&D and industrialization. He founded Hua Medicine in 2010 and led the team to successfully develop dorzagliatin, a firstinclass glucokinase activator (GKA) first launched in China. He spearheaded its R&D, marketing authorization approval and commercialization, delivering an innovative therapeutic option for patients with T2D. Dr. Li Chen is the recipient of the C.C. Tan Life Science Industrialization Award, the First Shanghai Distinguished Talent Award, the FirstClass Prize of the Chinese Pharmaceutical Association Science and Technology Award, and the Special Prize of the Shanghai Pharmaceutical Science and Technology Award, among other honors.



Raymond Swee Boon CHUA

the Deputy Director-General of Health (Health Regulation) at Singapore's Ministry of Health (MoH) and the Chief Executive Officer of the Health Sciences Authority (HSA)

Raymond Chua Swee Boon is a public health trained physician and presently the Deputy Director-General of Health (Health Regulation) at Singapore's Ministry of Health (MoH) and the Chief Executive Officer of the Health Sciences Authority (HSA), overseeing the regulations of healthcare services, information and health products respectively. He is currently leading a regulatory transformation review to synergize regulatory operations across healthcare services, information, and products. With over 25 years of experience in both public healthcare and the private pharmaceutical sector, he has driven transformative regulatory initiatives, including the enactment of the Human Biomedical Research Act and the Healthcare Services Act, which modernized Singapore's healthcare regulatory framework. He pioneered regulatory sandboxes for innovations such as telemedicine, mobile inpatient care-at-home, and clinical genomic services, and introduced governance measures for emerging technologies like precision medicine and AI. During the COVID-19 pandemic, he served as Deputy Commander of the Medical Operations Taskforce, playing a key role in clinical operations, testing infrastructure, and enforcement of control orders. Raymond holds adjunct positions at the NUS Saw Swee Hock School of Public Health and Duke-NUS Centre of Regulatory Excellence, and academic credentials including a Bachelor of Medicine and Surgery from NUS, an MSc in Public Health from the London School of Hygiene and Tropical Medicine, and an MBA from the University of Nottingham.



Qing DONG

VP, Group Pharmaceutical Commercialization of Hua Medicine

Mr. Qing Dong serves as VP, P Group Pharmaceutical Commercialization in Hua Medicine. Mr. Qing Dong brings over nearly 30 years' rich hands-on experience in the commercial management and business development in large multi-national pharmaceutical companies. Prior to joining Hua Medicine, he was National Commercial Sr. Director at Gilead Sciences. He served as National Commercial Director both with Consumer Health BU, Bayer Healthcare Company Ltd. and Sino-American Shanghai Squibb Pharmaceuticals Ltd. He held the positions of National Market Access Manager at Sandoz (China) Pharmaceutical Company and National Pricing Manager at Eli Lilly Asia Inc.

SPEAKERS - THEATER 2



Zhiyi HE

Chief Expert, Institute for Global Industry, Tsinghua University; Professor, Peking University; Dean, Xinrui Academy; Executive Editor-in-Chief, Peking University Business Review

Prof. He Zhiyi is a renowned Chinese scholar in strategic management and industrial studies. He serves as Chief Expert of the Institute for Global Industry at Tsinghua University, Professor at Peking University, Dean of Xinrui Academy, and Executive Editor-in-Chief of Peking University Business Review. His research interests include strategic management, marketing, corporate culture, social responsibility, and global industrial competitiveness. He is widely recognized for establishing and promoting Chinese management case studies and for leading influential research on global industrial patterns and corporate development.



Charles HU

Founder & CEO, Ryoden Medical Holdings & Incando Therapeutics Group

Dr Hu is a translational biomedical engineer with a strong background in business development. His passion is in building a vibrant biotech ecosystem through bridging stakeholders across relevant sectors. He heads Ryoden Medical where he oversees healthcare and biotech venture investments for his family office. He co-founded Incando Therapeutics and Cere Ventures to bring brain- and healthy aging-related developments to the market. Dr Hu currently serves as Chair of Biomedical Engineering Departmental Advisory Council and Adjunct Professor in Biomedical Sciences at the City University of Hong Kong, as well as board member or steering committee member to several charities, think-tanks, universities and government committees in Hong Kong, such as the Hong Kong Biotechnology Organization, the Asian Fund for Cancer Research Limited, the Hong Kong Professionals and Senior Executives Association, the Hong Kong Trade & Development Council, and the Hong Kong Innovation & Technology Commission. Dr Hu received his PhD in Tissue Engineering from Johns Hopkins University, BS in Bioengineering from the University of California, Berkeley, and has been awarded the Hong Kong-Zhuhai-Macau Greater Bay Area Most Talented Young Entrepreneur Award with the Best Technology Innovation Distinction in 2023.



Taruna IKRAR

Professor, Chairperson of Indonesian FDA

Prof. Taruna Ikrar, M.Biomed., Ph.D. is a prominent Indonesian physician-scientist and the current Chairperson of the Indonesian Food and Drug Authority (Badan Pengawas Obat dan Makanan - BPOM).Inaugurated into office on August 19, 2024, he brings an extensive background in pharmacology, cardiovascular research, and advanced neuroscience to Indonesia's primary food and drug regulatory agency.

SPEAKERS - THEATER 2



Nisa LEUNG

AulisCapital Managing Partner

Nisa Leung is founding Managing Partner at Aulis Capital. She served as Managing Partner at Qiming Venture Partners, where she founded and led the firm's healthcare practice since 2006.

Nisa has been consistently recognized as one of the most influential investors in the industry. She has been featured on the Forbes Midas List for seven consecutive years (2019–2025). In 2024, she was honored as one of Fortune Asia's Most Powerful Women (MPW Asia).

She has invested in and served as a board director for numerous leading healthcare and life sciences companies, including Zai Lab (NASDAQ:ZLAB; HKSE:9688), Gan & Lee (SSE:603087), Cansino Biologics (SSE:688185; HKSE:6185), Insilico Medicine (HKSE:3696), SinoCellTech (SSE:688520), Sino Biological (SZSE:301047), Schrödinger (NASDAQ:SDGR) , Structure Therapeutics (NASDAQ:GPCR), Berry Genomics (SZSE:000710), CITIC Pharma (acquired by Shanghai Pharmaceutical HKSE: 2607), Apollomics (NASDAQ:APLM), Crown Bioscience (acquired by JSR Life Sciences), Caidya, Belief BioMed, Alamar Biosciences (NASDAQ: ALMR), EpiBiologics, Aeira, Pluslife, Horizone, SinoUnited Health, Aeonmed, Novast, Nurotron, Origene Technologies (acquired by VCAN Bio SSE:600645), MedX, Goodwill (SSE:688246), Jacobio (HKSE:1167), Sesame Therapeutics, Hope Medicine, Chain Medical Labs, Sinotau, Zencore Biologics, Cognitact, Silicon Gene, Vision Pro, Thorough Future among many other groundbreaking companies in the life sciences and healthcare sectors globally.

Nisa earned her MBA from Stanford Graduate School of Business and a BS from Cornell University. She is visiting lecturer at Harvard Law School, a trustee of the Hotchkiss School, serves as a member of the Hong Kong University Court, Cornell University International Advisory Council and Stanford University International Advisory Council.



Zili LI

DIA Board Member

Dr. Zili Li is a U.S.-licensed physician and internationally recognized physician executive with more than 30 years of leadership experience in pharmaceutical regulation, drug development, and global health. He currently serves as Special Advisor to the Department of Health of the Hong Kong Special Administrative Region, supporting the establishment of the Centre for Medical Products Regulation (CMPR). He is also an Advisor to the Health Sciences Authority (HSA) of Singapore and a Fellow and Global Board Member of the Drug Information Association (DIA).

Dr. Li previously served twice at the U.S. Food and Drug Administration (FDA) and held global leadership positions at Merck & Co. and Johnson & Johnson. Throughout his career, he has been dedicated to advancing regulatory science, strengthening international regulatory collaboration, and leading the global development and registration of innovative medicines.

Dr. Li received his M.D. from Peking Union Medical College and completed his residency training at Johns Hopkins University. He also holds a Master of Public Health degree.

SPEAKERS - THEATER 2



Xiaoying LI

Professor and Chief Physician, Department of Endocrinology, Zhongshan Hospital, Fudan University, China; Director, Department of Endocrinology, Zhongshan Hospital, Fudan University

Professor Xiaoying Li is a leading endocrinologist and diabetes specialist in China. He serves as Director of the Department of Endocrinology and Professor at Zhongshan Hospital, Fudan University. His research focuses on the pathogenesis and clinical management of metabolic diseases, particularly obesity, nonalcoholic fatty liver disease (NAFLD), and type 2 diabetes. Professor Li has led numerous national research programs and made significant contributions to understanding the liver-related mechanisms of type 2 diabetes and metabolic dysfunction. He has published more than 130 papers in leading international journals, including Nature Medicine, Cell Metabolism, JAMA Internal Medicine, and Diabetes Care. In recognition of his scientific achievements, he has received several prestigious awards, including the Chinese Medical Science and Technology Award and the Outstanding Scientific Contribution Award of the Chinese Diabetes Society.



Obaidullah MALIK

Chief Executive Officer of Drug Regulatory Authority of Pakistan

Dr. Obaidullah is the Chief Executive Officer of the Drug Regulatory Authority of Pakistan (DRAP), Pakistan's national regulatory authority for therapeutic goods, including medicines and medical devices. With over 25 years of professional experience, he has played a leading role in strengthening and modernizing Pakistan's regulatory framework and advancing science-based, internationally harmonized regulation. A pharmacist by profession, Dr. Obaidullah holds a Ph.D. in Pharmaceutical Sciences and a Master of Public Health. His leadership experience spans Quality Management Systems, Market Authorization, Clinical Trials, Pharmacovigilance, Compliance and Enforcement, Post-Market Surveillance, and regulatory harmonization for medicines and medical devices. Dr. Obaidullah has extensive international regulatory experience through his work with the World Health Organization as a Consultant and Temporary Advisor. He has contributed to benchmarking national medicines regulatory authorities under the WHO Global Benchmarking Tool, including ML3 and ML4 assessments, and to international capacity-building and development of WHO regulatory guidance. Currently he holds the position of Vice Chair, Technical Advisory Group, WHO for the term 2026-2029. As CEO of DRAP since March 2025, he is leading institutional reforms, digital transformation, international partnerships, and regulatory modernization aimed at facilitating access to quality-assured health products and improving the ease of doing business. His work reflects a strong commitment to regulatory innovation, international convergence, and creating an enabling environment for pharmaceutical and biotechnology investment, technology transfer, and responsible innovation. In recognition of his reform leadership, he received Pakistan's Reform Champion Award in 2025.



Mohd Nasrul MOHAMAD NOOR

Senior Principal Assistant Director, National Pharmaceutical Regulatory Agency (NPRA), Ministry of Health Malaysia

Mr. Mohd Nasrul Mohamad Noor graduated with a B.Pharm from National University of Malaysia in 2002 and obtained a Master of Science in Pharmaceutical Analysis in 2024.

He is an experienced pharmaceutical regulator officer with more than 20 years of service at the National Pharmaceutical Regulatory Agency (NPRA), Ministry of Health Malaysia. He began his career as a pharmacist at NPRA in 2003 and served as Head of the Good Manufacturing Practice (GMP) section from 2021 to 2023. Prior to his current position as Head of the Generic Section, he was Head of the Surveillance and Complaints Section. Besides NPRA, he worked at the Pharmacy Practice and Development Division, Ministry of Health Malaysia, from 2008 to 2012.

As an experienced GMP Lead Inspector, he has audited local and overseas pharmaceutical manufacturing premises. His other work experiences include post-market surveillance, specifically risk-based product sampling and testing; handling cosmetic advertisement issues; and reporting medicine shortages and product discontinuations in Malaysia.

SPEAKERS - THEATER 2



Ruilin SONG

Chief Expert of China Pharmaceutical Innovation and Research Development Association (PhIRDA)

Mr. Song Ruilin, Chief Expert of China Pharmaceutical Innovation and Research Development Association (PhIRDA), Expert of Talent Pool for State Affairs of Chinese People's Political Consultative Conference (CPPCC), Advisor on Participation in and Deliberation of State Affairs for the Central Committee of Chinese Peasants and Workers Democratic Party. He is also L.L.B. of China University of Political Science and Law, EMBA of China Europe International Business School, Doctor of Social and Administrative Pharmacy of China Pharmaceutical University and Visiting Scholar of the University of Sydney. Mr. Song had served in the Legislative Affairs Office at State Council of China for a long time, engaging in health and drug policy, legal studies and in charge of law making and reviewing in the areas of pharmaceutical and healthcare industry. In recent years, he mainly engages in the research on China's pharmaceutical innovation policy.



Wenying YANG

National Distinguished Physician; Former Chair, Chinese Diabetes Society (CDS), Chinese Medical Association; Vice President, Asian Association for the Study of Diabetes (AASD)

Professor Wenying Yang, Chief Physician, doctoral and postdoctoral supervisor, is a nationally-renowned expert in endocrinology and diabetology and recipient of the National Distinguished Physician honor. She previously served as Director of the Department of General Internal Medicine and Director of the Center for Endocrinology and Metabolic Diseases at China-Japan Friendship Hospital, as well as Chair and Honorary Chair of the Chinese Diabetes Society, Chinese Medical Association. She was the founding Editor-in-Chief of the Chinese Journal of Diabetes and currently serves as its Honorary Editor-in-Chief. She holds concurrent positions as Vice-President of the Asian Association for the Study of Diabetes (AASD) and consultant for central healthcare services.

Devoted to diabetes epidemiology, metabolic syndrome and diabetes prevention-and-treatment research, she has led and participated in multiple key national research projects including national diabetes epidemiological surveys, providing critical scientific evidence for China's diabetes preventionandcontrol strategies. She has published over 400 academic papers, many in top-tier international journals such as New England Journal of Medicine, The Lancet Diabetes & Endocrinology and Diabetes Care. Her accolades include the First-Class Beijing Science and Technology Progress Award, Second-Class Chinese Medical Science and Technology Award, and the inaugural AASD Diabetes Epidemiology Award. She was listed among the World's Top 2% Scientists (2023-2025) for both lifetime and annual scientific impact, and received the Special Tribute Award of National Distinguished Physician in 2025.



Michael YIM

Chief Pharmacist, Drug Office, Department of Health

Mr YIM is current the Chief Pharmacist of the Drug Office, Department of Health overseeing a broad spectrum of drug regulatory activities including drug evaluation, pharmacovigilance as well as drug import and export control. He serves the Government for over 15 years and in particular he has been working in the field of drug registration for over 10 years. Mr YIM has also previously been seconded to the Health Bureau to support the early stage development of the GBAICTI that promote clinical trial development.

SPEAKERS - THEATER 2



Jinhua ZHANG

Founder, Chairwoman, and CEO, IASO Biotechnology

Ms. Jinhua Zhang has over 20 years of experience in securities market and corporate management. Prior to founding IASO Bio, she worked in investment banks and leading securities law firms, where she led overseas and domestic listing and M&A restructuring projects for many Chinese companies. She also previously invested as an angel investor in cell therapy startups and served as director.

Drawing on her extensive background in IPOs, mergers and acquisitions and investments in the biopharmaceutical field, Ms. Zhang founded IASO Bio in March 2017 with the vision of "focusing on innovative biotherapies to bring hope of cure to patients". Under her leadership, IASO Bio has grown into a leader in the cell therapy sector, with end-to-end capabilities across discovery, development, manufacturing and commercialization. The company successfully launched its blockbuster CAR-T product, Fucaso in 2023.

Ms. Zhang obtained her bachelor's degree in laws, and master's degree in laws, both majoring in economic law, from Dongbei University of Finance and Economics.
Accolades
· Selected for the 2024 China's New Drug Pioneer Award 20 Years 20 People
· Selected for the 2024 Fortune China's Most Powerful Women in Business Future List



Dalong ZHU

Professor of Endocrinology; Director, Endocrine and Metabolic Disease Medical Center, Nanjing Drum Tower Hospital, the Affiliated Hospital of Nanjing University Medical School; Former President, Chinese Diabetes Society (CDS), Chinese Medical Association.

Dalong Zhu, MD, PhD, is Professor of Endocrinology and Director of the Endocrine and Metabolic Disease Medical Center at Nanjing Drum Tower Hospital, the Affiliated Hospital of Nanjing University Medical School. He is a leading expert in diabetes, obesity, and metabolic diseases and previously served as President of the Chinese Diabetes Society. His research focuses on the pathogenesis, prevention, and treatment of diabetes and related metabolic disorders. Prof. Zhu has led numerous national research programs and published extensively in leading international journals, including Nature Medicine, Lancet Diabetes & Endocrinology, Diabetes Care, and Diabetology. He has played a key role in the development and clinical evaluation of innovative diabetes therapies in China.

SPEAKERS - THEATER 3



Helen CHEN

Global Sector Co-Head for Healthcare and Greater China Managing Partner, L.E.K. Consulting

Helen Chen is Global Sector Co-Head for Healthcare and a Greater China Managing Partner of L.E.K. Consulting based in Shanghai. Helen has over 30 years of consulting and industry experience in the U.S. and Asia markets and has lived in China since 2000. She helps companies expand their presence in China and Asia, and leverages Asia's innovation to improve their global businesses. Helen was named one of Consulting magazine's Global Leaders in Consulting in 2019. Prior to joining L.E.K., Helen was an associate director of finance at Genentech (now Roche) and a sales planner at Abbott Laboratories (now Abbvie). Helen has an honors B.A. degree in Applied Mathematics from Harvard University.



Johan H. FABER

CEO & Co-Founder, Cymab ApS & Cymab HK limited

Johan H. Faber, PhD, is CEO and Co-founder of Cymab, a Copenhagen-based biotech developing first-in-class multispecific antibodies for immuno-oncology, with lead program CYM-001 targeting cold tumors such as hepatocellular carcinoma. Johan is a serial biotech builder with a background in antibody development and protein R&D, including at Novo Nordisk. In 2018, he founded Hemab Therapeutics, Inc., a Nasdaq-listed, clinical-stage biotech focused on rare bleeding disorders, where he served as founding CEO and later CTO until 2023. He founded Cymab shortly after, building an experienced team and an international network of scientific advisors spanning Copenhagen, Hong Kong, Seattle, Palo Alto, Munich, Basel and Grenoble. Cymab's lead asset, CYM-001, is a first-in-class trispecific antibody built on the company's proprietary Targeted Immune Stimulation (TIMS™) platform, combining tumor-localized IFNγ delivery with dual checkpoint blockade to reprogram immunologically cold tumors. Johan holds a PhD from Julius Maximilian University of Würzburg, Germany, and is focused on advancing CYM-001 toward Phase 1 clinical development through an Asia-first strategy and co-development partnerships with investors and pharmaceutical companies.niversity.



Sherman K.W. FUNG

Co-Founder & CEO, North Edge Ltd.

Dr. Sherman K.W. Fung, DPhil (Oxford), FRSM, FRSC, CChem, CSci, is Co-Founder and CEO of North Edge Ltd. He is a biotech strategist and commercial scientist with more than 30 years of international experience in biomedical R&D, life science business development, regulatory affairs and healthcare innovation. Dr. Fung received his DPhil from the University of Oxford and his First Class Honours BSc in Chemistry from Imperial College London. He previously served as CEO of Talent Rise Corporation, Director of BioSciences and General Manager of Chemical Testing at SGS Hong Kong, COO of the Institute of Chinese Medicine at The Chinese University of Hong Kong, and CEO and Chief Product Developer of REGENE. Dr. Fung is also a recognised science communicator and life science content creator, active on YouTube,WeChat Video Channels and other major digital platforms, with more than million followers and over 50 million content views across platforms.

SPEAKERS - THEATER 3



Thomas FUNG

Assistant Professor of Instruction, Temple University's Fox School of Business

Tom Fung is Assistant Professor of Instruction and Academic Director of the M.S. in Supply Chain Management at Temple University's Fox School of Business. Prior to academia, he spent 30 years with The Campbell's Company in engineering, manufacturing, strategic planning, and operations, including serving as Director of Operations for its Foodservice Division with end-to-end supply chain responsibility. Tom holds undergraduate degrees in Chemical Engineering and Chemistry from Rensselaer Polytechnic Institute, an MBA and an M.S. in eBusiness from Temple University's Fox School of Business, and an M.S. in Organizational Dynamics from the University of Pennsylvania. Bringing together science, business, technology, organizational leadership, and global supply chain experience, Tom is particularly interested in how innovation moves from discovery to commercialization and scale. His extensive engagement across Asia has also shaped his interest in cross-border partnerships and the role of AI and digital technologies in building globally connected innovation ecosystems.



Simon HUA

Founder & Chairman, BioMetas Group

Mr. Simon Hua is the Founder and Chairman of BioMetas Group and China Finance Strategies Investment Holdings Limited. He previously served as CEO of ChemPartner PharmaTech Co., Ltd., Co-Founder and CFO of Viva Biotech Holdings, and Head of Direct Investment and Investment Banking at BOCOM International. With over 30 years of experience in finance and industry investment, he has completed 200 IPO and refinancing projects and 50 financial advisory projects, led investments in more than 100 companies totaling over US$100 billion, with nearly half focused on the life sciences and healthcare sector. He currently serves as an Independent Director of listed biopharmaceutical companies, including Lepu Biopharma Co., Ltd. and Biocytogen Pharmaceuticals (Beijing) Co., Ltd. He holds an EMBA from the China-Europe-Yale program and an MBA from the International University of Japan.



Hongbin JIAO

Partner, KING & WOOD

Ms. Jiao Hongbin specializes in intellectual property litigation and has over 20 years of experience in this practice area, representing clients in intellectual property-related cases in China, including those involving trademark, copyright (including software), domain name, and anti-unfair competition (including trade secrets). Ms. Jiao handled quite a few high-profile cases, such as disputes regarding the world famous online game, World of Warcraft, the dispute regarding ownership of the trademark, "iPad", the dispute regarding the specific packaging and decoration of the famous "Wang Lao Ji" herbal tea, "RedBull' series trademark disputes and assisted quite a few clients in successfully having their well-known trademarks judicially recognized. Ms. Jiao's practice areas also cover IP-related administrative litigation, administrative protection and IP transaction.

SPEAKERS - THEATER 3



Louis P. KASSA

President and Chief Executive Officer of the Pennsylvania Biotechnology Center, the Baruch S. Blumberg Institute, the Hepatitis B Foundation, and B+Labs, University City

Louis P. Kassa III is the President and Chief Executive Officer of the Pennsylvania Biotechnology Center, the Baruch S. Blumberg Institute, the Hepatitis B Foundation, and B+Labs, University City.

Kassa is also the co-founder of the HatchBio Fund, a $50 million venture capital fund investing in early-stage life sciences companies. In 2020, he was recognized as one of Industry Era's "10 Best COOs of 2020." He previously served as State Director and Chief Operating Officer at VisionQuest National, Ltd., a national behavioral health organization.

Kassa has been named to the Philadelphia Business Journal's Power 100 list of top business leaders for four consecutive years, and in 2024 was named a Trailblazer in Health Care by City & State Pennsylvania. In 2025, he received an honorary degree from Holy Family University.

He holds a Bachelor's degree from Penn State University and a Master of Public Administration from Villanova University.



Raju KUCHERLAPATI

Paul C. Cabot Professor of Genetics and Professor of Medicine at Harvard Medical School

Professor Raju Kucherlapati is the Paul C. Cabot Professor of Genetics and Professor of Medicine at Harvard Medical School since 2001. He obtained his PhD from the University of Illinois, was a research fellow at Yale University and started his academic career as a faculty member at Princeton University. Prior to joining the Harvard faculty, Professor Kucherlapati was the Lola and Saul Kramer Professor and University Professor at the Albert Einstein College of Medicine while he was the Chairman of the Department of Molecular Genetics. His research interests involved, gene targeting, human genetics, human genome project, cancer genome atlas project and has been a proponent of Precision Medicine. He is a member of the National Academy of Medicine of the United States.



Holly MENG

CEO / Exin BioPharma Inc. CEO / Global BioPharma Partnerships LLC.

Founder & CEO / Exin BioPharma Inc.
Co-founder & CEO / Global BioPharma Partnerships LLC.
Board of Director & SVP / Chinese Biopharmaceutical Association Greater Philadelphia Director / Temple University Office of Executive Leadership Education

SPEAKERS - THEATER 3



Masatomo SAKAIRI

Bound Therapeutics, Angel Investor, COO

Masatomo “Masa” Sakairi is Chief Operating Officer of Bound Therapeutics, bringing extensive experience in startups, private equity, international business, corporate strategy, and operational transformation.
Masa began his career in investment banking and private equity at Merrill Lynch and The Carlyle Group. He later co-founded VARECS Partners, an engagement fund in Japan focused on corporate value creation, and served as a trustee for Japan’s Enterprise Turnaround Initiative Corporation, where he contributed to major corporate restructuring efforts, including Japan Airlines.
He holds an MBA from Harvard Business School and a BA in Social Sciences from International Christian University in Tokyo, and also studied Industrial Management at Carnegie Mellon University.
Since relocating to New York City in 2018, Masa has invested in and mentored more than 20 startups across diverse sectors. In addition to his role at Bound Therapeutics, he advises companies in the U.S., Japan, and India on corporate strategy, cross-border growth, partnerships, and M&A.



Kelvin SHAO

Vice General Manager, Kexing Biopharm Co.,Ltd

As Vice General Manager of Kexing Biopharm for more than five years, Dr.Kelvin has contributed to the pharmaceutical and biotechnology industries through his expertise in life sciences, biotechnology, and technology transfer. His work focuses on driving innovation and strategic business development across the sector.
Having previously held senior leadership positions including Chief Marketing Officer and Chief Executive Officer, he has gained an in-depth understanding of both the operational and strategic requirements of biopharmaceutical organizations. Driven by a commitment to global healthcare, Dr.Kelvin aims to support sustainable growth and advance biotechnological innovations to address worldwide healthcare challenges.



Jiawei TANG

COO/GlobalBioPharmaPartnershipsLLC.

Jiawei Tang is the Co-founder and COO of Global Biopharma Partnerships. She holds a Master’s degree in Digital Transformation in Healthcare Management and brings over 15 years of extensive experience in the healthcare and life sciences industry, with a proven track record in sales, corporate strategy, and marketing.

Her professional background includes 12 years in management roles at Pfizer, a global pharmaceutical leader, and one year as Commercial Strategy Director at Resolian, a renowned contract research organization (CRO). She has successfully led and implemented numerous brand transformation, corporate strategy, integrated marketing communications, and business innovation projects across major markets, including the United States, the United Kingdom, Australia, and China.

In addition to her professional work, Jiawei serves in volunteer leadership roles at several non-profit healthcare organizations, including as a Geographic Expansion Leadership Member at the Healthcare Business Association, as an Advisory Board member of One Patient One Cure, and as Vice President of the Chinese Biopharmaceutical Association Greater Philadelphia.

SPEAKERS - THEATER 3



Yunfei WANG

Investment Promotion Manager at Haikou National Hi-Tech Zone International Investment Development Co., Ltd.

Currently serving as Investment Promotion Manager at Haikou National Hi-Tech Zone International Investment Development Co., Ltd.

Grounded in the industrial development layout of the Hainan Free Trade Port, I specialize in investment promotion within the environmental new materials sector, focusing on sub-tracks such as biodegradable materials, solid waste resource utilization, the circular economy, and green fine chemicals.

I oversee the full lifecycle of investment promotion—including industry research, project sourcing, enterprise engagement, due diligence and assessment, and landing services. By actively connecting domestic and international high-quality resources in environmental new materials, I contribute to the cultivation of the zone's green and low-carbon industrial clusters, as well as the strengthening and complementing of its industrial chains, thereby supporting the high-quality development of Haikou National Hi-Tech Zone's eco-environmental industry.



Fiona YU

Partner, RA Capital Management, L.P.

Fiona is a Partner at RA Capital Management based in Shanghai.
Prior to RA Capital, Fiona spent 13 years at Northern Light Venture Capital(NLVC), and served as Partner for 6 years. Earlier in her career, Fiona worked at Johnson & Johnson China for over 7 years, and also spent one year as a strategic consultant at Monitor Deloitte.
Fiona holds a BS from Beihang University, a MS from John Hopkins University and an MBA from Duke University.



Sheng ZENG

CEO, Susheng Biotech (Hainan) Co,. Ltd.

Born in 1986, Sheng went to the University of Zurich and ETH Zurich for his research in cell death regulation under the supervision of Prof. Dr. Michael Hengartner who is president of the ETH board, and Nobel laureate Prof. Dr. Robert Horvitz. Sheng published his scientific findings on Nature, and was awarded Doctor's degree in 2015.
Settle down in Hainan, a tropical island in south China, Sheng dedicates as head of the Key Laboratory of Skeletal Regeneration of Hainan Province. His research interests incorporate biomaterial scaffold, stem cell, and tissue engineering in regenerative sports medicine. Meanwhile, he is the founder of Susheng Biotech (Hainan) Co., Ltd, a cross-border leading company which develops high-end medical devices for sports injuries and artificial tissues for the regeneration of human cartilage and nerves.
Sheng is fluent in Mandarin, English, and German. He is an amateur tennis player, as well as a skilled sailor and a certified Swiss Ski Instructor.

SPEAKERS - THEATER 3



Jimmy ZHANG

Executive Mentor, QB3/Bakar Labs, UC Berkeley

Dr. Jimmy Zhang has 25+ years of experience in large pharmas and start-up companies, in strategy, business development, operations, and venture investments. Jimmy is executive mentor of biotech incubator QB3/Bakar Labs at UC Berkeley and UCSF, and advises companies in US, China and Korea on strategy, BD and other operation matters; and closed NewCo deals as Chief Business Officer for one of his advised companies Sciwind with Verdiva Bio (the largest NewCo raising over $410M) and another company Lynk with a US NewCo.

Jimmy was founder, Chairman and CEO of AccuGen Group and raised over US$64M from strategic and venture investors. He was Venture Partner at Lilly Asia Ventures, Board Director of Just Biotherapeutics when acquired by Evotec, VP Transactions at J&J, Managing Director of MSD Early Investments – Greater China at Merck. He was on the Board of BeiGene and Advisor Board of Cenova Ventures. Jimmy was SVP at Synergenics (an accelerator founded and led by Dr. Bill Rutter, one of the founding fathers and pioneers of the biotech industry), consultant at McKinsey, registered patent agent in the Palo Alto office of Morrison & Foerster, and project manager at Chiron (now Novartis).

Jimmy was a founding member and former Chairman of BayHelix Group. He is adjunct professor teaching business development and master degree mentor at Yeehong Business School, having taught over 1,500 students in both the US and China. He holds MBA from MIT Sloan, PhD in biomedical sciences from UT Southwestern Medical Center at Dallas, where he worked closely with three Nobel Laureates. Jimmy published in Cell, Nature, Neuron, and JBC, and holds multiple patents, authored a Book Chapter in Biotechnology Entrepreneurship 2nd edition published by Elsevier in 2020, and co-authored Harvard Business School case BeiGene.



Fang ZONG

Hainan Dermavon Pharmaceutical Technology Co., Ltd., Deputy General Manager

It is our honor to have Ms. Zong Fang, Deputy General Manager of Hainan Demei Pharmaceutical Technology Co., Ltd., as a speaker for this session.

SPEAKERS - THEATER 5



Kenneth Man Chee CHEUNG

President and Hospital Chief Executive, The University of Hong Kong–Shenzhen Hospital Chair Professor, Department of Orthopaedics and Traumatology The University of Hong Kong

Prof. Kenneth M.C. Cheung is the Jessie Ho Professor in Spine Surgery and Chair Professor at the Li Ka Shing Faculty of Medicine, the University of Hong Kong. He was the Head of the Department of Orthopaedics and Traumatology until December 2021 and officially takes the helm as Hospital Chief Executive of HKU-Shenzhen Hospital starting July 2022.

Prof. Cheung is a world-renowned academic spine surgeon with special expertise in the treatment of spinal deformities in children and adults. He is the Past President of the Hong Kong College of Orthopaedic Surgeons, and he was the first Chinese President of the international Scoliosis Research Society (SRS), the world's highest academic institution of spinal surgery (2016-2017). He not only led the development of orthopaedics in Hong Kong, but also played a significant role on the international stage on behalf of China's orthopaedics. In 2021, he was awarded the prestigious Walter P. Blount Humanitarian Award by the Scoliosis Research Society for his outstanding service to those with spinal deformity, and for generosity to the profession and society.



Duncan CHIU

Legislative Council Member (Technology and Innovation)

Duncan CHIU Tat-kun is a member of the Legislative Council of the HKSAR representing the Technology and Innovation functional constituency in Hong Kong's legislature

SPEAKERS - THEATER 5



Philip Wai Yan CHIU

Dean, Faculty of Medicine, The Chinese University of Hong Kong

Professor Philip Chiu is Dean of the Faculty of Medicine, Shun Hing Education and Charity Fund Professor of Robotic Surgery, Director of Multi-Scale Medical Robotics Center, and Director of Endoscopy Center, Institute of Digestive Disease of The Chinese University of Hong Kong. He is also a Steering Committee member of Health and Medical Innovation Development of the Health Bureau of the HKSAR Government.

Professor Chiu is a pioneer in minimally invasive procedures, having performed Hong Kong's first endoscopic submucosal dissection (ESD) for the treatment of early gastrointestinal cancers in 2004, as well as the world's first robotic gastric ESD and colorectal ESD in 2011 and 2020 respectively. His research interests include esophageal cancer management, minimally invasive and robotic esophagectomy, novel endoscopic technologies for diagnosis of early GI cancers, endoscopic surgery, as well as robotics for endoluminal surgery. Professor Chiu has published nearly 400 peer-reviewed manuscripts and 6 book chapters. Among these, his seminal world's first robotic colorectal ESD clinical study earned Endoscopy's Most Innovative Paper Award (2024). Other accolades include the State Scientific Technology and Progress Award from the People's Republic of China (2007), 2nd class award in Technological Advancement, Ministry of Education of the People's Republic of China (2011), Spirit of Hong Kong Award on Innovation (2020), two Gold Medals with Congratulations of Jury at the International Exhibitions of Inventions of Geneva (2019, 2023), Honorary Member of the European Association of Endoscopic Surgery (2023) and Foreign Member of the Academia Europaea (2025).



Hongjie DAI

Chair Professor, Department of Chemistry, the University of Hong Kong

Professor Hongjie Dai is the Sapientia Eminence Professor and Professor, Chair of Chemistry at the Department of Chemistry, The University of Hong Kong (HKU). Professor Dai's work is highly interdisciplinary, bridging chemistry, physics, materials and biomedical sciences, and his research group has been a leader in the area of nanoscience, nanotechnology and nanomedicine.
Professor Dai is a Member of the US National Academy of Sciences, the US National Academy of Medicine, Fellow of the American Academy of Arts and Sciences, and Foreign Member of the Chinese Academy of Sciences. He received the APS James McGroddy Prize for New Materials, the ACS Pure Chemistry Award, the MRS Mid-Career Researcher Award, the NIH Director's Pioneer Award, and the Humboldt Research Award, among others.



Meng DING

Partner, Sidley Austin LLP

MENG DING has extensive experience counselling issuers and investment banks on a broad spectrum of capital markets and M&A transactions. He focuses his practice on companies from Greater China and Asia companies, frequently advising on transactions that define their growth and success, from early-stage financing to listing to post-listing matters.
He has advised on a number of Hong Kong and U.S. IPOs, bond offerings, and many of Greater China's largest, most complex, and precedent-setting transactions. Meng is notable for his ground-up approach to gain deep understanding of industries, ranging from e-commerce platforms to specialist hard-tech companies such as semiconductor, AI, robotics, autonomous driving companies to life science and pharmaceutical firms to financial institutions.

SPEAKERS - THEATER 5



Chuwen LIU

Member of the Party Leadership Group and Deputy Director- General, Shenzhen Municipal Development and Reform Commission

Member of the Party Leadership Group and Deputy Director- General, Shenzhen Municipal Development and Reform Commission



Jian LIU

CEO, MGI Tech (SHA: 688114)

Liu Jian, is Director of BGI Group, CEO of MGI Tech and President of MGI Americas, and Director of MGI Hong Kong. With nearly 20 years of industrialization experience in medical devices and life sciences, he previously worked at Mindray, Danaher. Since joining BGI/MGI in 2014, he led the development and mass production of China's first domestically developed sequencing instrument, and successively oversaw R&D, manufacturing, quality and marketing. As a core executive, he took MGI from its founding and STAR Market IPO to a globally renowned life science company, and led a $100M level cross-border technology licensing deal — the first successful IP-outbound case for Chinese scientific instruments. He is a recipient of the China Patent Gold Award, holds 49 granted patents, and has led or contributed to 135 international, national and industry standards.



Yichong LI

President, Greater Bay Area International Clinical Trials Center (Bay Trial)

Dr. Yichong Li is an independent Principal Investigator and Professor at the National Clinical Research Center for Cardiovascular Diseases (Fuwai Hospital, Chinese Academy of Medical Sciences). He is currently jointly appointed as Director of the Greater Bay Area International Clinical Trial Centre (Bay Trial) at the Shenzhen Medical Academy of Research and Translation (SMART). Prior to his current role, he held research positions at the Chinese Center for Disease Control and Prevention (China CDC), the University of Washington, Stanford University, and Peking University Health Science Center. He has led over ten major health research and clinical research projects, including those funded by the Ministry of Science and Technology, National Natural Science Foundation of China (NSFC), and the Guangdong Pearl River Talent Program. He has published nearly 100 original research articles as first or corresponding author in leading medical journals, including JAMA, BMJ, and subjournals of JAMA and The Lancet. His Hindex was 57 in 2025, and he has been consecutively listed in Stanford University's World's Top 2% MostCited Scientists from 2022 to 2025.

SPEAKERS - THEATER 5



Jian MA

Co-Founder & CEO, XtalPi

Dr. Ma Jian, co-founder and CEO of XtalPi, Deputy to the 7th People's Congress of Shenzhen. Dr. Ma Jian holds various positions, including Vice-chairman of the Innovation Translation and Clinical Development Committee of the China Pharmaceutical Innovation and Research Development Association (PhIRDA), Member of the Editorial Board of Progress in Pharmaceutical Sciences, Co-Chairman of the Zhangjiang AI Drug Discovery Alliance, and Chairman of the Artificial Intelligence and Big Data Committee of the China Biopharmaceutical Industry Innovation and Transformation Alliance.He has received numerous honors, including the second prize of the Natural Science Award from the Ministry of Education, the Guangdong Youth May Fourth Medal, Shenzhen Locallevel Leading Talent, and the Shenzhen Youth Science and Technology Award. He has also been selected as one of the "Top 50 Young Innovators in Shanghai", named one of the "35 Innovators Under 35" by MIT Technology Review, honored with the "Best CEO for AI Drug Development" at the First AI Drug Developer Conference, and awarded the 2024 EY Entrepreneur Of The Year.



Vincent MA

Chief Executive Officer Hong Kong-Shenzhen Innovation and Technology Park Ltd.

Mr. Vincent Ma has been appointed as the Chief Executive Officer of Hong Kong-Shenzhen Innovation and Technology Park Limited (HSITPL) since January 2023.
Mr. Ma is a veteran with over 30 years of experience in the Information and Communication Technology (ICT) industry. Since joining Wharf T&T Limited in 1995, even before the Company was granted a fixed telecom network license, Mr. Ma grew with the Company and witnessed the deregulation journey of the telecom industry. From 2006 to 2019, Mr. Ma was appointed the President and then the Chief Executive Officer of Wharf T&T. Under his leadership, Wharf T&T became one of the most successful and highly profitable ICT service providers with an operation of over 1,800 staff, attaining an annual turnover of $2 billion and a valuation exceeding $10 billion, and serving over 50,000 business customers in Hong Kong. Robust strategy setting such as the unique B2B winning strategy outperforming competitions in the case of Wharf T&T, a true believer of customer centricity and operation excellence are some of the key management philosophies of Mr. Ma.
Before joining HSITPL, Mr. Ma was the Chief Digital Officer of Sun Hung Kai Properties. He set up a new Digital Office driving digital transformation and big data strategies across the diverse business portfolio of the Group.
Mr. Ma earned a bachelor's degree in computing studies from the Hong Kong Polytechnic University. He serves as a member of the Hong Kong Trade Development Council ("HKTDC") Technology and Digital Innovation Advisory Committee.



Andrew NG

Managing Director and Head of Healthcare, VMS Group; Investment Partner, Panacea Venture

Andrew Ng is a Managing Director and Head of Healthcare of VMS Group and an Investment Partner of Panacea Venture. He has over 13 years of experience in the healthcare industry across Asia and the US. Andrew has established the healthcare practice of VMS Group in 2017 and led multiple growth-stage investments for VMS across the therapeutics, diagnostics, medical device and CRO/CDMO verticals. He has also served as an Investment Partner of Panacea Venture, a global healthcare venture capital firm, since 2021. Prior to that, Andrew was responsible for the China Healthcare Equity Research at Barclays Capital based in Hong Kong. Before that, he was an investment banker covering healthcare clients across the Asia Pacific region at Barclays Capital with a focus in healthcare cross-border M&A. Andrew started his career as a management consultant at ZS Associate in the United States advising global pharma on sales & marketing strategy and operations. Andrew has been on the board of multiple companies that carry out product development, manufacturing and sales in the biotechnology, medical equipment and CXO industries. These companies include New Horizon Health, Chime Biologics, Jade Biomedical, SyMap Medical, Yizun Biomedicine and Profusa. Andrew received an MBA from INSEAD, a M.Eng. degree and a BS degree in Operations Research & Engineering from Cornell University.

SPEAKERS - THEATER 5



Yinxiao WU

President, Shenzhen- Hong Kong Science and Technology Innovation Cooperation Zone Development Co., Ltd.

Yinxiao WU is the President and Legal Representative of Shenzhen-Hong Kong Science and Technology Innovation Cooperation Zone Development Co., Ltd. , a key state-owned enterprise responsible for the comprehensive development, construction, and operation of the Shenzhen Park within the Hetao Shenzhen-Hong Kong Science and Technology Innovation Cooperation Zone



King-shun YAN

Director-General, Office for Attracting Strategic Enterprises, Financial Secretary's Office

Mr. Peter Yan King-shun, JP is the Director-General of the Office for Attracting Strategic Enterprises (OASES), operating under the Financial Secretary's Office of the Hong Kong SAR Government.Appointed to the post on October 29, 2024, Yan is an industry veteran with approx. 40 years of experience in the information technology and digital transformation sectors.



Jian ZHANG

Deputy Party Secretary and Director, Shenzhen Capital Group Co., Ltd.; Chairman, SCGC Guidance Fund Management(Shenzhen)Co.,Ltd.

Mr. Jian Zhang joined SHENZHEN CAPITAL GROUP CO., LTD. in 2019. He currently serves as Deputy Party Secretary and Director of the Group, and holds the positions of Chairman and General Manager of SCGC GUIDANCE FUND MANAGEMENT(SHENZHEN) CO. LTD. He boasts extensive experience in investment, financing and corporate management.He has received numerous honors, including being named in Zero2IPO's 2024 "Top 100 Investors in Investment Community", the 2021 "Most Influential Investor in China's Private Equity Fund Limited Partner Market", and the "Best Limited Partner Investment Figure in China of the year" by CBG for four consecutive years from 2021 to 2024.

SPEAKERS - THEATER 6



Hidekazu CHAYAMA

Chief Representative, Beijing Office, Japan Science and Technology Agency (JST)

Hidekazu CHAYAMA is Chief Representative of the Beijing Office, Japan Science and Technology Agency (JST). He has long- term experience in science and technology policy and international S&T cooperation. Having served in multiple Japanese governmental bodies including the Ministry of Education, Culture, Sports, Science and Technology, he commits to China- Japan research collaboration, industry- university- institute partnership and young researcher exchange, and actively facilitates practical S&T cooperation across diverse cutting- edge fields between China and Japan.



Yu FENG

Executive Chairman, Active Medicine Professional Committee, World Association of Artificial Consciousness; Academician, International Academy of Science and Technology

Feng Yu, M.D. in Surgery, Chief Physician, Professor, Renowned Doctor of TCM of Pudong New Area, and recipient of the Inaugural Pudong Healthcare Artisan Award. He serves as the President of Pudong New Area Traditional Chinese Medicine Hospital and Guangming Traditional Chinese Medicine Hospital. Additionally, he is the Executive Chairman of the Active Medicine Committee of the World Association of Artificial Consciousness, an expert in the TCM Standardization Expert Database of the National Administration of Traditional Chinese Medicine, and the Chairman-Elect of the Enhanced Recovery After Surgery (ERAS) Committee of the Shanghai Association of Chinese Integrative Medicine. He possesses unique expertise in the integrative Chinese and Western medicine treatment of thyroid nodules.



Lai-Ying FONG

Honorary Advisory Chairman, Hong Kong Food Professionals Association; Founder, Hong Kong Food Innovation and Technology Center

Currently, Prof. Fong serves as Executive Director of the Food Innovation, Technology and Safety Centre. She was formerly Associate Professor for the Bachelor of Science (Honours) in Food Science and Safety at the Technological and Higher Education Institute of Hong Kong. She also held the positions of Programme Leader and Senior Lecturer for the Higher Diploma in Food and Nutritional Science in the Department of Applied Science at Hong Kong Institute of Vocational Education (Chai Wan Campus). Prof. Fong's past appointments include Honorary Advisor of the Hong Kong Food Professionals Association, Certification Assessor of the Hong Kong Quality Assurance Agency, and Assessment Panel Expert in Food and Nutrition for the Hong Kong Council for Accreditation of Academic and Vocational Qualifications.

SPEAKERS - THEATER 6



Fu GAO

Vice President, China Council for the Promotion of Ethnic Trade

Fu GAO is Vice President of the China Council for the Promotion of Ethnic Trade. He holds a Ph.D. in Public Economics from Peking University and is a Chevening Scholar. He has accumulated profound experience in international trade, tourism economy, cross- border events and characteristic agri- food industry development. He is engaged in promoting economic development of ethnic- minority regions, cross- border trade and investment exchanges between China and global partners, advancing the “One Township- One Product” initiative, and facilitating practical industrial cooperation covering specialty agricultural products, food innovation, cultural tourism and cross- border resource docking across regions.



Paul-Éric JARRY

Founder, PhytoProd (France)

Paul- Éric JARRY is the Founder of PhytoProd (France). He has solid expertise in plant- based raw material development, bio- based ingredient innovation and organic agricultural industrialization. He devotes himself to R&D and industrialisation of natural plant- derived ingredients, supports cross- border industry- research collaboration in plant resources, bio- economy and sustainable agriculture, and promotes practical innovation cooperation between European and Asian agri- food sectors.



Kuei-Nan KAO

President, Singapore Sustainable Development Technology Center; President, China National Technology Transfer Hainan Center (Singapore Center)

Kuei- Nan KAO serves as President of the Singapore Sustainable Development Technology Center and President of China National Technology Transfer Hainan Center (Singapore Center). He has rich experience in international technology transfer, cross- border innovation cooperation and sustainable industry development. He is committed to building collaborative channels for technological achievement conversion between China and Southeast Asia, facilitating cross- border docking of innovative projects, resources and talents, and promoting practical cooperation on green technology and industrial innovation across regions.

SPEAKERS - THEATER 6



Jay D. KEASLING

Department of Chemical & Biomolecular Engineering and Department of Bioengineering, University of California, Berkeley Biological Systems & Engineering Division, Lawrence Berkeley National Laboratory Joint BioEnergy Institute (JBEI)

Jay Keasling is the Philomathia Distinguished Professor of Alternative Energy at the University of California, Berkeley in the Department of Bioengineering and the Department of Chemical and Biomolecular Engineering, senior faculty scientist at Lawrence Berkeley National Laboratory, and Chief Executive Officer of the Joint BioEnergy Institute (JBEI). Dr. Keasling's research focuses on metabolic engineering of microorganisms for environmentally friendly synthesis of drugs, chemicals, and fuels. Keasling received a B.S. in Chemistry and Biology from the University of Nebraska and M.S. and Ph.D. in Chemical Engineering from the University of Michigan, and did post-doctoral research in biochemistry at Stanford University. He is a member of the National Academy of Engineering, the National Academy of Inventors, and the American Academy of Arts and Sciences. Keasling has published over 550 papers in peer-reviewed journals and has over 75 issued patents. Keasling has won numerous awards. Keasling is the founder of Amyris, LS9, Lygos, Napigen, Demetrix, Maple Bio, Apertor Pharma, Zero Acre Farms, Cyklos Materials, BioMia, and ResVita Bio.



Jiuchi LAO

Chief Representative in China, Danish Agriculture & Food Council

Jiu- Chi Lao is Chief Representative in China of the Danish Agriculture & Food Council. He is responsible for managing the council's China operations, facilitating bilateral exchanges and business cooperation between Denmark and China within agriculture, food industry, sustainable farming, food safety and animal welfare. He maintains close connections with industry players, research institutions and government stakeholders, and actively promotes market access, technological exchange and practical partnership for Danish agri- food enterprises in China.



Simon LEE

Cally Kwong Mei Wan Professor in Biomedical Sciences and Chinese Medicine Innovation; Chair Professor of Biomedical Sciences

Prof Simon Lee's research interests interest lies in the discovery of drug-like agents from natural products including small molecules and biologics for use in various therapeutic areas, including brain disorder and neurodegenerative diseases. His dedication to education and research in the fields of omics, pharmacology and toxicology has led to over 360 scholarly articles, including Nature, Nature Genetics, Nature Communications (4×) and Science Advances, and over 20 granted patents. Simon is in Stanford university's list of top 2% of most-cited scientists in Pharmaceutical Science and Biology (with h-index: 65 from Scopus). His dedication to education and research in the fields of pharmacology and toxicology has led to over 300 scholarly articles, including Nature Communications (4×), and over ten granted patents. He has received over 30 grants (exceeding 80 million Hong Kong dollars),. Prof Simon Lee has extensive collaboration experience with pharmaceutical and biotechnology industries. He has founded AIM Pharmaceutical International Limited (AIM Pharma), specializes in developing innovative nutraceuticals and therapeutic drugs for neurodegenerative diseases, which has been selected for RAISe+ scheme in 2025.

SPEAKERS - THEATER 6



Elaine Lai Han LEUNG

Interim Director of the Institute of Collaborative Innovation, University of Macau; Head of the Centre for Innovation and Entrepreneurship; Professor, Faculty of Medicine

Prof. Elaine Lai-Han Leung is the Interim Director of the Institute of Collaborative Innovation, Head of the Centre for Innovation and Entrepreneurship (CIE), and Professor of the Faculty of Medicine at the University of Macau. She also serves as a Member of the Economic and Technological Development Committee of the Macao SAR Government. In 2020, she was named a Young Qihuang Scholar and appointed as a Distinguished Professor under the Guangdong Pearl River Talent Program. In 2024, she was recognized among the World's Top 2% Scientists in the field of Oncology and Carcinogenesis. Prof. Leung has long been dedicated to the research and development of traditional Chinese medicine-based targeted therapies for lung cancer. To date, she has published 199 SCI-indexed papers in leading international journals, including Nature (Outlook), Gut, JAMA Oncology, Nature Communications, Pharmacological Research, Pharmacology & Therapeutics, Oncogene, Cancer Letters, and the British Journal of Cancer. She has an h-index of 51, with more than 10,000 citations, and her most highly cited publication has received 1,006 citations.



Guangwei LIU

President, World Eatology Forum

Director of the Gastronomy Research Center of Renmin University of China, Founder of the Gastronomy Discipline System, President of the Beijing Oriental Cuisine Research Institute, and Chairman of the World Gastronomy Forum. **Main research interests**: food- related issues, holistic governance of food- related issues, and the development of the gastronomy discipline system. Over the past 40 years, Mr. Liu Guangwei has been engaged in fields including food crop cultivation, animal husbandry, culinary arts and food fermentation. He has founded multiple food- themed media outlets, research institutions and social organizations, organized various public- welfare food- related events, and authored more than 20 monographs on food studies. Through long- term professional practice, Mr. Liu Guangwei has continuously explored the root causes and fundamental solutions to food- related human challenges. He has identified the holistic nature of human food- related issues as well as the fragmentation in food- related cognition. On this basis, he has established a holistic knowledge framework for food- related cognition — Food Studies, which serves as a global public good for fundamentally resolving humanity's food- related challenges.



Rongrong LIU

Director General, Institute of Agro-Food Science and Technology, Chinese Academy of Agricultural Sciences (CAAS)

Rong- rong LIU is Director General of the Institute of Agro- Food Science and Technology, Chinese Academy of Agricultural Sciences (CAAS). Holding a Ph.D. in Biology and a research- professor title, she has rich experience in agricultural S&T administration, research institute governance and agricultural innovation management. She previously held key positions at CAAS Science and Technology Management Bureau and served as Deputy Director of the Institute of Plant Protection, CAAS. She now leads the institute's work on agro- food science research, industry- research translation and domestic- overseas innovation cooperation, and promotes technological upgrading and industrial practical development of China's agricultural and food sector.

SPEAKERS - THEATER 6



Yuk Lam LO

President of HK Bio-Med Innotech Association

Professor Lo has extensive experience in biotechnology industry, corporate management, academic research and community service. Currently Professor Lo is serving as the President of HK Bio-Med Innotech Association, Strategic Advisor to the President and Adjunct Professor to the Division of Life Science of Hong Kong University of Science and Technology. In the educational area, Professor Lo has been elected an Honorary Fellow of the Hong Kong University of Science and Technology. He is also the Honorary Professor of several universities in China. Professor Lo was heavily involved in several committees of the HKSAR Government. He was the Chairman of the Advisory Council for Food Safety of the Food and Health Bureau of HKSAR government from April 2015 to March 2021, Director of the Hong Kong Applied R&D Fund Co. Ltd., Chairman of the Biotechnology Committee of the Hong Kong Industry & Technology Development Council, and Chairman of Biotechnology Projects Vetting Committee of the Innovation and Technology Fund of the HKSAR government. In Mainland China, Professor Lo was a member of Chinese People's Political Consultative Conference in Jilin Province from 2007 to 2022. He was also a consultant of the Centre for Disease Control and Prevention of China. In recognition of his leadership in the community and dedication to his field, Professor Lo has received many awards, such as the "Pericles International Prize" in 2019. He is the second Asian and the first person from Hong Kong to be awarded the Prize since it was founded in 1986. In 2020, Professor Lo was awarded the Bronze Bauhinia Star from the HKSAR government for his outstanding services over the past decades. In the business sector, Professor Lo had been served as the Chairman of Asia Pacific of PerkinElmer (NYSE: PKI) and the President of Asia Pacific of Bio-Rad Laboratories (NYSE: BIO). Currently he is the Chairman of GT Healthcare Capital Partners, and Partner & Investment Committee Member of Hongsen Investment Management Limited.



Carmen MAN

Member of the Advisory Group of the Food and Environmental Hygiene Department (FEHD) of the Hong Kong Special Administrative Region Government

Ms. Carmen Man currently serves as a member of the Advisory Group of the Food and Environmental Hygiene Department (FEHD) of the Hong Kong Special Administrative Region Government. She has long been dedicated to the fields of public health, food safety management, and biotechnology, actively participating in the formulation of regulations and strategies related to food safety policies, environmental hygiene regulation, and public health consultations for the SAR Government.



Chunsheng MIAO

Special Envoy of former UN Secretary-General Ban Ki-moon

In international diplomacy and cultural exchange contexts, his role is often described as the Special Envoy or Representative of Ban Ki-moon (particularly for China region affairs), managing bilateral communications, scheduling, and strategic partnerships involving the former UN chief in China.

SPEAKERS - THEATER 6



Zhidong MIN

President, Hong Kong International Food Science & Technology Innovation Development Co., Ltd.; Chairman, Hong Kong Food Professionals Association

President, Hong Kong International Food Science & Technology Innovation Development Co., Ltd.; Chairman, Hong Kong Food Professionals Association



Ye TIAN

Secretary-General of China Good Agri-products Development & Service Association

Ye TIAN is the Secretary-General of the China Good Agri-products Development & Service Association (CGAPA).The CGAPA is a prominent national non-profit social organization approved by China's Ministry of Civil Affairs and operates under the professional guidance of the Ministry of Agriculture and Rural Affairs



Fengzhong WANG

Director General, Institute of Food and Nutrition Development, Ministry of Agriculture and Rural Affairs (MARA)

Wang Fengzhong, Ph.D., is a Research Professor and Doctoral Supervisor. He currently serves as Director General and Deputy Secretary of the Party Committee of the Institute of Food and Nutrition Development, Ministry of Agriculture and Rural Affairs (MARA), as well as Director General and Chief Scientist of the Institute of Agro-Food Processing Science and Technology, Chinese Academy of Agricultural Sciences (CAAS). He is a scientist for the processing post in the National Soybean Industry Technology System, a designated Leading Talent under MARA's "Shennong Elite Program," and among the first batch of "Technology Transfer Elites" selected by CAAS. Dr. Wang has long been dedicated to research on agro-product quality evaluation, processing technology, and nutrition and health. He has achieved remarkable results, particularly in the comprehensive utilization of agricultural products such as soybeans and highland barley, as well as in precision nutrition and dietary interventions for age-related chronic diseases. He proposed innovative concepts such as the "Three Knives Economics" in agriculture, led over 30 major research projects—including the National Key R&D Program of China—published over 200 academic papers, and received numerous awards, including the Outstanding Cadre Assisting Tibet honored by the Organization Department of the CPC Central Committee.

SPEAKERS - THEATER 6



Wei WEI

Professor, State Key Laboratory of Biopharmaceutical Preparation and Delivery, Institute of Process Engineering (IPE), Chinese Academy of Sciences (CAS)

Wei Wei, Ph.D., is a Professor and Doctoral Supervisor at the Institute of Process Engineering (IPE), Chinese Academy of Sciences (CAS), where he serves as Director of State Key Laboratory of Biopharmaceutical Preparation and Delivery. His research pioneers biomimetic formulation engineering, focusing on innovative preparation processes and the novel design of biomimetic carriers. Dr. Wei has published over 160 SCI papers, including three papers in Cell and Nature, and 22 in CNS sub-journals. He holds 22 authorized patents, with 7 formulations currently in Investigator-Initiated Trials (IIT). A recipient of the National Science Fund for Distinguished Young Scholars, his work has earned prestigious accolades, including the SCEJ Award for Outstanding Asian Researcher and the First Prize of the Beijing Natural Science Award, significantly advancing the field of biomimetic medicine.



Fuqing WU

Associate Researcher, School of Life Sciences, Tsinghua University; Deputy Director, Center for Synthetic and Systems Biology, Tsinghua University

Wu Fuqing, Associate Research Fellow at the School of Life Sciences, Tsinghua University, Deputy Director of Tsinghua Center for Synthetic and Systems Biology, co-founder of Beijing PhaBuilder Biotechnology Co., Ltd., and a member of the Beijing Municipal Committee of the Chinese People's Political Consultative Conference. Working closely with Professor Chen Guoqiang, he focuses on halophilic bacterial chassis cells and Next-Generation Industrial Biotechnology (NGIB). He leads the development of genetic editing tools for Halomonas, strain metabolic engineering, and scale-up of open unsterilized fermentation. He realizes the full industrial chain from wild strain isolation, chassis construction to large-scale PHA production, and oversees the construction of ten-thousand-ton PHA manufacturing lines. He also serves on committees of multiple biomaterial academic societies, committed to translating synthetic biology research into industrial applications.



Yi ZHANG

Deputy Director General, Bureau of Technology Transfer, Chinese Academy of Agricultural Science

Deputy Director- General of the Achievement Transformation Bureau, Chinese Academy of Agricultural Sciences (CAAS), Research Professor, Doctor of Agricultural Economics and Management. Director of the National Agricultural Science and Technology Achievement Transfer Service Center, and Vice- Chairman of the China Patent Protection Association. Her main work focuses on agricultural intellectual property management and achievement commercialization. She has long devoted to research on relevant laws, regulations, policies and practical cases. She has completed 2 projects under the EU Framework Programme, and more than 40 policy- research projects for the Ministry of Agriculture and Rural Affairs, the National Intellectual Property Administration, as well as local patent- transfer projects. She has published 25 academic papers, compiled over 40 policy recommendation reports, and co- authored/co- translated 3 books. She served as chief translator and reviewer for *Best Practice Handbook on Intellectual Property Management for Innovation in Agriculture and Health*.

SPEAKERS - THEATER 6



Yaping ZHANG

Elected Members and Principal Investigator, Chinese Academy of Sciences (CAS)

Prof Ya-Ping ZHANG, PhD, is an Elected Members and Principal Investigator of the Chinese Academy of Sciences (CAS), former Vice President of CAS, Foreign Academician of European Academy of Sciences, and an Academician of Third World Academy of Sciences. He also serves as Honorary President of Yunnan University and Chairman of the China National Committee for UNESCO's Man and the Biosphere Programme. He is a recipient of the 3rd International Biodiversity Leadership Awards (the first recipient in Asia). His long-term research focuses on evolutionary genetics. He pioneered the application of adaptive evolution theory to analyze complex animal traits and, in recent years, has focused on establishing a new system of domestic dog models for social disorder diseases and new drug development. He has published over 500 SCI papers in international journals such as Science, Nature, Nat Genet, and Proc Natl Acad Sci USA, and one monograph. His awards include the Ho Leung Ho Lee Prize for Scientific and Technological Progress, and the National Natural Science Award (Second Class, 2006 and 2014). He co-initiated the International Barcode of Life Project (iBOL), making China one of its four global nodes, led the World Cold Code Project for amphibians and reptiles, co-led the Dog10K international consortium, and represented China in the Genome 10K project, generating extensive international impact.



Danyu ZHAO

Associate Research Fellow, Institute of Nutrition and Food Safety, Chinese Center for Disease Control and Prevention (China CDC)

Danyu ZHAO serves as Associate Research Fellow at the Institute of Nutrition and Food Safety, Chinese Center for Disease Control and Prevention (China CDC). He focuses his research on food safety, nutrition- related public- health issues, food standard formulation and risk assessment. He participates in national research projects on food and nutrition, engages in domestic and international academic exchanges, and contributes scientific support to policy- making for food safety and public nutrition in China.



Wenrui ZHOU

Founder, CNI Group (Malaysia)

Wen- Rui ZHOU is Founder of CNI Group (Malaysia). With decades- long experience in food manufacturing, wellness product development and cross- border enterprise management, he leads the group's business covering food, health supplements and personal care across multiple Asia- Pacific markets. He actively promotes industry- university collaboration, sustainable product innovation and regional business exchanges, and is committed to advancing practical cooperation in agri- food technology and industrial transformation between Asia- Pacific countries.

AGENDA+ SPEAKERS BIOGRAPHIES

DAY TWO

10 September, Thu



10 September 2026 (THU), Day 2

09:00 – 10:00 | Main Stage

Biotech Investment Summit Opening Ceremony

09:00 – 13:00 | Theater 3

Cell and Gene Therapy Forum 1: Source Innovation & Commercial Breakthrough

---

09:00 – 13:00 | Theater 4

Strengthening GBA Clinical Trial Collaboration via "One Institute, One Center" (Co-organized by Greater Bay Area International Clinical Trial Institute)

09:00 – 14:00 | Theater 6

Longevity Forum:
Decoding the Biological Clock: Frontiers in Aging, Healthspan and the Longevity Industry (Co-organized by Unita Ventures)

09:00 – 10:30 | Theater 1

Reinventing Clinical Development in the AI Era — From Traditional CRO to AI-Native Clinical Development (Co- organized by Deep Intelligent Pharma)

10:00 – 12:00 | Main Stage

Keynote Speech

10:00 – 12:00 | Theater 2

Biotech Investment Summit 1: The Compass — Macro Trends and Policy Frameworks Shaping Global Biotech Investment

---

10:00 – 11:20 | Theater 5

The Hong Kong Ecosystem Session: The Full Map of Hong Kong's Biotech Ecosystem

---

10:30 – 12:00 | Theater 1

AI Forum 2: AI-Driven Science and Healthcare: From Foundation Models to a Healthier Future

---

11:20 – 13:00 | Theater 5

Biomanufacturing Forum 1: Manufacturing Beauty — Innovation, Production and Registration of Medical Aesthetics

---

12:10 – 13:10 Main Stage

Innovative Drug Forum 1: Policy, Regulation, and Translation—The Macro Landscape of Innovative Drug Development

---

13:30 – 18:00 Theater 1

TCM Innovation & Modernization Forum: From Targets to Translation
(Co-organized by School of Chinese Medicine, Hong Kong Baptist University)

13:30 – 17:30 Theater 2

Biotech Investment Summit 2:
Evolving Chapter 18A — New Paradigm of Hong Kong IPOs and Primary-Secondary Capital Pricing

---

14:00 – 18:00 Main Stage

Innovative Drug Forum 2: The Transformation and Globalization Path of Major Chinese Pharmaceutical Companies

---

14:00 – 18:00 Theater 3

AFCR Symposium --Cell and Gene Therapy Forum 2: Clinical Progress & Regulatory Innovation

---

14:00 – 16:00 Theater 4

Cross-Border Healthcare Synergy Forum

14:00 – 18:00 Theater 6

Innovative Drug Forum 3: Advancing Next-Generation Therapeutics: Discovery, Translation, and Collaboration (Co- organized by Biocytogen Pharmaceuticals)

14:40 – 18:00 Theater 5

Biomanufacturing Forum 2: Rewriting the Code of Life — The Synbio Toolbox Revolution
(Co-organized by School of Life Sciences, Tsinghua University)

16:00 – 18:00 Theater 4

Global Cooperation Forum 3： Latin- America Forum (Co-organized by Hony Capital)

17:00 – 18:00 Theater4

The future potential of Asia's biotech sector

09:00 - 10:00 (MAIN STAGE)

Biotech Investment Summit Opening Ceremony

Opening Remarks: **Paul Chan Mo-po**
Financial Secretary of the Hong Kong Special Administrative Region

09:00 - 13:00 (THEATER 3)

Cell and Gene Therapy Forum 1: Source Innovation & Commercial Breakthrough

Moderator: **Derek MA**
Executive Director, Beike Biotechnology (Qionghai) Co., Ltd

Speakers:

Wensheng WEI
Professor, Peking University
Speech Title: Programming the Cure: The Clinical Promise of Gene Editing

Jie MA
Head of National Center for Clinical Laboratories and Biotherapy Center, Beijing Hospital
Speech Title: Current research and application stutus of cell therapy in Chinese hospitals

Michelle CHEN
CEO, Form Bio
Speech Title: Scaling Genetic Medicine and Genome Engineering with AI

Reagan JARVIS
Co-Founder and CEO of Anocca
Speech Title: Systematised Discovery and Scalable Development of TCR-T Cell Therapies to Access Tumour- Selective Target Space for Cancer Treatment

Stanley SY
Co-Founder & CEO, Hong Kong Regen Medtech Limited
Speech Title: Advancing Clinical Translation: Navigating PIC/S GMP Standards for Clinical-Grade Stem Cell Therapies in Hong Kong.

Martin CHAN
Vice President, GenEditBio Limited
Speech Title: From Zero to One: The Journey of Our First Clinical Asset in Genome-Editing Therapy

Xian ZENG
CEO, Byterna Therapeutics Ltd.
Speech Title: Reprogramming Immunity in Autoimmune Disease: In Vivo CAR-T Powered by AI and Circular mRNA

Panel: Decoding Biotech Entrepreneurship – New Book Sharing Session

Panelist: Donglei MAO, Wei CAO

Panel: Cracking CGT — Manufacturing, Payment and Globalization

Moderator: Michelle CHEN
Panelist: Arthur ZHOU, Guokai CHEN, Lung-I CHENG, Reagan JARVIS

09:00 - 13:00 (THEATER 4)

Strengthening GBA Clinical Trial Collaboration via "One Institute, One Center" (Co-organized by Greater Bay Area International Clinical Trial Institute)

Opening Remarks: **Bernard CHEUNG**
Chief Executive Officer, Greater Bay Area International Clinical Trial Institute

Session I : The GBA Clinical Trial Platform in a New Policy Era

Speakers:

Yichong LI
President, Greater Bay Area International Clinical Trials Center (Bay Trial)
Speech Title: The "818 Decree" Opportunity: How the Greater Bay Area's Full-Service Clinical Trial Platform is Accelerating Biomedical Innovation

Andrea LUK
Director of the Clinical Research Management Office, The Chinese University of Hong Kong
Speech Title: In Trusted Hands: Turning Science into Solutions at CUHK

Stephanie WONG
Clinical Assistant Professor, Division of ENT, Department of Surgery, School of Clinical Medicine, The University of Hong Kong
Speech Title: Redefining Salvage Treatment in Locally Recurrent Nasopharyngeal Carcinoma: Neoadjuvant Immune-Chemotherapy as a Gateway to Surgical Cure

09:00 - 13:00 (THEATER 4)

Session II: Real-World Evidence in the GBA — Cross-Sector Collaboration for Healthcare Impact

Moderator: **Ching-lung CHEUNG**
Director, Real-World Study and Application Centre, Greater Bay Area International Clinical Trial Institute
Speech Title: Mission & Blueprint of RWSAC

Panel: Turning Real-World Data into Real-World Impact
Panelist: Bernard CHEUNG, Ching-lung CHEUNG, Elaine CHU, Ian C.K. WONG, Lap Gate WONG, Michael YIM, Sumitra SHANTAKUMAR, Wenting LI

Session III: Cross- Border Collaboration in Clinical Trials

Panel: One Protocol, Many Sites — Cracking the Code of Cross-Border Multicenter Trials

Moderator: Creany WONG
Panelist: Abdulrazaq AL-JAZAIRI, Andrea LUK, Danyi WEN, Stephanie WONG, Tong GUO, Yichong LI

09:00 - 14:00 (THEATER 6)

Longevity Forum: Decoding the Biological Clock: Frontiers in Aging, Healthspan and the Longevity Industry (Co-organized by Unita Ventures)

Opening Remarks: **Lan LU**
CEO, Unita Ventures

Christine HUANG
Founder & CEO, Quantum Life Limited; Managing Director, HK Longevity Medical Centre

Speakers (Part 1):

Raju KUCHERLAPATI
Paul C. Cabot Professor of Genetics and Professor of Medicine at Harvard Medical School
Speech Title: Decoding the Biological Clock: Genetics, Genomics and Precision Health

Morten SCHEIBYE-KNUDSEN
Associate Professor at the University of Copenhagen; President of the Nordic Aging Society
Speech Title: DNA Repair, AI and Drug Repurposing in Aging Research

Jeffrey EGLER
Chief Medical Officier, Noom
Speech Title: The Habit Catalyst: Operationalizing Clinical Longevity for the Masses

Hiroshi NOMURA
Medical Director, N2 Clinic Hotel Chinzanso Tokyo; Researcher, Department of Healthy Aging, Kyoto University Graduate School of Medicine; Special Medical Advisor, Gakken Dementia Prevention Research Laboratory
Speech Title: From Omics to Bio-Intelligence: Integrating Human and Cellular Data into AI-Guided Clinical Regenerative Medicine

Speakers (Part 2):

Barry WANG
Director of Technology, Quantum Life Limited
Speech Title: From Quantifying Aging to AI-Driven Longevity Medicine in Practice

Zhenglong GU
Professor, The Hong Kong University of Science and Technology (Guangzhou)
Speech Title: Mitochondrial DNA Mutation and Disease: Young and Old

Ronjon NAG
President of the R42 Group/ Adjunct Professor in Genetics at the Stanford School of Medicine
Speech Title: Accelerating Longevity: How AI and Venture Capital are Driving the Next Biotech Wave

Speakers (Part 3):

Aubrey DE GREY
President and Chief Science Officer, LEV Foundation
Speech Title: Taking rejuvenation to longevity escape velocity

Panel: From Biotechnology to Bio-Intelligence: Human-Centered AI, Longevity and the Future of Preventive Health

Moderator: Christine HUANG
Panelist: Hiroshi NOMURA, Huijun ZHOU, Jeffrey EGLER, Raju KUCHERLAPATI

Panel: From Science to Scale: Building and Financing the Global Longevity Industry

Moderator: Thian CHEW
Panelist: Frank LIU, Jean-Baptiste ROY, Philippe GERWILL, Ronjon NAG

09:30 - 10:30 (THEATER 1)

Reinventing Clinical Development in the AI Era — From Traditional CRO to AI-Native Clinical Development (Co- organized by Deep Intelligent Pharma)

Speakers (Part 1):

Xing LI
Founder, Chair of the Board, Deep Intelligent Pharma (DIP)
Speech Title: TBC

Jia DAN
Company Secretary, VP, Virogin Biotech
Speech Title: TBC

Speakers (Part 2):

Ashton JIANG
VP, Co-GM of Materials Science, DIP
Speech Title: TBC

Panel: How the Next Generation of Clinical Trials Will Really Work

Moderator: Will CHEN
Panelist: Fang XIA, Jinsong LI, Luke ZHOU, Qi JIN

10:00 - 12:00 (MAIN STAGE)

Keynote Speech

Speakers:

Yaping ZHANG
Elected Members and Principal Investigator of the Chinese Academy of Sciences (CAS)
Speech Title: A new canine model system for mental health

Jian Kang ZHU
President, Macau University of Science and Technology
Speech Title: Turning back the DNA methylation clock for health and longevity

Frances PLATT
Head of Department of Pharmacology, University of Oxford
Speech Title: From Curiosity to Therapies: Turning Academic Science into Patient Impact

Jay D. KEASLING
Department of Chemical & Biomolecular Engineering and Department of Bioengineering, University of California, Berkeley Biological Systems & Engineering Division, Lawrence Berkeley National Laboratory Joint BioEnergy Institute (JBEI)
Speech Title: Rewiring Microbes, Rewriting Health: Manufacturing Medicines in Engineered Yeast

Michael LU
Dean, School of Public Health, University of California Berkeley
Speech Title: Personal Healthcare Revolution: Healthcare Every Day, Everywhere, for Everyone

10:00 - 12:00 (THEATER 2)

Biotech Investment Summit 1: The Compass — Macro Trends and Policy Frameworks Shaping Global Biotech Investment

Chair:

Chuen Yan LEUNG
Partner (Private Investments) at Value Partners Group

Speakers:

Kim CHONG
Chief Risk Officer, Hong Kong Investment Corporation Limited
Speech Title: TBC

Zhijie ZHAO
Chief Analyst of Pharmaceutical, Medical and Healthcare, North Asia, CITIC Securities
Speech Title: China innovation-drugs outlook

Hua CAI
General Manager, CITIC MED FUNDS
Speech Title: TBC

Jialin SUN
General Manager, GTJA Investment Group
Speech Title: Global Opportunities for Chinese Innovative Drugs in the New Cycle

Kan CHEN
Co-lead of Healthcare, Qiming Venture Partners
Speech Title: TBC

Jinqiao ZHU
Founder & Chairman, Efung Capital
Speech Title: TBC

Dawei LIU
President, Shanghai Healthcare Capital
Speech Title: TBC

Alan WONG
Director, CITIC Securities Wealth Management (HK) Entrepreneur Office
Speech Title: Empowerment and Value Alignment: Wealth Architecture and Service Practices for Listed Biotech Companies and Core Shareholders

10:00 - 11:20 (THEATER 5)

The Hong Kong Ecosystem Session: The Full Map of Hong Kong's Biotech Ecosystem

Opening Remarks:
David FOSTER
Executive Director, Croucher Foundation

Moderator:
Russell CHAN
Co-founder and CEO, E-SENSE Innovation & Technology; Honorary Assistant Professor, School of Biomedical Engineering, The University of Hong Kong

Speakers:

Maggie LO
Chief Manager (Life and Health Technology) , The Office for Attracting Strategic Enterprises (OASES) of the Hong Kong SAR Government
Speech Title: Hong Kong as a Health and Medical Innovation Hub

Vicky TSE
Head of Life and Health Technology, HKSTP
Speech Title: From Hong Kong to the World: The Super-Connector Advantage for Biotech Globalization

Alex KWONG
Associate Director, Ecosystem Development(Life Science), HSITP (Hong Kong-Shenzhen Innovation and Technology Park)
Speech Title: TBC

Andy WONG
Head of Innovation and Technology at Invest Hong Kong (InvestHK)
Speech Title: Hong Kong is a thriving platform for biotechnology development

Crystal FOK
Head of Business Development at Hong Kong Cyberport Management Company Limited
Speech Title: TBC

10:30 - 12:00 (THEATER 1)

AI Forum 2: AI-Driven Science and Healthcare: From Foundation Models to a Healthier Future

Chair:
Xinzhu WANG
Co-Founder of Potentiam Biosciences

Speakers:

Aurel K. QIAN
Co-founder and Chief Medical Officer, SenseCare
Speech Title: TBC

Jason YAO
Vice President, Transfar Group
Speech Title: TBC

Allen GUO
Founder and CEO, Shuimu Future; Founding CEO, Baihe.com (Heyou.com); Founding Partner, 2048 Capital
Speech Title: TBC

Chenchong LYU
Founder & CEO, Zhejiang Yizhun Intelligent Technology Co., Ltd.
Speech Title: TBC

11:20 - 13:00 (THEATER 5)

Biomanufacturing Forum 1: Manufacturing Beauty — Innovation, Production and Registration of Medical Aesthetics

Speakers:

Hongyi ZHAO (Chair)
Director, Department of Plastic Surgery, National Center for Geriatrics, Beijing Hospital
Speech Title: A Review of NMPA Medical Device Registration and Evaluation Requirements for Injectable Tissue Fillers in Medical Aesthetics and the Current Status of Their Market Approval and Application in China

Ju NING
Founder of Shenzhen Mibai Medical Aesthetic Clinic
Speech Title: Collagen-Based Periorbital Rejuvenation and Strengthening of the Orbicularis Oculi Muscle

Piero BAGLIONI
Professor, Physical Chemistry/CSGI, Department of Chemistry, University of Florence, Italy
Speech Title: Nanostructured Twin Hydrogels for Applications in Art Conservation and Bacterial Inactivation

Zhongli LUO
Professor, Chongqing Medical University; Boarding director, Molecular Frontiers Foundation
Speech Title: The study and Applications of Chiral Self-Assembling Peptides in Regenerative Medicine for Rapid Wrinkle Reduction and Anti-Aging

Hao WANG
Head of Synthetic Biology R&D, Bloomage Biotechnology Corporation Limited
Speech Title: Repairing the Cellular "Soil": Green Biomanufacturing of Key Extracellular Matrix Actives Enabled by Synthetic Biology

12:00 - 13:00 (MAIN STAGE)

Innovative Drug Forum 1: Policy, Regulation, and Translation—The Macro Landscape of Innovative Drug Development

Speakers:

Ruiping XIAO
College of Future Technology at Peking University
Speech Title: Translational Medicine Drives Innovative Drug Discovery and Development

Yaning WANG
Founder and CEO, Rui Ning Kang Pharma
Speech Title: Impact of US FDA New Policy on China Innovative Drug Development

Sabrina CHAN
Senior Executive Director, The Hong Kong Association of the Pharmaceutical Industry
Speech Title: Policy trend on pharmaceutical and the regulation evolution

13:30 - 18:00 (THEATER 1)

TCM Innovation & Modernization Forum: From Targets to Translation (Co-organized by School of Chinese Medicine, Hong Kong Baptist University)

Chair:

Ning ZHANG
CSO, Baiyao Group; Professor, PKU Medicine

Wen Luan Wendy HSIAO
Professor (retired), State Key Laboratory of Quality Research in Chinese Medicine, Macau University of Science & Technology

Session I : Hong Kong–Mainland Chinese Medicine Talent Co-development Initiative

Speakers:

Yibin HU
Director & General Manager, Beijing Xinyi Health Technology Co., Ltd.
Speech Title: TBC

Session II: Decoding the Science, Mechanisms and Targets

Speakers:

Xin CHEN
Director, Institute of Chinese Medical Sciences; Director, SKL of Mechanism and Quality of Chinese Medicine, University of Macau
Speech Title: TNFR2 as a Therapeutic Nexus of Treg cells and a Mechanistic Basis of Immunoregulation Through Chinese Medicine

Kewu ZENG
Professor, Peking University
Speech Title: Discovery of target proteins of natural active molecules

Haitao LYU
Associate Professor, School of Chinese Medicine; Associate Director, Hong Kong TCM Phenome Research Center, Hong Kong Baptist University
Speech Title: Molecular decoding of novel targets and mechanisms underlying complex diseases via multimodal functional metabolomics

Session III: From Lab to Market, Clinical Practice and Industry

Speakers:

Ning ZHANG
CSO, Baiyao Group; Professor, PKU Medicine
Speech Title: Translational And Clinical Studies on QiXueKang

Peng Fei TU
Professor, Peking University
Speech Title: Functions Exploration and Development and Utilization of Cistanches Herba

Karl Wah-Keung TSIM
Chair Professor, Division of Life Science; Director, Center for Chinese Medicine Research & Development, The Hong Kong University of Science and Technology
Speech Title: Chinese herbal formulation – mechanistic studies

Jing HU
General Manager, Beijing Increasepharm Corp. Ltd.
Speech Title: R&D Pathways and Trends of New Traditional Chinese Medicine Drugs

Zhigang LAI
General Manager, SupremeLife Therapeutics Inc.
Speech Title: China TCM Solution for Diabetes and Metabolic Disease

Elaine Lai Han LEUNG
Interim Director of the Institute of Collaborative Innovation at the University of Macau; Head of the Centre for Innovation and Entrepreneurship; Professor of Faculty of Medicine
Speech Title: Research Translation of Natural Products Based on Gut Microbiota and Novel AI4Glyco Platform

13:30 - 18:00 (THEATER 1)

Session III: From Lab to Market, Clinical Practice and Industry

Speakers:

Hor-Yue TAN
Associate Professor, Centre for Chinese Herbal Medicine Drug Development, School of Chinese Medicine, Hong Kong Baptist University
Speech Title: Development of a novel Chinese herbal drug formulation for ulcerative colitis

Lixiang ZHAI
Assistant Professor Centre for Chinese Herbal Medicine Drug Development Limited, School of Chinese Medicine, Hong Kong Baptist University
Speech Title: Gut Microbiota and Classical Chinese Medicine Formulas: Interaction and Translational

13:30 - 17:30 (THEATER 2)

Biotech Investment Summit 2: Evolving Chapter 18A — New Paradigm of Hong Kong IPOs and Primary-Secondary Capital Pricing

Speakers (Part 1):

Kelvin TEO
Managing Director, Head of Asia, Global Issuer Services Hong Kong Exchanges and Clearing Limited

Speakers (Part 2):

Chuen Yan LEUNG
Partner (Private Investments) at Value Partners Group

Regina GREBLA
Head of Equity Research, Selesta Partners

Yang GU
Partner, Shanghai Office, Han Kun Law Offices

Roadshow

Moderator: Da LIU

Presenters: Julie ZHOU, Olivia CHEN, Adam ZHAO, Eric LUO, Chenying ZHANG

Panel: From China Innovation to Global Innovation: What's Next for China Biotech?

Moderator: Zhu CHEN

Panelists: Qiang LU, Stella XING, Wilson XU, Xiaoqiang KANG, Zhongyuan ZHU

Panel: Capital, Innovation and the Next Chapter of China Biotech

Moderator: Regina GREBLA

Panelists: Cyber CAO, Fran CHEN, Ji WANG, Kan CHEN

14:00 - 18:00 (MAIN STAGE)

Innovative Drug Forum 2: The Transformation and Globalization Path of Major Chinese Pharmaceutical Companies

Moderator:

Xiaoyan HE
Vice President, Arton Economic Institute; Deputy Director, Special Committee of the Guangdong-Hong Kong-Macao Greater Bay Area Biotechnology Alliance; Endocrinologist, Boao Super Hospital

Speakers (Part 1):

Bin LI
Vice President, Hengrui Pharma
Speech Title: From Fast Follower to Global Innovator: Hengrui's Innovation Transformation Journey and Globalization Strategies

Bo CHEN
Chief Scientific Officer, China Resources Pharmaceutical Group Limited
Speech Title: Innovative Drug R&D: Emerging Trends and Tech Disruptions

Yi LIU
Executive Director and Chief Executive Officer, Fosun Pharma
Speech Title: Innovation Transformation and Globalization – Perspectives from Fosun Pharma

Hsin TSE
Executive Director, Senior Vice President, Sino Biopharmaceutical Limited
Speech Title: Ecosystem Restructuring, Global Leap: Sino Biopharmaceutical's Innovation Narrative

Speakers (Part 2):

Bin YANG
Senior Vice President, Head of Global Clinical Operations, HutchMed
Speech Title: Challenges and strategy for the globalization of China Biotech

Youchen CHEN
CFO, Harbour BioMed
Speech Title: From Platform to Global: A New BD Paradigm for China's Biopharma Innovative

Tony HE
CFO, 3S BIO
Speech Title: China's innovative drug industry in global BD deals

Kaijun BAO
Vice President of Commercial Strategy & Assistant to Chairman, Xianweida Biotech
Speech Title: Think Smart, Aim Global: A Differentiated Path in the Metabolic Race

14:00 - 18:00 (MAIN STAGE)

Innovative Drug Forum 2: The Transformation and Globalization Path of Major Chinese Pharmaceutical Companies

Panel: MNC–China Pharma Dialogue

Moderator: Yu WANG

Panelist: Bin LI, Bo CHEN, Francois MAISONROUGE, Mia HU, Peter YU

14:00 - 18:00 (THEATER 3)

AFCR Symposium --Cell and Gene Therapy Forum 2: Clinical Progress & Regulatory Innovation

Chair: **Sujuan BA**
President & CEO, Founder of the Asian Fund for Cancer Research

Moderator: **Derek MA**
Executive Director, Beike Biotechnology (Qionghai) Co., Ltd

Speakers:

Heng Phon TOO
Co-founder and Chairman, MiRXES Pte Ltd
Speech Title: Two Singapore biotech ventures. One laboratory. One vision.

Han Chong TOH
Deputy CEO, National Cancer Centre Singapore (NCCS); Senior Consultant, Division of Medical Oncology, NCCS
Speech Title: T Cell Therapy for Cancer - How to Create More Precise Shots at Goal For The Win

Chi-kong LI
Research Professor, Department of Paediatrics, The Chinese University of Hong Kong
Speech Title: Clinical trial of cellular therapy and gene therapy for blood disorders in Hong Kong

Abdulrazaq AL-JAZAIRI
Director, Clinical Trials Transformation Division King Faisal Specialist Hospital & Research Center Riyadh, Saudi Arabia
Speech Title: Clinical Trials Ecosystem in Saudi Arabia: Potential and Attractiveness

Jianxun WANG
Chief Scientific Officer / Shenzhen Cell Valley Biopharmaceuticals Co., LTD
Speech Title: Manufacture of CAR-NK cells using eVLP-based CRISPR gene editing

Gina JIANG
Managing Director, Hong Kong Institute of Biotechnology
Speech Title: Agentic GMP Blueprint: Unlocking CGT Pipelines from AI Discovery to Patient Delivery

Kwong Hang TAM
Vice President& Chair Professor/Macau University of Science and Technology
Speech Title: Regenerative Medicine for Liver Diseases

Nancy Kwan MAN
Chair Professor, Department of Surgery, The University of Hong Kong; Founder and Director, Oncoimmunostics Ltd.
Speech Title: The Impact of Bionic Platforms for Precision Oncology

Sean HU
Chairman, Beike Biotech
Speech Title: TBC

Panel: The Last Mile to Market — How Regulators and Innovators Can Run Together

Moderator: Sherman K.W. FUNG

Panelists: Andy ZANG, Bev MENNER, Jasna CANADI, Rose Ching Kei CHING

10 September 2026 (THU), Day 2

14:00 - 16:00 (THEATER 4)

Cross-Border Healthcare Synergy Forum

Moderator: **Cecilia SHU**
Overseas BD of Carev International Technology Service Limited

Speakers:

Roben LIANG
Founder of "Health Policy 2050"
Speech Title: Exploratory Pilot Schemes for International Medical Services in China and Cross-Border Medical & Health Management Cooperation

KK TONG
Chief Executive Officer of New Frontier Health (Hong Kong)
Speech Title: Rethinking Cross-Border Cancer Care The "NGS" Approach from a Hong Kong Provider's Perspective

Zhen DING
Vice President, Xi'an International Medical Investment Co,. Ltd.
Speech Title: Professional Translation Differentiated and Coordinated Development of International Medical Services in Comprehensive Chinese Medical Institutions

Xiaolin LIU
Chairman, China Biotech Services Holdings Limited
Speech Title: BNCT-The Seventh Charioit Of Cancer Treatment

Panel: From Referral to Payment: Building the Cross-Border Healthcare Service Chain — with Hong Kong as the Hub

Moderator: Cecilia SHU

Panelists: Jacqueline CHOI, Kim Seck YEO, KK TONG, Roben LIANG, Yibin HU, Zhen DING

14:00 - 18:00 (THEATER 5)

Biomanufacturing Forum 2: Rewriting the Code of Life — The Synbio Toolbox Revolution (Co-organized by School of Life Sciences, Tsinghua University)

Chair: **Fuqing WU**
Associate Researcher, School of Life Sciences, Tsinghua University; Deputy Director, Center for Synthetic and Systems Biology, Tsinghua University

Speakers:

Xianen ZHANG
Dean and Chair Professor, Faculty of Synthetic Biology, Shenzhen University of Advanced Technology
Speech Title: Emerging biotechnologies for medical applications

Jing WANG
Researcher, National Institute of Metrology, China
Speech Title: Development and research of biometrology and biological phenotype standards

Junjie LIU
Associate Professor, School of Life Sciences, Tsinghua University; Associate Professor, Center for Synthetic and Systems Biology, Tsinghua University
Speech Title: Development and application of gene-editing tools

Fuqing WU
Associate Researcher, School of Life Sciences, Tsinghua University; Deputy Director, Center for Synthetic and Systems Biology, Tsinghua University
Speech Title: Development and Application of Next-Generation Industrial Biotechnology Based on Halophiles

Xinhui XING
Professor, Shenzhen International Graduate School, Tsinghua University; Professor, Center for Synthetic and Systems Biology, Tsinghua University
Speech Title: AI empowered Biofunction Mining and Manufacturing for pharmaceuticals and nutraceuticals

Ying ZHANG
Founder and Chief Scientific Officer (CSO), Liying Biotech
Speech Title: AI Agents + Automated Cell-Free Systems for Next-Gen Protein Engineering

Runming WANG
Associate Professor, Shenzhen International Graduate School, Tsinghua University; Associate Professor, Center for Synthetic and Systems Biology, Tsinghua University
Speech Title: Illuminating the Dark Matter of the Manganese Metalloproteome: A Metal-Competition Regulatory Principle for Cell Factory Engineering

Haifeng WANG
Associate Professor, School of Life Sciences, Tsinghua University; AssociatProfessor, Center for Synthetic and Systems Biology, Tsinghua University
Speech Title: Efficient and precise programmable DNA knock-in without double strand breaks

Wei CHAO
Senior Vice President, Beijing Shougang Lanzatech Technology Co., Ltd.
Speech Title: Integrated Bio-Fermentation Technology for Ethanol & Microbial Protein from Carbon-Rich Industrial Exhaust Gases

14:00 - 18:00 (THEATER 6)

Innovative Drug Forum 3: Advancing Next-Generation Therapeutics: Discovery, Translation, and Collaboration (Co- organized by Biocytogen Pharmaceuticals)

Opening Remarks:

Benny YANG
CSO, Biocytogen

Speakers:

Zhiwei CHEN
Director, AIDS Institute; Chair Professor, Department of Microbiology, LKS Faculty of Medicine, The University of Hong Kong
Speech Title: Advancing First-in-Class Immunotherapeutics Originated in Hong Kong

Xiaoyi Benjamin LI
Chairman & CEO, Zhaoke Ophthalmology Limited
Speech Title: Next Generation ADCs, from payload delivery to dual pharmacology

Yujie LIU
Director of Pharmacology Department, Biocytogen Pharmaceuticals (Beijing) Co., Ltd
Speech Title: Humanized Animal Models Advanced Preclinical Tools for Translational Research and Clinical Insights

Shui On LEUNG
Chairman, Executive Director and Chief Executive Officer, SinoMab BioScience
Speech Title: Modulating the Immune System for Improved Clinical Outcomes

Emily TAN
Chief Operating Officer, Sequencio Therapeutics
Speech Title: Strategies for Clinical Development of Therapeutic Cancer Vaccines

Benny YANG
CSO, Biocytogen
Speech Title: RenSuper™ Biologics: Empowering Next-Gen ADCs with AI-Driven Precision and Scalability

Panel: The practical implementation of next-generation innovative therapies, collaboration between industry, academia, and research, and cross-sector asset trading

Panelists: Benny YANG, Emily TAN, Gergely TOTH, Shui On LEUNG, Xiaoyi Benjamin LI, Zhiwei CHEN

14:40 - 18:00 (THEATER 5)

Biomanufacturing Forum 3: Rewriting the Code of Life — The Synbio Toolbox Revolution (Co-organized by School of Life Sciences, Tsinghua University)

Chair:

Fuqing WU
Deputy Director, Center for Synthetic and Systems Biology, Tsinghua University

Speakers:

Fuqing WU
Deputy Director, Center for Synthetic and Systems Biology, Tsinghua University
Speech Title: Development and Application of Next-Generation Industrial Biotechnology Based on Halophiles

Haifeng WANG
Associate Professor, Tsinghua University
Speech Title: Efficient and precise programmable DNA knock-in without double strand breaks

Junjie LIU
Associate Professor, Tsinghua University
Speech Title: Development and application of gene-editing tools

Runming WANG
Associate Professor, Tsinghua University
Speech Title: Illuminating the Dark Matter of the Manganese Metalloproteome: A Metal-Competition Regulatory Principle for Cell Factory Engineering

Wei CHAO
Senior Vice President, Beijing Shougang Lanzatech Technology Co., Ltd.
Speech Title: Integrated Bio-Fermentation Technology for Ethanol & Microbial Protein from Carbon-Rich Industrial Exhaust Gases

Xian-En ZHANG
Dean and Chair Professor, Faculty of Synthetic Biology, Shenzhen University of Advanced Technology
Speech Title: Emerging biotechnologies for medical applications

Xinhui XING
Professor, Shenzhen International Graduate School, Tsinghua University
Speech Title: AI empowered Biofunction Mining and Manufacturing for pharmaceuticals and nutraceuticals

Yazhuo LI
Deputy General Manager, Science and Technology Innovation Department, China Merchants Innovation Technology (Group) Co., Ltd.
Speech Title: China Merchants Group's Thoughts, Visions, and Strategies in the Biotechnology Sector

Ying ZHANG
Founder and Chief Scientific Officer (CSO), Liying Biotech
Speech Title: AI Agents + Automated Cell-Free Systems for Next-Gen Protein Engineering

16:00 - 17:00 (THEATER 4)

Global Cooperation Forum 3: Latin America Forum (Co-organized by Hony Capital)

Panel: Bridging Continents: China–Latin America–US Pathways in Clinical Trials and Partnerships

Moderator: Xin LIU
Panelists: Angelo ORRU NETO, Daniel ZEQUETO, Joshua CARLE, Michael LIANG, Ming TANG, Nikhil SHAH

17:00 - 18:00 (THEATER 4)

The future potential of Asia's biotech sector

Opening Remarks: **Albert Cheung Hoi YU**
Chairman of Hong Kong Biotechnology Organization

Magazine Introduction: **Toh Han SHIH**
Chief editor, Asia Bio Inc; Consultant, Headland Intelligence

Panel: Hong Kong's competitiveness vs. Singapore, Shanghai, and other Asia-Pacific hubs

Moderator: Donglei MAO
Panelists: Albert Cheung Hoi YU, Fang XIA, Peter GUY, Toh Han SHIH

KEYNOTE SPEAKERS - MAINSTAGE



Tim HUNT

2001 Nobel Prize in Physiology or Medicine, the Francis Crick Institute

Tim Hunt grew up in Oxford, where he became fascinated by science at the Dragon School. At 14, he entered Magdalen College School, where his interest in biology grew. Tim entered Clare College, Cambridge in 1961 to read Natural Sciences. He joined the Department of Biochemistry in 1964 as a graduate student working on the control of haemoglobin synthesis. In 1968 he moved to the Albert Einstein College of Medicine in New York as a postdoctoral Fellow with Irving London. Tim returned to the Department of Biochemistry in Cambridge in 1971 where he continued to work on translational control throughout the 1970s. He taught summer courses at the Marine Biological Laboratory, Woods Hole, Massachusetts from 1977 to 1983, looking at changes in protein synthesis in sea urchin and clam eggs after fertilisation. In 1979, he helped Joan Ruderman and Eric Rosenthal with experiments on the translational control of maternal mRNA in clam eggs, where two of the major mRNAs concerned later turned out to be the A and B-type cyclins. By 1982, Tim had almost exhausted the potential of sea urchin eggs, but it was then that he performed the experiment that led to the discovery of cyclins and subsequent research on the control of the cell cycle. In 1990, Tim joined ICRF (subsequently Cancer Research UK) in London. He became a fellow of the Royal Society in 1991, a foreign associate of the US National Academy of Sciences in 1999 and shared the Nobel Prize for Physiology or Medicine with Lee Hartwell and Paul Nurse in 2001. He enjoys cooking, photography and making up problems for Molecular Biology of the Cell with his friend John Wilson. In 2016, he and his wife Mary Collins moved to Okinawa, where Mary was the Provost of OIST (Okinawa Institute of Science and Technology). In 2022, Mary was appointed Director of the Blizard Institute of QMUL and they returned to London, where Tim holds an emeritus position at the Francis Crick Institute.



Jay D. KEASLING

Department of Chemical & Biomolecular Engineering and Department of Bioengineering, University of California, Berkeley Biological Systems & Engineering Division, Lawrence Berkeley National Laboratory Joint BioEnergy Institute (JBEI)

Jay Keasling is the Philomathia Distinguished Professor of Alternative Energy at the University of California, Berkeley in the Department of Bioengineering and the Department of Chemical and Biomolecular Engineering, senior faculty scientist at Lawrence Berkeley National Laboratory, and Chief Executive Officer of the Joint BioEnergy Institute (JBEI). Dr. Keasling's research focuses on metabolic engineering of microorganisms for environmentally friendly synthesis of drugs, chemicals, and fuels. Keasling received a B.S. in Chemistry and Biology from the University of Nebraska and M.S. and Ph.D. in Chemical Engineering from the University of Michigan, and did post-doctoral research in biochemistry at Stanford University. He is a member of the National Academy of Engineering, the National Academy of Inventors, and the American Academy of Arts and Sciences. Keasling has published over 550 papers in peer-reviewed journals and has over 75 issued patents. Keasling has won numerous awards. Keasling is the founder of Amyris, LS9, Lygos, Napigen, Demetrix, Maple Bio, Apertor Pharma, Zero Acre Farms, Cyklos Materials, BioMia, and ResVita Bio.



Michael LU

Dean, School of Public Health, University of California Berkeley

Dr. Michael C. Lu, MD, MS, MPH is the Dean of the School of Public Health at the University of California, Berkeley. Prior to coming to Berkeley, Lu served as Director of the federal Maternal and Child Health Bureau. During his tenure, he transformed key federal programs in maternal and child health, and launched major initiatives to reduce maternal, infant, and child mortality across the nation. For his leadership, he was awarded the prestigious U.S. Department of Health and Human Services' Hubert H. Humphrey Service to America Award in 2013. Prior to his government service, Lu was a professor of obstetrics-gynecology and public health at UCLA, where his research focused on racial-ethnic disparities in birth outcomes from a life-course perspective. As a practicing obstetrician for nearly two decades, he attended more than 1000 births, and was voted one of the Best Doctors in America. Lu is a member of the National Academy of Medicine. Lu received his bachelor's degrees in political science and human biology from Stanford University, master's degrees in health and medical sciences and public health from UC Berkeley, medical degree from UC San Francisco, and residency training in obstetrics and gynecology from UC Irvine.

KEYNOTE SPEAKERS - MAINSTAGE



Frances PLATT

Head of Department of Pharmacology, University of Oxford

Professor Frances Platt obtained her BSc in Zoology from Imperial College London and her PhD from the University of Bath, UK. She undertook postdoctoral training at Washington University School of Medicine in St. Louis, USA. She was a Lister Institute Senior Research Fellow and is currently Professor of Biochemistry and Pharmacology at the University of Oxford. Her research focuses on the biology and pathobiology of glycosphingolipids and lysosomal disorders. This work has led to the development of miglustat and Aqneursa for the treatment of glycosphingolipid lysosomal storage diseases. Professor Platt was elected a Fellow of the Academy of Medical Sciences in 2011, appointed Head of the Department of Pharmacology in 2020, and elected a Fellow of the Royal Society in 2021. She was elected a foreign member of the Royal Swedish Academy of Sciences in 2025.



Yaping ZHANG

Elected Members and Principal Investigator of the Chinese Academy of Sciences (CAS)

Prof Ya-Ping ZHANG, PhD, is an Elected Members and Principal Investigator of the Chinese Academy of Sciences (CAS), former Vice President of CAS, Foreign Academician of European Academy of Sciences, and an Academician of Third World Academy of Sciences. He also serves as Honorary President of Yunnan University and Chairman of the China National Committee for UNESCO's Man and the Biosphere Programme. He is a recipient of the 3rd International Biodiversity Leadership Awards (the first recipient in Asia). His long-term research focuses on evolutionary genetics. He pioneered the application of adaptive evolution theory to analyze complex animal traits and, in recent years, has focused on establishing a new system of domestic dog models for social disorder diseases and new drug development. He has published over 500 SCI papers in international journals such as Science, Nature, Nat Genet, and Proc Natl Acad Sci USA, and one monograph. His awards include the Ho Leung Ho Lee Prize for Scientific and Technological Progress, and the National Natural Science Award (Second Class, 2006 and 2014). He co-initiated the International Barcode of Life Project (iBOL), making China one of its four global nodes, led the World Cold Code Project for amphibians and reptiles, co-led the Dog10K international consortium, and represented China in the Genome 10K project, generating extensive international impact.



Jian Kang ZHU

President of Macau University of Science and Technology

Professor Jian-Kang Zhu is a world-renowned molecular geneticist and plant biologist, elected to the U.S. National Academy of Sciences, and currently President and Chair Professor at Macau University of Science and Technology. He earned his Ph.D. in Plant Physiology from Purdue in 1993. He has held professorships at Arizona, UC Riverside (where he directed the Institute for Integrative Genome Biology and held the Jane Johnson Chair), KAUST as Center Director, and Purdue as Distinguished Professor. He also served as Director of the Shanghai Center for Plant Stress Biology, CAS, from 2012–2021, and since 2022 as Director of the Institute for Advanced Biotechnology at Southern University of Science and Technology. His research spans plant stress biology, epigenetics, and gene-editing technology. He pioneered the SOS pathway for salt tolerance, uncovered mechanisms of drought and cold stress, and developed highly efficient gene-editing tools used in crop breeding and cell/gene therapy. He also discovered DNA demethylation, enabling methylation editing for disease treatment and anti-aging. With hundreds of publications, his work has garnered over 185,000 citations and an h-index of 204. He is a perennial Highly Cited Researcher and serves on editorial boards of leading journals, exerting global influence in stress biology, epigenetics, and biotechnology.

SPEAKERS - MAINSTAGE



Kaijun BAO

Vice President of Commercial Strategy & Assistant to Chairman, Xianweida Biotech

Work Resume Current: Vice President of Commercial Strategy, Assistant to Chairman, Xianweida Biotech; Former: Secretary of the Board, Executive Director of Strategy Development, Simcere Pharmaceutical Group; Former: Vice President, Commercialization & BD, Hengrui Medicine Autoimmune Subsidiary; Participant of 2025 National Major Special Project for Innovative Medicines *Research and Development of Novel Biologic Drugs for Metabolic Diseases Based on Cytokines*; Expert, CITIC Medical Expert Committee; Postgraduate Supervisor, Southeast University; Former: Director of Science Development Department, National Key Laboratory of Neural and Tumor Drug Research and Development; Domain Performance Familiar with pipeline planning, commercial strategy and securities market investment in the innovative drug field; During the tenure in charge of strategy at Simcere, led and promoted the project initiation and transactions of autoimmune JAK1, insomnia orexin and other projects; During the tenure as Board Secretary at Simcere, promoted the Hong Kong- stock listing and fundraising process; In early years, served as Business Division Head, Product Director and other positions, engaged in product and marketing management for more than 15 years; Graduated from Nanjing University.



Paul Mo-po CHAN

Financial Secretary of the Hong Kong Special Administrative Region

Mr Chan is a Certified Public Accountant. He is a former President of the Hong Kong Institute of Certified Public Accountants.
Before joining the Government, Mr Chan held a number of public service positions including member of the Legislative Council and Chairman of Legal Aid Services Council. Mr Chan served as Secretary for Development from July 2012 to January 2017. He has been Financial Secretary since 2017.

SPEAKERS - MAINSTAGE



Sabrina CHAN

Senior Executive Director, The Hong Kong Association of the Pharmaceutical Industry

Sabrina is the Senior Executive Director of the Hong Kong Association of the Pharmaceutical Industry (HKAPI). She is currently member of Postgraduate Pharmacy Training and Development Committee, the Pharmacy and Poison Board of Hong Kong and member of Wholesales & Retail Task Force under Business Facilitation Advisory Committee, the government of HKSAR. She is also the Chair of the Advisory Board of Pharmacy Education, Department of Pharmacology and Pharmacy, the University of Hong Kong as well as member of Primary and Community Health Committee, HK Young Women's Christian Association (YWCA); member of Steering Committee, Asia Partnership Conference of Pharmaceutical Associations (APAC); member of APEC Biopharmaceutical Working Group on Business Ethics and member of Inter-governmental Organisation, Ethics and Compliance Committee, International Federation of Pharmaceutical Manufacturers Associations (IFPMA).

She was honored with the 2025 HKSAR Chief Executive's Commendation for Community Services in recognition of her contributions to health and medical development in Hong Kong and received the APEC 2020 Lighthouse Award on Business Ethics for Small and Medium Enterprises—marking the first time a person from Hong Kong has received this prestigious accolade.

Sabrina studied Communications in Hong Kong when she began her tertiary education. She holds a graduate degree in International Studies from the University of Sheffield (UK), as well as law degrees from University of Tsinghua (China) and the Chinese University of Hong Kong.



Bo CHEN

Chief Scientific Officer, China Resources Pharmaceutical Group Limited

Dr. Bo Chen is a specially-appointed expert for overseas high-level talents . He is currently the Chief Scientific Officer at China Resources Pharmaceutical Group Limited. He has more than 20 years of international career in the biotechnology and pharmaceutical industries, including basic research and innovative drug R&D team leadership in top scientific research institutions and pharmaceutical companies such as the National Institutes of Health, AstraZeneca, etc.

He has R&D background in the entire R&D value chain from target discovery to clinical development and commercial operation. He received his PhD. degree from the Air Force Medical University (China), completed the postdoctoral fellowship at the National Institutes of Health in the United States, and later obtained an MBA degree from Hood College (U.S.A)

He has published dozens of academic papers, book chapters and patents in peer-reviewed journals, including papers published in top journals such as Annals of the Rheumatic Diseases, Nature Communication, Nature Immunology, Nature Medicine, PNAS, etc.

He has won the second prize of the Ministry of Health's Science and Technology Progress Award, the AstraZeneca Staff Platinum Award and Silver Award, the NIH Outstanding Researcher Award, Qilu Pharmaceutical Group's Outstanding Leadership Award, etc.

SPEAKERS - MAINSTAGE



Youchen CHEN

CFO, Harbour BioMed

Mr. Youchen (YC) Chen is Chief Financial Officer, based in Shanghai and Hong Kong, China. At Harbour BioMed, YC is responsible for developing and managing global financial operation strategy, investments, capital markets activities and investor relations.
YC holds a Bachelor in law from Fudan University and an MBA from McDonough School of Business, Georgetown University. He is also pursuing an advanced degree at Harvard Medical School. Before taking on CFO role, he was VP of Finance, Corporate Development, IR and Strategy at Harbour BioMed and successfully led a series of landmark transactions with global partners. Prior to Harbour BioMed, he was CFO at a clinical-stage radiopharmaceutical startup and also worked as Vice President at Credit Suisse China Investment Banking and Capital Market team, advising Greater China healthcare and tech companies on strategic and financing transactions. Prior to rejoining Credit Suisse, he worked as Head of Corporate Finance at Yidu Tech (2158. HK) and audit assistant manager at KPMG.



Mia HU

Senior Director, Investment – Global BI Venture Fund

Dr. Mia Hu, PhD is Senior Director at the Boehringer Ingelheim Venture Fund (BIVF), based in Hong Kong. She leads therapeutic investments and startup incubation activities across Asia, helping identify and support breakthrough innovations in biotechnology, pharmaceuticals, and digital health.

Holding a PhD in Biomedical Sciences from The University of Hong Kong, Dr. Hu began her career in academic research, focusing on aging, regenerative medicine, and oncology. Since transitioning into healthcare investment in 2017, she has built expertise at the intersection of science, venture capital, and innovation commercialization.

Since joining BIVF in 2021, Dr. Hu has played a key role in expanding the fund's presence in Asia through therapeutic investments, venture building, and ecosystem partnerships. She currently serves on the boards of Nuevocor and Synthetica Pioneering and was instrumental in launching the HKSTP × BIVF Co-incubation Program to foster healthcare innovation in Hong Kong.



Tony HE

CFO, 3S BIO

-Responsible for international business, financial mgmt., capital markets, and investor relations
-Previously worked for Citi and JPMorgan in their Hong Kong and US offices
-15 years experience in capital markets across various sectors in China and the US
-Master of Arts in Finance from Guanghua Management School, Peking University

SPEAKERS - MAINSTAGE



Xiaoyan HE

Vice President, Arton Economic Institute; Deputy Director, Special Committee of the Guangdong-Hong Kong-Macao Greater Bay Area Biotechnology Alliance; Endocrinologist, Boao Super Hospital

Dr. He holds a PhD in Hospital Management from Fudan University and an EMBA from Washington University in St Louis. With over a decade of clinical practice at Shanghai Ruijin Hospital and another decade as China Medical Affairs Head at Pfizer, AbbVie and other multinational corporations, she is uniquely positioned to bridge clinical medicine, industry, management and capital. Dr He is committed to advancing the integration of medical research, industry and capital, alongside regulatory innovation. In the fields of cardiovascular-metabolic diseases, oncology immunology and cell therapy (TCR-T, bispecific antibodies), she excels in clinical development, product lifecycle management, and investment-grade medical due diligence and asset transactions. She actively promotes the application of AI and real-world evidence, and contributed to the compilation of China Medical Artificial Intelligence Legal and Compliance Guidelines – the country's first authoritative framework establishing ethical, safety and regulatory standards for AI in healthcare.



Bin LI

Vice President, Hengrui Pharma

Bin Li，Vice President, Head of Preclinical Development and Translational Medicine at Hengrui Pharma. Education: MD, China Medical University Master's in Molecular Biology and Genetics, Ph.D. in Bioinformatics, University of Alberta Postdoctoral Fellow, Harvard Medical School / Massachusetts General Hospital Work Experience: Vice President, Head of Preclinical Development and Translational Medicine, Hengrui Pharma, 2021–present Executive Director and Early Asset Lead, Translational Medicine, Boehringer Ingelheim, 2021–2025 Director, Translational Medicine, Bristol Myers Squibb, 2018–2021 Associate Director, Translational Medicine, Novartis, 2009–2018



Yi LIU

Executive Director and Chief Executive Officer, Fosun Pharma

Mr. Yi LIU, holds a Bachelor's degree in Engineering from Beijing Institute of Technology, a Master's degree in Management from Peking University, and a Ph.D. in Biomedical Engineering from Beihang University. Prior to joining Fosun Pharma, Mr. Liu had extensive experience focusing on the medical devices and medical diagnosis fields, accumulating profound industry expertise and professional insights.

Current Positions
Mr. Liu currently serves as the Chief Executive Officer and President of Fosun Pharma, as well as the Chairman and Chief Executive Officer of the Medical Diagnostics & Technology Division. In addition, he holds key management and directorship positions in several holding subsidiaries and entities of Fosun Pharma, including:
Sisram Medical Ltd (a company listed on The Stock Exchange of Hong Kong Limited, Stock Code: 01696): Executive Director and Chairman of the Board
Shanghai Henlius Biotech, Inc. (a company listed on The Stock Exchange of Hong Kong Limited, Stock Code: 02696): Non-executive Director

Note on Official Terminology Sources:
Fosun Pharm and Sisram Medical Ltd English translations and official entity names are sourced directly from their official corporate governance filings, annual reports, and Hong Kong Stock Exchange (HKEX) disclosures.
Shanghai Henlius Biotech, Inc. is the official English corporate name registered and used by the company in its HKEX announcements and public filings.

SPEAKERS - MAINSTAGE



Yi LIU

Executive Director and Chief Executive Officer, Fosun Pharma

Mr. Yi LIU, holds a Bachelor's degree in Engineering from Beijing Institute of Technology, a Master's degree in Management from Peking University, and a Ph.D. in Biomedical Engineering from Beihang University. Prior to joining Fosun Pharma, Mr. Liu had extensive experience focusing on the medical devices and medical diagnosis fields, accumulating profound industry expertise and professional insights. Current Positions Mr. Liu currently serves as the Chief Executive Officer and President of Fosun Pharma, as well as the Chairman and Chief Executive Officer of the Medical Diagnostics & Technology Division. In addition, he holds key management and directorship positions in several holding subsidiaries and entities of Fosun Pharma, including: Sisram Medical Ltd (a company listed on The Stock Exchange of Hong Kong Limited, Stock Code: 01696): Executive Director and Chairman of the Board Shanghai Henlius Biotech, Inc. (a company listed on The Stock Exchange of Hong Kong Limited, Stock Code: 02696): Non-executive Director Note on Official Terminology Sources: Fosun Pharm and Sisram Medical Ltd English translations and official entity names are sourced directly from their official corporate governance filings, annual reports, and Hong Kong Stock Exchange (HKEX) disclosures. Shanghai Henlius Biotech, Inc. is the official English corporate name registered and used by the company in its HKEX announcements and public filings.



Michael LU

Dean, School of Public Health, University of California Berkeley

Dr. Michael C. Lu, MD, MS, MPH is the Dean of the School of Public Health at the University of California, Berkeley. Prior to coming to Berkeley, Lu served as Director of the federal Maternal and Child Health Bureau. During his tenure, he transformed key federal programs in maternal and child health, and launched major initiatives to reduce maternal, infant, and child mortality across the nation. For his leadership, he was awarded the prestigious U.S. Department of Health and Human Services' Hubert H. Humphrey Service to America Award in 2013. Prior to his government service, Lu was a professor of obstetrics-gynecology and public health at UCLA, where his research focused on racial-ethnic disparities in birth outcomes from a life-course perspective. As a practicing obstetrician for nearly two decades, he attended more than 1000 births, and was voted one of the Best Doctors in America. Lu is a member of the National Academy of Medicine. Lu received his bachelor's degrees in political science and human biology from Stanford University, master's degrees in health and medical sciences and public health from UC Berkeley, medical degree from UC San Francisco, and residency training in obstetrics and gynecology from UC Irvine.

SPEAKERS - MAINSTAGE



Francois MAISONROUGE

Senior Managing Director, Evercore Partners

Francois Maisonrouge is the chairman of Evercore's Global Healthcare Group.

At Evercore, among other transactions, Mr. Maisonrouge was involved in advising Star on its sale to Incyte, Apellis on its sale to Biogen, GSK on its acquisitions of Rapt and of Boston Pharma, Cidara on its sale to Merck, Regulus on its sale to Novartis, Novo Nordisk on its acquisition of manufacturing facilities from Catalent; Takeda on its acquisition of Nimbus; Arena Pharmaceuticals on its sale to Pfizer; Novo Nordisk on its acquisition of Dicerna Pharmaceuticals; Parexel on its sale to EQT; AstraZeneca on its acquisition of Alexion; Sanofi on its acquisition of Principia; Nestlé on its sale of Nestlé Skin Health to EQT and ADIA; Bristol-Myers Squibb on its acquisition of Celgene; Takeda on its acquisition of Shire; AstraZeneca on its defense across from Pfizer; and Sun Pharmaceutical Industries on its acquisition of Ranbaxy Laboratories from Daiichi-Sankyo.

In addition, Mr. Maisonrouge has advised on numerous IPOs (including most recently the IPO of Parabilis, the largest Biotech IPO of all time) and follow-on equity offerings, principally for biotech companies, as well as structured capital raising transactions.

Prior to joining Evercore, Mr. Maisonrouge was a managing director and chairman of life sciences at Credit Suisse.

He is a member of the Board of Advisors of the Harvard Business School Health Care Initiative, and the chairman of the Pasteur Foundation. In 2014, Mr. Maisonrouge was awarded the rank of Chevalier de la Légion d'Honneur.

Mr. Maisonrouge holds an M.S. in engineering from Ecole Centrale de Lyon and an MBA from Harvard Business School.



Hsin TSE

Executive Director, Senior Vice President, Sino Biopharmaceutical Limited

Mr. Tse Hsin, is an executive director, a member of the executive board committee and a senior vice president of the Company. Mr. Tse Hsin is mainly responsible for mergers and acquisitions and financing activities of the Group.

Mr. Tse Hsin graduated from the University of Hong Kong with a Bachelor's Degree (Honors) in Industrial Engineering. He joined the Group in August 1995 as an assistant to the president of the Company and served as the general manager of Xian C.P. Pharmaceutical Co., Ltd.

Mr. Tse Hsin was a council member of the first council and an executive council member of the second council of Chaozhou Natives Chamber of Commerce Beijing. He was also an executive member of the Right Protection Association for the Medical Treatment Equipment Enterprises of the Shaanxi Province, a vice chairman of the fourth council of the Foreign Invested Enterprises Association of the Shaanxi Province, an executive member of the third committee of the Shaanxi Cancer Fighting Association and a vice chairman of the World Chinese Medicine and Pharmaceutical Professional Joint Committee.

He was awarded the "Outstanding Management Award for Foreign-invested Enterprises of Shaanxi Province" by the Shaanxi Provincial Government and the "Outstanding entrepreneur who cares about his staff" by the Shaanxi Foreign Invested Enterprises Association.

Mr. Tse Hsin was a director of CT Tianqing, Beijing Tide, and CP Pharmaceutical (Qingdao) Co., Ltd., and is currently a director of NJCTTQ, HanchorBio Inc. and CP Boai Investment Ltd., the chairman of Chia Tai Shaoyang Orthopedic Hospital, and a supervisor of CT Tianqing.

SPEAKERS - MAINSTAGE



Yu WANG

Chairman, Chinese Foundation for Hepatitis Prevention and Control

Wang Yu is the chairman of the China Foundation for Hepatitis Prevention and Control.
He received his M.D. from Beijing Medical University and Ph.D. from Japan Jichi Medical University. He has a professional background in viral molecular biology and immunology and has been engaged in research on hepatitis viruses and related diseases. He has successively served as the Director of the Hepatology Institute of Beijing Medical University, the Vice President of Beijing Medical University, the Deputy Director of the China National Biotechnology Development Center, and the Deputy Director of the Department of Rural and Social Development of the Ministry of Science and Technology. From 2004 to 2017, he served as the director General of the Chinese Center for Disease Control and Prevention. He is currently an executive director of the Chinese Medical Association, a member of the Expert Advisory Committee of the National Immunization Program, and a member of the World Health Organization's Western Pacific Region Polio Eradication Certification Committee.



Yaning WANG

Founder and CEO, Rui Ning Kang Pharma

Dr. Yaning Wang is the Founder and CEO of Rui Ning Kang Pharma, providing consulting service for new drug discovery and development, dose optimization, trial design, biomarker/surrogate/clinical endpoints justification, regulatory interactions, IND/NDA/BLA package preparation, asset and company evaluation, and license in/out negotiation. Between 2021 and 2024, he was the CEO of Createrna, a clinical-stage biopharmaceutical company developing novel therapeutics for multiple diseases. Under his leadership, 500 million RMB was raised during a capital-winter period and multiple billion-dollar license-out deals were achieved. Before 2021, he was the Director of the Division of Pharmacometrics at US FDA and oversaw reviews, research projects, and policy development for all disease areas. Before joining FDA, Dr. Wang received his Ph.D. in Pharmaceutics and master's degree in Statistics from the University of Florida in 2003. He also obtained a master's degree in Biochemistry (1999) from National Doping Control Center and a bachelor's degree in Pharmacy (1996) from Peking University in China. Dr. Wang is an Adjunct Professor in University of Florida, Beijing University, Shanghai University of Traditional Chinese Medicine, and Central South University. Dr. Wang has published over 120 papers and given over 500 presentations at various national and international meetings as an expert in new drug development and regulation. He was selected to be one of the top Healthcare Technology Leaders of Washington, DC for 2023. He is the external advisor for Chinese National Medical Products Administration and the expert reviewer for Chinese Ministry of Science and Technology. He also serves as an expert advisor for Shanghai Free Trade Zone Fund and a senior consultant to multiple American investment companies and banks.

SPEAKERS - MAINSTAGE



Ruiping XIAO

College of Future Technology at Peking University

Professor Rui-Ping Xiao is a distinguished molecular pharmacologist. She is a Chair Professor and the founding dean of the College of Future Technology at Peking University, and the founding dean of School of Pharmacy at Southeast University. She serves as an Associate Editor of the New England Journal of Medicine. She is appointed as a distinguished professor under the Yangtze River Scholars Program by the Ministry of Education of China and has been awarded the National Science Fund for Distinguished Young Scholars. Professor Xiao is a Member of the Academic Advisory Committee of the Chinese Academy of Medical Sciences. She is a Fellow of the American Society for Clinical Investigation (ASCI) and a Fellow of the International Society for Heart Research (ISHR). She also serves an Executive Council Member of the Biophysical Society of China, and Council Member of the Chinese Association for Laboratory Animal Sciences.
With a distinguished background in both medicine and biology, Professor Xiao has dedicated over 30 years to elucidating the molecular mechanisms of cardiometabolic and endocrine diseases. Her systematic work in basic and translational research, particularly in receptor signaling, has earned her international recognition in the global scientific community.
She has published more than 200 papers in prestigious academic journals, such as Nature, Nature Medicine, Nature Metabolism, Nature Cell Biology, Cell, and Cell Metabolism, with over 16,000 SCI citations. She holds 9 patent families (comprising 25 national patents), including 6 international patent families. She has successfully completed two Phase II clinical trials, and has one global multicenter phase III trial and II investigator-initiated trials underway.
Professor Xiao's work bridges groundbreaking theoretical advancements, innovative drug design, and clinical trials, establishing her as a visionary leader in translational medicine.



Bin YANG

Senior Vice President, Head of Global Clinical Operations, HutchMed

Bin Yang is the Senior Vice President and Head of Global Clinical Development Operations at HUTCHMED.He is a seasoned executive with extensive global leadership experience in pharmaceutical clinical operations, spanning major international markets including the US, Europe, Australia, and China.



Peter YU

Director Search and Evaluation, Novartis

Peter Yu is Director of Search and Evaluation of Novartis. He is responsible for the sourcing and evaluation of external opportunities that complement the companies' internal pipeline. Novartis is a leading global pharmaceutical company. The company has done over $5B transactions with Chinese companies including Argo, Peplib, SciNeuro etc in recent years. Focusing on Oncology, Immunology, Cardiovascular-Metabolism and Neuroscience, Novartis is steadily increasing its investment in China to bolster its leadership in these therapeutic areas.

SPEAKERS - THEATER 1



Will CHEN

VP, MD of Strategic Investment Department, DIP

Dr. Chen was initially trained in Chinese medicine and obtained bachelor's, master's, and doctoral degrees in this field. He also earned a PhD in Medical Sciences/Immunology from Radboud University Nijmegen. In 1999, he began working with Dr. Joost J. Oppenheim at NCI/NIH. He became a Scientist II in 2003 and later a Senior Scientist at SAIC-Frederick, Inc. and Leidos Biomedical Research, Inc. He joined the University of Macau in 2014. Currently, he is a distinguished professor and the director of the Institute of Chinese Medical Sciences, as well as the director of the State Key Lab of Quality Research in Chinese Medicine (UM).



Xin CHEN

Director, Institute of Chinese Medical Sciences; Director, SKL of Mechanism and Quality of Chinese Medicine, University of Macau

Dr. Chen was initially trained in Chinese medicine and obtained bachelor's, master's, and doctoral degrees in this field. He also earned a PhD in Medical Sciences/Immunology from Radboud University Nijmegen. In 1999, he began working with Dr. Joost J. Oppenheim at NCI/NIH. He became a Scientist II in 2003 and later a Senior Scientist at SAIC-Frederick, Inc. and Leidos Biomedical Research, Inc. He joined the University of Macau in 2014. Currently, he is a distinguished professor and the director of the Institute of Chinese Medical Sciences, as well as the director of the State Key Lab of Quality Research in Chinese Medicine (UM).



Jia DAN

Company Secretary, VP, Virogin Biotech

Ph.D. in Pharmacology from Sun Yat-sen University and postdoctoral training at the First Affiliated Hospital of Sun Yat-sen University. As principal investigator, led a research project funded by the National Natural Science Foundation of China (NSFC). Published multiple research papers as first or corresponding author in journals including Cell Reports Medicine, Clinical Cancer Research, Annals of Surgery, JHEP Reports, and the International Journal of Biological Sciences. Currently serves as Director of Companion Diagnostics and Business Development, as well as Secretary to the Board, at Guangzhou Weirongte. Responsible for developing companion diagnostic products for the oncolytic virus VRT106 and promoting the company's business in Japan and Hainan.

SPEAKERS - THEATER 1



Allen GUO

Founder and CEO, Shuimu Future; Founding CEO, Baihe.com (Heyou.com); Founding Partner, 2048 Capital

Allen Chunlong Guo holds a Bachelor's degree in Engineering Physics from Tsinghua University and pursued doctoral studies at UC Berkeley EECS as Hitachi Fellow and Haas School of Business as Mayfield Fellow. Prior to founding Shuimu with Prof. Hongwei Wang, he built a distinguished career as a serial entrepreneur and technology investor. He co-founded Baihe.com, one of China's leading online matchmaking platforms, and subsequently founded 2048 Capital. He also worked at Accenture Technology Labs in Palo Alto, where he led research in wireless sensor networks and data mining.Drawing on his cross-disciplinary experience spanning nuclear physics, semiconductor, internet technology, and life sciences, Mr. Guo has guided Shuimu Biosciences through three core strategic pillars: cryo-EM structural determination services, AI driven TOTEM 300kv and 400kv CyroEM and SMART platform development, and building future AI4S data infrustructure. The company recently achieved a world-first high-resolution cryo-EM structure of the obesity drug target GPR75, demonstrating the platform's capability to accelerate small-molecule drug discovery and to shape the next-generation structural data foundation to power AI models in life sciences.



Alireza HAGHIGHI

Chief Executive and Founding Director, Harvard International Center for Genetic Disease; Professor of Medicine, Harvard Medical School; President of the Advancement Initiative for Medicine and Science

Prof. ALIREZA HAGHIGHI
Professor of Medicine, Harvard University
Chief Executive and Director, Harvard International Center for Genetic Disease, Harvard Medical School
President of the Advancement Initiative for Medicine and Science

Dr. Alireza Haghighi is a Pioneering leader transforming global health through groundbreaking advancements in life science and AI. He is internationally recognized for his leadership in projects aimed at improving health and well-being worldwide. Dr. Haghighi regularly advises government leaders and industry executives on national health policies and initiatives. He is the founder of multiple startups at the intersection of AI and life sciences.

Dr. Haghighi is the Director and Principal Investigator of the Bahrain National Genome Program and has contributed to the design, development, and leadership of national projects in other countries. He is also the Founding President of the Advancement Initiative for Medicine and Science (AIMS), a global foundation dedicated to advancing medical science and healthcare worldwide, which has improved the health of people across the globe.

Dr. Haghighi has received numerous prestigious awards and prizes, including the Global Health Pioneer Award for his innovative strategies and initiatives to enhance the quality of life of people around the world and the International Genetic Disorders Prevention Award.

Dr. Haghighi is an American board-certified geneticist, and a clinician-scientist at Mass General Brigham. He completed his graduate and clinical training at the University of Oxford and Harvard Medical School.

SPEAKERS - THEATER 1



Wen Luan Wendy HSIAO

Professor (retired), State Key Laboratory of Quality Research in Chinese Medicine, Macau University of Science & Technology

Professor (retired), State Key Laboratory of Quality Research in Chinese Medicine, Macau University of Science & Technology, and served as a faculty member and the Associated Dean at the School of Chinese Medicine, Baptist University. E-mail: bowhsiao@gmail.com Professor Hsiao obtained her BA degree from National Taiwan University in Phytopathology, and her Ph. D. degree from Columbia University, majoring in cancer molecular biology, with a recent research focus on anti-inflammatory, anti-cancer, and cancer-preventive herbal medicines. She has published over 100 articles in major journals including Science, Nature, Cell, Molecular Cellular Biology, Oncogene, Cancer Research, Clinical Cancer Research, Carcinogenesis, J Pathology, J Natural Products, and Planta Medica. She was the awardee for funding for several major research projects, including an Area of Excellence Project on Nasopharyngeal Cancer Research; a Collaborative Research Project on searching biomarkers for evidence-based Chinese medicines using modern technology; and several ITF projects. At Macau University of Science & Technology, Prof. Hsiao has launched another pioneer work, harnessing the role of gut microbiota in the functionality of Chinese herbal medicines in various disease models. For that, she gained generous funding support from the Science and Technology Development Fund of Macau, published over 30 high-impact papers, and holds patents in the US, Europe, and China.



Jing HU

General Manager, Beijing Increasepharm Corp. Ltd.

Dr. Hu Jing, Researcher, General Manager of Beijing Yingkerui Innovative Drug Research Co., Ltd. and Yingkerui (Hong Kong) Innovative Pharmaceutical Co., Limited. Member of the 15th Tianjin Municipal Committee and the 10th Xiqing- district Committee of the Chinese People's Political Consultative Conference (CPPCC). Industry Doctoral Supervisor at Tianjin University and Master's Supervisor at Tianjin University of Traditional Chinese Medicine.Dr. Hu possesses extensive experience in the R&D and industrialization of innovative and generic drugs covering oncology, orthopedics, respiratory diseases and other therapeutic areas. She has led more than 30 pharmaceutical- research projects, of which ten have obtained marketing approval from the National Medical Products Administration (NMPA). She has published over 20 papers and been granted 9 patents. Her achievements have won multiple honors, including the Second Prize of Tianjin Innovation and Entrepreneurship Competition and the Third- Class Award of Tianjin Science and Technology Progress Award.

SPEAKERS - THEATER 1



Yibin HU

Director & General Manager, Beijing Xinyi Health Technology Co., Ltd.

Representative of CITIC Medical & Health Industry Group Co., Ltd., the dedicated healthcare platform of CITIC Group. Experienced in healthcare industry integration and cross-regional collaboration, with a commitment to advancing TCM innovation and facilitating two-way talent exchange between Hong Kong and mainland China.



Ashton JIANG

VP, Co-GM of Materials Science, DIP

Mr. Jiang holds bachelor's and master's degrees from the School of Mathematical Sciences, Fudan University, with an interdisciplinary background in mathematics, artificial intelligence and quantitative finance. His research focuses on machine learning and deep convolutional neural networks. With nearly a decade of experience across financial groups, investment institutions and AI companies, he now serves as VP & Co-GM of Materials Science at DIP, leading strategy, operations, industrial collaboration and commercialization of AI for Science in materials science. Previously, he worked in technology investment and IPO sponsorship across advanced manufacturing, semiconductors, robotics, biopharmaceuticals and AI.



Qi JIN

Managing Partner, Kaitai Capital

Jin Qi is a Managing Partner at Kaitai Capital, with over 10 years of investment experience in the life sciences sector. He leads the firm's life science investment practice, with a key focus on investment opportunities.

SPEAKERS - THEATER 1



Zhigang LAI

General Manager, SupremeLife Therapeutics Inc.

Mr. Lai has rich experience in operational management and investment, having worked for ETP, Keytone Venture, GE and Siemens responsible for investment, marketing and sales work.
Obtained MBA from the Wharton School of the University of Pennsylvania, MS from Boston University, and BS from Beihang University.



Elaine Lai Han LEUNG

Interim Director of the Institute of Collaborative Innovation at the University of Macau; Head of the Centre for Innovation and Entrepreneurship; Professor of Faculty of Medicine

Prof. Elaine Lai-Han Leung is the Interim Director of the Institute of Collaborative Innovation, Head of the Centre for Innovation and Entrepreneurship (CIE), and Professor of the Faculty of Medicine at the University of Macau. She also serves as a Member of the Economic and Technological Development Committee of the Macao SAR Government. In 2020, she was named a Young Qihuang Scholar and appointed as a Distinguished Professor under the Guangdong Pearl River Talent Program. In 2024, she was recognized among the World's Top 2% Scientists in the field of Oncology and Carcinogenesis.
Prof. Leung has long been dedicated to the research and development of traditional Chinese medicine-based targeted therapies for lung cancer. To date, she has published 199 SCI-indexed papers in leading international journals, including Nature (Outlook), Gut, JAMA Oncology, Nature Communications, Pharmacological Research, Pharmacology & Therapeutics, Oncogene, Cancer Letters, and the British Journal of Cancer. She has an h-index of 51, with more than 10,000 citations, and her most highly cited publication has received 1,006 citations.



Jinsong LI

Co-founder, Chairman & General Manager, Usynova Pharmaceuticals

Dr. Jinsong Li, Co- founder, Chairman and General Manager of Usynova Pharmaceuticals. He holds a PhD in Biophysics from Kansai Medical University, Japan. Dr. Li once engaged in clinical medicine and biophysics research. With more than ten- year experience in financial industry, he used to serve as General Manager of Asset- Management Department at Guotai Junan Securities, in charge of industry research and direct investment. He has extensive experience in pharmaceutical- sector research as well as primary- and secondary- market investment, and has founded and invested in multiple biotech firms. Under his leadership, Usynova focuses on innovative- drug R&D for oncology and autoimmune diseases, developing pipelines of small- molecule, recombinant- protein and antibody therapeuticsen.usynova...

SPEAKERS - THEATER 1



Xing LI

Founder, Chair of the Board, Deep Intelligent Pharma (DIP)

Xing Li graduated from Peking University School of Pharmaceutical Sciences and is Founder, Board Chair and CEO of Deep Intelligent Pharma (DIP). With over 20 years in pharmaceutical R&D, innovation and AI technology management, she previously worked at Pfizer, Sanofi and Johnson & Johnson and led an Asia-Pacific AI-for-pharma initiative. Since founding DIP in 2017, she has advanced AI-native clinical R&D by uniting specialized agents, data, quality systems and experts for auditable end-to-end trials.



Chenchong LYU

Founder & CEO, Zhejiang Yizhun Intelligent Technology Co., Ltd.

Master of Software and Microelectronics, Peking University.
He previously worked at GE Healthcare and Siemens Healthineers.
He serves as Member of the Expert Committee of the Internet Healthcare Industry Alliance and Standing Committee Member of the Healthcare Branch China Nonpublic edical Institutions Association.



Haitao LYU

Associate Professor, School of Chinese Medicine; Associate Director, Hong Kong TCM Phenome Research Center, Hong Kong Baptist University

Professor Haitao Lyu is the Associate Director and Principal Investigator at the Hong Kong Chinese Medicine Phenome Research Center, School of Chinese Medicine, Hong Kong Baptist University. Professor Lyu is an elected member (Class of 2024: Medicine) of the European Academy of Sciences and Arts, a Fellow of the Royal Society of Chemistry, a Zhujiang Distinguished Professorship, Guangdong Prince. He serves as Principal Investigator at the State Key Laboratory of Medical Genomics (SJTU). Professor Lyu has secured 18 competitive research grants from various funding agencies, including the Ministry of Science and Technology (MOST), etc. He has authored or co-authored 71 papers in leading peer-reviewed journals, with 8 recognized as highly cited papers by Clarivate Web of Science. Professor Lyu serves as Vice Chairman of the Fangjiomics Committee of the Chinese Pharmaceutical Association, Section Editor for Pharmacological Research (Q1, IF 12.2), and Associate Editor for Phytomedicine (Q1, IF 11.3). His achievements have been recognized with numerous prestigious awards and honors, including the Agilent Application Core Technology-University Research Award (2021), the Faculty Opinion Member Award of the Year (2022), and the Springer Nature Editors of Distinction Award (2025), the World Top 200 High Impact Researchers of Traditional Medicine (Clarivate).

SPEAKERS - THEATER 1



Kun QIAN

Co-founder and Chief Medical Officer, SenseCare

Professor Aurel K. Qian is the Cofounder and Chief Medical Officer at SenseCare. She also serves as an adjunct professor at the Institute for Artificial Intelligence Innovation and Industry at Fudan University. She was recognized as the National Outstanding Leadership Figure in Hospital Informatization and a Forbes China Young Elite Returnee. Prof. Qian led the digital transformation project at Zhongshan Hospital from 2019 to 2025, which was selected by Harvard Business Review as China's first healthcare digital transformation case. Her current research focuses on clinical applications of foundation models in healthcare, privacy-preserving computation, distributed multimodal data integration, and trustworthy AI.



Hor-Yue TAN

Associate Professor, Centre for Chinese Herbal Medicine Drug Development, School of Chinese Medicine, Hong Kong Baptist University

Prof. Tan Hor-Yue, Hoey is currently the Associate Professor at the Centre for Chinese Herbal Medicine Drug Development (CHMD), School of Chinese Medicine, Hong Kong Baptist University. She completed her PhD in Chinese medicine pharmacology at The University of Hong Kong. Her research primarily focuses on immune-targeted drug discovery from natural products, as well as the cellular interactions and molecular mechanisms within the inflammatory microenvironment. At CHMD, Prof. Tan serves as the project coordinator for the discovery and development of Chinese herbal formulation pipelines targeting ulcerative colitis. She has published over 100 research articles in high impact factor journals, including Journal of Advanced Research, Advanced Science, Hepatology, and Pharmacological Research, with an H-index of 46.



Karl Wah-Keung TISM

Chair Professor, Division of Life Science; Director, Center for Chinese Medicine Research & Development, The Hong Kong University of Science and Technology

Prof Karl Tsim graduated from The Chinese University of Hong Kong where he received his BSc and MPhil degrees. He pursued his research in molecular neurobiology at the University of Cambridge, UK, and obtained his PhD in 1987. After his post-doctoral training at the University of Cambridge, UK, and Stanford University, USA, he joined The Hong Kong University of Science and Technology (HKUST) in 1992. Currently, he is a Chair Professor of Division of Life Science, and the Director of Center for Chinese Medicine R & D at the university.

SPEAKERS - THEATER 1



Peng Fei TU

Professor, Peking University

Tu Pengfei, Ph.D., is a professor at Peking University. He is the director of the Modern Research Center for TCM at Peking University; an executive member of the 12th National Pharmacopoeia Committee and the chairperson of the first professional committee for Chinese herbal medicines and Decoctions.
His research focuses on the study of the active constituents of TCMs and the creation of new drugs, as well as the research on TCMs resources and quality control. He has successfully developed two new drugs with effective fractions of TCMs, obtained 4 new drug certificates and received 9 clinical approval documents. He has published over 400 papers as the corresponding author in internationally renowned journals such as PNAS and Nat Commun. He has 175 patents granted. As the first principal investigator, he has won two National Science and Technology Progress Awards (Second Prize), five ministerial-level first prizes, and received the "National Poverty Alleviation Award" in 2016, the "National Innovation Award Certificate" in 2017, the "Wu Jieping Medical Innovation Award", and the 16th China Pharmaceutical Development Award.



Xinzhu WANG

Co-Founder of Potentiam Biosciences

Xinzhu Wang is a Co-Founder of Potentiam Biosciences, a drug discovery company developing novel therapeutics against targets identified through AI-powered platforms. She also serves as Secretary General of HKBIO, Hong Kong's biotechnology industry organization.



Fang XIA

Vice President, Board Secretary, and Head of Board Affairs & Capital Markets at 3D Medicines; Co-founder, CEO, and Legal Representative of Sandi Bio

— Master's degree from Peking University Health Science Center, Master of Business Administration from Harvard University. — Formerly Deputy Director of the Beijing Product Design Center at Taiji Group and Secretary of the Taiji Anti-Cancer Science Foundation. — Joined 3D Medicines in 2016, successively serving as Head of Regulatory Affairs and Deputy General Manager. — Member of the Hong Kong Investor Relations Association and member of the 4th Pharmaceutical Innovation Investment Professional Committee of the China Pharmaceutical Innovation and Research Development Association (PhIRDA).

SPEAKERS - THEATER 1



Jason YAO

Vice President, Transfar Group

Yao Chenpeng PhD, MPAMaster of Engineering in International Logistics, College of Transportation Engineering, Tongji UniversityMaster of Public Administration, Nottingham Trent University, UKDoctor of Engineering in Biomedicine, School of Pharmacy, Zhejiang UniversityMr. Yao Chenpeng currently serves as Vice President of Transfar Group, with responsibility for the Group's development strategy, public affairs, and technological innovation. He has 10 years of experience in local government economic administration and development planning, and 12 years of experience in corporate management, industrial park development and operations, and investment in biotechnology and life and health industries. He concurrently serves as Vice Chairman of the Zhejiang Overseas Industrial Parks Association, Executive Vice Chairman of the Hangzhou Entrepreneurship & Venture Association, Vice Chairman of the Hangzhou Federation of Returned Overseas Chinese, and Vice Chairman of the Hangzhou Entrepreneurs Association.



Kewu ZENG

Professor, Peking University

Ke-Wu Zeng is working in School of Pharmaceutical Sciences, Peking University. Zeng mainly focus on the cellular target identification of natural products. Zeng lab has pioneered the application of chemical biology approaches to develop biotin- or fluorescent-labeled natural product probes, enabling the systematic identification of direct target proteins in both cellular systems and pathological tissue samples for over 30 natural compounds. Then, Zeng lab has characterized the natural product-binding pockets in target proteins for elucidating the ligand-induced conformational changes. These studies have uncovered novel molecular mechanisms for natural products-mediated neuroprotection, bone metabolism, immune homeostasis, and platelet activation, thereby providing insights for novel target in rational pharmaceutical design. Zeng has published about 130 research papers in PNAS, Sci Adv, Adv Sci, ACS Cent Sci, etc. His researches have been reported by NSFC and ScienceNet, and selected as China's Top Ten Medical Advances for 2017 and Top Ten Traditional Chinese Medicine Advances for 2022.



Lixiang ZHAI

Assistant Professor Centre for Chinese Herbal Medicine Drug Development Limited, School of Chinese Medicine, Hong Kong Baptist University

Professor Zhai Lixiang is an Assistant Professor at the Centre for Chinese Herbal Medicine Drug Development (CDD) and the School of Chinese Medicine at Hong Kong Baptist University (HKBU), as well as the founder of GastroEase Biotech Limited. Playing a core research-driving role, he spearheaded the advancement of CDD-2101 to gain U.S. FDA approval for Phase II clinical trials, marking it as the first traditional Chinese medicine (TCM) compound from Hong Kong to enter the FDA clinical stage. He has published over 30 papers in journals such as Cell Host & Microbe, Nature Metabolism, and Nature Communications, with an H-index of 18, over 2,000 total citations, and 5 applied invention patents. His research achievements were honored with a Silver Medal at the International Exhibition of Inventions of Geneva (2025) and a Silver Medal at the China (Shanghai) International Exhibition of Invention and Innovation (2025).

SPEAKERS - THEATER 1



Ning ZHANG

CSO, Baiyao Group; Professor, PKU Medicine

Ning Zhang, obtained his Ph.D. degree from the Johns Hopkins University School of Medicine in 2001, followed by CRTA fellowship training in National Cancer Institute, USA. He is a professor in cancer biology in the Peking University First Hospital. His laboratory is interested in the molecular mechanism of cancer metastasis, the genetic characteristics of hepatoma, discovery of drug targets and biomarkers.



Luke ZHOU

CEO of Santo Therapeutics Co., Ltd.

Dr.Zhou Lu is currently the CEO of Santo Therapeutics Co., Ltd. He has received the Overseas Student Scholarship from the Chinese Embassy in the UK, a full doctoral scholarship from Heriot-Watt University, the Drug Discovery Award from Cancer Research UK (or British Cancer Research Foundation), the Young Investigator Award from the Children's Tumor Foundation, and was named to the Forbes China 100 Outstanding Overseas Returnees list. In 2014, he founded Beyond Lab, dedicated to building a Sino-British medical technology platform. He hosted the Sino-British Medical Conference for three consecutive years, during which he built an extensive network. His partners include the British royal family, government departments, top universities, hospitals, and numerous biopharmaceutical and AI companies.

SPEAKERS - THEATER 2



Hua CAI

General Manager, CITIC MED FUNDS

Cai Hua, General Manager, CITIC Medical Fund. His key concurrent appointments include: Expert, CITIC Think Tank; Senior Research Fellow, CITIC Foundation for Reform and Development Studies; Vice President, China Medical Pharmaceutical Material Association; Deputy Director, Internet Medical Health Working Committee, Internet Society of China; Council Member, Chinese Association of Geriatric Research; and Standing Committee Member, Pharmacoeconomics and Drug Evaluation Special Committee, China Association for Research and Promotion of Traditional Chinese Medicine. He holds dual bachelor's degrees in Pharmacy and Law from Shandong University, an Executive MBA from CEIBS, and is currently pursuing a doctorate in Pharmacoeconomics at China Pharmaceutical University. He formerly served as Regional General Manager at MSD (China) and Managing Director at China eCapital Corporation.



Cyber CAO

Managing Director , HSG

Cyber Cao is a Managing Director Cyber Cao is a Managing Director at Hongshan(HSG). 10+ of his investmented companies from Biotech, Medical device, and healthcare services sector that have successfully listed in A-share, HKEX and U.S. markets.
He also served as a Managing Director at Vivo Capital, where he was involved in the majority of China-focused investments for Funds VII/VIII.
Previously, Mr. Cao led Nycomed(now part of Takeda)North Asia strategy and business development, where he helped Nycomed refurbish China business and played an integral role in its acquisition of Techpool, a leading Chinese Biopharma company. This is the largest deal MNC in China made for prescription drug acquisition.
In his early career, Cyber was at McKinsey & Company where he worked with both multi-national and local healthcare companies on corporate strategy.
Mr. Cao holds a Master's degree in Pharmaceutical Administration and a Bachelor's degree in Pharmacy from Peking University.



Fran CHEN

Managing Partner, Transfar Capital

Managing Partner at Transfar Capital with 12year equity investment experience. He is in charge of FOF and direct investment, with personal invested capital exceeding RMB 2 billion. Focusing on biomedicine and hightech sectors, he has invested in renowned funds including Huagai Medical, Tsinghua Shuimu and Oriental Fortune Capital. His directinvestment portfolio covers Huafu Information, Lipin Pharma, Tianchen Biotech, Duality Biologics and MindRank AI. He excels in fund evaluation and fullcycle investment, empowering innovative enterprises with industrial resources.

SPEAKERS - THEATER 2



Kan CHEN

Co-lead of Healthcare, Qiming Venture Partners

Kan Chen is co-head of healthcare and partner at Qiming Venture Partners. He got his PhD from Case Western Reserve University and did his postdoctoral training at Harvard Medical School. Before joining Qiming, he was a senior scientist at JNJ. Before JNJ, he served as a group leader at Hengrui Pharmaceutical.

He is an investor in Structure Therapeutics (NASDAQ: GPCR), Abbisko (HKEX: 02256), Vor Bio (NASDAQ: VOR), Insilico Medicine (HKEX: 03696), LaNova Medicine (acquired by Sino Biopharma for $1B), Candid Tx (acquired by UCB for $2.2B), Longbio (HKEX: 01779), Serapha Bio, Medilink, Pinnacle Medicine, Vivacta, Vivatides, Chemlex, Convergen, etc.



Olivia CHEN

Chairlady Secretary, Pulnovo Medical

Ms. Olivia Chen serves as Head of the Chairlady Office at Pulnovo Medical. She leads the Group's worldwide brand positioning, public image, and stakeholder engagement strategies, media relations, international public affairs, and ESG communications.As one of the Group's Spokespersons, she oversees all external disclosures and senior executive external appearances, ensuring global consistency and impact. She also holds key responsibilities in the Chairlady Office, supporting corporate governance and special projects.Prior to joining Pulnovo Medical, she accumulated over 10 years of experience in multinational corporate strategy and global brand management across various industries.



Zhu CHEN

Chief Healthcare Analyst, Research Department, CITIC Securities

Mr. Zhu Chen is Chief Analyst of the Healthcare Industry, Head of the Healthcare Industry Research Group, and Executive Director (ED) at the CITIC Securities Research Department. He holds a Bachelor's and a Master's degree in Pharmacy from Wuhan University and is a licensed pharmacist (执业药师). He previously worked in business development (BD) at major pharmaceutical companies including Sinochem Group and Shanghai Pharmaceuticals, before joining CITIC Securities in 2014. He ranked second in the 2017–2019 Asiamoney Brokers Poll for "Best for Healthcare Research – China (A & B shares)." He currently leads a 26-member healthcare industry research team, which is organized into three subgroups covering the pharmaceutical value chain, the healthcare industry chain, and innovative drugs. He is adept at identifying opportunities across specialized industry segments, and his team's institutional commission ranking has consistently ranked among the top in the field for consecutive years. He also serves as a think tank expert for the China Securities Index Financial Research Institute and the CITIC Group.

SPEAKERS - THEATER 2



Kim CHONG

Chief Risk Officer, Hong Kong Investment Corporation Limited

Kim is the Chief Risk Officer of the Hong Kong Investment Corporation Limited ("HKIC"). He is responsible for all aspects of enterprise risk management and compliance function of the HKIC. Prior to his current position, Kim headed up the Risk function at the Hong Kong Monetary Authority ("HKMA") and was responsible for risk management of the reserve assets of the HKMA. Before taking up his risk role, Kim held various roles at the HKMA including Chief Representative at its New York and London Offices and head of the Internal Audit function. Outside of the HKMA, his role included Chief Financial Officer at MF Global in Hong Kong and internal audit at Natwest Markets in London. Kim is a fellow member of the Institute of Chartered Accountants in England and Wales. He obtained his Bachelor of Science Degree in Computer Science and Management Studies at Leeds University, England.



Regina GREBLA

Head of Equity Research, Selesta Partners

Regina Grebla, PhD is Head of Equity Research at Selesta Partners, a Hong Kong-based healthcare and life sciences boutique dedicated to Asia's emerging biotech and pharmaceutical companies. Selesta supports clients through fundamental analysis, capital markets introduction and education, industry insights, and asset in- and out-licensing and partnering. Her research spans the breadth of the China and broader Asia-Pacific innovation landscape, including oncology, metabolic disease, antibody-drug conjugates, cell and gene therapy, and RNA therapeutics.

Trained as an epidemiologist, she brings clinical and quantitative lens to research, pairing primary trial-data analysis with valuation and competitive-landscape modeling. She previously served as a Vice President at Evercore ISI, supporting research coverage of biotechnology and pharmaceutical companies, and held a buy-side research role at Eagle Health Investments, covering biotechnology, medical devices, and life science companies.

She holds a PhD in Epidemiology from Brown University, an MPH from Columbia University, and an MSc with Distinction from the London School of Economics. Her peer-reviewed work has appeared in JAMA and Health Affairs.



Yang GU

Partner, Shanghai Office, Han Kun Law Offices

Mr. Gu specializes in corporate, regulatory compliance, and transactional services for life sciences, biopharmaceutical, medical and healthcare industries, including biosecurity and human genetic resource issues, clinical trial matters, product marketing authorizations, GxP co8615921530577nces industry, including renowned multinational pharmaceutical companies, leading Chinese innovative drug and biotechnology companies, and top domestic and international investment institutions, Mr. Gu has received numerous accolades from prestigious institutions such as Chambers and Partners, The Legal 500, China Business Law Journal, Lexpress, LegalOne, Lex Falcon Global Awards, Asian Legal Business (ALB), Legalband and Mondaq.

SPEAKERS - THEATER 2



Xiaoqiang KANG

Founder, Chairman & CEO, Leads Biolabs

Postdoctoral Fellow at the US National Cancer Institute (NCI), conducting research on tumor immunotherapy in the laboratory of Dr. Steven Rosenberg, Chief of Surgery · Over 30 years of experience in innovative drug R&D, including more than 17 years in antibody drug development, having led multiple anti-cancer antibody drug development programs · Former Principal Scientist and Senior Principal Investigator at Eli Lilly and Company, contributing to the development and successful launch of Erbitux · Master's degree in Hematology from Tongji Medical College; Ph.D. in Biomedical Sciences from the University of North Texas, USA



Chuen Yan LEUNG

Partner (Private Investments) at Value Partners Group

Dr. Chuen Yan LEUNG is Partner (Private Investments) at Value Partners Group, one of Asia's leading independent asset management firms, and Managing Partner of Silver Dart Capital, a boutique healthcare investment firm.
His experience spans private equity, biotechnology startups, and academia, including roles as an investment professional at EQT Group, a global top-tier private equity firm, and founding scientist at Procella Therapeutics, a Sweden-based stem cell therapeutics startup.

Dr. Leung serves as Non-Executive Director of Insilico Medicine (3696.HK), Non-Executive Director of Phase Scientific, and Vice President of the Hong Kong Biotechnology Organization.
He holds a PhD in Stem Cell Biology from the University of Cambridge and a BSc in Biochemistry from Imperial College London.

SPEAKERS - THEATER 2



Da LIU

Managing Director, China Resources CP Life Science Fund

Mr. Liu currently serves as the Managing Director of the CR-CP Life Science Fund, whose shareholders, China Resources Group and Charoen Pokphand Group, are both ranked among the Fortune Global 500.Previously, Mr. Liu served as Business Director of the Strategic Management Department at China Resources Group, where he was responsible for strategic research and project investment in the life sciences sector. He also served as a Senior Director at China Resources Pharmaceutical Group Limited (HK: 03320), overseeing business development and international cooperation.In addition, Mr. Liu held the positions of Senior Director at China Resources Pharmaceutical Business Group, General Manager of China Resources Pharmaceutical Airport (Beijing) International Trading Co., Ltd., Deputy General Manager of Beijing Pharmaceutical Co., Ltd., and Chief Operating Officer (COO) of Zhoulin Biospectrum Technology Co., Ltd.Prior to 2004, Mr. Liu served as a Pharmacy Manager at CVS Health Corporation (USA) and worked as a Clinical Pharmacist at the New York Healthcare Group.



Dawei LIU

President, Shanghai Healthcare Capital

Mr. David Liu possesses over 20 years of experience in biopharmaceutical enterprise management, financial operations, and equity investment. He has led and designed dozens of major domestic and international transactions, including mergers and acquisitions, mixed-ownership reforms, minority equity investments, business incubation, and fund investments. He currently serves as President of Shanghai Healthcare Capital, President of Shanghai Healthcare M&A Capital, President of SIIC Capital (Hong Kong), Chairman of Hong Kong Biotech Fund, and Chairman of Kanghua Biological (300841.SZ). Additionally, he holds several social positions, including Executive Vice President of the Shanghai Youth Entrepreneurs Association and Vice Chairman of the Shanghai Youth Federation of Medicine and Health.



Qiang LU

Co-Founder & Chairman, GenFleet Therapeutics

Dr. Lv, a national-level specially-appointed expert, has over 20 years of experience in life science research and the innovative drug industry. In 2017, he co-founded GenFleet Therapeutics and has served as its Chairman, leading the team to focus on oncology, autoimmune diseases, and other therapeutic areas, dedicated to the research and development of original "First-in-Class" (globally novel) drugs.

SPEAKERS - THEATER 2



Eric LUO

Vice President & Chief Financial Officer, HAOXINQING HEALTH INDUSTRY GROUP CO.LTD.

With 14year profound experience in finance, covering investment banking, audit and senior corporate management. Adept at industrial resource connection and highpressure task delivery. Led two rounds of equity financing over RMB 500 million for Haoxinqing. Wellversed in China's financial regulatory regime and fullcycle financing processes. Led multiple IPO, restructuring and refinancing projects, focusing on capital operations in healthcare and TMT sectors. Expert in investmentfinancing scheme design, commercial negotiation and resource integration, with sharp market insight and riskcontrol capability, plus solid financial analysis competence. MBA from Central University of Finance and Economics, holding key qualifications including Sponsor Representative, CPA and SFC Authorized Representative.



Jialin SUN

General Manager, GTJA Investment Group

Master of International Economic Law, Soochow University. He serves as Director of the VC Special Committee of China Investment Association, Director of China Healthcare Industry Investment 50- People Forum (CH50), Vice Chairman of the Pharmaceutical Innovation Investment Special Committee of China Pharmaceutical Innovation and Promotion Association, and Vice President of Shenzhen Venture Capital Association.

With 18- years of in- depth experience in healthcare equity investment, he possesses profound understanding and insights into investment and financing across the broader health sector. He has extensive expertise in private equity investment & financing, capital strategy formulation, industrial resource integration, and corporate M&A transactions.

He has led and participated in investments in nearly 20 healthcare projects, among which multiple high- quality companies have achieved successful IPOs. Selected investment cases: Changfeng Pharmaceutical (02652), Zhijiang Biology (688317), ViaBio (01873), Sinobal Pharmaceutical (300294), Huahan Plastic Surgery (430335), Ark Pharmaceutical (002513), Weimou Bio, Luoyi Bio, Meihua Medical, etc.

Awards & Honors
- Top 50 Influential PE Investors in China, 2022- 2025
- Top 50 Best Private Equity Investors in China, 2022- 2025
- Top 30 Outstanding Healthcare Investors, 2025
- Top 30 Most Influential Healthcare Investors in Asia, 2022- 2023

SPEAKERS - THEATER 2



Kelvin TEO

Managing Director, Head of Asia, Global Issuer Services Hong Kong Exchanges and Clearing Limited



Ji WANG

Managing Director, OrbiMed

Ms. Ji Wang is a Managing Director on the Asia team at OrbiMed, where she focuses on growthstage and earlystage investments on biotech and medtech companies. Prior to joining OrbiMed, Ms. Wang served as a Vice President of Investments at Hony Capital, where she concentrated on the pharmaceutical, biotechnology, and healthcare services sectors. She holds a Master's degree in Biotechnology Management and Finance from Johns Hopkins University and the University of Virginia, as well as a Bachelor's degree in Economics from Boston University.



Alan WONG

Director, Entrepreneur Office, CITIC Securities Wealth Management (HK)

Mr. Alan Wong is currently a director at CITIC Securities Wealth Management (HK) Entrepreneur Office. He has over 10 years of experience providing comprehensive financial services to listed companies, entrepreneurs, and ultra-high net worth clients. His main responsibilities include assisting listed companies and investors in designing and implementing effective equity management and wealth management solutions, for optimizing asset allocation arrangements. Meanwhile, he leads offshore investment banking initiatives for the Wealth Management division, coordinating client participation in all 29 CITIC- sponsored projects in 2025, totaling over HKD 6.5 billion in subscriptions. Prior to joining CITIC Securities Wealth Management (HK), he worked in investment banking departments and global top management consulting firms such as Credit Suisse, CICC, and BNP Paribas. He has participated in and completed over 25 financing and financial advisory projects in the Greater China region, including initial public offerings, private placements, bond issuances, mergers and acquisitions/privatizations of listed companies, and other advisory transactions. Some notable projects include the IPOs of Alibaba, Blue Moon, Haier Smart Home, GDS 19C listing in Hong Kong, Mingyuan Cloud, Xinyi Energy, Midea Real Estate, Hong Kong listings of MicroPort and WuXi group companies, various privatization projects, and secondary equity/bond offerings.

SPEAKERS - THEATER 2



Stella XING

Managing Director, Asia Public Equity Team, OrbiMed

Stella joined OrbiMed in 2021. She is currently a Managing Director on the Asia Public- Market Equity Investment Team, with responsibility for China market research.Prior to OrbiMed, Stella served as Executive Director and Head of China Healthcare Research at UBS. Earlier in her career, she was Head of China Healthcare Research at Nomura.Stella holds a Bachelor of Business Administration (BBA) from The University of Hong Kong.



Wilson XU

Head of International Business, Healthcare Coverage, Investment Banking Management Committee, CITICS; Head of Healthcare, IBD, CLSA

Mr. Xu currently serves as Head of International Business for the Global Healthcare Industry Group within the Investment Banking Management Committee at CITIC Securities, and concurrently holds the position of Head of the Healthcare Industry Group at CITIC Securities (Hong Kong). With nearly 20 years of experience in capital markets, he has led teams in executing dozens of high-profile onshore and offshore IPOs, follow-on offerings, and M&A transactions in recent years. He has also represented multiple multinational corporations with global operations in executing various capital market transactions in China, demonstrating exceptional expertise in designing complex transaction structures and executing innovative solutions. Prior to joining CITIC Securities, Mr. Xu worked at a leading global foreign financial institution and a prestigious law firm. He has been deeply involved in cross-border capital market exchange visits and policy seminars with regulatory authorities, driving the implementation of key connectivity policies and landmark demonstration projects. Through these efforts, he has accumulated extensive practical experience in fostering cross-border capital market collaboration and institutional innovation.



Chenying ZHANG

BD & Clinical Program Director, CentryMed

Bob Zhang is BD & Clinical Program Director at CentryMed, where he leads global business development and supports the clinical development of the company's oncology pipeline. He has formal training in medical sciences and extensive experience in global drug development and clinical development. Before joining CentryMed, Bob spent more than ten years in Denmark, working at Rigshospitalet, Ferring Pharmaceuticals and Novo Nordisk. At Novo Nordisk, he was involved in global clinical development, as well as portfolio management, asset evaluation, strategic assessment and post-acquisition integration. Bob holds a Master's degree in Medical Sciences from the Faculty of Health and Medical Sciences, University of Copenhagen, and received his undergraduate education from Zhejiang University.

SPEAKERS - THEATER 2



Adam ZHAO

Chairman & CEO at Anlong Bio

Adam Chunlin Zhao, Ph.D, Founder of the AnlongBio/AnlongMed. Dr. Zhao is among the first class graduated from Biological Science and Biotechnology department at Tsinghua University in 1990. He received his Ph.D in molecular biology from University of Pittsburgh School of Medicine and MBA from University of Chicago in the United States. Dr. Zhao was a senior manager at Pfizer in US. After returning to China in 2003, he founded Beijing LongMed Inc. and later became partner of CASH and C-Bridge Capital. Dr. Zhao has over 30 years of industry experience and excellent investment achievements, invested in Innovent, BerryGenomics, ASLETIS, I-Mab, Laekna, and GKHT. Dr. Zhao is the founding Chairman of Tsinghua Alumni Association for School of Life Sciences , School of Medicine and School of Pharmaceutical Sciences, a senior member of BayHelix group. AnlongMed is a leading venture fund in Chinese life sciences and Biotech, focusing on biotech & biopharma, medical devices, life sciences and medical services in China. Dr. Zhao also founded AnlongBio in 2019, a leading player in genetic medicine discovery in China, focusing on gene therapy, iRNA, mRNA, and other genetic medicines, with a leading product in gene therapy for ophthalmology already in clinical stages. Outside of his professional life, Dr. Zhao is a DJ, soccer player, ski lover, and has three lovely daughters.



Zhijie ZHAO

Managing Director, Head of North Asia Healthcare Research, CITIC Securities International

Mr. Zhao holds a Master's degree in Basic Medical Sciences from Tongji University and a Bachelor's degree in Mathematical Sciences from Imperial College Business School, United Kingdom. He previously served as Head of Healthcare Research for Greater China at HSBC and HSBC Qianhai Securities. In recent years, he has been consecutively ranked among the top three "Best Pharmaceutical Analyst in Asia Pacific" in the Asiamoney Brokers Poll. He joined the CITIC Securities Research Department in 2020 and currently covers sectors including pharmaceutical retail, biopharmaceuticals, CRO/CDMO, active pharmaceutical ingredients (API), life science services, and blood products.



Jinqiao ZHU

Founder & Chairman, Efung Capital

Honorary President of the Hong Kong Association of the Pharmaceutical and Biotechnology Industries (HKAPI), Initiator of the Investment Committee of the China Pharmaceutical Innovation Association (PhIRDA), Member of BayHelix Group, and Distinguished Lecturer at Duke Kunshan University. He has also been invited as a guest speaker at Sun Yat-sen University, Hunan University, and other leading academic institutions, bringing his frontline industry experience into the classroom.
With over two decades of investment experience focused exclusively on the biopharmaceutical sector, he has been instrumental in advancing the pharmaceutical industry through landmark investments in companies such as Heyuan Biotechnology, Chipscreen Biosciences, Ascentage Pharma, Frontier Biotechnologies, Qyuns Therapeutics, Harbour BioMed, and Genuine Biotech. His outstanding contributions have been widely recognized, including being named among the "30 Most Influential Investors in China 2023" by Zero2IPO Wealth and included in the "Top 100 Best Venture Capital Investors in China 2021" by ChinaVenture.

SPEAKERS - THEATER 2



Zhongyuan ZHU

Founder, Chairman & CEO, DualityBio

Dr. Zhu, a former partner at a renowned investment institution, has over 20 years of entrepreneurial and investment experience in the healthcare sector. He has led investments in and incubation of multiple successful companies, including CStone Pharmaceuticals, RemeGen, and Gan & Lee Pharmaceuticals. Dr. Zhu holds a Ph.D. from the University of Massachusetts Medical School and an MBA from the Haas School of Business, University of California, Berkeley. He is committed to advancing innovation and development in the global biopharmaceutical industry.



Julie ZHOU

Board Secretary at CuroVax, and Head of Corporate Development at Delonix Bioworks

Dr. Julie Zhou serves as Board Secretary at CuroVax, and Head of Corporate Development at Delonix Bioworks. She brings expertise in biotech strategy, venture investment, and corporate development across the global vaccine and biopharma ecosystem. Prior to Delonix, Julie was a strategy consultant and venture capitalist focused on life sciences. She started her career at L.E.K. Consulting, advising biotech and pharmaceutical clients on commercial and R&D strategy. She later joined Pivotal bioVenture, dedicating to biotech incubation and early-stage investment.
Julie received B.Eng. in Chemical Engineering from Tianjin University and Ph.D. in Chemical and Biomolecular Engineering from the Hong Kong University of Science and Technology (HKUST). She is also a CFA Charterholder.

SPEAKERS - THEATER 3



Abdulrazaq AL-JAZAIRI

Director, Clinical Trials Transformation Division King Faisal Specialist Hospital & Research Center
Riyadh, Saudi Arabia

Dr. Al-Jazairi is a Clinical Pharmacy Consultant in the field of Cardiovascular Pharmacotherapy and the Director, Clinical Trials Transformation Division at the prestigious King Faisal Specialist Hospital and Research Center (KFSH&RC), Riyadh Saudi Arabia. He received his Doctor of Pharmacy degree from Campbell University at Buies Creek, North Carolina, USA, and a general Pharmacy Practice Residency at Duke University Medical Center (DUMC), Durham, NC. In 2000, Dr. Al-Jazairi completed a two-year Specialty Residency in Cardiovascular Pharmacotherapy from Philadelphia College of Pharmacy (PCP), University of the Sciences in Philadelphia in conjunction with the Hospital University of Pennsylvania (HUP), Philadelphia, Pennsylvania. More recently, 2014, Dr. Al-Jazairi earned a Master degree in Pharmaceutical and Healthcare Business from Mayes College, University of the Sciences in Philadelphia. Dr. Al-Jazairi is a board certified pharmacotherapy specialist with Cardiology added-qualification.

Dr. Al-Jazairi has more than 60 original research publications, and delivered many national and international presentations. Dr. Al-Jazairi is the Founder of the Saudi Clinical Pharmacy Society, 2018. He is an editorial board member of prime journals, including Annals of Pharmacotherapy and the Annals of Saudi Medicine, for more than 25 years. He sets in several committees in Saudi-FDA, Saudi Commission for Health Specialties and Saudi Health Council. He is a member of the International Accreditation Commission, ASHP. Dr. Al-Jazairi enjoys training students and residents in Cardiology, Clinical Research and Evidence-based Medicine. Dr. Al-Jazairi is the Director of the first and only Cardiology Residency Program accredited by ASHP outside the States, at King Faisal Specialist Hospital and Research Center (KFSH&RC). He also serves as an Associate Professor, School of Pharmacy and School of Medicine in Alfaisal University, Qassim University, and adjunct Assistant Professor in Princess Nora University and member of the Advisory Board for College of Pharmacy.



Sujuan BA

President & CEO, Founder of the Asian Fund for Cancer Research

Dr. Sujuan Ba is a prominent leader in the field of cancer research and a co-founder of several organizations that support innovative and collaborative cancer research projects. She is the President & CEO, Founder of the Asian Fund for Cancer Research. She also serves as the President & CEO of the National Foundation for Cancer Research, the Co-founder & CEO of the AIM-HI Accelerator Fund, and the Co-Founder & Board Member of the Global Coalition for Adaptive Research. She is one of the instrumental leaders in establishing GBM AGILE, the first-ever paradigm-shifting adaptive clinical trial platform for brain cancer and other rare cancers. She is also a scientific advisor and a board member for more than half a dozen oncology start-ups. She is also a scientific advisor and a board member for more than half a dozen oncology start-ups. Dr. Ba has led the establishment of NFCR's annual Szent-Györgyi Prize for Progress in Cancer Research, an international prize recognizing outstanding scientific achievement in the war against cancer, and has served continuously as co-chair of the Prize Selection Committee since 2006. The prize has now grown into one of the premier cancer research awards in the world. Dr. Ba launched the AIM-HI Women's Venture Competition in 2020, a first-of-its-kind program that provides investment, coaching, and networking opportunities to women-led oncology start-ups. More than 200 women-led oncology start-ups have gone through the rigorous review and judging process of the Women's Venture Competition platform. Dr. Ba also established the AIM-HI Beacon Award for Women Leaders in Oncology in 2022, a one-of-its-kind program recognizing outstanding women pioneers who have significantly impacted cancer patients worldwide through developing, commercializing novel technologies, and implementing public policy. Dr. Ba received the Leadership Award for Global Advocate for Cancer Research from HKBIO in 2023. Dr. Ba also received the NBC4 WORKING 4 THE COMMUNITY Award in 2019, recognizing her outstanding achievements as a scientist, leader, and role model in the STEM field. Dr. Ba also received the inaugural Outstanding Achievement Award from the Society for Neuro-Oncology of the Chinese Medical Doctor Association for her outstanding contribution to international cooperation in 2017. She was named one of the "Top 300 Women Leaders in Global Health" in 2015 by the Graduate Institute of International and Development Studies' Global Health Programme. She was also awarded the Public Service Award in 2014 by the Chinese Biopharmaceutical Association–USA for her long-term devotion and distinguished service to the global biopharmaceutical community. She was selected to receive the CRS WOMEN IN SCIENCES Award in 2011. Dr. Ba received her B.S. in radiochemistry from Peking University and her Ph.D. in chemistry from the University of Pennsylvania.

SPEAKERS - THEATER 3



Jasna CANADI

Senior Bioanalytical Consultant; Executive Coach & Advisor, Nextimpact

Jasna Canadi Semadeni is a senior bioanalytical consultant providing specialist consulting to biotechnology and pharmaceutical organizations, supporting the development and delivery of bioanalytical strategies for complex biologic programmes. She advises partners on biologics and multispecific therapeutics, developing and optimizing analytical strategies across PK, PD, immunogenicity and biomarker assays, with particular expertise in ligand-binding methods. Jasna guides assay development and GLP/GCP method validation aligned with regulatory expectations and scientific best practice and collaborates with cross-functional teams to ensure methods are fit-for-purpose for programme milestones and regulatory decision-making. She has led outsourced bioanalysis with CRO partners worldwide, including strategic partnerships in China, directing sample analysis for preclinical and clinical studies and ensuring high data quality across global vendor networks.
Previously, Jasna held bioanalytical leadership positions at Roche as Head of Regulated Large Molecules Bioanalytics and various scientific roles at Novartis in Basel, Switzerland. Over more than 20 years, she has supported drug development across various stages and diverse therapeutic modalities through robust bioanalytical assessments.



Wei CAO

Founder, Former Chairman & CEO, Gracell Biotechnologies Ltd., AstraZeneca

Dr. William Cao brings over 30 years of R&D experience in biotech industry, including founding two Nasdaq-listed companies: Gracell Biotechnologies (formerly Nasdaq: GRCL) and Cellular Biomedicine Group (formerly Nasdaq: CBMG), with focus on novel cell therapies for cancer and autoimmune diseases. His industry experience also includes roles at Chiron (later Novartis and Bayer) and Affymetrix (now ThermoFisher Scientific).
Dr. Cao holds a Bachelor of Medicine degree from Fudan University Medical College of Shanghai, China, and a Ph.D. in Pharmacology from the Medical College of Virginia. He pursued extensive academic research in immunopharmacology at Harvard Medical School and Stanford Medical Center, authoring over 100 publications, including manuscripts, issued patents, and applications for advanced cell therapies.
On February 22, 2024, Gracell was successfully acquired by AstraZeneca for $1.2 billion, marking it as the first Chinese biotech company fully acquired by a multinational corporation. Dr. Cao has received several prestigious honors, including PharmaVoice 100 Most Inspiring Life Science Leaders Award, BioCentury/BayHelix M&A Deal of the Year 2024, and the HYSTA Entrepreneur of the Year Award 2024.
Dr. Cao is a sought-after speaker at professional conferences, such as the 2024 Harvard China Forum to share his entrepreneurial insights.



Martin CHAN

Vice President, GenEditBio Limited

Dr Chan has a diverse career trajectory uniquely spans academia, government, and biotech industry, equipping him with a well-rounded perspective on translating biomedical research. With over 20 years of experience in molecular and clinical virology, he is currently Vice President of GenEditBio Limited, a clinical-stage gene therapy startup with a strategic goal of developing in vivo genome-editing therapeutic solutions. Prior to joining GenEditBio, he held positions in academia and a government body. He served as an Assistant Professor in the Department of Microbiology at The Chinese University of Hong Kong (CUHK), and as a Senior Scientific Reviewer for the Health and Medical Research Fund managed by the Hong Kong SAR Government. He has co-authored 79 peer-reviewed publications and served as a reviewer for over 50 scientific and medical journals. Dr. Chan holds a BSc in Molecular Biotechnology, an MPhil in Biochemistry, and a PhD in Biomedical Sciences from CUHK. Strategically bridging cutting-edge science with technology transfer, he recently earned an LLM in the areas of intellectual property and bioethics from the University of Hong Kong.

SPEAKERS - THEATER 3



Guokai CHEN

Director of Zhuhai UM Science & Technology Institute, Executive Deputy Director of University of Macau Advanced Research Institute in Hengqin(HUMRI), Professor of Faculty of Medicine

Prof. Guokai CHEN is the Executive Deputy Director of the University of Macau Advanced Research Institute in Hengqin and a Professor in the Faculty of Medicine at the University of Macau.He has held leadership positions for many years and brings extensive management experience. He previously served as Associate Dean (Academic Affairs) of the Faculty of Health Sciences at the University of Macau.
After receiving his PhD from Baylor College of Medicine, Professor Chen conducted postdoctoral research at Baylor College of Medicine and the University of Wisconsin. Prior to joining the University of Macau, he served as an Assistant Scientist at the University of Wisconsin. He subsequently established the Pluripotent Stem Cell Core and the Genome Engineering Core at the U.S. National Institutes of Health (NIH), where he served as Director.
Professor Chen also serves as Chairman of the Executive Committee of the Macau Society for Stem Cell Research and is a member of the Chinese Biological Investigators Society (CBIS).



Michelle CHEN

CEO, Form Bio

Michelle Chen, Ph.D., is President, CEO, and Board Member of Form Bio, the first spin-off from Colossal Biosciences, where she leads the company's efforts to apply AI to genetic medicine design, scale up, and genome engineering applications.
Previously, she served as Chief Business Officer at Insilico Medicine, where she built and led strategic partnerships that translated AI-driven drug discovery into major platform and pipeline deals with biopharma.
Michelle brings cross-functional leadership experience spanning R&D, product, operations, and commercial strategy. She has held leadership roles at WuXi Biologics, BioMarin, Roche, Merck, and Agilent Technologies, and has advised venture capital firms and biotech startups. Over her career, she has led company formations, executed numerous M&A, licensing, collaboration transactions, and worked with investors across the U.S., Europe, and Asia.
Michelle earned her Ph.D. in Biochemistry from the University of Washington, completed postdoctoral research at UC San Francisco, and trained in bioinformatics at Stanford University.



Lung-I CHENG

Vice President, Global Value & Access, AESARA

Lung-I Cheng, PhD, is Vice President, Global Value & Access at AESARA and a healthcare executive specializing in commercialization, pricing, and market access for cell and gene therapies, oncology, and rare diseases. His career spans biopharma, pharmaceutical distribution, and payer-focused organizations, giving him a cross-functional perspective on how innovative therapies move from development to real-world adoption.
Previously, Lung-I served as Vice President and Head of Cell & Gene Therapy at Cencora, where he advised biopharma companies on end-to-end commercialization strategies, including launch planning, distribution, patient services, market access, and stakeholder engagement. At Takeda Oncology, he led global value and access strategies for cell therapies, pipeline assets, and antibody drug conjugates, advancing innovative pricing, reimbursement, and evidence approaches across markets.
Lung-I holds a PhD and MS in Health Economics and Outcomes Research from The University of Texas at Austin and a BS in Pharmacy from National Taiwan University.

SPEAKERS - THEATER 3



Rose Ching Kei CHING

Senior Manager, Life Health Science, Pharmaceuticals and Therapeutics, Hong Kong Science and Technology Parks Corporation

Dr. Ching Kei Ching is employed at Hong Kong Science and Technology Parks Corporation (HKSTP), where she serves as a Senior Manager in Life and Health Technology, focusing on pharmaceuticals and advanced therapeutics. She also holds an honorary research fellowship in the Department of Internal Medicine at The University of Hong Kong. With over ten years of experience in cell therapy, she specializes in the research and development of innovative cell and gene therapies, clinical translation, GMP manufacturing, and quality control. Dr. Ching is dedicated to advancing the development of Hong Kong's advanced therapy industry and has extensive experience in establishing GMP production facilities that meet international PIC/S standards. She actively promotes the growth of Hong Kong's biomedical sector, fosters international collaboration, and
supports biopharmaceutical companies within the Hong Kong Science Park.
Dr. Ching earned her Master's and Ph.D. in Physiology from China Medical University. She was a visiting scholar at the University of Connecticut Health Center and a postdoctoral fellow in the School of Biomedical Sciences at The University of Hong Kong. In 2020, she obtained a Postgraduate Diploma in GMP Manufacturing and Quality Control from The University of Strathclyde in the UK. She has been awarded a National Young Scientists Fund and has published nearly 20 international academic papers, including in journals such as Nature Cardiovascular Research and Circulation.



Sherman K.W. FUNG

Co-Founder & CEO, North Edge Ltd.

Dr. Sherman K.W. Fung, DPhil (Oxford), FRSM, FRSC, CChem, CSci, is Co-Founder and CEO of North Edge Ltd. He is a biotech strategist and commercial scientist with more than 30 years of international experience in biomedical R&D, life science business development, regulatory affairs and healthcare innovation. Dr. Fung received his DPhil from the University of Oxford and his First Class Honours BSc in Chemistry from Imperial College London. He previously served as CEO of Talent Rise Corporation, Director of BioSciences and General Manager of Chemical Testing at SGS Hong Kong, COO of the Institute of Chinese Medicine at The Chinese University of Hong Kong, and CEO and Chief Product Developer of REGENE. Dr. Fung is also a recognised science communicator and life science content creator, active on YouTube,WeChat Video Channels and other major digital platforms, with more than million followers and over 50 million content views across platforms.



Sean HU

Chairman, Beike Biotech.

Ph.D Bio-Chemistry and Molecular Biology.
Founder and Chairman of Shenzhen Beike Biotechnology Co. Ltd.

SPEAKERS - THEATER 3



Reagan JARVIS

Co-Founder and CEO of Anocca

Reagan Jarvis is the Co-Founder and CEO of Anocca, a T cell immunotherapy company based out of Sweden, commencing first-in-human clinical trials in 2025 with gene-edited TCR-T cell therapy products in oncology. A New Zealander, Jarvis obtained his PhD in Biochemistry at University of Otago and performed postdoctoral research at the University of Otago and thereafter the German Cancer Research Center (DKFZ) in Heidelberg. He founded Anocca with Mikael Blomqvist in 2014. Anocca currently has a pipeline of over 40 products. It has over 130 staff members, with more than 40 nationalities and operates its own cGMP cell therapy manufacturing site in Södertälje, south of Stockholm.



Gina JIANG

Managing Director / Hong Kong Institute of Biotechnology

Dr. Gina Jiang is the Managing Director of the Hong Kong Institute of Biotechnology (HKIB), affiliated with The Chinese University of Hong Kong, where she has led the institute since April 2020. A key architect behind the development of a GMP-certified facility for Advanced Therapy Products, Dr. Jiang is accelerating the growth of cell and gene therapy capabilities in Hong Kong. Her international background spans leadership roles and entrepreneurial ventures in the San Francisco Bay Area and Taipei. She holds degrees from the University of Toronto and Peking University and conducted research at the NIH and Stanford University.



Chi-kong LI

Research Professor, Department of Paediatrics, The Chinese University of Hong Kong

Prof. Chi-kong LI currently is Research Professor at Department of Paediatrics of The Chinese University of Hong Kong, and honorary consultant at Hong Kong Children's Hospital. Dr. Li is specialized in paediatric haematology, oncology, stem cell transplantation and cellular therapy. He was the past Continental President of Asia of International Society of Pediatric Oncology. His main interest is in childhood leukaemia, palliative care and bioethics. He has published over 400 peer-reviewed papers.

SPEAKERS - THEATER 3



Derek MA

Executive Director, Beike Biotechnology (Qionghai) Co., Ltd

Ma Ye, a tech blogger and former traditional- media journalist, focuses on science communication for emerging biotechnologies, cell and gene therapy and medical sciences. As the official Science Popularization Ambassador of Boao Lecheng Pilot Zone and Executive Director of Beike Biotechnology (Qionghai) Co., Ltd., he has spearheaded two biotech projects in Lecheng and Shanxi's first nationally dual- filed cell- therapy project. He is also an academic committee member of Hainan Special Committee for Health Communication. He dedicates himself to making advanced science accessible to the public and advocates technology for good.



Jie MA

Head of National Center for Clinical Laboratories and Biotherapy Center, Beijing Hospital

Ma Jie is the head of the National Center for Clinical Laboratories and the Biotherapy Center at Beijing Hospital, and a doctoral supervisor.

Professor Ma is one of the Beijing 100 Leading Talents in Science and Technology, one of the national candidates for the New Century Millions of Talents Project, a State Council Special Allowance expert, the chief expert of a state - key research and development project, the chief expert of a national science and technology major project, and an expert for the "12th Five-Year Major New Drug Creation" and "14th Five-Year Special Guidelines for Stem Cell and Tissue Repair".

The tumor cell immunotherapy program developed by Professor Ma received two phase II clinical trial approvals from the State Food and Drug Administration in 2022. Currently, Professor Ma has carried out a number of phase I clinical research projects of tumor immunotherapy, and has won the First Prize of the Beijing Medical Science and Technology Award, the Third Prize of the Beijing Science and Technology Award, and the Second Prize of the China Medical Science and Technology Award, making important contributions to the promotion of tumor immunotherapy in China.

Professor Ma's research interests include target screening and new technology development for tumor immunotherapy; Research and development of anti-tumor nanomedicine and new dosage forms modified by nanotechnology; Clinical application of tumor targeting therapy and immunotherapy, etc.



Nancy Kwan MAN

Chair Professor, Department of Surgery, The University of Hong Kong; Founder and Director: Oncoimmunostics Ltd.

Dr Nancy Kwan MAN is the Chair Professor of Transplant Oncology and Immunology, Director, Clinical and Translational Research; Director of the Laboratory for Liver Transplantation and Liver Cancer; Director of the Laboratory for Organ Transplantation and Regeneration, in Department of Surgery, School of Clinical Medicine, LKS Faculty of Medicine, The University of Hong Kong. Nancy is currently the President of Hong Kong Scientist Association (HKSA), and the President of Hong Kong Society of Immunology (HKSI). She is also the Founder and Director of OncoImmuNostics Ltd with the IncuBio and Raise+ support. Nancy is well-recognized internationally for the advancements of liver transplantation research. Her innovative development and successful application of integrated clinical, translational and basic research for liver graft injury and cancer recurrence after transplantation, has resulted in major advances and impact on transplant oncology and immunology in the world. Her research achievements have been dully recognized by her numerous prestigious international awards, invited plenary and state-of-art lectures in leading congresses of transplantation, leaderships of international academic societies, such as the presidency of International Liver Transplantation Society (ILTS) (2018-19), journal editorship and leading role of international consensus/guideline of transplant oncology and immunology.

SPEAKERS - THEATER 3



Donglei MAO

Editor-in-Chief and Co-founder of PharmaDJ, Deputy Chief Editor of Asia Bio Inc., Columnist of Biotechgazine, Strategic Advisor of BIOHK, Strategic Advisor of GBAAPI

Donglei Mao holds an MSc in Drug Regulatory Affairs and Policy (DRAP) from The Hong Kong University of Science and Technology. She began her career in 2000 at the Southern Institute of Pharmaceutical Economics (under the National Medical Products Administration), writing for Pharmaceutical Economics News. She was one of the earliest journalists to provide sustained, in-depth coverage of China's drug regulatory reform, and has interviewed multiple NMPA officials and directors of the Center for Drug Evaluation (CDE).
In 2014, she co-founded PharmaDJ, which has since grown into a well-respected and influential media platform in the pharmaceutical industry. She closely follows drug regulatory trends in China and abroad, covering regulatory science, clinical trials, and biopharmaceutical innovation, and is proficient in both Chinese and English professional writing.
PharmaDJ serves as a media partner to the China Pharmaceutical Innovation Association (PhIRDA), DIA, and the Hong Kong Association of the Pharmaceutical Industry. Donglei also holds advisory and editorial roles, including Strategic Advisor to the Greater Bay Area Biomedical Innovation Alliance, Columnist for the Hong Kong Biotechnology Association, and Deputy Editor-in-Chief of Asia Bio Inc.



Bev MENNER

Chief Executive Officer of Cell Therapies Pty Ltd

Dr Bev Menner is the Chief Executive Officer of Cell Therapies Pty Ltd, where she leads at the frontier of advanced cell and gene therapies. After earning a PhD in Molecular Medicine at the Walter and Eliza Hall Institute, she completed postdoctoral fellowships at the Memorial Sloan Kettering Cancer Center in New York and the Peter MacCallum Cancer Centre. In a unique professional pivot, she also qualified as a Genetic Counsellor - clinical experience that provides her with insights into the human impact of genetic medicine – and then led the delivery of clinical trials in a global CRO. During a 14-year tenure at CSL, Dr Menner held several leadership roles, including establishing and leading the global Alliance Management function.
In her leadership role at Cell Therapies, Australia's leading GMP manufacturer of clinical- grade cell therapies, Bev's deep operational expertise drives the delivery of programs that advance products from preclinical development through clinical manufacturing. Bev is widely recognised for strengthening Australia's sovereign advanced- therapy manufacturing capacity and supporting global developers entering the Asia- Pacific region. Her leadership ensures that cutting- edge cell and gene therapy programs can scale safely, efficiently and to international quality standards, reinforcing Australia's growing position in the worldwide CGT ecosystem.

SPEAKERS - THEATER 3



Stanley SY

Co-Founder & CEO, Hong Kong Regen Medtech Limited

Mr. Stanley Sy Ming Yiu has been dedicated to promoting the development of Hong Kong's biotechnology industry. After graduating with a Master's degree as a postgraduate from The Chinese University of Hong Kong, he joined the Prince of Wales Hospital to participate in various biotechnology research projects. Later, he joined Sanomics Limited to provide genetic testing services for cancer patients, helping physicians formulate personalized treatment plans. In 2020, he founded Curative Biotech Limited to develop telehealth services. In 2021, Mr. Sy joined Action Genomics to continue serving cancer patients in Southeast Asia. Meanwhile, he also pursued his Ph.D. degree at Vinnytsia National Technical University in Ukraine and founded A-Square Life Sciences Limited, further advancing the development of life sciences and innovative healthcare. In addition, he co-founded Hong Kong Regen Medtech Limited, a Hong Kong stem cell biotechnology company focusing on the research and application of stem cell technology.

Mr. Sy not only earned his Bachelor's degree in Electronic Engineering (Biomedical Engineering) and Master's degree in Electronic Engineering (Biomedical Engineering) with outstanding results from The Chinese University of Hong Kong, but he also served as a Biomedical Engineer at the Prince of Wales Hospital, during which he published 11 related articles in journals. In addition, he successfully applied for government funding, bringing resources and training to many junior researchers. Before joining Sanomics Limited, Mr. Sy also worked as a Global Business Services Consultant at International Business Machines Corporation (IBM), responsible for concept development and process auditing for various businesses. This year, Mr. Sy further obtained the Certified Clinical Research Professional (CCRP) qualification as well as SFC Type 4 and Type 9 licenses.In 2015, Mr. Sy joined Sanomics Limited with the determination to improve cancer treatment methods. Starting as a Sales Representative, through hard work and accumulated experience, he was promoted to Chief Executive Officer and Executive Director of the company. During the research process, Mr. Sy has worked hand-in-hand with multiple national-level medical professors, such as Professor Tony Mok and Professor Dennis Lo, cooperating with various manufacturers and cancer patients to successfully apply for patents for new drug research and development, providing doctors with innovative treatment solutions, and more importantly, bringing new hope to millions of patients.In 2018 and 2020, Mr. Sy led Sanomics Limited in establishing biotechnology laboratories in Wuxi, Thailand, and Vietnam, serving as important bases for the company's development in the "Belt and Road" markets.

Meanwhile, Mr. Sy has also established friendly relationships with multiple pharmaceutical enterprises such as AstraZeneca and Zai Lab, laying a solid foundation for the development of Hong Kong's biotechnology industry.At the end of 2019, Mr. Sy successfully introduced several Hong Kong biotechnology companies to China's biotechnology cradle, such as Wuxi in the Yangtze River Delta. Through years of accumulated experience and continuous learning of various professional knowledge, he has become a pragmatic, prudent, and inspiring leader, effectively supervising the company's various strategies and business development over the years.Mr. Sy has also served as a member of multiple government committees. In October 2018, he was appointed as a member of the Technology Voucher Programme Committee under the Innovation and Technology Commission. In December of the same year, he was appointed as a committee member of the Chongqing Youth Federation. Since 2020, Mr. Sy has been appointed by the Commissioner for Transport as a member of the Personalized Registration Markings Assessment Committee and by the Financial Secretary of the HKSAR Government as a member of the Business Facilitation Advisory Committee. In addition, in the same year, Mr. Sy also served as an advisor to the Hong Kong Wai Tse Elders Fund. In 2021, Mr. Sy was appointed by the Chief Secretary for Administration of the HKSAR Government as a member of the Appeal Board (Administrative Review). In the same year, he was also appointed by the Hong Kong Science and Park as a TVI Committee member, and was further appointed as a Biotechnology Committee member the following year.As the Chairman of the Hong Kong Youth Association, Mr. Sy helps Hong Kong youth discover their self-worth. Utilizing the resources he gained in the biotechnology sector, he leads Hong Kong youth to participate in various exchange and study tours to broaden their horizons. At the same time, he also encourages youths to join the innovation and technology industry through various methods, successfully uniting a group of ambitious young people.In 2020, Mr. Sy was selected as a Greater Bay Area Youth Leader in recognition of his outstanding contributions to the field of biotechnology.Since 2020, Mr. Sy has started serving as a mentor for the student mentorship programs of The Chinese University of Hong Kong, The Hong Kong University of Science and Technology, and the Life Science Youth Society of Hong Kong. Through knowledge exchange, collaboration, and participation, he aims to nurture and unite a cohort of life science talents.In the same year, undaunted by the epidemic and amidst a sluggish market, Mr. Sy founded Curative Biotech Limited. Through an online medical platform, it provides specialized oncology telehealth services, successfully breaking through the geographical limitations of traditional healthcare and providing revolutionary cancer treatment approaches.

Mr. Sy's current outstanding performance in the biotechnology industry is entirely attributable to his years of hard work and perseverance. When those around him considered the prospects of biomedical engineering to be uncertain, he silently marched toward his goals, forging ahead with determination to promote the development of Hong Kong's biotechnology industry.

SPEAKERS - THEATER 3



Kwong Hang TAM

Vice President& Chair Professor/Macau University of Science and Technology

JP; MBBS(HK); ChM(Liv); FRCS(Eng, Edin, Glas, and Ire); FRCPCH; FHKAM (Surgery);HKAS member
Prof. Paul K.H. Tam is a renowned surgeon, scientist, educator and university leader. He is Chair Professor and Vice-President of the Macau University of Science and Technology, and Emeritus Professor and Honorary Clinical Professor of the University of Hong Kong
Professor Tam has special interests in minimal invasive surgery, genetics and regenerative medicine of birth defects especially Hirschsprung's disease and biliary atresia. He has published 505 articles in internationally refereed journals with 35,314 citations and h-index = 66.
He has received numerous awards including the 2017 Denis Browne Gold Medal- the highest award of the BAPS, the 2020 Rehbein Medal by the European Paediatric Surgeons' Association.



Han Chong TOH

Deputy CEO, National Cancer Centre Singapore (NCCS); Senior Consultant, Division of Medical Oncology, NCCS

Dr Toh Han Chong is Deputy CEO (Strategic Partnerships), National Cancer Centre Singapore and Professor at Duke NUS Medical School. He completed the International Baccalaureate at Lester B Pearson College, British Columbia, Canada, on a United World College scholarship, obtained his BSc (Intercalated) from the University of London in 'Infection and Immunity' and his medical degree from the University of Cambridge, UK. His oncology and translational research fellowships were at the Singapore General Hospital, Massachusetts General Hospital, Harvard Medical School and at the Center for Cell and Gene Therapy, Baylor College of Medicine, Houston Texas, USA. Dr Toh is alumni of the Harvard Business School General Management Program. He received the National Senior Clinician Scientist Award in 2017, National Medical Excellence Award (NMEA) in 2018 and the NMRC STaR Award in 2022. Dr Toh is currently Programme Lead for the National Cell Therapy Manufacturing and Development Grant ASPHALT pivoting on CAR T cell manufacturing and development. He is in the Governance Committee KKH Children's Blood and Cancer Centre. Dr Toh is co-founder of the Asia-Pacific Gastrointestinal Cancer Summit (APGCS). He is European Society for Medical Oncology (ESMO) Scientific Faculty for Cancer Immunology & Immunotherapy and Chair of Investigational Immunotherapy at ESMO Annual Congress 2026 in Madrid, Spain. He is on the Scientific Committee for ESMO TAT 2027 Paris. He is incoming Council Member of the Asia-Pacific Primary Liver Cancer Expert Association. As co-founder of a clinical stage startup, he and Team NeoTILa won 1st prize (global health category) and overall 3rd prize at the 2024 Wolfson Entrepreneurship Competition, Cambridge University.



Heng Phon TOO

Co-founder and Chairman of MiRXES Pte Ltd

Prof Too Heng Phon was appointed as a Director and re-designated as a non-executive Director in January 2021. He was appointed as the Chairman of the Board in January 2021. He currently also serves as the Chief Scientific Adviser of the Company. He is mainly responsible for participating in formulating the corporate and business strategies of our Group.

Prof Too has over 23 years of research experience in biochemistry. He was appointed Associate Professor at the National University of Singapore in 2016. Previously, he was a Fellow in the Singapore-MIT Alliance (2001–2006), later co-chairing its Chemical Pharmaceutical Engineering program (2006–2016). He also served as Adjunct Scientist at ASTAR's BTI (2010–2016) and Lead Scientist at its Biotransformation Innovation Platform (2014–2018). Prof Too earned his Biochemistry degree from Imperial College London (1982) and PhD from the University of London's Institute of Ophthalmology (1985), followed by training at the MRC Cambridge and Harvard Medical School. He received the ASTAR Scientist-Entrepreneur Award in 2017 and the President's Technology Award in 2021.

SPEAKERS - THEATER 3



Jianxun WANG

Chief Scientific Officer / Shenzhen Cell Valley Biopharmaceuticals Co., LTD

Professor Jianxun Wang is a Ph.D. graduate and postdoctoral researcher from the University of California, San Diego, a Second-Class Professor and doctoral supervisor at Beijing University of Chinese Medicine, and Chief Scientist of Shenzhen Cell Valley Biomedicine Co., Ltd. A former student of U.S. National Academy of Sciences members Michael G. Rosenfeld and Christopher K. Glass, Professor Wang is an epigenetics expert focused on enhancing T-cell tumor recognition and killing capabilities through epigenetic modifications, achieving breakthroughs in CAR-T therapy for solid tumors. As a senior scientist at Sorrento Therapeutics, he pioneered CAR-T cGMP development from scratch, accumulating extensive experience in industrial-scale production of cell therapies. Recognized as a world-class expert in constructing viral vectors including retroviruses and lentiviruses, Professor Wang has established cutting-edge standards for cellular therapy production.



Wensheng WEI

Professor, Peking University

Wensheng Wei received his bachelor degree in Biochemistry from Peking University, Ph.D. in Genetics from Michigan State University. After postdoctoral training and working as a research associate at Stanford University School of Medicine, Dr. Wei became a principle investigator in the School of Life Sciences at Peking University from 2007. He is currently a professor at the Biomedical Pioneering Innovation Center, Peking-Tsinghua Center for Life Sciences, and the School of Life Sciences at Peking University, Director of the Genome Editing Research Center at Peking University, and Lead Scientist at Changping Laboratory. The Wei group's research primarily focuses on advancing eukaryotic gene editing tools, with particular emphasis on high-throughput functional genomics, gene and cell therapy, and innovative RNA therapeutics utilizing circular RNAs.



Andy ZANG

Vice President, Business Development and Strategic Planning, CARsgen Therapeutics Holdings Limited

Dr. Andy (Peng) Zang is the Vice President, Head of Business Development and Strategic Planning at CARsgen Therapeutics. In his role, Dr. Zang leads CARsgen's overall business development efforts, alliance management, and corporate strategic planning initiatives. Additionally, he oversees the strategy and management of the CARsgen's product pipeline, as well as the company's public relations and government relations functions. Dr. Zang joined CARsgen from Roche, where he served as Strategic Planning Lead for Hematology and Early Assets within Roche China. He brings over a decade of professional experience across GSK, BMS, and Roche, spanning medical affairs, clinical science, marketing, portfolio and project management, and business development.

Dr. Zang holds a doctoral degree from Peking University Health Science Center and a double major Bachelor's degree from Peking University China Center for Economics Research.

SPEAKERS - THEATER 3



Xian ZENG

CEO， Byterna Therapeutics Ltd.

Dr. Xian Zeng is the Co-Founder and Chief Executive Officer of Byterna Therapeutics, a biotechnology company dedicated to advancing next-generation circular mRNA-based immunotherapies. He leads the company's strategic vision and innovation efforts in developing transformative in vivo CAR-T therapeutics enabled by proprietary circular mRNA platforms and targeted delivery technologies. Dr. Zeng earned his PhD in AI-Pharmaceutical Science from the National University of Singapore. Prior to co-founding Byterna Therapeutics, he served at the Fudan University School of Pharmacy, where he led interdisciplinary research spanning pharmaceutical sciences, artificial intelligence, and mRNA drug discovery. His work has focused on integrating cutting-edge computational approaches with therapeutic innovation to accelerate the development of novel RNA medicines. Recognized for his cross-disciplinary expertise and international perspective, Dr. Zeng is committed to translating scientific breakthroughs into clinically meaningful solutions for patients worldwide. Under his leadership, Byterna Therapeutics is pursuing a new generation of SEAA therapeutics—Safe, Effective, Accessible, and Affordable—with the goal of expanding the global reach of advanced cell and gene therapy approaches.



Jinhua ZHANG

Founder, Chairwoman, and CEO, IASO Biotechnology

Ms. Jinhua Zhang has over 20 years of experience in securities market and corporate management. Prior to founding IASO Bio, she worked in investment banks and leading securities law firms, where she led overseas and domestic listing and M&A restructuring projects for many Chinese companies. She also previously invested as an angel investor in cell therapy startups and served as director.

Drawing on her extensive background in IPOs, mergers and acquisitions and investments in the biopharmaceutical field, Ms. Zhang founded IASO Bio in March 2017 with the vision of "focusing on innovative biotherapies to bring hope of cure to patients". Under her leadership, IASO Bio has grown into a leader in the cell therapy sector, with end-to-end capabilities across discovery, development, manufacturing and commercialization. The company successfully launched its blockbuster CAR-T product, Fucaso in 2023.

Ms. Zhang obtained her bachelor's degree in laws, and master's degree in laws, both majoring in economic law, from Dongbei University of Finance and Economics.
Accolades
· Selected for the 2024 China's New Drug Pioneer Award 20 Years 20 People
· Selected for the 2024 Fortune China's Most Powerful Women in Business Future List



Arthur ZHOU

Head of International Commercialization at IASO Bio

Lead IASO Bio's international commercialization across SEA, Oceania, Central and North Asia, the Middle East, North Africa and Türkiye (MENAT), and Latin America. Serve as Principal for IASO Bio's acquisition of Medisix, a Singapore-based CAR-T company.

SPEAKERS - THEATER 4



Abdulrazaq AL-JAZAIRI

Director, Clinical Trials Transformation Division King Faisal Specialist Hospital & Research Center
Riyadh, Saudi Arabia

Dr. Al-Jazairi is a Clinical Pharmacy Consultant in the field of Cardiovascular Pharmacotherapy and the Director, Clinical Trials Transformation Division at the prestigious King Faisal Specialist Hospital and Research Center (KFSH&RC), Riyadh Saudi Arabia. He received his Doctor of Pharmacy degree from Campbell University at Buies Creek, North Carolina, USA, and a general Pharmacy Practice Residency at Duke University Medical Center (DUMC), Durham, NC. In 2000, Dr. Al-Jazairi completed a two-year Specialty Residency in Cardiovascular Pharmacotherapy from Philadelphia College of Pharmacy (PCP), University of the Sciences in Philadelphia in conjunction with the Hospital University of Pennsylvania (HUP), Philadelphia, Pennsylvania. More recently, 2014, Dr. Al-Jazairi earned a Master degree in Pharmaceutical and Healthcare Business from Mayes College, University of the Sciences in Philadelphia. Dr. Al-Jazairi is a board certified pharmacotherapy specialist with Cardiology added-qualification.
Dr. Al-Jazairi has more than 60 original research publications, and delivered many national and international presentations. Dr. Al-Jazairi is the Founder of the Saudi Clinical Pharmacy Society, 2018. He is an editorial board member of prime journals, including Annals of Pharmacotherapy and the Annals of Saudi Medicine, for more than 25 years. He sets in several committees in Saudi-FDA, Saudi Commission for Health Specialties and Saudi Health Council. He is a member of the International Accreditation Commission, ASHP. Dr. Al-Jazairi enjoys training students and residents in Cardiology, Clinical Research and Evidence-based Medicine. Dr. Al-Jazairi is the Director of the first and only Cardiology Residency Program accredited by ASHP outside the States, at King Faisal Specialist Hospital and Research Center (KFSH&RC). He also serves as an Associate Professor, School of Pharmacy and School of Medicine in Alfaisal University, Qassim University, and adjunct Assistant Professor in Princess Nora University and member of the Advisory Board for College of Pharmacy.



Joshua CARLE

Chief Business Officer, Hinge Bio, Inc.

Joshua Carle, Chief Business Officer at Hinge Bio, Inc., is a cross-functional executive with over 20 years of strategic transaction and R&D investment experience while in Management Consulting and BioPharma. Mr. Carle has led or advised more than fifty potential strategic transactions, resulting in the successful execution of greater than $2 billion in disclosed deal value and committed R&D funds. Mr. Carle was previously at Triumvira Immunologics Inc., a next-gen immuno-oncology biotech, where he served as Vice President of Business Development. In this role he executed multiple types of agreements to support the substantial growth of the company, including a clinical collaboration, innovative technology enabling collaboration, in-license, and investor interactions/outreach, while additionally leading corporate strategy and R&D prioritization. Prior to Triumvira, Mr. Carle was at Pfizer Inc., where he drove BD strategy, commercial assessments, and broad transaction support for licensing/M&A efforts for Pfizer Oncology. Previously, Mr. Carle held roles of increasing responsibility in business development activities at Daiichi Sankyo Inc. and Clearview Projects Inc., a strategic advisory firm focused on licensing/M&A for the BioPharma industry. Mr. Carle received his undergraduate degree in Economics from the University of Pennsylvania and MBA from the Villanova School of Business.

SPEAKERS - THEATER 4



Bernard CHEUNG

Chief Executive Officer, Greater Bay Area International Clinical Trial Institute

Professor Bernard Cheung
PhD(Cantab), FRCP, FRCPE, FHKCP, FHKAM(Medicine), FBHS, FBPhS

Professor Bernard Cheung is the Chief Executive Officer of the Greater Bay Area International Clinical Trials Institute (GBAICTI), where he leads strategic efforts to strengthen Hong Kong's role as an internationally credible clinical trials hub and to advance cross boundary clinical research collaboration within the Greater Bay Area.
He was educated at the University of Cambridge and has had a distinguished academic career in clinical pharmacology and medicine. He previously served as Professor of Clinical Pharmacology and Therapeutics at the University of Birmingham, and the Sun Chieh Yeh Heart Foundation Professor in Cardiovascular Therapeutics at the University of Hong Kong.
His career spans clinical medicine, academic research, and the development and governance of clinical trial infrastructure, including early phase and investigator initiated studies. He served as Director of the Phase 1 Clinical Trials Units at Queen Mary Hospital and the University of Hong Kong–Shenzhen Hospital, and was previously the Biotechnology Director at the HKSAR Government's Innovation and Technology Commission.
Professor Cheung currently serves as President of the Federation of Medical Societies of Hong Kong and is Editor in Chief of the Postgraduate Medical Journal. His research interests focus on cardiovascular diseases and metabolic disorders, including the metabolic syndrome, with an emphasis on generating robust evidence to support clinical practice and healthcare decision making.



Ching-lung CHEUNG

Director, Real-World Study and Application Centre, Greater Bay Area International Clinical Trial Institute

Professor ChingLung Cheung is a leading expert in realworld evidence and musculoskeletal research, and currently serves as Director of the RealWorld Study and Application Centre (RWSAC) at the Greater Bay Area International Clinical Trial Institute (GBAICTI).
He obtained his undergraduate degree from The Hong Kong Polytechnic University and completed his PhD at The University of Hong Kong (HKU). He further strengthened his research training through postdoctoral fellowships at Harvard Medical School, A*STAR Singapore, and HKU.
Before joining GBAICTI, Professor Cheung was an Associate Professor in the Department of Pharmacology and Pharmacy of HKU, with research interests focusing on the epidemiology and genetics of osteoporosis. His work leverages realworld data to generate clinically relevant evidence and improve patient care.
He holds several prominent leadership roles, including elected Fellow and committee member of the American Society of Bone and Mineral Research, and currently serves as President of the Osteoporosis Society of Hong Kong, contributing actively to regional and international initiatives in bone health research.
Professor Cheung has authored over 180 peerreviewed publications in leading international journals such as The Lancet, JAMA, Cell, and Nature Genetics.

SPEAKERS - THEATER 4



Jacqueline CHOI

Medical Director, CUHK Medical Centre

Dr. CHOI Hiu Yeung (Jacqueline) is an experienced specialist in public health medicine and currently serves as Medical Director of Business Development, as well as a Consultant Physician at the Chinese University of Hong Kong (CUHK) Medical Centre. Her contributions to public health and primary care are well recognized. She also holds honorary clinical professorships at the Jockey Club School of Public Health and Primary Care of the CUHK Faculty of Medicine, as well as at the Li Ka Shing Faculty of Medicine of the University of Hong Kong.

Dr. CHOI holds several professional qualifications, including a Bachelor of Medicine and Bachelor of Surgery from CUHK, a Fellowship of the Royal College of Physicians (UK), and a Master of Public Health from the National University of Singapore. She also holds a Diploma in Internal Medicine from CUHK and is a Fellow of the Hong Kong College of Community Medicine, the Royal College of Physicians (Public Health) (UK), and the Hong Kong Academy of Medicine (Community Medicine).

Dr. CHOI serves as Medical Director at CUHK Medical Centre, where she is responsible for business development, management of allied health services, clinic operations, and direct patient care as a primary care physician. In this role, she actively explores new business opportunities and partnerships to enhance service efficiency and improve patient experience.

In a previous appointment as a government official in the Department of Health of the Hong Kong Special Administrative Region Government, Dr. CHOI led initiatives in primary care development, community liaison, and chronic disease surveillance. She also provided direct patient care in the internal medicine stream of the Hong Kong Hospital Authority.

With her strong academic background, extensive clinical experience, and integrated expertise in business development, Dr. CHOI is dedicated to advancing public health policy and contributing to the improvement of community health.



Zhen DING

Vice President, Xi'an International Medical Investment Co,. Ltd.

Mr. DING Zhen is the Vice President of Xi'an International Medical Investment Company Limited, responsible for the group's international medical and strategic development operations, as well as international exchange and cooperation related to clinical practice, education, research, management, and academic exchanges. He also serves as a standing committee member of the International Medical Tourism Branch of the China Non-Government Medical Institutions Association, a member of the Healthcare Industry Committee of the China Association for Public Companies, and a council member of the Shaanxi Provincial People's Association for Friendship with Foreign Countries.

Xi'an International Medical Investment Company Limited (International Medical, IMIC) is a large Chinese medical group listed on the Shenzhen Stock Exchange. It operates Xi'an Gaoxin Hospital and Xi'an International Medical Center Hospital, with a total of 10,137 medical service beds. In 2025, it served 2.7 million patient visits, and has cumulatively served over 28 million patient visits to date. The hospital under the group has been accredited as National Grade A Tertiary hospital and has received international JCI accreditation. In 2021, they became member hospitals of the Mayo Clinic Care Network (2021–2025).

SPEAKERS - THEATER 4



Tong GUO

CEO of Clinical Research Center, Gobroad HealthCare Group

Dr. Tong Guo serves as CEO of Clinical Research Center at Gobroad Healthcare Group. Early in his career, he served as Principal Biostatistician at Bristol-Myers Squibb in US. After returning to China, he served as VP at WuXiPRA, Executive Director of Data Science Asia at Bayer, Head of Biometric Asia and Africa at Quintiles, and Head of Sales at IQVIA. He was CEO and Board of Directors of the first ARO in China; and Executive VP of an oncology big data company.
Dr. Guo also serves as multiple high-level advisory and leadership roles including: Advisor to the Clinical Oncology Committee and Deputy Director of the Clinical Trial Committee of the China Pharmaceutical Innovation Promotion Association; Lead to ICH M14 Guiding Principles; Member of the IFPMA International Expert Working Group; Secretary-General of the Precision Medicine and Industry Development Alliance; Lecturer in the Master of Health Leadership Program at Tsinghua University School of Medicine; and former Advisor of the DIA Advisory Committee China.
Dr. Guo holds a master's and a Ph.D. degree in biostatistics from McGill University, Canada.



Peter GUY

Resident Financial Expert, RTHK Radio

A broadcaster for RTHK covering financial markets. Former venture capital and private equity manager, formerly an officer with the World Bank. A leading financial journalist in HK.



Michael LIANG

Managing Partner, InVivium Capital

Michael Liang, Ph.D. has been a venture capital investor for the past 25 years and is currently a Founder and Managing Partner of InVivium Capital, focusing on investments across life sciences. Previously, Mike spent 16 years as a Partner with Baird Capital, overseeing healthcare venture investments. Prior to joining Baird Capital, Mike was a healthcare investor with Advent Venture Partners (London, U.K.) and before that served in an operating role as a Director of R&D at Cortek, a spinal orthopedics company. Mike currently serves on the Board of Directors of Onchilles Pharma and Infinant Health and was also previously a Board Member of Alto Neuroscience (NYSE: ANRO), GreenLight Biosciences (NASDAQ: GRNA), Interlace Medical (sold to Hologic), OncoHealth (sold to Arsenal Capital Partners), Veniti (sold to Boston Scientific), and a board observer of TomoTherapy (NASDAQ: TOMO, sold to Accuray). Mike received a B.S. in bioorganic chemistry from the University of California, Berkeley, completed a Ph.D. in biophysical chemistry from Stanford University, and conducted a postdoctoral fellowship at Harvard University.

SPEAKERS - THEATER 4



Roben LIANG

Founder, National Health Policy Platform 2050

Mr. Roben LIANG, Researcher. Research directions: National health governance and health strategic communication. Founder of 'Health Policy 2050', Council Member of the Population Association of China, Council Member of the Chinese Association for Health and Medical Ideological and Political Work, Standing Committee Member of the Special Committee on Public Hospital Medical Insurance Management of the China Medical Insurance Research Association, Member of the Medical Insurance Special Committee of the China Association of Social Security, and Standing Committee Member of the Digital and Intelligent Health Special Committee of the China Health Management Association.



Yichong LI

President, Greater Bay Area International Clinical Trials Center (Bay Trial)

Dr. Yichong Li is an independent Principal Investigator and Professor at the National Clinical Research Center for Cardiovascular Diseases (Fuwai Hospital, Chinese Academy of Medical Sciences). He is currently jointly appointed as Director of the Greater Bay Area International Clinical Trial Centre (Bay Trial) at the Shenzhen Medical Academy of Research and Translation (SMART). Prior to his current role, he held research positions at the Chinese Center for Disease Control and Prevention (China CDC), the University of Washington, Stanford University, and Peking University Health Science Center. He has led over ten major health research and clinical research projects, including those funded by the Ministry of Science and Technology, National Natural Science Foundation of China (NSFC), and the Guangdong Pearl River Talent Program. He has published nearly 100 original research articles as first or corresponding author in leading medical journals, including JAMA, BMJ, and subjournals of JAMA and The Lancet. His Hindex was 57 in 2025, and he has been consecutively listed in Stanford University's World's Top 2% MostCited Scientists from 2022 to 2025.



Wenting LI

Head of Real-World Evidence Department

Dr. Li Wenting is Head of RWE at the Greater Bay Area International Clinical Trial Center. A U.S.-trained health economist and certified expert by Capital Medical University, she has led numerous NRDL negotiations and RWE studies. Her work has been published in Value in Health, and she has a manuscript under review at Nature Reviews Bioengineering.

SPEAKERS - THEATER 4



Xiaolin LIU

Chairman, China Biotech Services Holdings Limited

Chairman, China Biotech Services Holdings Limited Vice Chairman, Nanjing Medical University Chairman, CBSH Flourish (Hong Kong) BNCT Medical Centre Ltd Chairman, Longyao Biotech (Hong Kong) Ltd



Xin LIU

Director of Healthcare Fund, Hony Capital

Professional experience:
Hony Capital | Director of Healthcare Fund
Joined in 2023; leading investments across innovative therapeutics, advanced therapies, medical devices, and healthcare services.
CCB PE | Founding Member, Biopharma Investment Team
Co- built CCB's healthcare investment platform in partnership with China Construction Bank.
Fosun International (New York Office)
Flagship Pioneering

Investment portfolio:
Innovative Therapeutics
Excalipoint Therapeutics · SKYEMED · Fosun Kite · Simnova · LaNova Medicines · IncTAC
Medical Devices & Advanced Supply Chain
Spirometrix · Intuitive Surgical · OptoMedic · Allyuos

Investment Focus:
Innovative drugs · Frontier therapies · Innovative diagnostics & devices · Healthcare services

Education:
Massachusetts Institute of Technology
Sloan School of Management · M.S. in Finance (Honors)
Washington University in St. Louis
B.S. with Honors · Biostatistics & Mathematics- Finance (double major)

SPEAKERS - THEATER 4



Andrea LUK

Director of the Clinical Research Management Office, The Chinese University of Hong Kong

Professor Andrea Luk is the Professor of the Department of Medicine and Therapeutics, the Director of the CUHK Clinical Research Management Office, the Director of the GBA Clinical Research Office, and Medical Director (non-oncology) of the CUHK Phase 1 Clinical Trial Centre. She is also a practising endocrinologist and serves as an Honorary Consultant at the Prince of Wales Hospital. Professor Luk obtained her Bachelor of Medicine and Surgery at the University of Auckland, New Zealand, and completed her specialist training in Endocrinology, Diabetes and Metabolism in Hong Kong in 2007. Her primary research interests include young-onset diabetes, precision medicine, translational research, and big data analysis. She has received multiple competitive research grants and has been the principal or co-investigator of over 160 clinical trials on treatment of diabetes and metabolic diseases. Dr Luk has published over 230 articles in peer reviewed journals, with over 10,000 citations and has an H-index of 49. She has received several awards including the Xiaoren Pan Distinguished Research Award for Epidemiology of Diabetes in Asia in 2022 and the Harry Keen Memorial Award of the International Diabetes Epidemiology Group in 2019.



Donglei MAO

Editor-in-Chief and Co-founder of PharmaDJ, Deputy Chief Editor of Asia Bio Inc., Columnist of Biotechgazine, Strategic Advisor of BIOHK, Strategic Advisor of GBAAPI

Donglei Mao holds an MSc in Drug Regulatory Affairs and Policy (DRAP) from The Hong Kong University of Science and Technology. She began her career in 2000 at the Southern Institute of Pharmaceutical Economics (under the National Medical Products Administration), writing for Pharmaceutical Economics News. She was one of the earliest journalists to provide sustained, in-depth coverage of China's drug regulatory reform, and has interviewed multiple NMPA officials and directors of the Center for Drug Evaluation (CDE). In 2014, she co-founded PharmaDJ, which has since grown into a well-respected and influential media platform in the pharmaceutical industry. She closely follows drug regulatory trends in China and abroad, covering regulatory science, clinical trials, and biopharmaceutical innovation, and is proficient in both Chinese and English professional writing. PharmaDJ serves as a media partner to the China Pharmaceutical Innovation Association (PhIRDA), DIA, and the Hong Kong Association of the Pharmaceutical Industry. Donglei also holds advisory and editorial roles, including Strategic Advisor to the Greater Bay Area Biomedical Innovation Alliance, Columnist for the Hong Kong Biotechnology Association, and Deputy Editor-in-Chief of Asia Bio Inc.



Angelo ORRU NETO

CEO, iHealth Group; Founder & CEO, DoctorAssistant.ai

Angelo Orru Neto is a Brazilian healthcare technology entrepreneur focused on artificial intelligence, clinical data and clinical development. He is CEO of iHealth Group and Founder & CEO of DoctorAssistant.ai, which build data and AI infrastructure to turn unstructured medical records into actionable intelligence for patient finding, trial feasibility, recruitment and real-world evidence. He works with hospitals, physician networks, research sites and biopharma partners, connecting clinical data with operational execution. Angelo is also developing cross-border partnerships that position Brazil as a clinical-development and evidence-generation gateway for Chinese and global biotechnology companies expanding into Latin America.

SPEAKERS - THEATER 4



Nikhil SHAH

CEO and Co-Founder, Nephrodite Inc.

Dr. Shah serves as CEO and is a co-Founder of Nephrodite Inc. He is a board-certified Urologist and Urologic Oncologist with subspecialty training in Urologic Oncology, transplantation and surgical diseases of the Kidney. He has performed thousands of minimally invasive surgical procedures. Dr. Shah has served as Professor at the Georgia Institute of Technology in the Department Computer Science, Divisions of Robotics as well as Human-Machine Interactions. He has been a medical, clinical and strategic Advisor to Industry and has held many executive leadership positions within healthcare systems. Dr. Shah has been involved in several medical device start-ups and continues to educate and mentor students at different levels across many varying areas of study.



Sumitra SHANTAKUMAR

Senior Director, Global Real-World Evidence & Health Outcomes Research, GSK

Dr. Sumitra Shantakumar is a global healthcare executive and epidemiologist with over 20 years of experience leading real-world evidence, health outcomes research, development strategy, and access initiatives across oncology, vaccines, respiratory, and specialty care. In her current role at GSK, she leads the Zoster Vaccines global evidence generation programme that informs regulatory, reimbursement, and development decisions across global markets.
A recognised thought leader in epidemiology and real-world evidence, Dr. Shantakumar has collaborated with regulators, health technology assessment bodies, academic institutions, and healthcare organisations globally to advance evidence-based decision-making. Her work includes establishing one of Singapore's pioneering healthcare real-time data ecosystems to enhance patient care for respiratory diseases, shaping global regulatory submissions, and accelerating innovative evidence programs in healthy aging. She holds a PhD in Cancer Epidemiology from the University of North Carolina at Chapel Hill where she also was a National Cancer Institute training grant recipient, and an MPH in Epidemiology and Biostatistics from Boston University.



Toh Han SHIH

Chief editor, Asia Bio Inc; Consultant, Headland Intelligence

Toh Han Shih is a consultant for Headland Intelligence, a Hong Kong risk consultancy. He was senior Asia correspondent of MLex, a media organisation focusing on regulatory risk, from November 2015 to March 2018. Prior to that, he was a reporter at the South China Morning Post in two stints for roughly 10 years.

SPEAKERS - THEATER 4



Cecilia SHU

Overseas BD of Carev International Technology Service Limited

Founder of the China-Europe Innovation Cooperation Cente / 10 years experience of European business development



Ming TANG

Chief Executive Officer, YNBY International Limited

Executive Director and Chief Executive Officer of YNBY International Limited. Over 25 years international market development experience. Specialize in building global strategies, setting local teams, and familiar with local regulations and ecosystem to start the new business. Have rich experience across marketing and sales, R&D, supply chain, GTM, etc. Have been worked in Europe, North America and APAC with top tier customers on different verticals.



KK TONG

Chief Executive Officer of New Frontier Health (Hong Kong)

Mr. KK Tong is the Chief Executive Officer of New Frontier Health (Hong Kong) and the Executive Vice Secretary-General of the New Frontier Greater Bay Area Medical Executive Committee. He is responsible for overseeing the group's medical operations in Hong Kong, which include the Hong Kong Integrated Oncology Centre, Heal Oncology Centre, Heal Medical Centre and Hong Kong Integrated Diagnostic Imaging Centre. With over 20 years of experience in the pharmaceutical industry, KK has held key positions at multinational companies such as GlaxoSmithKline and UCB, managing marketing operations across various Asian markets, including Taiwan region, South Korea, and other ASEAN countries. Prior to joining the Hong Kong Integrated Oncology Centre in October 2018, he served as the General Manager for Hong Kong SAR and Macau SAR at Amgen, the world's largest independent biotechnology company, where he led the establishment of Amgen's Hong Kong SAR branch and was responsible for strategic decision-making and operational management. KK has actively contributed to the advancement of innovative healthcare in the medical community. Since 2019, he has been the founding director of the Hong Kong Society for Innovative Medicine and served as a visiting lecturer at the Polytechnic University of Hong Kong's School of Professional and Continuing Education. KK holds a degree in Biochemistry from The Chinese University of Hong Kong and a Master's degree in Health Services Management from The Hong Kong Polytechnic University, as well as a Master's degree in Data Science and Business Statistics from The Chinese University of Hong Kong.

SPEAKERS - THEATER 4



Danyi WEN

Founder, President & CEO, Shanghai LIDE Biotech. Co. Ltd

Danyi Wen, Founder, President & CEO of Shanghai LIDE Co. Ltd. Register on 2011, Shanghai LIDE focus on providing services and biomarker product R&D to support "Personalized Precision Medicine". There are two subsidiary companies under Shanghai LIDE: Xian LIDE Biotech and Shanghai LIWEN Clinical Testing Lab.

B.S from the Forth Military Medical University; M.S from Peking Union Medical University/Chinese Academy of Medical Sciences; MBA from Suffolk University; Post-Doc and Instructor of Medicine at Harvard Medical School (Brigham & Women's Hospital); 12 years industry experience at Millennium Pharmaceutical, Biogen-Idec.
Returning to China on 2007 as VP of Biology at Shanghai ChemPartner.
Founded Shanghai LIDE Biotech at the end of 2011.
Adiourn professor of Beiing Xiehe Hospital and School of Pharmacy of Fudan University; Industry instructor of Shanghai Technology University.
Editor, Progress In Pharmaceutical Science.
Senior Council Member, Innovation Translation and Clinical Development Specialty Committee, China Pharmaceutical Innovation and Research Development Association (PhIRDA).
Standing Council Member of CBIITA and Chair of the Precision Medicine & IVD Committee.
Member of the Shanghai Clinical Cohort Expert Committee, Shanghai Hospital Development Center (SHDC).
Vice President of the Zhangjiang Branch, Shanghai Enterprise Development Promotion Association for Headquarters (SHEDPA).
Vice Chair, Drug Discovery and Innovation Translation Working Group, China Innovative Medicine Academic Conference (CMAC).
Former Executive President, Sino Drug Discovery Association (SDDA).
Executive Deputy Leader of the PDX Group/Biobank Branch, Chian Medicinal Biotech Association (CMBA).
Vice Chair, Hepato-Pancreato-Biliary Branch of the Rehabilitation Committee, China Anti-Cancer Association (CACA).
Member of the Academic Committee, Precision Cancer Therapy Committee, China Anti-Cancer Association (CACA).
Selected for the Shanghai Talent Program in 2013.



Creany WONG

Deputy Managing Director, Clinical Trials Centre, The University of Hong Kong

BSc (Food and Nutritional Science), MPhil, PhD

Creany Wong is the Group COO of HKU Clinical Research Group, Deputy Managing Director of HKU Clinical Trials Centre, Deputy Managing Director of Gleneagles Hospital Hong Kong Clinical Trials Centre, Honorary Assistant Professor of Macau University of
Science and Technology (MUST) and Non-executive Director of MUST Clinical Trials Centre. Creany also undertakes different roles in many local and international bodies such as Member of Genetically Modified Organisms (Control of Release) Expert Group of AFCD of HKSAR, Member of the Working Group on Good Governance Practice for Research Institutions of the Council for International Organizations of Medical Sciences (CIOMS), Member of WHO Technical Advisory Group on Clinical Research Ecosystem Strengthening and Advisor (Asia) of Training and Resources in Research Ethics Evaluation Program (TRREE).

SPEAKERS - THEATER 4



Ian C.K. WONG

Professor in Pharmacy, The University of Hong Kong; Director, Centre for Safe Medication Practice and Research, The University of Hong Kong

Professor Wong is the Professor of Department of Pharmacology & Pharmacy and holder of the Lo Shiu Kwan Kan Po Ling Professorship in Pharmacy. He is also the Co-Director of the Centre for Safe Medication Practice and Research. His brief profile can be found at Lancet Psychiatry. His expertise is using big data research to investigate safety and optimum use of medications for treatment of various conditions specifically cardiovascular, neurological and psychological conditions. As part of this work, he conducts research at Queen Mary Hospital, Hong Kong to evaluate the safety and effectiveness of medication in patients with these and other illnesses. In recognition of his research, Professor Wong has received various awards and fellowships for his work as an academic pharmacist. He was awarded the Chemist and Druggist Pharmacy Practice Research Conference Medal from the Royal Pharmaceutical Society of Great Britain in 2004. He is the only pharmacist to date to have received a UK Department of Health Public Health Career Scientist Award in 2002. He was awarded an Honorary Fellowship from the Royal College of Paediatrics and Child Health in the UK in 2011, an Honorary Fellowship from the College of Pharmacy Practice in Hong Kong in 2013, and a Fellowship from the Royal Pharmaceutical Society of Great Britain in 2013. Professor Wong was commissioned by the Hong Kong SAR Government to monitor the safety of COVID-19 vaccines on behalf of the Department of Health, for his contribution to the fighting against COVID-19 pandemic, he received commendation from the Chief Executive of Hong Kong SAR Government in 2022. Professor Wong was the Vice-President of the International Society of Pharmacovigilance between 2016 and 2019. He has also been an expert witness for many legal cases in the UK and Hong Kong regarding medication safety on behalf of victims of medication errors and adverse drug reactions, and for pharmaceutical companies.



Lap Gate WONG

Director of Quality and Safety of the Hospital Authority (HA)

Dr Wong is currently the Director of Quality and Safety of the Hospital Authority (HA). Under his leaderships, the Quality & Safety Division oversees the quality standards, patient safety, clinical incident management, patient relations management, healthcare technology assessment, disasters response and infection control for the public hospitals under HA.

Dr Wong is a specialist in haematology & haematological oncology, and has also attained fellowship qualification in pathology. Prior to his current appointment, he has been the Chief Manager (Cluster Performance) in Head Office, Chief Manager of Kowloon West Cluster, Deputy Hospital Chief Executive of the North Lantau Hospital and Deputy Hospital Chief Executive (Operation) of Princess Margaret Hospital.

SPEAKERS - THEATER 4



Stephanie WONG

Clinical Assistant Professor, Division of ENT, Department of Surgery, School of Clinical Medicine, The University of Hong Kong

Dr. Stephanie Nga-sze Wong is a dedicated otolaryngologist and head and neck surgeon, committed to advancing clinical practice and research in the field. She graduated from the Chinese University of Hong Kong and attained her specialist qualification in otolaryngology, earning fellowship from the Royal College of Surgeons of Edinburgh.
Her notable achievements include receiving the prestigious George Choa Prize for Outstanding Presentation from the Hong Kong College of Otorhinolaryngologists in 2017. She further specialized in head and neck surgery, completing her post-fellowship training in 2021.
Dr. Wong's pursuit of excellence is exemplified by her honours recognition in the Global Online Fellowship in Head and Neck Surgery and Oncology, conferred by the International Federation of Head and Neck Oncologic Societies (IFHNOS). In 2025, she was awarded the G.B. Ong Travelling Fellowship to Japan to deepen her expertise in the management of hypopharyngeal cancer.
Currently serving as a Clinical Assistant Professor in the Department of Surgery at the University of Hong Kong, she also holds the positions of Honorary Associate Consultant in the Departments of Surgery and the Department of Ear, Nose, and Throat at Queen Mary Hospital.
Her clinical focus centers on head and neck conditions, with particular expertise in managing head and neck malignancies. Her research interests include the management and rehabilitation of patients with nasopharyngeal carcinoma and other head and neck cancers, reflecting her dedication to improving treatment outcomes and patient care.



Fang XIA

Vice President, Board Secretary, and Head of Board Affairs & Capital Markets at 3D Medicines; Co-founder, CEO, and Legal Representative of Sandi Bio

— Master's degree from Peking University Health Science Center, Master of Business Administration from Harvard University. — Formerly Deputy Director of the Beijing Product Design Center at Taiji Group and Secretary of the Taiji Anti-Cancer Science Foundation. — Joined 3D Medicines in 2016, successively serving as Head of Regulatory Affairs and Deputy General Manager. — Member of the Hong Kong Investor Relations Association and member of the 4th Pharmaceutical Innovation Investment Professional Committee of the China Pharmaceutical Innovation and Research Development Association (PhIRDA).

SPEAKERS - THEATER 4



Kim Seck YEO

CEO, Royallee Cancer Hospital

Boasting over 20 years in Singapore healthcare, he masters full-cycle operationof public & private hospitals with mature experience in top-tier oncology institutemanagement, quality control and business expansion.Serving as Senior Operations Manager, AVP then CEO of Parkway CancerCentre from 2012, he built it into Asia' s leading oncology centre via refinedmanagement, attracting high-end Southeast Asian patients and sustainingsteady growth during his tenure.



Michael YIM

Chief Pharmacist, Drug Office, Department of Health

Mr YIM is current the Chief Pharmacist of the Drug Office, Department of Health overseeing a broad spectrum of drug regulatory activities including drug evaluation, pharmacovigilance as well as drug import and export control. He serves the Government for over 15 years and in particular he has been working in the field of drug registration for over 10 years. Mr YIM has also previously been seconded to the Health Bureau to support the early stage development of the GBAICTI that promote clinical trial development.



Albert Cheung Hoi YU

Chairman of Hong Kong Biotechnology Organization

- Professor Yu is a world-renowned bio-entrepreneur and scientist with over 30 years of experience in the field of neuroscience and molecular diagnostics. He received his PhD from the University of Saskatchewan, Canada and spent subsequent years in UCSF, Stanford, HKUST and Peking University. He has published 176 peer review scientific papers, several commentaries in NEJM, Science and Nature Biotechnology, and 15 books. He has invented numerous technologies including 80 global patents. Professor Yu has many awards such as “National Science and Technology Progress Award”, “China Cooperative Innovation Award”, “Asia Pacific Frost & Sullivan Product Differentiation Excellence Award for In-Vitro Diagnostics”, “Hong Kong Industry Award”. He founded HKLife and is leading a research team to develop the BioRadar® System, an automatic diagnostic platform. Recently, he pushes forward a major international biotech convention - BIOHK, so as for all of us to have a global biotech platform in Asia to showcase the accomplishments, exchange ideas, trade our products, fundraising, and more.

SPEAKERS - THEATER 4



Daniel ZEQUETO

Founder & CEO, ODC Life Sciences

Daniel Zequeto is the Founder and CEO of ODC Life Sciences, a specialized clinical research partner supporting biopharma companies across Latin America. He founded ODC to help sponsors translate global development objectives into regionally coordinated strategies that reflect the distinct regulatory, clinical, and patient-access realities of each market. Daniel's work focuses on country prioritization, partnership architecture, and the orchestration of local research ecosystems, helping reduce fragmentation and improve predictability across complex development programs. He advocates positioning Latin America as an integrated, high-quality clinical development platform for innovative therapies, with local expertise and patient impact at the center

SPEAKERS - THEATER 5



Piero BAGLIONI

Professor, Physical Chemistry/CSGI, Department of Chemistry, University of Florence, Italy

Piero Baglioni is professor of Physical Chemistry at the University of Florence. He was appointed as Visiting Scientist/Professor by the Department of Chemistry of the University of Houston, the Weizmann Institute, the Collège de France, and the MIT. He is the President of the Center for Colloid and Surface Science (CSGI). Member of the Editorial/Advisory Board of intentional Journals and of several national and international Academies and Societies (European Academy of Science, Academia Europaea, Swedish Royal Academy of Science and Art, etc.). Piero Baglioni is author of about 600 publications and 29 patents in the field of Soft Matter and colloids. For his scientific activity he received several international recognitions as Rhodia Prize from from European Colloid Society, the European Grand Prix for Innovation Awards; "The Caballero Aguila" INHA, Mexican Federal Government; Chen Distinguished Lectureship, Taiwan Ministry of Science; The Overbeek medal; The Japan Chemical Society Award; McGee Lecture award, etc.
He pioneered methods and materials worldwide used for the conservation of Cultural Heritage, as nanoparticles (calcium, magnesium hydroxides, carbonates and silica hybrids), micellar systems, microemulsions, chemical hydrogels and organogels. These materials have a wide range of applications spanning from cosmetic, drug delivery, fertilizers' time release, and others.



Russell CHAN

Co-founder and CEO, E-SENSE Innovation & Technology; Honorary Assistant Professor, School of Biomedical Engineering, The University of Hong Kong

Dr. Russell Chan is the co-founder and CEO of E-SENSE Innovation & Technology, and an Honorary Assistant Professor at The University of Hong Kong School of Biomedical Engineering. He obtained his B.Eng. in biomedical engineering and Ph.D. in electrical and electronic engineering from The University of Hong Kong (HKU). He was a post-doctoral research fellow at Stanford University in Neurology and Neurological Sciences, and New York University in Neuroscience, Tech4Health, and Ophthalmology. Previously CTO of a Forbes Asia 100 to Watch startup, he was named REVIVE 2023 CTO of the Year and received the HKEST award in 2022. Under his leadership, E-SENSE has received the 2025 HK Tech Fest – Tech Impact Company of the Year, and Gold Medal with Jury Congratulations at the 2025 Geneva Inventions Exhibition. Recently, he was named HK Tech Fest 2026 Founder of the Year. Dr. Chan is an elected Junior Fellow of International Society of Magnetic Resonance in Medicine (ISMRM), a prestigious and highly selective award for young scientists from the leading global MRI society. He is the Chair of the Young Member Section at the Hong Kong Academy of Engineering (HKAE). He is the ex-co member and R&D focus group lead of the Hong Kong Institute of Engineers (HKIE) Biomedical Division. His focus is the research, development, application, and commercialization of state-of-the-art multi-modal and multi-scale biomedical imaging devices to improve quality of life.



Wei CHAO

Senior Vice President, Beijing Shougang Lanzatech Technology Co., Ltd.

PhD in Physical Chemistry from Peking University, Professor-level Senior Engineer. He has long been engaged in the research, industrialization and promotion of technologies for producing ethanol and protein via biological fermentation of industrial tail gas. He has published more than 10 academic papers and been granted over 40 authorized patents. As the principal investigator, he has presided over two national key R&D programs. His honors include the Patent Gold Award of China Petroleum and Chemical Industry Federation, the First Prize of Beijing Modern Enterprise Management Innovation Achievement Award, the Second Prize of Hebei Provincial Science and Technology Progress Award, and the Second Prize of Science and Technology Progress Award from China Petroleum and Chemical Industry Federation. He serves as a member of the Monocarbon Biotechnology Committee of the Chinese Society of Biotechnology, member of the 1st New Protein Committee of the Chinese Institute of Food Science and Technology, member of the Carbon Capture, Utilization and Storage Committee of Chinese Society for Environmental Sciences, and Deputy Director of the Green Carbon Resource Utilization Committee of Chemical Industry and Engineering Society of China.

SPEAKERS - THEATER 5



Crystal FOK

Head of Business Development at Hong Kong Cyberport Management Company Limited

Dr. Crystal Fok is the Head of Business Development at Hong Kong Cyberport Management Company Limited, where she leads initiatives to advance AI development. Her focus is on building a comprehensive AI ecosystem and enhancing infrastructure support to drive innovation in the field. Previously, Dr. Fok was the Head of the Digital Service Hub at Hong Kong Science and Technology Parks Corporation (HKSTP). In this capacity, she directed various innovation and technology initiatives aimed at promoting technology adoption across industries and enabling cross-industry data collaboration. Her career began at the Applied Science and Technology Research Institute (ASTRI), where she managed a diverse project portfolio, including market analysis, feasibility studies, product development, and technology commercialization. Additionally, as a Consultant at the Hong Kong Productivity Council, she led the optical design team and provided consultancy services focused on precision manufacturing. Dr. Fok earned her PhD in Automation and Computer-Aided Engineering from the Chinese University of Hong Kong (CUHK). Her research interests include artificial intelligence, robotic arm manipulation, micro-robotics, MEMS, and micro-optics.



David FOSTER

Executive Director, Croucher Foundation

David Foster was appointed Director of the Croucher Foundation in October 2008. Earlier in his career he worked on scientific exchanges and strategic aspects of the funding of science programmes at the Royal Society in London, and then at the British Council in Hong Kong and mainland China. David graduated with a BA Honours in Modern Chinese Studies from the University of Leeds, and studied and worked in Beijing in the early 1980s.



Alex KWONG

Associate Director, Ecosystem Development(Life Science), HSITP (Hong Kong-Shenzhen Innovation and Technology Park)

Dr. Alex Kwong is Associate Director, Ecosystem Development at HSITP (Hong Kong-Shenzhen Innovation and Technology Park), where he drives ecosystem partnerships and innovation initiatives in life sciences and health technology. Prior to joining HSITP, he served as Head of Biotechnology and Entrepreneurship Support at the Hong Kong University of Science and Technology (HKUST), supporting technology commercialization, startup incubation, and industry-academia collaboration. Over his career, he has mentored technology startups across healthcare, biotechnology, fintech, materials science, electronics, and software sectors, contributing to ventures that collectively attracted significant investment and strategic partnerships. Dr. Kwong holds a PhD in Biosensor and Bioelectronics and has extensive experience spanning technology transfer, intellectual property strategy, venture development, and innovation ecosystem building. He is passionate about accelerating the translation of research into real-world impact through cross-sector collaboration.

SPEAKERS - THEATER 5



Junjie LIU

Associate Professor, Tsinghua University

Dr. Jun-Jie (Gogo) Liu obtained his PhD in Biology from Tsinghua University and pursued postdoctoral studies at UC Berkeley. Launching his independent research group at Tsinghua in 2020, he explores the diversity of biological macromolecular machines (e.g., prokaryotic immune systems, ribozymes) and leverages novel macromolecular tools for nucleic acid manipulation and detection. His research also employs computational approaches to model genome diversity, simulate evolutionary processes, and investigates how AI and robotics can transform the future of life sciences research.



Maggie LO

Chief Manager (Life and Health Technology) , The Office for Attracting Strategic Enterprises (OASES) of the Hong Kong SAR Government

Dr. Maggie Lo serves as Chief Manager (Life and Health Technology) at the Office for Attracting Strategic Enterprises (OASES) of the Hong Kong SAR Government, where she leads efforts to attract leading Mainland and international technology companies to establish or expand their presence in Hong Kong.
She brings over 15 years of international experience across Hong Kong, the United Kingdom, and Canada, with expertise spanning clinical research, health policy to trade and investment promotion. Prior to joining OASES, she held roles at InvestHK and the British Consulate-General in Hong Kong, where she led healthcare-focused trade and investment initiatives.
Dr. Lo holds a PhD in Psychiatry from the University of Liverpool.



Zhongli LUO

Professor, Chongqing Medical University; Boarding director, Molecular Frontiers Foundation

Dr. Zhongli Luo， Professor and Ph.D. Supervisor, Chongqing Medical University； Boarding director, Molecular Frontiers Foundation.
Research Areas: Current research interests including Innovative drug discovery, anti-aging engineering, organoid chip engineering, brain-computer interface （Neural Repairing） engineering, etc.
Publications & Patents: Author of nearly 100 academic papers and patents.
Academic Contributions: Pioneered the development of chiral self-assembling peptide systems and their technological platform applications, with sustained, in-depth research in this field over many years.
Translational Impact: Several research outcomes have been successfully commercialized, while others hold significant strategic value and promising translational potential across relevant domains.

SPEAKERS - THEATER 5



Ju NING

Founder of Shenzhen Mibai Medical Aesthetic Clinic

Practical Injection Experience: 18 Years
Attending Dermatologist, Master of Medicine;
Founder of Shenzhen Mibai Medical Aesthetic Clinic;
Deputy Director of the Executive Committee, Medical Aesthetic Industry Branch, China Anti-Aging Promotion Association;
Winner of "Excellent Aesthetic Practitioner in Shenzhen", Chinese Doctors' Day;
National Two-Star Outstanding Mentor of Fillderm; 3rd Place Nationwide & 1st Place in Southern China, Fillderm Clinical Case Competition; Collagen Injection Mentor for Shenzhen Public Hospitals;
National Injection Mentor, Feilinpuli; Recipient of Master of Thousands of Bottles Award;
Authorized Injection Mentor, RuBai Angel;
National Technical Mentor, Meteora Suture Lifting Technique;
Authorized Injection Mentor, Dr.An Collagenase;
Recipient of Master of Hundred Bottles Award, Loviselle;
Speaker at the 16th International Cosmetic Technology Exchange Conference and OAPAC Oriental Plastic Surgery & Aesthetic Arts Conference



Vicky TSE

Head of Life and Health Technology, HKSTP

Ms. Vicky Tse is the Head of Life and Health Technology in Hong Kong Science and Technology Parks Corporation (HKSTP)
Vicky is a well-versed executive in the Life-Science industry. She served as the General Manager at Sanofi Greater China in Shanghai, where she spearheaded successful launches and market expansion, forged key partnerships, enhancing the patient journey through innovative ecosystem collaborations. Prior to Sanofi, she spent over 13 years in progressive leadership roles at Novartis, most recently as Commercial Director for the Asia Pacific, Middle East, and Africa regions, where she led strategic initiatives that accelerated the launch of innovative portfolio across diverse markets. Her impactful journey at Novartis also included pivotal positions as General Manager and President of Taiwan, as well as senior Head roles across Greater China and Hong Kong, where she excelled in steering strategic portfolio growth and building robust commercial foundations. Vicky's earlier roles included strategy development at various managerial levels within Schering-Plough, Roche, and MSD, where she consistently achieved strong performance, built purposed driven team and clear strategy with good execution and collaboration.
Vicky holds a Bachelor of Science from The University of Hong Kong and a Master of Business Administration from the Hong Kong University of Science and Technology.



Andy WONG

Head of Innovation and Technology at Invest Hong Kong (InvestHK)

Mr. Andy Wong is the Head of Innovation and Technology at Invest Hong Kong (InvestHK). His key focus technology segments include artificial intelligence, biotech, medical device and healthcare services. Mr. Wong has wealth strategy consulting and business development experience in high tech sector. Before joining InvestHK, Mr. Wong held various senior positions at a global leading consulting firm and a global Fortune 500 technology company specialising in corporate strategy and business development. Mr. Wong has Bachelor degree in Electronic and Electrical Engineering and Master degree in Commerce. He is a Chartered Engineer (CEng) from The Institution of Engineering and Technology, the UK; and is a Fellow of Certified Practicing Accounting, (FCPA) Australia by training.

SPEAKERS - THEATER 5



Haifeng WANG

Associate Professor, Tsinghua University

Dr. Haifeng Wang is an Associate Professor at the School of Life Sciences, Tsinghua University, and a Principal Investigator at the Tsinghua-Peking Center for Life Sciences. He received his Ph.D. in Molecular, Cellular, and Developmental Biology from the University of California, Davis, followed by postdoctoral research in the Department of Bioengineering at Stanford University. He joined the School of Life Sciences at Tsinghua University in August 2021. Dr. Wang has long been dedicated to the development and application of CRISPR technologies, with a particular focus on utilizing CRISPR tools to decipher genome regulation mechanisms. His related work has been published as first or corresponding author (including co-authorship) in journals such as *Science*, *Cell*, *Nature*, *Nature Biotechnology*, *Nature Genetics*, and *Nature Reviews Genetics*.



Hao WANG

Head of Synthetic Biology R&D, Bloomage Biotechnology Corporation Limited

Dr. Wang Hao is the Head of Synthetic Biology R&D at Bloomage Biotechnology Corporation Limited. He has long been engaged in research and industrialization in the fields of synthetic biology and green biomanufacturing, focusing on the efficient production of key functional bioactive molecules for medical aesthetics and healthcare applications using microbial cell factories. He has led his team to achieve multiple breakthrough results in strain construction, metabolic engineering, and fermentation process optimization for various ECM actives including hyaluronic acid, chondroitin sulfate, PDRN, and recombinant collagen, facilitating the industrial-scale production of these products. He is committed to leveraging synthetic biology innovations to overcome resource dependence and environmental bottlenecks associated with traditional raw material acquisition, providing safer, more efficient, and more sustainable solutions for the industry.



Jing WANG

Researcher, National Institute of Metrology, China

Jing wang， PhD， Senior Research Fellow, National institute of metrology (NIM), China. Leader of the Biometrology Innovation Team and founder of the National Biometrology science. Chief Scientist of the National Key R&D Program. The leading project was awarded the Second Prize of the 2020 National Science and Technology Progress Award. Serves as Standing Deputy Director and Secretary-General of the Biometrology Committee in CSM, Vice President of the China Association For Standardization(CAS) and Chairman of the Biological Resources and Facilities Committee, Deputy Director and Secretary-General of Standardization-Working Group 34 (SAC/SWG 34) on biological phenotypes (phenomics).

SPEAKERS - THEATER 5



Runming WANG

Associate Professor, Tsinghua University

Dr. Runming Wang is an Associate Professor and Principal Investigator at the Institute of Biopharmaceutical and Health Engineering (iBHE), Tsinghua Shenzhen International Graduate School (SIGS). He received his Ph.D. in Bioinorganic Chemistry from the University of Hong Kong (2018) under the supervision of Prof. Hongzhe Sun, followed by postdoctoral training in the same group (2018-2021). He joined Tsinghua SIGS in 2022. His research focuses on the synthetic biotechnology and biomedical applications of functional metal-biomolecules, spanning three interconnected areas: (1) AI-driven mining and design of biological metal elements; (2) precision creation and synthesis of functional metal molecules; and (3) translational research of metal-based pharmaceuticals. Dr. Wang has been recognized as an MIT Technology Review "Innovators Under 35" (TR35) Asia Pacific (2022), a recipient of the National Overseas High-Level Talent (Youth) Program (2022), and a WLA Young Scientist New Face (2024). His team has published in Nature Microbiology, Nature Communications, PNAS, and Chemical Science, with an h-index of 26 and over 3,000 citations. He holds four U.S. granted patents.



Fuqing WU

Deputy Director, Center for Synthetic and Systems Biology, Tsinghua University

Wu Fuqing, Associate Research Fellow at the School of Life Sciences, Tsinghua University, Deputy Director of Tsinghua Center for Synthetic and Systems Biology, co-founder of Beijing PhaBuilder Biotechnology Co., Ltd., and a member of the Beijing Municipal Committee of the Chinese People's Political Consultative Conference. Working closely with Professor Chen Guoqiang, he focuses on halophilic bacterial chassis cells and Next-Generation Industrial Biotechnology (NGIB). He leads the development of genetic editing tools for Halomonas, strain metabolic engineering, and scale-up of open unsterilized fermentation. He realizes the full industrial chain from wild strain isolation, chassis construction to large-scale PHA production, and oversees the construction of ten-thousand-ton PHA manufacturing lines. He also serves on committees of multiple biomaterial academic societies, committed to translating synthetic biology research into industrial applications.



Xinhui XING

Professor, Shenzhen International Graduate School, Tsinghua University

Prof. Xin-Hui XING received his Ph.D. from Tokyo Institute of Technology in 1992. He had been the Assistant Professor at Tokyo Institute of Technology from 1992 to 1998, and Associate Professor at Yokohama National University from 1998 to2001. He was selected as a full professor by the 100-Telent Scholar Program of Tsinghua University in 2000 and joined Department of Chemical Engineering since then. He had served the director of Institute of Biochemical Engineering from 2002 to 2022. He had been the vice department chairman from 2009 to 2018. From 2019, he has being served the Institute of Biopharmaceutical and Health Engineering, Tsinghua Shenzhen International Graduate School as the Deputy Dean. His research field covers biochemical engineering, biobreeding technology and instrumentation, synthetic biology and bio anufacturing, glycodrug and bioactive peptide mining and biomanufacturing. He has published more thank 350 papers, co-authored 8 books, translated 2 books, and published 1 English monograph. He has been listed in the "Career-Long Impact" and "Single-Year Impact" ranking (World's Top 2% Scientists) by Stanford University & Elsevier (2025). He serves as the editor-in-chief of Health Engineering, editor of Biochemical Engineering Journal, and editorial board of more than 10 domestic and international journals. He has cofounded 3 venture companies for transforming research. In recent years, he has received 10 research awards and honors.

SPEAKERS - THEATER 5



Hongyi ZHAO

Director, Department of Plastic Surgery, National Center for Geriatrics, Beijing Hospital

Director, Department of Plastic Surgery, Beijing Hospital (National Center for Geriatrics)
Postgraduate Supervisor, Peking Union Medical College
External Expert, Center for Drug and Medical Device Evaluation, NMPA
Member, Medical Device Classification Technical Committee, Standards Management Center, NMPA
Chairman, Plastic Surgery & Aesthetic Medicine Branch, China Medical Device Industry Association
Vice President, Plastic Surgery and Aesthetic Medicine Branch, China Association of Non-Public Medical Institutions
Vice President, Minimally Invasive & Dermatological Aesthetics Branch, Chinese Association of Plastics and Aesthetics
Deputy Group Leader, Minimally Invasive & Injection Subcommittee, Plastic Surgery and Aesthetic Medicine Branch, Chinese Medical Doctor Association
Standing Committee Member, Plastic Surgery Branch, Beijing Medical Association
Standing Committee Member, Medical Aesthetics and Cosmetology Branch, Beijing Medical Association
Vice President, Plastic Surgery Branch, Beijing Medical Doctor Association
Vice President, Medical Aesthetics Branch, Beijing Medical Doctor Association



Xian-En ZHANG

Dean and Chair Professor, Faculty of Synthetic Biology, Shenzhen University of Advanced Technology

Xian-En Zhang is a Chair Professor of the Faculty of Synthetic Biology, Shenzhen University of Advanced Technology and retired PI Professor of the Inst. Biophys, Chinese Acad. Sci. (CAS). He received MPhil. And Ph.D. from the CAS institutes, and Honorary Doctor of Science Degree from the University of Alberta, Canada. He became a full professor in 1993 at the Wuhan Inst. Virol., CAS.
He has been engaged in interdisciplinary research at the intersection of biosensing, nanobiology, and synthetic biology, applying these approaches to address scientific questions in virology and cancer biology.
His is an elected Fellow of American Institute of Medicine and Biological Engineering and a Fellow of Royal Society Chemistry. He serves as the coordinator of the expert group of the China synthetic biology research program. He also serves as the Vice President of Chinese Society of Biotechnology, member of the organizing committee of the World Congress on Biosensors, and founding co-chair of the Division of Nanobiotechnology/Biosensors/Biochips, Asian Federation of Biotechnology.



Ying ZHANG

Founder and Chief Scientific Officer (CSO), Liying Biotech

Dr. Zhang Ying is a Category B recruited under Shenzhen's Overseas High-Caliber Personnel Program (Peacock Plan). With 10+ years in the UK, he returned to China in 2018 as a young academic leader via Sun Yat-sen University's "Hundred Talents Program." Trained under Royal Society Fellows Prof. David Barford and Prof. Dale Wigley, he published first-author papers in Science and Nature Communications (IF 40+). Formerly a Senior Research Scientist at the Francis Crick Institute, Europe's largest biomedical research institute, he solved structures of multiple key proteins. With years of deep expertise in structural biology, Dr. Zhang has mastered state-of-the-art, end-to-end technologies for protein design and performance optimization, bridging fundamental R&D with industrial translation.. He founded LYBio in 2022.

SPEAKERS - THEATER 6



Thian CHEW

Exec Chair & CEO, Invion Ltd

Professor Thian Chew is a healthcare executive, board leader and academic whose career spans life sciences innovation, global finance, corporate transformation and health-focused education, with a particular emphasis on translating science into scalable, real-world impact. Thian's work sits at the intersection of science, capital and governance. His board and executive roles reflect a hands-on approach to building organisations that can navigate regulatory complexity, clinical translation and commercial scale.

Thian is currently Executive Chair and CEO of Invion Limited, a clinical stage ASX-listed life sciences company developing next-generation photodynamic therapy technology for applications in cancer, ophthalmology and infectious diseases. He is also a Co-Founder of Chronic Airway Therapeutics, a clinical-stage company advancing treatments for acute and chronic airway diseases, including COPD (Chronic Obstructive Pulmonary Disease).

As Managing Partner of Polar Ventures, he has spent more than a decade providing capital and strategic guidance to companies critical to Asia's long-term development. Earlier in his career, Thian was an Executive Director at Goldman Sachs, working across New York and Hong Kong on the firm's proprietary investments, including private equity, growth capital and special situations. Before that, he held roles at Morgan Stanley's Strategic Services Group and spent a decade at KPMG as a management consultant across the Asia-Pacific region, where he led large-scale business transformation, post-merger integration and operational restructuring programmes.

In parallel with his executive work, Thian has maintained a long-standing commitment to education and public service. He is an Adjunct Associate Professor at the Hong Kong University of Science and Technology, teaching across both the School of Business and the Life Sciences Division, and since 2025 has served as Visiting Professor and Health Executive in Residence at UCL Global Business School for Health, the world's first business school dedicated exclusively to health and healthcare management.

He also sits on the Advisory Board of Stanford Medicine's Center for Asian Health Research and Education (CARE), contributing to efforts aimed at addressing health disparities and advancing precision health for Asian populations globally.

Thian holds an MBA from the Wharton School (Palmer Scholar), an MA from the Lauder Institute at the University of Pennsylvania, and a Bachelor of Information Systems from Monash University. Earlier in his career, he qualified as a chartered accountant.



Zhiwei CHEN

Director, AIDS Institute; Chair Professor, Department of Microbiology, LKS Faculty of Medicine, The University of Hong Kong

Prof. Zhiwei Chen is a Chair Professor of Immunology and Immunotherapy and the Suen Chi-Sun Professor in Clinical Science in HKUMed. He received his PhD from New York University School of Medicine in 1996 and progressed from an NIH F32 Post-doctoral Fellow to Assistant Professor at the Aaron Diamond AIDS Research Center of the Rockefeller University from 1996 to 2002. In 2007, he joined HKUMed as an Associated Professor and the Founding Director of the HKUMed AIDS Institute.

His research focuses on AIDS/SARS/COVID-19 pathogenesis and immunotherapy, with an emphasis on the early events of viral infection. He pioneered the creation of HKU-patented platforms of technologies, including the PD1-based vaccine, the tandem anti-HIV-1 bi-specific antibody, and an anti-Δ42PD1 antibody drug for the fight against viral infection and cancer. He has been ranked by Clarivate Analytics among the top 1% of researchers worldwide by citations and a Highly Cited Researcher in 2022, 2023 and 2024. He has won numerous research grants as PI from RGC GRF/CRF/TRS, ITC RAISe+, HMRF, NIH RO1, amfAR, the Bill & Melinda Gates Foundation, and so forth. He also won the HKU Knowledge Exchange Excellence Award 2019, Outstanding Researcher Award 2021 and Outstanding Research Student Supervisor Award 2021.

SPEAKERS - THEATER 6



Aubrey de GREY

President and Chief Science Officer, LEV Foundation

Dr. Aubrey de Grey is a biomedical gerontologist based in Silicon Valley, California, USA, and is the founder, President and Chief Science Officer of LEV Foundation, a biomedical research and advocacy charity focused on repairing the molecular and cellular damage of aging. He received his BA in computer science and Ph.D. in biology from the University of Cambridge. His research interests encompass the characterisation of all the types of damage that constitute mammalian aging and the design of interventions to repair and/or obviate that damage. Dr. de Grey is a Fellow of both the Gerontological Society of America and the American Aging Association, and sits on the editorial and scientific advisory boards of numerous journals and organisations. He is a highly sought-after speaker who gives frequent invited talks at scientific conferences, universities, companies in areas ranging from pharma to life insurance, and to the public.



Jeffrey EGLER

Chief Medical Officier, Noom

Dr. Jeffrey Egler, MD, is a double board-certified physician in Family Medicine and Lifestyle Medicine. After completing an academic medicine fellowship in Faculty Development at UCLA, Dr. Egler went on to practice the full spectrum of family medicine (including adult medicine, pediatrics, surgery, emergency and hospital medicine, and obstetrics and gynecology) and subsequently became an Assistant Clinical Professor of Family Medicine at USC.

He obtained a master's degree in Spiritual Psychology and completed certification training with the Institute of Functional Medicine and the American College of Lifestyle Medicine. He was the founding Medical Director of Parsley Health in Los Angeles and later of the Inspire Health Center, a wellness center at the Adventist Health corporate headquarters. He most recently had been practicing Longevity Medicine, the ultimate culmination of these arts and sciences, as the Medical Director of Next Health in Los Angeles.

Now as Noom's Chief Medical Officer, Dr. Egler is leading Noom's longevity strategy integrating innovations into products and programs that inspire users and employees by sharing actionable, science-backed strategies to enhance health span and lifespan.



Philippe GERWILL

Founder & Managing Director, PGEA Ltd (Abu Dhabi, UAE)

Philippe Gerwill is a Global Digital Healthcare Humanist, Futurist, International Keynote Speaker, Executive Advisor and Innovation Key Opinion Leader. With more than 30 years of global leadership experience in the pharmaceutical and specialty chemicals industries, including senior roles at Novartis, Ciba and Lonza, he brings a unique perspective at the intersection of healthcare, technology, innovation and human-centered transformation.
He advises companies and organizations across Europe, the Middle East, Asia, Africa and the Americas, with a strong focus on artificial intelligence in healthcare, digital health, longevity, healthcare in the metaverse, precision medicine, innovation ecosystems and the future of preventive health.
Philippe is also an Adjunct Professor at Rome Business School, a LinkedIn Top AI Voice, and a globally recognized speaker regularly invited to international conferences and executive forums. His work emphasizes that technology should never be the final objective, but a powerful enabler to improve human lives, strengthen healthcare systems and create more inclusive, ethical and sustainable futures.

SPEAKERS - THEATER 6



Zhenglong GU

Professor, The Hong Kong University of Science and Technology (Guangzhou)

Professor at The Hong Kong University of Science and Technology (Guangzhou). His research focuses on the role of mitochondrial DNA mutations in diseases, including childhood diseases, aging, and related disorders. He has made critical contributions to understanding why mtDNA mutations have been traditionally underappreciated (due to technical difficulties and perceptive negligence) and has advanced the field through innovative multi-omics and mathematical modeling approaches. He has published over 70 papers in top-tier international journals such as Nature, Nature Genetics, Nature Communications, PNAS, Genome Research, and MBE. He has been invited to speak at many institutions including Duke University, Harvard University, Columbia University, and Peking University. He was named a Future Leader in Nutrition in North America in 2011.



Christine HUANG

Founder & CEO, Quantum Life Limited; Managing Director, HK Longevity Medical Centre

Dr.Christine Yuan HUANG is the Founder and CEO of QuantumLife. Dr. Huang is also the Technology Transfer Director of Hong Kong Quantum AI Lab, and Managing Director of HK Longevity Medical Centre, focusing on providing end-to-end precision longevity medical technology solutions to improve health-span. Dr. Huang has vast experience in the biotechnology and longevity field and shares her professional insights as a Venture Partner of LongeVC. Dr. Huang was selected as one of Forbes China 2020 “30 Under 30 (Healthcare and Science)” for her development of cancer liquid biopsy technology, and she was awarded as the “Pioneer of Genome Technology ”in 2025. In 2022, she was elected as a Fellow of the Royal Society of Medicine in the UK, and in 2024, she became a Fellow of the European Society of Preventive Medicine. She is also a member of the Advisory Board of Wing Wah Charity Foundation Hong Kong, and a columnist of Forbes China. Dr. Huang was elected as a Fellow of Guangzhou Youth Federation in November 2022. Dr. Huang obtained Doctor of Medicine from the Southern Medical University and Master of Public Health from the University of Hong Kong, Li Ka Shing Faculty of Medicine. Now she is also an Honorary Senior Research Associate at the University of Hong Kong.



Raju KUCHERLAPATI

Paul C. Cabot Professor of Genetics and Professor of Medicine at Harvard Medical School

Professor Raju Kucherlapati is the Paul C. Cabot Professor of Genetics and Professor of Medicine at Harvard Medical School since 2001. He obtained his PhD from the University of Illinois, was a research fellow at Yale University and started his academic career as a faculty member at Princeton University. Prior to joining the Harvard faculty, Professor Kucherlapati was the Lola and Saul Kramer Professor and University Professor at the Albert Einstein College of Medicine while he was the Chairman of the Department of Molecular Genetics. His research interests involved, gene targeting, human genetics, human genome project, cancer genome atlas project and has been a proponent of Precision Medicine. He is a member of the National Academy of Medicine of the United States.

SPEAKERS - THEATER 6



Shui On LEUNG

Chairman, Executive Director and Chief Executive Officer, SinoMab BioScience

Dr. Shui On Leung is the Founder, Chairman, Executive Director and Chief Executive Officer of SinoMab BioScience Limited, a listed on the Main Board of The Stock Exchange of Hong Kong Limited (stock code: 3681). He holds a PhD in Molecular Biology from the University of Oxford and an EMBA from The Chinese University of Hong Kong. His career spans scientific research, biotechnology management and biopharmaceutical entrepreneurship, including postdoctoral research at Yale University, experience at Immunomedics in the United States, and service as Managing Director of the Hong Kong Institute of Biotechnology.

Founded by Dr. Leung in 2001, SinoMab has established itself as a Hong Kong-listed biotechnology company focused on the discovery and development of first-in-class and potentially best-in-class therapeutic antibodies for autoimmune, inflammatory, neurological and other debilitating diseases. Its key programmes include SM17, targeting the interleukin-25 receptor; hC2, targeting the common gamma-chain receptor pathway; and an innovative bispecific antibody targeting RANKL and sclerostin.

Under Dr. Leung's leadership, SinoMab continues to strengthen its position in the Hong Kong capital market while advancing original scientific innovation, translational research, clinical development and global partnerships to bring differentiated antibody therapies to patients worldwide.



Frank LIU

Co-founder and CEO, EonArk.AI; Executive Director, Longevity Virtual Cell R&D Center, Research Institute of Tsinghua University in Shenzhen

Dr. Liu is Co-founder and CEO of EonArk AI, a frontier AI-driven drug discovery company, and Executive Director of the Longevity Virtual Cell R&D Center at the Research Institute of Tsinghua University in Shenzhen. He is also a member of the Longevity Biotech Fellowship, a global longevity community supported by Jeff Bezos and Peter Thiel. Dr. Liu previously served as CEO of the BGI Innovation Center for ten years, where he founded the BGI Life Science Accelerator and its venture capital fund. He helped incubate more than 300 frontier biotechnology companies and led investments in over 30 companies, including Neurophth Therapeutics and WeGene. Earlier in his career, he conducted postdoctoral research in artificial intelligence at the Massachusetts Institute of Technology, focusing on multimodal data analysis. He also served as Investment Director at Shanghai Guosheng Group and Deputy Director of the Administrative Committee of Changzhou National Hi-Tech District. He has extensive experience in AI-driven drug discovery, life science commercialization, technology investment, and government-industry collaboration.



Xiaoyi Benjamin LI

Chairman & CEO, Zhaoke Ophthalmology Limited

Dr. LI Xiaoyi Benjamin holds a PhD in Pharmacology from University of Illinois at Chicago. As the founder of "Lee's Pharmaceutical" and "Zhaoke Pharmaceutical" since 1994, Dr. Li had concentrated his professional efforts throughout from startup to the listed fully integrated pharmaceutical company with global perspectives. In April 2021, Zhaoke Ophthalmology was successfully listing on HKEx, under his leadership again.
Dr. Li was conferred Honorary Fellowship of the Hong Kong University of Science and Technology in 2016 and currently is the HKUST's adjunct professor. He is also vice chairman of Hong Kong Biotechnology Organization, director of Hong Kong Bio-Med Innotech Association, member of HKSAR Innovation & Technology Fund, and member of the Chinese People's Political Consultative Conference of Anhui Province, who is committed to supporting the development in the biotech industry not only a businessman, but contributing as a leader, entrepreneur, innovator and mentor.

SPEAKERS - THEATER 6



Yujie LIU

Director of Pharmacology Department/Biocytogen Pharmaceuticals （Beijing） Co., Ltd

Dr. Yujie Liu is Director of Pharmacology at Biocytogen. She received her Ph.D. from Peking University School of Pharmaceutical Sciences and subsequently served as a senior researcher at Illinois Institute of Technology and Northwestern University, focusing on blood–brain barrier (BBB) drug-delivery systems and mechanisms of lung injury.
Since joining Biocytogen in 2020, Dr. Liu has held roles including Study Director and Manager of Pharmacology Resources and Products. She led the development of a standardized pharmacology database covering more than 300 patient-derived xenograft (PDX) models and an integrated intelligent data service system. Her team has supported more than 8,000 client projects worldwide across oncology, metabolic and autoimmune diseases, neuroscience, immune-reconstituted models, and non-GLP preclinical toxicology.
Dr. Liu has extensive experience in target-humanized and immune-reconstituted mouse models, PDX applications, antitumor antibody evaluation, and BBB-penetrating therapeutics. By integrating advanced animal models with standardized pharmacology platforms, she is committed to generating decision-ready evidence and accelerating the clinical translation of innovative therapeutics.



Lan LU

CEO, Unita Ventures

Lan Lu, Co-Founder & CEO, Unita Ventures | Longevity Global APAC Ambassador | CEIBS MBA Family Business Club President
Lan manages a family office and leads Unita Ventures (UnitaVentures.com)—dedicated to extending the human healthspan by unifying cross-border longevity ecosystems.



Ronjon NAG

President, R42 Group; Adjunct Professor in Genetics, Stanford School of Medicine

Ronjon Nag is an inventor, teacher and entrepreneur. He is an Adjunct Professor in Genetics at the Stanford School of Medicine, becoming a Stanford Distinguished Careers Institute Fellow in 2016. He teaches AI, Genes, Ethics, Longevity Science and Venture Capital. He is a founder and advisor/board member of multiple start-ups and President of the R42 Group, a venture capital firm which invests in, and creates, AI and Longevity companies. As an AI pioneer of smartphones and app stores, his companies have been sold to Apple, BlackBerry, and Motorola. More recently he has worked on the intersection of AI and Biology. He has been awarded the IET Mountbatten Medal by the Institution of Engineering and Technology, the 2021 IEEE-SCV Outstanding Engineer Award, the $1m Verizon Powerful Answers Award, the 2023 COGX AI Lifetime Achievement Award, the 2023 MIT Great Dome Award, and was the 2024 Inductee in the Silicon Valley Engineering Hall of Fame. Professor Nag has a Ph.D from Cambridge, an M.S from Massachusetts Institute of Technology and a B.Sc. from Birmingham in the UK. He has numerous interests in the intersection of AI and Healthcare including being CEO of Agemica.ai working on creating a vaccine for aging. In 2026 he was awarded Officer of the Order of the British Empire (OBE) in King Charles III Birthday Honors. He is a Fellow of the Royal Society of Medicine.

SPEAKERS - THEATER 6



Hiroshi NOMURA

Medical Director, N2 Clinic Hotel Chinzanso Tokyo; Researcher, Department of Healthy Aging, Kyoto University Graduate School of Medicine; Special Medical Advisor, Gakken Dementia Prevention Research Laboratory

After graduating from the Faculty of Medicine at the University of Tokyo, Hiroshi Nomura, M.D., joined the Department of Plastic and Reconstructive Surgery at the same university, where he initiated a breast reconstruction project using adipose-derived stem/stromal cells (ADSCs). He subsequently conducted basic research in regenerative medicine and biomaterials at Boston University in the United States. After returning to Japan, he has focused on clinical research in regenerative medicine and worked to translate scientific findings into practical medical applications.
Dr. Nomura currently serves as a Researcher in the Department of Healthy Aging at Kyoto University Graduate School of Medicine and as a Special Medical Advisor to the Gakken Dementia Prevention Research Laboratory. He also collaborates on academic and industry–academia projects with researchers and companies in Japan and internationally. His academic work includes the safety assessment of exosome-based products for clinical use and the development of techniques to isolate stromal vascular fraction (SVF) from adipose tissue without enzymatic digestion or cell culture, with the aim of enhancing the safety and clinical applicability of regenerative medicine.
In 2021, he founded N2 Clinic Hotel Chinzanso Tokyo based on the concept of “personalized optimization of regenerative medicine.” His current work focuses on developing an integrated assessment and treatment system that analyzes whole-genome and epigenomic data, clinical laboratory findings, aging- and regeneration-related biomarkers, and the quality and functional characteristics of the stem cells to be administered. Based on these assessments, both the patient’s biological environment and the condition of the stem cells are optimized before and after treatment to improve the safety, reproducibility, and therapeutic effectiveness of regenerative medicine.



Jean-Baptiste ROY

Partner at Seveno Capital

Jean-Baptiste Roy is a Partner at Seveno Capital, a venture firm dedicated to the healthspan economy. He has built and backed sports, wellness and technology companies across 18+ years in Asia: founding Asia Sports Tech, leading private equity for a European family office, and advising global giants like Decathlon, Hyrox, PSG.



Morten SCHEIBYE-KNUDSEN

Associate Professor at the University of Copenhagen; President of the Nordic Aging Society

Morten Scheibye-Knudsen is the president of the Nordic Aging Society, a founding member of the European Federation for Aging Research, a chief editor at Frontiers in Aging, a co-founder of Senoscope, he is the owner of MSK Consulting and consults for the Healthy Longevity Clinic where he acts as CSO, he consults for BOLD Longevity Growth Fund and Deep Longevity, where he is a shareholder.”

SPEAKERS - THEATER 6



Emily TAN

Chief Operating Officer/ Sequencio Therapeutics

Ms. Emily Tan is the COO of Sequencio Therapeutics. She is responsible for Sequencio global business operations and advancing clinical translation of the oncology vaccine pipeline. Ms. Tan has thirty years of experience in the biopharmaceutical field spanning MNCs, CROs and biotech startups. She possesses deep expertise in clinical development and operations management, quality control and regulatory enforcement, and business strategy.
Ms. Tan has held former C suite roles at China biotech companies in Cell and Gene Therapy, where she successfully built operations and led submissions for China-US IND and China IIT. Ms Tan holds an honors bachelor's degree in pharmacy from the National University of Singapore and a master's degree in epidemiology from the London School of Hygiene & Tropical Medicine.



Gergely TOTH

Chief Executive & Scientific Officer, Cantabio Pharmaceuticals; Honorary Associate Professor, University College London

Gergely Tóth, PhD, MBA is the CEO, CSO and founder of Cantabio Pharmaceuticals, a biopharmaceutical company focusing on developing novel disease modifying precision therapeutics and diagnostics for neurodegenerative diseases. Dr. Tóth is also an Honorary Associate Professor at the School of Pharmacy at University College London, where he lectures about the business of biotech. Dr. Tóth previously held various research roles in small and global biopharmaceutical companies in the U.S. and later was a Welcome Trust funded research fellow at the University of Cambridge. Dr. Tóth has over 20 years of experience in the research of therapeutics and diagnostics for Alzheimer's, and Parkinson's disease. His research and publications were highlighted in articles by Biocentury Innovations, Scientific American and the World Economic Forum's 'Top 10 Emerging Technologies 2019.



Barry WANG

Director of Technology, Quantum Life Limited

Barry Wang is Director of Technology at Quantum Life, specializing in AI longevity, aging biomarkers, aging clocks, multi-omics, and statistical modeling. His recent work focuses on biological age and personalized health assessment using DNA methylation, clinical biomarkers, and multi-omics data. He is also exploring the integration of causal inference, human multi-omics, and artificial intelligence for aging mechanism discovery, AI-driven target identification, and precision intervention design. His work aims to connect aging assessment, mechanistic discovery, and healthy longevity interventions through data-driven approaches.

SPEAKERS - THEATER 6



Benny YANG

CSO, Biocytogen

Dr. Yang graduated from Fudan University with a Master's degree in Microbiology. He received his Ph.D. degree in Immunology from the University of Connecticut and completed his postdoctoral training at New York University School of Medicine in Dr. Dan Littman's research group. Then Dr. Yang was recruited to the Medical University of South Carolina (MUSC) as a tenure-track Assistant Professor in the Department of Microbiology and Immunology. In 2016, he joined Biocytogen as the Chief Scientific Officer, where he leads the Institute for Biologics. Dr. Yang has been instrumental in spearheading antibody drug discovery and has overseen the development of dozens of therapeutic antibody-based drugs, successfully advancing multiple projects to IND and clinical stages.



Huijun ZHOU

Professor, Stanford University School of Medicine; Serial Entrepreneur; Global leader in AI longevity medicine and East–West integrative health

Prof. Huijun Zhou Ring is a Professor at the Stanford University School of Medicine. She received her PhD in Molecular Biology and Genetics from Cornell University and completed her postdoctoral training in Medical Genetics at Stanford University. Her research focuses on AI-enabled healthcare foundation models, precision medicine, and longevity science, with an emphasis on translating cutting-edge technologies into scalable health solutions.

Prof. Ring is the primary instructor of MED 272, Science and History of Traditional Chinese Medicine, one of Stanford's most highly rated interdisciplinary courses. A strong advocate for cross-disciplinary innovation, she mentors Stanford students to become scientist-entrepreneurs, guiding the creation of high-impact ventures shaping the future of global health.

Prof. Ring is a board-certified clinical molecular geneticist and a recipient of multiple honors, including the McCormick Scientist Award, Incyte Innovation Award, and Morgan Lewis Entrepreneur Award. She serves on the Board of Directors of the Asia America Multitechnology Association (AAMA) Silicon Valley, a leading global platform connecting technology, business, and innovation leaders.

AGENDA+ SPEAKERS BIOGRAPHIES

DAY THREE

11 September, Fri



11 September 2026 (FRI), Day 3

AGENDA

09:00 – 09:40 — Main Stage

Keynote Speech

09:00 – 18:00 — Theater 1

International Symposium on Infectious Spatiotemporal Omics (Co-organized by BGI Group)

09:00 – 12:30 — Theater 2

Biotech Investment Summit 3:
Incubate and Innovate, Go Global — Value Creation via Investment Incubation and BD Transactions

---

09:00 – 11:30 — Theater 3

Cell and Gene Therapy Forum 3: Regenerative Medicine Seminar: Commercialization Opportunities Through Industrial Collaboration (Co-organized by DEFTA Partners)

09:00 – 13:00 — Theater 4

Brain-Computer Interface (BCI) Forum 1: Decoding the Mind: Frontiers of Brain-Computer Interfaces (Co-organized by Basic and Translational Neuromodulation Branch, Chinese Neuroscience Society)

09:00 – 10:00 — Theater 5

China Clinical Capability as a Global Value-Creation Driver: Opportunities and Challenges

---

09:00 – 11:00 — Theater 6

Global Cooperation Forum 4: From European Depth to Asian Markets

---

09:40 – 13:00 — Main Stage

Biopharmaceutical Innovation and Industrialization — From Discovery to Global Manufacturing

---

10:00 – 12:00 — Theater 5

Cell and Gene Therapy Forum 4: Frontier Exosome Therapies and Diagnostic Translation

---

11:00 – 13:00 — Theater 6

Global Cooperation Forum 5: Cross-border Collaboration and Southeast Asia Synergy

---

11:40 – 13:00 — Theater 3

Cancer Therapeutics- New era of mRNA Medicine

13:30 – 18:00 — Main Stage

Innovative Drug Forum 4: From Zero to One, From One to N: Source Innovation and the Full Value Chain

---

13:30 – 18:00 — Theater 3

Biomanufacturing Forum 3: Preparing for the Next Pandemic — Vaccines and Microbial Manufacturing (Co-organized by Chinese Society of Biotechnology)

14:00 – 17:00 — Theater 2

Biotech Investment Summit 4: Roadshow — Asia Gateway Medical Innovation Day (Co-organized by Li Ka Shing Faculty of Medicine, The University of Hong Kong)

14:00 – 18:00 — Theater 4

Brain-Computer Interface (BCI) Forum 2: From Synapse to Market: BCI Industry & Ecosystem (Co-organized by Basic and Translational Neuromodulation Branch, Chinese Neuroscience Society)

14:00 – 18:00 — Theater 5

Novel Cancer Drug Target Discovery & Science Cafe Salon (Co-organized by Science/AAAS)

14:00 – 15:30 — Theater 6

Rare Disease outlook- Global Collaboration in the Era of Genetic Medicine

---

15:40 – 18:00 — Theater 6

Fintech and Global Innovation Harmonized Forum

09:00 - 10:00 (MAIN STAGE)

Keynote Speech

Speakers:

Guanghui MA
Academician of Chinese Academy of Sciences； Professor, Institute of Process Engineering, Chinese Academy of Sciences
Speech Title: Microparticles in biopharmaceutical industry: design, preparation and industrialization

Raju KUCHERLAPATI
Paul C. Cabot Professor of Genetics and Professor of Medicine at Harvard Medical School
Speech Title: Impact of AI on Cancer Precision Medicine

09:00 - 18:00 (THEATER 1)

International Symposium on Infectious Spatiotemporal Omics (Co-organized by BGI Group)

Session 1: Keynote Lectures

Speakers:

Erling NORRBY
Former Permanent Secretary of The Royal Swedish Academy of Sciences, Sweden
Speech Title: Nobel Prizes in Virology; from biology to biochemistry to omics

Andrea COSSARIZZA
Professor of Pathology and Immunology School of Medicine University of Modena and Reggio Emilia, Modena, Italy
Speech Title: The Silent Infection Load: How Lifelong Asymptomatic Infections May Contribute to Inflammaging and Represent an Evolutionary Tradeoff of Longevity

Yi SHI
Principal Investigator, Guangzhou National Laboratory
Speech Title: RNA virus replication and intervention

Quan NGUYEN
Professor, School of Medicine, Westlake University
Speech Title: Spatial Analysis of the Infected Tissue Microenvironment in the Lung, Liver, Gut and Skin

Lai Guan NG
Professor, School of Medicine, Westlake University
Speech Title: Neutrophils: Born Different, Adapted for Purpose

Chuanyu LIU
Director, BGI Research, Shenzhen
Speech Title: Chinese Immune Multi-Omics Atlas

Session 2: Pathogen–Host Interactions & Infectious Disease Intervention

Speakers:

Qihui WANG
Deputy Director-General, Institute of Microbiology, Chinese Academy of Sciences
Speech Title: Engineering IgM Antibodies and Exploring Their Applications

Jasper CHAN
Assistant Dean & Clinical Professor, Li Ka Shing Faculty of Medicine, The University of Hong Kong; Chief of Department, Department of Infectious Disease and Microbiology, The University of Hong Kong-Shenzhen Hospital
Speech Title: Modeling SARS-CoV-2 Omicron-associated microstructural brain changes in children and young adults with a Syrian hamster spatiotemporal atlas

Zhiwei CHEN
Director, AIDS Institute; Chair Professor, Department of Microbiology, LKS Faculty of Medicine, The University of Hong Kong
Speech Title: Viral receptor-anchored tandem bi-specific neutralizing antibody for infection prevention and treatment

Qing MIAO
Department of Infectious Disease，Zhongshan Hospital，Fudan University
Speech Title: mNGS 臨床解讀策略的持續改進

Session 3: Pathogen Surveillance and Evolution

Speakers:

Huachen ZHU
Associate Professor, School of Public Health, The University of Hong Kong
Speech Title: Emerging Infectious Diseases: Surveillance and Research at the HumanAnimal Interface

Maggie WANG
Professor, School of Public Health and Primary Care, CUHK
Speech Title: Novel methods for predicting influenza virus evolution

Tsan Yuk Tommy LAM
Associate Professor, The University of Hong Kong
Speech Title: Phylodynamics of viral pathogens

Session 4: Microbiome, Antimicrobial Resistance & One Health

Speakers:

Patrick BUTAYE
Head, Department of Infectious Diseases and Public Health, City University of Hong Kong
Speech Title: Bacteriophages in medicine: From believers to precision medicine

Margaret IP
Professor and Chairman, Dept of Microbiology, CUHK; Honorary Consultant Microbiologist, New Territories East Cluster of Hospitals, Hospital Authority
Speech Title: Genomic Surveillance for Tackling Antimicrobial Resistance

Ye PENG
Research Assistant Professor, JC School of Public Health and Primary Care, The Chinese University of Hong Kong
Speech Title: Gut Microbiome in the Developmental Origins of Atopy: Large-Scale Metagenomics, Mechanistic Insights, and Potential Targeted Therapy

Una DING
Technical Specialist, Omics Empower Co., Limited
Speech Title: Stereo-seq Based One-stop Spatial Transcriptomics Research Service

09:00 - 12:30 (THEATER 2)

Biotech Investment Summit 3: Incubate and Innovate, Go Global — Value Creation via Investment Incubation and BD Transactions

Chair:

Mark TANG
Founder, 111 Longevity LLC; Founder, Phagionics Inc.; Founding Partner, Good Health Capital, New York

Speakers (Part 1):

Zhefeng ZHANG
Founder & Chairman, Nanjing Chiheal Bio Medicine Technology Co., Ltd.

Speakers (Part 2):

Xinrui LI
Head of New Business Development, Nutraceutical & Wellness Division, Guyu Biotechnology Group Ltd.
Speech Title: From Raw Material Technology to Systematic Anti-aging Solution

Zhili RAO
Researcher, Shenzhen Winkey Technology Co., Ltd

Harm-Jan BORGELD
Head of Roche Pharma Partnering Asia

Panel: The NewCo 2.0 Era: Paradigm Reconstruction and Implementation Pathways for the Global Capitalization of Chinese Innovative Drugs (Co-organized by Hony Capital)

Moderator: Xin LIU

Panelists: Francois MAISONROUGE, Harm-Jan BORGELD, Kenneth SUN, Lei FANG, Ruchun JI, Wen WANG

Panel: In- Depth Value Exploration：BD Empowerment and Capital Catalysis Exploration：BD Empowerment and Capital Catalysis within the win the Global Biopharma Innovation Chain(Co-organized by GTJA Investment Group & Innokylin)

Moderator: Linda ZHANG

Panelists: Irene CHEN, Jialin SUN, Jing QIAN, Kim PNG, Peter HAMES, Yuk Lam LO

09:00 - 11:30 (THEATER 3)

Cell and Gene Therapy Forum 3: Regenerative Medicine Seminar: Commercialization Opportunities Through Industrial Collaboration (Co-organized by DEFTA Partners)

Opening Remarks:

George HARA
Group Chairman and CEO, DEFTA Partners

Speakers:

Hung Fat TSE
Chairperson, the Department of Medicine, School of Clinical Medicine, Li Ka Shing Faculty of Medicine, the University of Hong Kong
Speech Title: Precision Cardiac Innovation: Leveraging Pluripotent Stem Cell for Drug Discovery to Cellular Therapy

Yoko FUJIMOTO
Managing Director and Chief Medical Officer (CMO), ROHTO Pharmaceutical Co., Ltd.
Speech Title: Connecting Well-being: Rohto's Approach to Regenerative Medicine

Moderator:

Abby GAO
Director of Investment Research Deputy Head, DEFTA Partners (Hong Kong)

Barbara CHAN
Au Chik Ko and Au Leung Shook Yin Professor of Biomedical Engineering
Speech Title: Opportunities and Challenges in Developing Tissue Engineered Advanced Therapy Products (ATPs)

Jimmy HUI
Scientist, ROHTO Pharmaceutical Co., Ltd.
Speech Title: Advancing Regenerative Medicine: Rohto's Journey from Cell Therapy to Next-Generation Innovation

Panel: Opportunities & Challenges in the Commercialization of Stem Cell research

Moderator: Abby GAO

Panelists: Barbara CHAN, Hung Fat TSE, Jimmy HUI, Yoko FUJIMOTO

09:00 - 13:00 (THEATER 4)

Brain-Computer Interface (BCI) Forum 1: Decoding the Mind: Frontiers of Brain-Computer Interfaces (Co-organized by Basic and Translational Neuromodulation Branch, Chinese Neuroscience Society)

Special Remarks: **Representative of the Government of the Hong Kong Special Administrative Region**

Moderator: **Shouyan WANG**
Deputy Dean, Institute of Science and Technology for Brain-inspired Intelligence, Director, Neuromodulation and Brain-machine-interface Centre, Fudan University

Speakers:

Philip SABES
CEO, Forest Neurotech; Prof. Emeritus, UCSF
Speech Title: The Fastest Path to Reliable Neuromodulation: How neurotechnology can accelerate treatment and discover

Minmin LUO
Director and Distinguished Investigator, Chinese Institute for Brain Research, Beijing
Speech Title: Development and Clinical Application of Fully Implantable High Throughput Brain Machine Interfaces

Lei SUN
Director of Non-invasive Brain Computer Interface, Professor of Biomedical Engineering, The Hong Kong Polytechnic University
Speech Title: Acoustic Brain Computer Interface and Ultrasound Neuromodulation

Hanna LU
Assistant Professor, The Chinese University of Hong Kong
Speech Title: Applying brain's digital twin in the clinical trials of personalized non-invasive neuromodulation

Jonathan BERENT
Chief Executive Officer, NextSense, Inc
Speech Title: From Apps to Abilities: How Real-World Neural Interfaces Are Redefining Brain-Computer Interfaces

Jingsong WU
Chief, Shanghai Key Laboratory of Clinical and Translational Brain-Computer Interface Research; Vice-chair (research), Neurosurgery, Huashan Hospital
Speech Title: Chinese Linguistic Brain-Computer Interface System

Ka Kit Gilberto LEUNG
Director, School of Clinical Medicine, HKU; Tsang Wing-Hing Professor in Clinical Neuroscience, HKU; Co-Director, Centre for Medical Ethics and Law, HKU.
Speech Title: The Issue of Personhood in Adopting Advanced Neurotechnology

Wai Kong William TSANG
Senior Medical and Health Officer, Department of Health, Government of HKSAR
Speech Title: TBC

Panel: Two Cities, One Mind — Shanghai × Hong Kong, Co-Creating the Future of BCI

Moderator: Zhihai QIU

Panelists: Fred LI, Jingsong WU, Lei SUN, Shouyan WANG, Zaicun WANG

09:00 - 10:00 (THEATER 5)

China Clinical Capability as a Global Value-Creation Driver: Opportunities and Challenges

Moderator: **Miron LILA**
Chief Corporate Development Officer, Caidya

Panelists: Bosun HAU, Otto CHEUNG, Susan KONG, Vishal GULATI

09:00 - 11:00 (THEATER 6)

Global Cooperation Forum 4: From European Depth to Asian Markets

Panel: Europe Meets Asia 1: European Expertise, Asian Opportunity — A Cross-Border Dialogue on Healthcare Transformation

Moderator: Chris LLOYD

Panelists: Claude FUHRER, Diana VIOLA, Jasna CANADI, Philippe GERWILL

Panel: Europe Meets Asia 2: The Future of Healthy Longevity Begins with WE: What Can the West Learn from the East?

Moderator: Lucy ROBERTSHAW

Panelists: Gigi NGAN, Johnny Chung Yin HO, Stina LUNDGREN, Wing CHENG, Zongli ZHENG

09:40 - 13:00 (MAIN STAGE)

Biopharmaceutical Innovation and Industrialization — From Discovery to Global Manufacturing

Moderator: **Jie ZHANG**
Institute Committee Member, Director of Division of Scientific Strategic Planning and Major Programs, Institute of Microbiology, Chinese Academy of Sciences

Speakers:

Jiandong HUANG
L & T Charitable Foundation, Professor in Biomedical Sciences Chair Professor of Synthetic Biology, The University of Hong Kong
Speech Title: Reimaging Immunotherapy: Engineering the Tumor, Not Just the Immune System

Zonghai LI
Founder, Chairman of the Board, CEO and CSO of CARsgen Therapeutics Holdings Limited
Speech Title: CAR-T Cell Therapy Advancement: From Innovation to Industrialization

Zhi YANG
Director, Researcher, Doctoral Supervisor, Department of Nuclear Medicine, Peking University Cancer Hospital
Speech Title: HER2-targeted radiopharmaceuticals and the practical experience from Beijing Cancer Hospital

Chao ZHONG
Professor, Shenzhen Institutes of Advanced Technology, Chinese Academy of Sciences
Speech Title: Biomaterials Design via Synthetic Biology

Rui QING
Tenure-track Associate Professor, Shanghai Jiao Tong University
Speech Title: Solubility design for membrane proteins and biomedical applcations

Jing LOU
Chairman, Shenyang Sunshine Pharmaceutical Co Ltd (3SBio Inc)
Speech Title: Innovation and Industrialization Practices of 3SBio

Weihong XIAO
Chairman of Zhejiang Hisun Pharmaceutical Co.,Ltd.
Speech Title: From raw materials to technology: Hisun Pharmaceutical's answer to the age of biomanufacturing

Panel: The Critical Leap in Biopharmaceutical Industrialization — A Dialogue Between Academicians and Industry Leaders

Moderator: Jinghua CAO

Panelists: Guanghui MA, Jing LOU, Ken LIANG, Weihong XIAO

10:00 - 12:00 (THEATER 5)

Cell and Gene Therapy Forum 4: Frontier Exosome Therapies and Diagnostic Translation

Speakers:

Hang Hubert YIN
Distinguished Professor at Beijing Normal University, Executive Dean of the Advanced Research Institute, Director of the Frontier Biotechnology Center, Director of the Key Laboratory of Radiopharmaceuticals, Ministry of Education
Speech Title: Purifying, Probing, Profiling, and Programming Extracellular Vesicles

Eva ROHDE
Chair, Department of Transfusion Medicine, University Hospital Salzburg, Paracelsus Medical University
Speech Title: First-in-Human Data of Extracellular Vesicle-enriched Secretome Fractions to Prevent Acute Cochlea Implantation- or Surgical Injury-Related Traumatic Tissue Injury

Wei Seong TOH
Research Director, Associate Professor, Department of Orthopaedic Surgery, Yong Loo Lin School of Medicine, National University of Singapore
Speech Title: MSC-EVs and Their Key Attributes in Joint Repair

Minh LE (Moderator)
Associate Professor and Graduate Program Director, Department of Pharmacology; Principal Investigator, Institute for Digital Medicine, Yong Loo Lin School of Medicine, National University of Singapore
Speech Title: Engineering Extracellular Vesicles for Therapeutic Delivery

Panel: Novel therapeutic and diagnostic development based on extracellular vesicles

Moderator: Minh LE

Panelists: Eva ROHDE, Hang Hubert YIN, Wei Seong TOH

11:00 - 13:00 (THEATER 6)

Global Cooperation Forum 5: Cross-border Collaboration and Southeast Asia Synergy

Panel: Uniting Southeast Asia to Build a New Ecosystem for Cross-border Collaboration in Life and Health

Moderator: Da LIU

Panelists: Lihan ZHOU, Nathan TIRTANA, Pharima PONGPAIROJ, Simon TSOI, Sunny SONG, Xiaoying MAI

11:40 - 13:00 (THEATER 3)

Cancer Therapeutics- New era of mRNA Medicine

Speakers:

Aimin HUI
Founder, Chair and CEO, EnCureGen Pharma
Speech Title: AI Meeting mRNA at enCureGen Pharma

Panel: Cancer Therapeutics- New era of mRNA Medicine

Moderator: Julie ZHU

Panelists: Aimee WANG, Aimin HUI, JiaYee LEE, Xin LIU

14:00 - 18:00 (MAIN STAGE)

Innovative Drug Forum 4: From Zero to One, From One to N: Source Innovation and the Full Value Chain

Moderator:

Xiaoyan HE
Vice President, Arton Economic Institute; Deputy Director, Special Committee of the Guangdong-Hong Kong-Macao Greater Bay Area Biotechnology Alliance; Endocrinologist, Boao Super Hospital

Session 1: Launch of the CityU TOPGBR Global Healthcare and Life Sciences Brand Ranking13:30-13:50

Speakers:

Forrest Zhilin YANG
Professor, City University of Hong Kong
Speech Title: TBC

Session 2: Fundamental Breakthroughs & Frontier Therapeutics

Speakers:

Wenhui LI
Investigator, National Institute of Biological Sciences, Beijing
Speech Title: Understanding HBV/HDV Biology And Working Toward a Cure

Gergely TOTH
Chief Executive & Scientific Officer, Cantabio Pharmaceuticals; Honorary Associate Professor, University College London
Speech Title: Development of a novel brain shuttle peptide based protein replacement therapy for the potential treatment of Parkinson's and Alzheimer's disease

Shengjiang LIU
CEO & CSO, Avirmax Inc.
Speech Title: TBC

Jiejing LI
Chief Scientist, Guangzhou Dongyuan Pharmaceutical Technology Co., Ltd.
Speech Title: Interfacial water reprogram metabolism to coordinate wound healing

Session 3: Innovative Technology Platforms & Precision Translation

Speakers:

JiaYee LEE
Director, Strategy and Alliance, BioNTech Australia
Speech Title: Accelerating research translation on mRNA-based innovation

Grace ZHOU
CEO & Chairperson, ImmVira Bioscience Inc.
Speech Title: Oncolytic Viruses: From First-in-Class to Clinical Scale-Up

Lance HAN
Founder CEO & Chief Innovation Officer, Cyagen Biosciences
Speech Title: Next-Generation chVHH Nanobodies: Innovative Discovery Strategies & Platform in Drug Development

Lei KANG
Professor, Chief Physician, Chief, Department of Nuclear Medicine, Peking University First Hospital
Speech Title: Precision evaluation by BCMA targeted-PET imaging in multiple myeloma

14:00 - 18:00 (MAIN STAGE)

Session 4: R&D Ecosystem, Global Strategy & Business Development

Speakers:

Stanley LI
Founder and Chairman, DXY
Speech Title: When Doctors Become Your R&D Partners

Joaquim Lopes JUNIOR
General Manager,Boehringer Ingelheim Hong Kong and Macau
Speech Title: From Global Innovation to Local Impact: Unlocking Earlier Access to Life-Changing Medicines

Cynthia WANG
Director, Global Business Development, Asia Pacific Region, Servier China
Speech Title: MNC Business Development in China: Navigating partnership and ecosystem synergy

Peter ZHANG
Partner, YAFO Fund
Speech Title: MNC BD Priorities under Portfolio Pressure

14:00 - 18:00 (THEATER 3)

Biomanufacturing Forum 3: Preparing for the Next Pandemic — Vaccines and Microbial Manufacturing (Co-organized by Chinese Society of Biotechnology)

Moderator:

Jie ZHANG
Institute Committee Member, Director of Division of Scientific Strategic Planning and Major Programs, Institute of Microbiology, Chinese Academy of Sciences

Juncai MA
Director of WFCC-MIRCEN World Data Center for Microorganisms(WDCM) The Institute of Microbiology, Chinese Academy of Sciences

Speakers:

Xi ZHOU
Deputy Director-General, Wuhan Institute of Virology, CAS
Speech Title: A Foundation Model of Coordinated Gene Dynamics Simulating ViralInfectious Diseases

Wei WEI
Professor, State Key Laboratory of Biopharmaceutical Preparation and Delivery, Institute of Process Engineering (IPE), Chinese Academy of Sciences (CAS)
Speech Title: Innovative formulations for precision treatment of leukemia

Diwei ZHENG
Researcher, Beijing Institute of Process, Chinese Academy of Sciences
Speech Title: Bacterial Biomaterials and Their Applications in the Treatment of Major Diseases

Xiangxi WANG
Professor, Principal Investigator Institute of Biophysics, Chinese Academy of Sciences
Speech Title: A hierarchical activation threshold shapes RSV F antibody repertoires from toddler vulnerability to adult protection

Qiubin LIN
Founder and CEO, Delonix Bioworks
Speech Title: OMV Plus® Platform and its applications in bacterial vaccine innovation

Mang SHI
Professor, Sun Yat-sen University
Speech Title: A Suite of Biological Sequence Language Models for Virus Discovery and Characterization

Zhou TONG
Associate Professor, Institute of Microbiology, Chinese Academy of Sciences (CAS); Deputy Director, Division of Scientific Strategic Planning and Major Programs; Deputy Secretary-General, Chinese Society of Biotechnology;
Speech Title: Beyond conventional antibody development: Addressing rapid mutation challenges in SARS-CoV-2 with new strategic frameworks

Tao DENG
Professor, Principle Investigator; Institute of Microbiology, Chinese Academy of Sciences
Speech Title: The Dynamic Regulatory Functions of NS2 During Influenza Virus Replication

Zhaoming SU
Principle Investigator, West China Hospital Sichuan University
Speech Title: Discovery of RNA quaternary assemblies and RNA-targeted small molecules accelerated by AI

Qi ZHANG
Research associate professor, School of Medicine, Tsinghua University
Speech Title: MabSeek: An AI-Powered Platform for Automated Antibody Discovery

Xiaotian TAN
Associate Professor, Shenzhen Institutes of Advanced Technology
Speech Title: TRACE: Multiplexed Antibody Fingerprinting from Dried Blood Spots for Decentralized Respiratory Virus Surveillance

14:00 - 18:00 (THEATER 2)

Biotech Investment Summit 4: Roadshow — Asia Gateway Medical Innovation Day (Co-organized by Li Ka Shing Faculty of Medicine, The University of Hong Kong)

Judge:

Bo CHEN
Chief Scientific Officer, China Resources Pharmaceutical Group Limited

Chuen Yan LEUNG
Partner (Private Investments) at Value Partners Group

James CHAN
Associate Investment Director of Beyond Ventures

Jimmy TAO
Chairman, Federation of Hong Kong Industries (FHKI)

Nicholas WONG
Co-Founder and Chief of Staff of Full-Life Technologies

Project Pitching:

Dr. Lanqi GONG
Speech Title: AI-Driven Broad-spectrum PD-L1-AOAH Fusion Protein for Refractory Tumors

Prof. Hung-Fat TSE
Speech Title: Compositions for Non-Viral Provision of LAMP2 and Their Translational Applications

Prof. Jiandong HUANG
Speech Title: NOVOMI VAX Tumor Vaccine

Prof. John LEUNG
Speech Title: Histology at the Operating Table: Rapid Reversible Clearing and Volumetric Imaging of Intact Specimens

Prof. Leo POON
Speech Title: C2iVax: A Universal Live-Attenuated Influenza Vaccine Platform for Broad Seasonal and Pandemic Influenza Protection

Prof. Michael CHAN
Speech Title: Scalable Patient-Derived Organoid Platform for Precision Medicine and Human Disease Modeling

Prof. Stephanie MA
Speech Title: Killing from the Root - First-in-Class Cancer Stem Cell Inhibition Platform

Prof. Wenwei TU
Speech Title: Innovative "off-the-shelf" γδ-T Exosome Therapies for Solid Tumors

Prof. Yu WANG
Speech Title: Unlocking the Therapeutic Potential of OB001: a First-in-Class GlycoPeptide Drug for Obesity

Prof. Zhiwei CHEN
Speech Title: Δ42PD1 Antibody: A Novel Immunotherapy for Liver Cancer

14:00 - 18:00 (THEATER 4)

Brain-Computer Interface (BCI) Forum 2: From Synapse to Market: BCI Industry & Ecosystem (Co-organized by Basic and Translational Neuromodulation Branch, Chinese Neuroscience Society)

Moderator:

Lei SUN
Director of Non-invasive Brain Computer Interface, Professor of Biomedical Engineering, The Hong Kong Polytechnic University

Speakers:

Shouyan WANG
Deputy Dean, Institute of Science and Technology for Brain-inspired Intelligence, Director, Neuromodulation and Brain-machine-interface Centre, Fudan University
Speech Title: Translation from Forefront Research in Brain-computer Interface into Industry of Healthcare

Xufeng WEI
Chairman, Medphoenix Group, General Manager, GoldenWing (Suzhou) Medical Technology, Industry Professor, Nanjing Medical University
Speech Title: The risk control and evaluation of the Innovative BCI devices

Paddy Kwok Leung CHAN
Founder, Brainsmart Technology Limited Associate Professor, Department of Mechanical Engineering, Faculty of Engineering, The University of Hong Kong Centre Co-Director, Advanced Biomedical Instrumentation Centre
Speech Title: Minimally Invasive ECoG devices for BCI applications

Ludovic SEREX
CTO, Neurosoft Bioelectronics
Speech Title: Building the BCI of the Future: Soft, Full-Cortex Interfaces as the Foundation for Brain AI

Dongdong ZHANG
BCI BU Director, OYMotion
Speech Title: From Non-Invasive BCI to a BCI Platform

Bashar BADRAN
Gestala, VP, Head of Clinical and Science
Speech Title: Ultrasound: The History and Future of Next-Generation Brain-Computer Interfaces

14:00 - 18:00 (THEATER 4)

Speakers:

Christoph GUGER
CEO, g.tec medical engineering GmbH
Speech Title: Current and Future BCI Technology and Global BCI Excellence Network

Frank YANG
Founding Partner & CEO
Speech Title: China BCI Development 0->N: Idea, Incubation and Scale Up

Panel: BCI Investment and Industrial Ecosystem

Moderator: Frank YANG

Panelists: Christoph GUGER, Jonathan BERENT, Paddy Kwok Leung CHAN, Steven LU, Steven JIANG, Xufeng WEI,

14:00 - 18:00 (THEATER 5)

Novel Cancer Drug Target Discovery & Science Cafe Salon (Co-organized by Science/AAAS)

Moderator:

Shoupeng LIU
Associate Director, Outreach and Strategic Partnerships, Asia Science/AAAS

Speakers:

Stephen Lam CHAN
Clinical Professor in the Department of Clinical Oncology at the Chinese University of Hong Kong
Speech Title: Clinical Trial Testing of Novel Cancer Therapies: Experiences and Emerging Trends

Yajie WANG
Assistant professor, Westlake University
Speech Title: Exploring Functional Innovation in the Enzyme Twilight Zone

Dan LIU
Associate Professor, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology
Speech Title: Genomic instability drives POSTN+ myofibroblasts via STING–WNT axis to promote immunosuppression and PARPi resistance in ovarian cancer

Bobo DANG (Presented by Dr. Tian Li)
Associate Professor, School of Life Sciences, Westlake University; Principal Investigator, Laboratory of Protein Engineering and Protein Therapeutics; Program Associate Director, Chemical Biology
Speech Title: A high-throughput selection system for fast-acting covalent protein drugs

Xiaofei GAO
Professor, Westlake University
Speech Title: In vivo generation of CAR myeloid cells for cancer immunotherapy using erythrocyte-mediated mRNA delivery

Panel: Oncology Drug Screening: Bridging Target and Clinic

Moderator: Shoupeng LIU

Panelists: Bobo DANG, Dan LIU, Stephen Lam CHAN, Xiaofei GAO, Yajie WANG

14:00 - 15:30 (THEATER 6)

Rare Disease Outlook- Global Collaboration in the Era of Genetic Medicine

Chair:

Kathryn S.E. CHEAH
Emerita Chair of Biochemistry and Professor at The University of Hong Kong

Speakers:

Frances PLATT
Head of Department of Pharmacology, University of Oxford
Speech Title: Beyond the Challenges: A New Era for Rare Diseases

Panel: Rare Disease outlook- Global Collaboration in the Era of Genetic Medicine

Moderator: Jiawei TANG

Panelists: Dong DONG, Frances PLATT, Jin LEE, Tianqiang LU

15:40 - 18:00 (THEATER 6)

Fintech and Global Innovation Harmonized Forum

KEYNOTE SPEAKERS - MAINSTAGE



Raju KUCHERLAPATI

Paul C. Cabot Professor of Genetics and Professor of Medicine at Harvard Medical School

Professor Raju Kucherlapati is the Paul C. Cabot Professor of Genetics and Professor of Medicine at Harvard Medical School since 2001. He obtained his PhD from the University of Illinois, was a research fellow at Yale University and started his academic career as a faculty member at Princeton University. Prior to joining the Harvard faculty, Professor Kucherlapati was the Lola and Saul Kramer Professor and University Professor at the Albert Einstein College of Medicine while he was the Chairman of the Department of Molecular Genetics. His research interests involved, gene targeting, human genetics, human genome project, cancer genome atlas project and has been a proponent of Precision Medicine. He is a member of the National Academy of Medicine of the United States.



Guanghui MA

Academician of Chinese Academy of Sciences； Professor, Institute of Process Engineering, Chinese Academy of Sciences

Guanghui Ma is a professor of Institute of Process Engineering (IPE), CAS. She received Bachelor degree from Gunma University, Master and PhD degrees from Tokyo Institute of Technology, Japan, respectively. She worked at Tokyo University of Agriculture and Technology (TUAT) as an assistant professor during 1994-2001. She joined IPE as a professor in 2001. She has published over 600 papers, including Nature, Cell, Nat. Mater., Nat Nanotechnol., Nat. Biomed. Eng., Sci Transl Med., Cell Host & Microbe, Cell Biomater., Cell Rep. Med., Sci. Adv., Nat. Commun., JACS, Adv. Mater., edited several books such as “Microspheres and Microcapsules in Biotechnology”. She has more than 90 patents authorized, and the technology and products have been commercialized in companies. She has received the State National Invention Award (2nd Class, 2009), the Beijing Science and Technology Award (1st Class, 2005; 1st Class, 2025), the Beijing Natural Science Award (1st Class, 2025), the Basic Research Achievement Award (1st Class, 2020) of the Chemical Industry and Engineering Society of China. She was elected as the member of Chinese Academy of Sciences, the Fellow of TWAS, the Fellow of the American Institute of Medical and Biological Engineering (AIBME), and the member of the Academic Advisory Committee of CAMS.

SPEAKERS - MAINSTAGE



Jinghua CAO

Director, Committe for International Cooperation and Overseas Affairs of the Chinese Society Biotechnology

Prof. CAO Jinghua， Director, Committe for International Cooperation and Overseas Affairs of the Chinese Society Biotechnology. Prior to this position， he served as Executive Director of the Secretariat of the Alliance of International Science Organizations (ANSO). An English major and graduate from the Beijing Foreign Languages Institute in 1982 and a master in international politics from CCNY, US in 1987, he worked in different posts in international affairs at the Chinese Academy of Sciences (CAS) such as Deputy Director of the Office of External Financing, the Chinese Academy of Sciences (CAS), Deputy Director and Director of the Office of American and Oceanian Affairs, Bureau of International Cooperation (BIC), Assistant Director, Deputy Director General and Director General of BIC, CAS. He also worked as a Second and First Secretary in the S&T Section of the Chinese Embassy in Washington D.C. from 1995 to 1997. His research interests are science policy and international cooperation in science and engineering. His publication includes a few articles in international SCI journals.



Lance HAN

Founder CEO & Chief Innovation Officer, Cyagen Biosciences

Lanqing (Lance) Han, a Tsinghua University alumnus with a Bachelor of Engineering (1988) and a Master of Engineering from McGill University, is a distinguished engineer turned entrepreneur. His academic journey included pivotal research on life sciences imaging equipment at MIT, igniting his passion for biotechnology. In 2006, after acquiring an MBA from Queen's University, Han founded Cyagen Biosciences, where he serves as CEO. Under his leadership, Cyagen has become a leader in providing innovative solutions for life sciences research and drug development. Beyond his corporate role, Han leads a research group at Innovation Center for Artificial Intelligence, Reseach Institute of Tsinghua, Pearl River Delta in Guangzhou, focusing on medical artificial intelligence and the application of large language models in bioinformatics. His work has earned international acclaim, yielding numerous scientific publications and patents.



Xiaoyan HE

Vice President, Arton Economic Institute; Deputy Director, Special Committee of the Guangdong-Hong Kong-Macao Greater Bay Area Biotechnology Alliance; Endocrinologist, Boao Super Hospital

Dr. He holds a PhD in Hospital Management from Fudan University and an EMBA from Washington University in St Louis. With over a decade of clinical practice at Shanghai Ruijin Hospital and another decade as China Medical Affairs Head at Pfizer, AbbVie and other multinational corporations, she is uniquely positioned to bridge clinical medicine, industry, management and capital. Dr He is committed to advancing the integration of medical research, industry and capital, alongside regulatory innovation. In the fields of cardiovascular-metabolic diseases, oncology immunology and cell therapy (TCR-T, bispecific antibodies), she excels in clinical development, product lifecycle management, and investment-grade medical due diligence and asset transactions. She actively promotes the application of AI and real-world evidence, and contributed to the compilation of China Medical Artificial Intelligence Legal and Compliance Guidelines – the country's first authoritative framework establishing ethical, safety and regulatory standards for AI in healthcare.

SPEAKERS - MAINSTAGE



Jiandong HUANG

L & T Charitable Foundation, Professor in Biomedical Sciences Chair Professor of Synthetic Biology, The University of Hong Kong

Prof. Huang earned his BS degree from Fudan University, Shanghai and went to the US through the CUSBEA program to pursue his PhD study in transcriptional regulation during fruit fly embryonic pattern formation. He earned his PhD degree from the University of California, Los Angeles. Thereafter, Prof. Huang received his postdoctoral training in mouse genetics at National Cancer Institute, NIH in the USA. During this period, Prof. Huang was the first to report that the two major intracellular transportation systems of mammalian cells, the microtubule- and actin-filament-based systems directly interact with each other through their motor proteins, kinesin and myosin. Later, he established his own laboratory at the University of Hong Kong. Prof. Huang is now the Chair Professor of Synthetic Biology and the L & T Charitable Foundation Professor in Biomedical Sciences in the School of Biomedical Sciences, the University of Hong Kong. His current work focuses on using synthetic biology approach for vaccine development and cancer therapy.



Joaquim Autunes LOPES Junior

General Manager,Boehringer Ingelheim Hong Kong and Macau

Joaquim Lopes Junior is the General Manager of Boehringer Ingelheim Hong Kong and Macau, leading the organization with a strong commitment to innovation, collaboration, and patient-focused healthcare. He brings more than 20 years of experience in pharmaceutical sales and marketing, having worked across a broad range of therapeutic areas in both primary care and specialty care. Throughout his career, he has developed deep expertise in commercial strategy, market development, team leadership, and business growth, consistently driving performance and delivering results in highly competitive environments.

Joaquim joined Boehringer Ingelheim Brazil in 2018 and has since contributed to the company's success through his strategic mindset and passion for improving healthcare outcomes. Before joining Boehringer Ingelheim, he built a solid track record at Sanofi Brazil and Hypera Pharma, one of the largest and most respected local pharmaceutical companies in the Brazilian market. His diverse background has enabled him to gain valuable insights into different healthcare segments and customer needs.

Today, Joaquim continues to champion innovation and foster continuous and collaborative dialogue among multiple stakeholders to ensure medical innovation continuous to flow into Hong Kong in an expected and sustainable way. His leadership is guided by a focus on excellence, innovation, and creating meaningful value for patients, healthcare professionals, and the communities the company serves across Hong Kong and Macau today.



Lei KANG

Professor, Chief Physician, Chief, Department of Nuclear Medicine, Peking University First Hospital

Lei Kang, M.D., Ph.D. is a professor, chief physician, and the director of the nuclear medicine department of Peking University First Hospital. As a doctor in nuclear medicine, he serves in clinical nuclear medicine and in basic applied science in molecular imaging. He developed several radiolabeled antibodies, peptides, and nucleotides for the in vivo theragnostic of malignant tumors for future clinical translation. He has published nearly 200 papers (H-index 43) as first or corresponding authors (including co-authors). His articles have been published in Advanced Science, Nat Commun, Proc Natl Acad Sci, J Clin Invest, J Am Chem Soc, J Nucl Med, and Eur J Nucl Med Mol I. His studies have been supported by more than 32 grants from NSFC, the Chinese Education Ministry, Beijing Science, and Technology Commission. He has been awarded by Higher School Natural Science Outstanding Achievement Second Prize, Beijing Distinguished Youth Scientist, Beijing Nova Scientist, Xiaolun Youth Science Award, 2019 SNMMI CMIIT (Center for Molecular Imaging Innovation & Translation) YIA First Place, Hope Star Award of Chinese Nuclear Medicine Society and Peking University Outstanding Doctoral Dissertation. He has been granted 1 patent from US and 5 patents from China. He has given more than 30 oral presentations and posters at top international academic conferences, such as SNMMI and EANM annual meetings.

SPEAKERS - MAINSTAGE



JiaYee LEE

Director, Strategy and Alliance, BioNTech Australia

Dr. JiaYee Lee is based at the BioNTech Australia Innovation Centre in Melbourne, where she leads and shapes strategic engagement and ecosystem development activities that accelerate innovation in mRNA therapeutics and vaccines. Working closely with researchers, clinicians, entrepreneurs, industry partners, and investors, she helps identify emerging scientific opportunities and fosters collaborations to enable the translation of mRNA-based innovation along the portfolio development pathway. Her career spans medical research, technology innovation, venture creation, commercialisation, and policy development, providing a unique end-to-end perspective on how scientific discoveries progress from the laboratory into products and technologies that deliver real-world impact. Prior to joining BioNTech, JiaYee was Professor of MedTech at the University of Melbourne, where she led multidisciplinary initiatives at the interface of academia, industry, healthcare, and government. She also served as Director of the Health and Life Sciences Business Team at National ICT Australia (NICTA), now CSIRO's Data61, where she drove research translation and commercialisation across diagnostic genomics, biomedical informatics, digital health, and assistive technologies. Earlier in her career, JiaYee led virology research programs funded by Australia's National Health and Medical Research Council at the Victorian Infectious Diseases Reference Laboratory and the Macfarlane Burnet Centre (now Burnet Institute for Medical Research and Public Health). Dr Lee has an Adjunct Professor appointment at La Trobe University and graduated with a BSc (Hons), PhD, and MBA from the University of Melbourne.



Ken LIANG

Deputy General Manager, Andgel Industrial (Shanghai) Co., Ltd.

Joined Andgel in 2012 and currently serves as Deputy General Manager. With a combined background in biopharmaceuticals and business management, he has been deeply involved in marketing and process technology development planning in the biotechnology equipment field. Over the years, he has been dedicated to promoting high-quality development and localization upgrades in the biomanufacturing industry. Key achievements include:

• Driving industry upgrades and cost reduction: Long-term promotion of domestic large-scale cell culture bioreactor production line construction, helping the industry achieve localized large-scale bioreactor production lines.

• Leading process and digital innovation: Led the establishment of the 'Anjiyi Process Innovation Center,' launched the AndgelX cloud software platform, continuously providing domestic clients with cutting-edge process innovation products and services.

• Empowering pilot scale-up and commercialization: Focusing on the technical bottlenecks of biomanufacturing, he has led the construction of the Anjiyi small-scale and pilot-scale bioprocess platform in recent years, successfully helping multiple biomanufacturing clients complete process optimization and industrial-scale scaling.



Jiejing LI

Chief Scientist, Guangzhou Dongyuan Pharmaceutical Technology Co., Ltd.

Professor Li Jiejing is the Chief Scientist of Dongyuan Pharmaceutical and a developer of National Class 1 Innovative Drugs, dedicated to the research, development, and application of natural botanical medicines. He graduated from the Kunming Institute of Zoology, Chinese Academy of Sciences, and later pursued further studies in the United States, completing his postdoctoral research in Cell Biology at the University of Iowa. He subsequently served as an Assistant Professor in the Department of Biology and the Center for Neuroscience at West Virginia University. Upon returning to China, Professor Li joined Kunming University of Science and Technology as the Head of the Laboratory for Genetic & Developmental Diseases and Drug Screening, focusing on the R&D of innovative drugs. He has developed various methods for isolating and purifying active ingredients from natural plants. He has published over a dozen SCI-indexed papers as first or corresponding author, secured 4 national and provincial-level research projects, and applied for 20 invention patents. He has received prestigious honors including the Yunnan "Thousand Talents Program," the Yunnan "Yunling Elite Program," and the title of Yunnan High-Level Talent. He was awarded the Third Class Prize of the Yunnan Provincial Science and Technology Progress Award. In addition to leading the Laboratory for Genetic & Developmental Diseases and Drug Screening at Kunming University of Science and Technology, he serves as a dual-appointed mentor at First Affiliated Hospital of Jinan University (Overseas Chinese Hospital) and has been recognized as a Distinguished Scientist by the American Association for the Advancement of Science (AAAS).

SPEAKERS - MAINSTAGE



Stanley LI

Founder and Chairman, DXY

Tiantian Stanley Li is the founder and chairman of DXY. Established in 2000, DXY has evolved into China's most prominent and active online community for medical professionals. It offers high-quality academic support to more than 4 million licensed Chinese physicians, achieving over 92% nationwide coverage. Stanley graduated from the Clinical Medicine of Harbin Medical University in 1999 and pursued a master's in Tumor Immunology at the same institution. In 2006, he gave up his doctoral studies in Neurology at Peking Union Medical College to focus on his business full-time. He is now a member of the health expert group of the Belt and Road Initiative Action Platform of the United Nations Global Compact, a consulting member in the Digital Health Strategy for the World Health Organization/West Pacific Region Office (WHO/WPRO), the Vice President of the Internet Medical Health of the China Non-Public Medical Institutions Association, and the Vice President of the m-Health of the China Information Association. He now holds guest professorships at the Harbin Medical University and the AnTai College of Economics and Management at Shanghai Jiao Tong University. He also serves as an Independent Director of DiAn Diagnostics (300244.SZ) for its fourth and fifth terms. His diverse affiliations include being the Vice President of the Zhejiang Health Services Industry Promotion Association, Vice President of the Heilongjiang Province Health Industry Association, director of the Zhejiang Merchants General Association, council member of the Zhejiang Province Private Hospital Association, and director of the Alumni Association of Harbin Medical University and Peking Union Medical College.



Wenhui LI

Investigator, National Institute of Biological Sciences, Beijing

Wenhui Li is an investigator at the National Institute of Biological Sciences (NIBS), Beijing, and a professor at the Tsinghua Institute of Multidisciplinary Biomedical Research, Tsinghua University. His group works on molecular mechanisms of viral infection of hepatitis B and D virus. Dr. Li and his colleagues identified sodium taurocholate co-transporting polypeptide (NTCP), a liver bile acid transporter, as an essential receptor for viral infection of HBV and HDV. His group also develops interventions against HBV and HDV infection. Dr. Li's work has been recognized by multiple awards including Baruch S. Blumberg Prize (2021), Future Science Prize in Life Sciences (2022), and the Distinguished Award in Hepatitis B Research (2024).



Zonghai LI

Founder, Chairman of the Board, CEO and CSO of CARsgen Therapeutics Holdings Limited

Dr. Li was the former leader of the biotherapy research team at the State Key Laboratory of Oncogenes and Related Genes of Shanghai Cancer Institute; professor at Shanghai Cancer Institute and a doctoral supervisor at Renji Hospital.
Dr. Li has approximately 20 years of work experience in the biopharmaceutical field. One of his early career achievements is the identification of GE11, a peptide ligand of EGFR which has become a widely used unnatural peptide in antitumor study now. He is also the inventor of new technologies such as Hpd3cell, a new phage display technology; FR806, a new safety switch for T cell therapy; CycloCAR technology to increase the antitumor activities of chimeric antigen receptor (CAR) T cells. He published the first papers of CAR T cell therapy against GPC3, Claudin18.2 and EGFR/EGFRvIII worldwide.

SPEAKERS - MAINSTAGE



Shengjiang LIU

CEO & CSO, Avirmax Inc.

Dr. Liu is an experienced biotechnologist, virologist, biochemist, and serial entrepreneur. He leads Avirmax team to innovate, develop and manufacture the next generation of AAV gene therapeutics (NGAGT) for eye diseases. Prior to Avirmax, Dr. Liu was the chief scientist of biological development in Bayer Pharmaceuticals. Dr. Liu was a cofounder and the president of Abmaxis, Inc. which was acquired by Merck in 2006. Dr. Liu was the group leader of Genentech BSL-3 Virology Lab. He developed many bioprocess technologies implemented in biologics manufacturing. In the past 30 years, he played important roles in the innovation, development, manufacturing and regulatory submissions of 35 biologic products including AAV genetic products, out of which 10 are widely used biologics in the market. He co-discovered and characterized a new virus, rabbit hemorrhagic disease virus (RHDV), rabbit calicivirus in 1984.
Dr. Liu received his Ph.D. from Biochemistry from Kansas State University and his post-doctoral training with Dr. Arthur Kornberg (Nobel Laureate), Stanford University. Dr. Liu is a member of ASGCT, AAO, ARVO and an advisor of Bioengineering Department of Santa Clara University.



Jing LOU

Chairman, Shenyang Sunshine Pharmaceutical Co Ltd (3SBio Inc)

EDUCATION :
MD, Medicine Major
Second Military Medical University, Shanghai, China
Sep 1980 – Jul 1985

Immunology (Graduate School)
Second Military Medical University, Shanghai, China (Early quit to work)
Sep 1985 – Jul 1986

Ph.D., Molecular and Cellular Biology
Fordham University, New York City, USA
Jan 1989 – Jul 1993

EMBA
China Europe International Business School (CEIBS), Shanghai, China
Sep 2005 – Jul 2007

WORK HISTORY :
Research/Teaching Associate, Dept of Microbio & Immuno
2nd Military Medical University, Shanghai, China
Sep 1986 – Jul 1988

Postdoc, NICHD
National Institutes of Health, Bethesda, MD, USA
Sep 1993 – Sep 1995

Vice President, R&D/Manufacture
Shenyang Sunshine Pharmaceutical Co Ltd, Shenyang, China
Dec 1995 – Nov 2000

President & CEO
Shenyang Sunshine Pharmaceutical Co Ltd (3SBio Inc), Shenyang, China
Dec 2000 – May 2012

Chairman & CEO
Shenyang Sunshine Pharmaceutical Co Ltd (3SBio Inc, Hong Kong Sansheng Medical Ltd), Hong Kong/Shanghai, China
May 2012 – Present

SPEAKERS - MAINSTAGE



Rui QING

Tenure-track Associate Professor, Shanghai Jiao Tong University

Dr. Rui Qing is a tenure-track Associate Professor at the School of Life Sciences and Biotechnology at Shanghai Jiao Tong University and a member of the State Key Laboratory of Microbial Metabolism. With a multidisciplinary background in bioengineering and materials science, his focuses lie on synthetic biology. His research evolves around the water-soluble design and application of membrane proteins. During his time at the MIT Media Lab and the Koch Institute, he and his collaborators established a groundbreaking new set of design principles for membrane protein solubilization—known as the QTY code—which differs fundamentally from the traditional approach of modifying surface hydrophobic residues. As a platform technology, the QTY code enables the universal design and large-scale synthesis of water-soluble variant membrane proteins that retain molecular activity for mechanistic studies, which has also opened avenues for applications such as next-generation functional nanomaterials, antibody-like therapeutics, and highly specific high-density biomimetic sensing systems. Currently, he is dedicated to developing deep learning–based methods for next-generation membrane protein design, as well as low-dimensional bioelectronic integrated interfaces that combine designed molecules with mini-scale electrochemical devices. Starting from fundamental molecular biology, he explores application prospects in biomedicine, biosensing, and other fields.



Gergely TOTH

Chief Executive & Scientific Officer, Cantabio Pharmaceuticals; Honorary Associate Professor, University College London

Gergely Tóth, PhD, MBA is the CEO, CSO and founder of Cantabio Pharmaceuticals, a biopharmaceutical company focusing on developing novel disease modifying precision therapeutics and diagnostics for neurodegenerative diseases. Dr. Tóth is also an Honorary Associate Professor at the School of Pharmacy at University College London, where he lectures about the business of biotech. Dr. Tóth previously held various research roles in small and global biopharmaceutical companies in the U.S. and later was a Welcome Trust funded research fellow at the University of Cambridge. Dr. Tóth has over 20 years of experience in the research of therapeutics and diagnostics for Alzheimer's, and Parkinson's disease. His research and publications were highlighted in articles by Biocentury Innovations, Scientific American and the World Economic Forum's 'Top 10 Emerging Technologies 2019.



Cynthia WANG

Director, Global Business Development, Asia Pacific Region, Servier China

Cynthia Wang Joined Servier China as Business Development Director since July 2015. Ever since April 2020, Cynthia serves as Global Business Development Director for Asia Pacific region, to co-create and drive innovation in therapeutic options

Cynthia brings with her over 20 years of Healthcare/pharmaceutical industrial experience in China. Prior to Servier China, Cynthia worked at Pfizer Strategy and Business Development for Vaccine BD global M&A projects and managing full TAs out-licensing BD activities. Before joining Pfizer, Cynthia held a series of positions in Business Development, New Product Introduction, Product launch, Strategic Alliance Management, Business planning and Operational Management at Janssen/Johnson & Johnson and Agilent Technologies. Cynthia has broad BD network in China serving as Rotating Chairperson of CHBD(China Healthcare BD) organization and China Healthcare development(expert) committee member, Cynthia has proven BD track records of closing multiple BD deals.

Cynthia holds a Master of Business Administration from Peking University, a Master of Global Finance from Fordham University in NYC, a Pharmacy degree from Peking University Health Science Centre.

SPEAKERS - MAINSTAGE



Weihong XIAO

Chairman of Zhejiang Hisun Pharmaceutical Co.,Ltd.

Weihong Xiao, male, born in September 1968, is a member of the Chinese Peasants' and Workers' Democratic Party (CPWDP). He graduated from the University of International Business and Economics (UIBE) with a Bachelor's degree in Economics, majoring in Foreign Trade English. He is currently a Doctor of Professional Studies (DPS) candidate in the Peking University-Fordham University Joint Program, and a Global Alumnus of the Wharton School, University of Pennsylvania. He currently serves as Chairman and President of Zhejiang HISUN Pharmaceutical Co., Ltd., and Vice Chairman of BioRay Biopharmaceutical Co., Ltd.

Active in social and professional organizations, his concurrent roles include Standing Committee Member of the Shanghai Pudong New Area CPPCC, Invited Vice Chairman of the China Association of Fragrance Flavour and Cosmetic Industries (CAFFCI), Honorary Vice Chairman of the Chinese Pharmaceutical Association (CPA), Executive Member of the Chinese National Health Association (CNHA), Vice Chairman of the Zhejiang Pharmaceutical Association (ZPA), member of the Shanghai Young Intellectuals Friendship Association, and MBA Career Mentor at the National School of Development (NSD) at Peking University.



Forrest Zhilin YANG

Professor, City University of Hong Kong

TopGBR Global Healthcare & Life Sciences Brand Rankings" is a research project initiated by the GBR Global Brand Research Institute and independently conducted by an academic team from City University of Hong Kong. Leveraging Hong Kong's strategic position as a hub connecting global research, industry, and capital markets, the ranking establishes a scientific, rigorous, data-traceable, and sustainably iterative brand evaluation system, providing professional brand value references for institutions across pharmaceuticals, biotechnology, medical devices, and healthcare services. The project's initial phase focuses on evaluating globally listed innovative pharmaceutical companies, with plans to gradually expand into more specialized sectors. Guided by the principles of global comparability, data compliance and traceability, quantitative analysis supplemented by expert consultation, and phased iterative development, the ranking aims to address gaps in existing industry evaluation systems. It offers objective references for enterprises, investment institutions, and researchers while building an international dialogue platform bridging academia, industry, and the public sector.



Zhi YANG

Director/ Researcher/ Doctoral supervisor Department of Nuclear Medicine, Peking University Cancer Hospital

Dr. Yang Zhi serves as the Director of the Department of Nuclear Medicine at Peking University Cancer Hospital, Chairman of the Nuclear Medicine Branch of Beijing Medical Association, and Director of the Beijing Key Laboratory for Radiopharmaceutical Research and Experimental Evaluation. He has long been dedicated to the research and clinical translation of novel radiopharmaceutical molecular probes. He has led more than 90 clinical translation projects of radionuclide probes and holds over 40 authorized invention patents. Seven patented technologies have achieved industrial transformation with a total contract value exceeding 180 million RMB. Notably, two Class I innovative drug probes have obtained CDE IND approval and advanced into Phase III clinical trials. In the past five years, he has published over 300 academic papers and has been awarded numerous national and provincial science and technology prizes, as well as prestigious industry outstanding contribution awards.

SPEAKERS - MAINSTAGE



Jie ZHANG

Institute Committee Member, Director of Division of Scientific Strategic Planning and Major Programs, Institute of Microbiology, Chinese Academy of Sciences

Jie ZHANG, Principal Investigator and Recipient of the Excellent Young Scientists Fund from the National Natural Science Foundation of China. His research mainly focuses on the mechanisms of microbial pathogenesis and environmental adaptation. He has elucidated the biochemical functions of multiple regulatory factors governing microbial environmental adaptation, as well as their molecular mechanisms in manipulating plant immune signaling pathways. He has led a series of research projects, including the Strategic Priority Research Program of the Chinese Academy of Sciences, sub-projects of the National Key R&D Program, and programs funded by the National Natural Science Foundation of China. He is also a member of the Youth Innovation Promotion Association, Chinese Academy of Sciences. His research has been published in top international journals, such as Cell Host & Microbe, Developmental Cell, The Plant Cell, Molecular Plant, and FEMS Microbiology Reviews.



Peter ZHANG

Partner, YAFO Fund

Mr. Zhang is a partner at YAFO Fund, bringing over 10 years of experience in BD and investment with leading Chinese domestic companies and MNCs. He served as the Investment Head for ACROBiosystems and BD Manager for AutoBio. Prior to that, he held marketing manager roles at Novartis, B Braun, and Fresenius Kabi, where he led marketing campaigns and strategies for star products such as Diovan, Entresto, and Cosentyx. He holds an MBA degree from Cheung Kong Graduate School of Business and a bachelor's degree in material science and engineering from the University of Illinois at Urbana-Champaign. Additionally, he is a CFA Charter holder.



Chao ZHONG

Professor, Shenzhen Institutes of Advanced Technology, Chinese Academy of Sciences

Dr. Chao Zhong is a Professor at the Shenzhen Institutes of Advanced Technology, Chinese Academy of Sciences, where he serves as Vice Director of the Institute of Synthetic Biology. He also holds leadership roles as Deputy Director of the National Key Laboratory of Quantitative Synthetic Biology and Director of the Shenzhen Key Laboratory of Materials Synthetic Biology. A recipient of the National Science Fund for Distinguished Young Scholars, he serves as Topic Editor for ACS Synthetic Biology (2023–2024) and sits on the editorial boards of Materials Today Bio and Current Research in Chemical Biology.
His research bridges synthetic biology and materials science, focusing on engineered living materials and programmable biomaterials. He has published over 80 papers, with corresponding-author contributions in Nature, Nature Biotechnology, Nature Chemical Biology, and Nature Reviews Materials. He holds 12 granted patents and over 30 pending applications. In 2021, he founded PAM2L Biotechnologies Co., Ltd., a company dedicated to leveraging the power of synthetic biology to advance biomaterials for health, longevity, and beauty applications.

SPEAKERS - MAINSTAGE



Grace ZHOU

CEO & Chairperson, ImmVira Bioscience Inc.

Dr. Grace Zhou holds a Ph.D. from the Shanghai Institute of Biochemistry, Chinese Academy of Sciences. She is a recipient of China's National Thousand Talents Plan award, was named one of China's Top 10 Outstanding Innovative Women (2024), and is the sole winner of the 2019 International "Antiviral Women Scientist Award". Additionally, she was honored as one of China's Top 10 Outstanding Female Entrepreneurs (2021), "Scientific Chinese of the Year" (2017), and a recipient of the "State Council Special Allowance" (1998). Formerly an Associate Professor in the Department of Microbiology at the University of Chicago (1999–2014), Dr. Zhou dedicated 15 years to herpesvirus research and has nearly 30 years of expertise in antiviral infection and oncolytic herpesvirus-based tumor immunotherapy. In 2015, Dr. Zhou founded ImmVira Pharma, which has since established the proprietary OVPENS platform—a fully integrated system combining scientific rationale, R&D technology, and manufacturing processes. Building on this foundation, the company has developed two key platforms: Oncolytic Virus Immunotherapy and Engineered Exosome Delivery. Oncolytic Virus Pipelines focus on multiple solid tumors with various routes of administration (intratumoral, intravenous, and intravesical). Exosome Delivery Pipelines targeting applications in large health markets, including complex metabolic, immune, respiratory, ocular, and dermatological diseases.

SPEAKERS - THEATER 1



Patrick BUTAYE

Head, Department of Infectious Diseases and Public Health, City University of Hong Kong

Professor Patrick Butaye is STEM-professor at City University's Jockey Club College of Veterinary Medicine and Life Sciences. Patrick graduated with a degree of Veterinary Medicine from Ghent University in 1994. In 2000, he obtained his PhD from the same university. Following this, he worked as Senior researcher and head of division at the former Veterinary and Agrochemical Research institute in Brussel until 2015. In 2006, he became Adjunct Professor at Ghent University and still holds that position. In 2015, he started a Professorship at Ross University School of Veterinary Medicine, whereafter in 2023, he started at City University of Hong Kong. He is also senior research fellow at the One Health Research Foundation, Miramar Florida.
Patrick is or has been member of several national and international advisory committees and expert panels and has been ad hoc expert on a multitude of occasions. These include the European Food Safety Authority (EFSA), World Health Organization (Who), Pan American Health Organisation (PAHO), Food and Agriculture Organisation (FAO), Belgian Food safety authority (FAVV), ...
He is member of the Executive board of the European Study Group on Veterinary Microbiology (ESGVM), as part of the European Society of Clinical Microbiology and Infectious Diseases (ESCMID).
He has been member of several project review panels worldwide.
Patrick was in the organising and/or scientific committee of several national and international conferences, including but not limited to ARAE, ICOHAR, ECVM, Belgian Wildlife Disease Society,...
Patrick is Editor in Chief of the journal Veterinary Sciences (MDPI), member of the Editorial Board of BMC Veterinary Research and Editor for PlosOne and Associate Editor for Frontiers in Antimicrobials, Resistance and Chemotherapy as well as Guest Editor for Frontiers in Veterinary Science.



Jasper Chan

Assistant Dean (Global Engagement), Li Ka Shing Faculty of Medicine; Deputy Chairperson & Clinical Professor, Department of Microbiology, School of Clinical Medicine, The University of Hong Kong (HKU)

Professor Jasper Fuk-Woo Chan is currently Assistant Dean and Clinical Professor at Li Ka Shing Faculty of Medicine, The University of Hong Kong, and Chief of Department, Department of Infectious Disease and Microbiology, The University of Hong Kong-Shenzhen Hospital. His research focuses on the diagnosis, treatment, and control of emerging infectious diseases with pandemic potential or special relevance in Asia. He has published more than 380 papers in these areas, including first/corresponding author publications in The Lancet, Science, and Nature. He has been ranked by Clarivate as a "Highly Cited Researcher" (2 fields: "Microbiology" and "Immunology") since 2021 and top 1% scholar since 2015. He was elected as Fellow of the Infectious Diseases Society of America in 2022 and Member of the Hong Kong Young Academy of Sciences in 2024. He has served as expert member or ambassador of various international organizations, including member of the World Health Organization ad hoc Expert Group focused on COVID-19 disease modelling (WHOCOM) and Young Ambassador of Science of the American Society for Microbiology. He is an Associate Editor / Editorial Advisory Board member for Clinical Microbiology Reviews, Virologica Sinica, Open Forum Infectious Diseases, Journal of Medical Virology, American Journal of Transplantation and Microbes & Immunity. His research is supported by funding from the Ministry of Science and Technology (National Key R&D Programme of China), National Natural Science Foundation of China (NSFC Young Scientist Fund (Type A) and General Program), Research Grants Council (RFS, CRF and GRF), Health and Medical Research Fund, and Innovation and Technology Commission. Professor Chan and his team reported the world's first familial cluster of COVID-19 that confirmed person-to-person transmission of SARS-CoV-2 in January 2020, which resulted in major policy changes for controlling the pandemic worldwide (Chan JF et al., Lancet 2020). This paper was selected by The Lancet as 1 of 34 articles highlighted in the "200 years of The Lancet" timeline. His team also established the world's first golden Syrian hamster model for COVID-19, which has now become one of the most commonly used animal models for COVID-19 research.

SPEAKERS - THEATER 1



Zhiwei CHEN

Director, AIDS Institute; Chair Professor, Department of Microbiology, LKS Faculty of Medicine, The University of Hong Kong

Prof. Zhiwei Chen is a Chair Professor of Immunology and Immunotherapy and the Suen Chi-Sun Professor in Clinical Science in HKUMed. He received his PhD from New York University School of Medicine in 1996 and progressed from an NIH F32 Post-doctoral Fellow to Assistant Professor at the Aaron Diamond AIDS Research Center of the Rockefeller University from 1996 to 2002. In 2007, he joined HKUMed as an Associated Professor and the Founding Director of the HKUMed AIDS Institute.
His research focuses on AIDS/SARS/COVID-19 pathogenesis and immunotherapy, with an emphasis on the early events of viral infection. He pioneered the creation of HKU-patented platforms of technologies, including the PD1-based vaccine, the tandem anti-HIV-1 bi-specific antibody, and an anti-Δ42PD1 antibody drug for the fight against viral infection and cancer. He has been ranked by Clarivate Analytics among the top 1% of researchers worldwide by citations and a Highly Cited Researcher in 2022, 2023 and 2024. He has won numerous research grants as PI from RGC GRF/CRF/TRS, ITC RAISe+, HMRF, NIH RO1, amfAR, the Bill & Melinda Gates Foundation, and so forth. He also won the HKU Knowledge Exchange Excellence Award 2019, Outstanding Researcher Award 2021 and Outstanding Research Student Supervisor Award 2021.



Andrea COSSARIZZA

Professor of Pathology and Immunology School of Medicine University of Modena and Reggio Emilia, Modena, Italy

He took the degree in Medicine and Surgery at the University of Padua, then he did his PhD in Oncology at the University of Bologna and University of Modena, and the Specialization in Clinical Pathology and Immunohematology at the University of Modena and Reggio Emilia. As medical student, he visited the Basel Institute of Immunology and then the New York University (NYU) Medical Center. After the degree, he spent some periods in different Institutes (London; Paris; Los Angeles), in 1998 he became Associate Professor of General Pathology and Immunology at the University of Modena and Reggio Emilia, and in 2010 was appointed Full Professor. He was President of the International Society for Advancements of Cytometry (ISAC). Main scientific interests: characterization of the immune response and search for predictive markers in patients treated with biological drugs or monoclonal antibodies, especially in patients with tumors or COVID-19; analysis of immune changes during different human diseases, sepsis and infections and during aging and longevity. He was one of the scientists that in the late '90s have developed the concept of "inflammaging"; role of mitochondria in the process of apoptosis and importance of mitochondrial DNA in different pathologies.



Ziqing DENG

Director, Beijing BGI Biological and Information Fusion Technology Research Institute

Dr. Ziqing Deng is a Professor and Director of the Beijing BGI Biological and Information Fusion Technology Research Institute. He received his Ph.D. in Biology from The University of Hong Kong. He is a doctoral supervisor at the University of Chinese Academy of Sciences and a mentor at Tsinghua University Xingjian College.
His research focuses on microbiology and omics technologies, with major interests in emerging infectious diseases, infection and immunity, bacterial antimicrobial resistance, and environmental microbiome. He has published over 30 papers in leading international journals including Science and Nature Biotechnology.
He serves as a member of the Expert Panel of the National Key R&D Program of China on "Frontier Biotechnology". He was honored as an "Advanced Individual in the National Science and Technology System's Fight Against COVID-19" by the Ministry of Science and Technology in 2021.

SPEAKERS - THEATER 1



Una DING

Technical Specialist, Omics Empower Co., Limited

Una DING Technical Specialist, Omics Empower Una Ding holds a Master's degree in Biotechnology from KTH Royal Institute of Technology in Sweden. She previously worked as a Research Engineer at SciLifeLab in Stockholm, where she focused on droplet microfluidic platform development and its applications in single-cell sorting. Combining a research background with experience in commercial omics services, Una works with spatiotemporal omics technologies, including single-cell and spatial transcriptomics. She focuses on connecting these technologies with the practical needs of academic researchers and supporting the implementation of spatiotemporal omics studies.



Margaret IP

Professor and Chairman, Dept of Microbiology, CUHK; Honorary Consultant Microbiologist, New Territories East Cluster of Hospitals, Hospital Authority

Dr Margaret IP
BM(Soton), MSc(LSHTM), DTM&H, FRCPath, FRCP(Lond & Glasg), FRCPA, FHKCPath (Clin Micro and Infection), FHKAM(Pathology)
Margaret Ip is Professor and Chairperson at the Department of Microbiology, the Chinese University of Hong Kong. She is Honorary Consultant Microbiologist at the New Territories East Cluster of Hospitals of Hospital Authority of Hong Kong. She received her medical training at the University of Southampton and London School of Hygiene and Tropical Medicine, UK. She has over 30 years of experience as a clinical microbiologist and is a Fellow of respective Colleges of Pathologists in Australasia, U.K, and of Hong Kong. Her research interests focus on molecular epidemiology of drug-resistant pathogens, inc. Streptococcus pneumoniae, MRSA, Group B Streptococcus (GBS) and other multidrug-resistant organisms. She has published over 320 international peer-reviewed papers and 6 book chapters. She serves as an Advisor and Member of Scientific Committees on antimicrobial resistance and infection control and in Expert groups on GBS with WHO.



Tsan Yuk Tommy LAM

Associate Professor, The University of Hong Kong

Professor Tommy Lam received his BSc (Bioinformatics) and PhD (Molecular Virology) in The University of Hong Kong, and had postdoctoral training in Pennsylvania State University and University of Oxford. His main research interest is the evolution, epidemiology and ecology of infectious diseases. He uses integrative genomic approach to determine the patterns, drivers and mechanisms of the emergence of pathogens at human-animal interface including influenza viruses and coronaviruses, as well as some bacterial pathogens and their antibiotic resistance emergence. His research has contributed to important understanding of the origins, evolution and transmission of newly emerging pathogens such as H7N9 influenza (Nature 2013, Nature 2015), MERS coronavirus (EID2013, Science 2016) and COVID-19 coronavirus (Nature 2020). He is also leading research studies on mosquitoes and their arboviruses in Hong Kong, China. Professor Lam is interested in bioinformatics methods. He is leading the development of several computational tools and databases for the genomic analysis.

Professor Lam received Novartis Vaccines Award for Epidemiology of Infectious Diseases from International Society for Infectious Diseases in 2008, and the Newton Research Fellowship from Royal Society UK in 2010. He received National Science and Technology Progress Award (Special Award, 2017) from State Council of the People's Republic of China. He has been ranked top 1% scholars at HKU based on Essential Science Indicators between 2016-2020. He was awarded with The National Natural Science Foundation of China (NSFC) Excellent Young Scientists Fund (Hong Kong and Macau) in 2019.

In addition to the teaching undergraduate and postgraduate courses in the University, Professor Lam also taught in several international workshops and online courses. He organised the Croucher Summer Course: Computational Genomics of Viral Evolution and Epidemiology to promote high-quality technical training and research collaboration among the local and international scientists in this field.

SPEAKERS - THEATER 1



Chuanyu LIU

Director, BGI Research, Shenzhen

Chuanyu Liu is the Director of the Branch of BGI-Research, Researcher at the State Key Laboratory of Genome and Multi-omics Technologies. His research focuses on the development of single-cell multi-omics technologies and their applications in cellular pathology. He has published over 40 papers as the first or corresponding author in Nature (2022a，2022b), Science (2025，2026), and Cell (2026).



Qing MIAO

Department of Infectious Disease，Zhongshan Hospital，Fudan University

MD, PhD Associate Chief Physician, Department of Infectious Diseases, Zhongshan Hospital, Fudan University Executive Deputy Director, Department of Infectious Diseases, Fudan University Zhongshan Hospital (Xiamen Branch) Youth Committee Member, Branch of Bacterial Infection and Antimicrobial Resistance, Chinese Medical Association Committee Member, Nontuberculous Mycobacteria Group, Chinese Antituberculosis Association Committee Member, Severe Tuberculosis Group, Tuberculosis Branch, Chinese Medical Association Committee Member, Infectious Diseases Branch, Shanghai Medical Association Committee Member, Clinical Microbiology Committee, Shanghai Society for Microbiology Principal Investigator of one national-level research project and one provincial/ministerial-level research project Deputy Chief Translator of Bailey & Scott's Diagnostic Microbiology Research interests: clinical interpretation of pathogen sequencing, nontuberculous mycobacterial diseases, and cardiovascular and implant-associated infections.



Lai Guan NG

Professor, School of Medicine, Westlake University

Dr. Ng conducted his PhD studies at the Garvan Institute of Medical Research in Sydney, Australia. Following his postdoctoral training, Dr. Ng joined the Singapore Immunology Network (SIgN) in 2009 to establish his own laboratory. Over the next 13 years, he established himself as a leader in the field of myeloid cell biology. His research primarily focuses on unraveling the complexities of myeloid cell ontogeny, cellular behavior, and tissue adaptation. In 2023, Dr. Ng accepted a new position as a Senior Investigator at the Shanghai Immune Therapy Institute, where he also serves as the Director of the Center for Systems Immunology and as a Professor at Shanghai Jiao Tong University in China. More recently, Dr. Ng relocated to the School of Medicine at Westlake University in Hangzhou, China. Dr. Ng's contributions to the field of immunology are exemplified by his numerous publications in leading journals such as Science, Nature, Science Immunology, Immunity, Journal of Experimental Medicine, Science Advances, Advanced Materials, and Nature Protocols. He has also been listed as one of Clarivate's Highly Cited Researchers for six consecutive years (2020–2025). Most recently, he was selected to join the prestigious New Cornerstone Investigator program.

SPEAKERS - THEATER 1



Quan NGUYEN

Head Genomics and Machine Learning Lab, Director of National Centre for Spatial Tissue and AI Research (NCSTAR)

Assoc. Prof. Quan Nguyen is Head of the Genomics and Machine Learning Laboratory, Scientific Director of the National Centre for Spatial Tissue and AI Research (NCSTAR), and founder of an emerging QIMRB spin-out company (STARCO). He is a former Australian Research Council DECRA Fellow and holds an NHMRC Leadership Fellowship (EL2, L1). He serves as Co-Chair of the international SpatioTemporal Omics Consortium and is among the leaders of the Human Cell Atlas Spatial Analysis Taskforce. His team develops and applies machine learning approaches to analyse single-cell and spatial multiomics data from patient samples and preclinical models. They aim to discover diagnostic biomarkers, identify drug targets involved in cell–cell interactions, predict disease progression, and stratify patient responses to therapies. Ultimately, his research focuses on developing scalable precision medicine approaches that benefit broader patient populations.



Erling NORRBY

Former Permanent Secretary of The Royal Swedish Academy of Sciences, Sweden

Erling Norrby has an MD and PhD from the Karolinska Institute, the School of Medicine, Stockholm. He was the professor of virology and chairman at the Institute for 25 years. During that time he also served as Dean of the Faculty of Medicine for 6 years and was deeply involved in the work on Nobel prizes in physiology or medicine for 20 years. After leaving the Institute he became Permanent Secretary of the Royal Swedish Academy of Sciences for six years. During this time he had overriding responsibility for the Nobel Prizes in physics and chemistry and was a member of the Board of the Nobel Foundation. Presently he is at the Center for the History of Sciences at the Academy. In 2010 he published the book Nobel Prizes and Life Sciences, in 2013 a second book Nobel Prizes and Nature's Surprises, in 2016 a third book Nobel Prizes and Notable Discoveries, in 2019 a fourth book entitled Nobel Prizes – Cancer, Vision and the Genetic Code and finally in 2022 a fifth book with the title Nobel Prizes – Genes, Viruses and Cellular Signaling. He has had one of the leading functions at the Royal Swedish Court as Lord Chamberlain-in-Waiting.



Ye PENG

Research Assistant Professor, JC School of Public Health and Primary Care, The Chinese University of Hong Kong

Dr. Ye Peng is a microbiome scientist specializing in the early-life gut microbiome and its role in immune development, metabolic health, and disease susceptibility. He completed his PhD at the University of Hong Kong and received postdoctoral training at the Chinese University of Hong Kong. His research has demonstrated how perinatal exposures shape both the gut bacteriome and virome, influencing childhood obesity, food sensitization, vaccine immunogenicity, neurodevelopmental outcomes, and colonization resistance against antimicrobial-resistant bacteria. Through interdisciplinary approaches integrating multi-omics, epidemiology, and machine learning, Dr. Peng's work advances understanding of microbial ecology and host–microbe interactions in early life. His long-term vision is to define healthy microbiome trajectories and translate these insights into precision diagnostics and interventions that promote lifelong immune and metabolic health.

SPEAKERS - THEATER 1



Yi SHI

Principal Investigator, Guangzhou National Laboratory

Dr. Yi Shi currently works as a principal investigator and full-time professor in the Guangzhou National Laboratory, China. He has graduated from Zhejiang University in 2006, and then moved to the Institute of Microbiology, Chinese Academy of Sciences (CAS) to continue his PhD training under the supervision of Prof. George Fu Gao. He has obtained his PhD degree in 2011, and then he worked as assistant professor and associate professor in different institutions of CAS. Since 2016, he started to work independently as principal investigator and full-time professor in the Institute of Microbiology, CAS, and from March 2025, he moved to the Guangzhou National Laboratory. His expertise mainly focuses on the molecular mechanisms of emerging virus infection and regulation by the host, especially how the virus breakthrough the host barrier to infect humans, and the development of broad-spectrum antivirals and vaccines against different emerging viruses. He has made remarkable progress on a range of important human pathogens including influenza virus, Ebola virus, ZIKV, arenaviruses, coronaviruses and mpox virus. He has published more than 140 refereed papers in the international academic journals including Cell, Nature, and Science.



Maggie WANG

Professor, School of Public Health and Primary Care, CUHK

Maggie Wang is a Professor at the JC School of Public Health and Primary Care, Faculty of Medicine, The Chinese University of Hong Kong (CUHK). A recipient of the RGC Research Fellow award and the NSFC Excellent Young Scientists Fund (Hong Kong & Macau), she holds key leadership roles as Director of the Center for Clinical Research and Biostatistics and Director of the Master of Epidemiology and Biostatistics program at CUHK. She also serves as Editor- in- Chief of Human Genetics (Springer Nature).Her research focuses on elucidating mutation patterns in viral and human genomes through the development of innovative statistical and computational methodologies. She has authored over 170 publications and is a lead author on papers featured in leading journals such as Nature Medicine, Nature Communications, PLOS Genetics, Nucleic Acids Research, and Bioinformatics. As Principal Investigator, she has secured multiple grants from the RGC- GRF, the National Science Foundation of China (NSFC), and the Health and Medical Research Fund (HMRF).In addition to her academic pursuits, she is the founder of Beth Bioinformatics, a startup dedicated to translating cutting- edge biotechnologies to accelerate vaccine antigen design and therapeutic development in collaboration with international pharmaceutical industry partners.



Huachen ZHU

Associate Professor, School of Public Health, The University of Hong Kong

Huachen Maria Zhu is a Tenured Associate Professor at the School of Public Health, The University of Hong Kong (HKU). She also serves as a Visiting Professor at Shantou University (STU) and the Deputy Director of the State Key Laboratory of Emerging Infectious Diseases (HKU Shenzhen Branch). She is an internationally recognized scholar specializing in virology, bioinformatics, and public health.

SPEAKERS - THEATER 2



Harm-Jan BORGELD

Head of Roche Pharma Partnering Asia

Harm-Jan, Vice President, Head of Roche Pharma Partnering Asia is responsible for the negotiations of innovative, Asia sourced, deals to transform R&D strategic wants into global research and development plans to improve Roche's external innovation portfolio. Harm-Jan is based in Shanghai and is a member of the Leadership Team of Roche Pharma Partnering.



James CHAN

Associate Investment Director of Beyond Ventures

James is a healthcare specialist with expertise in biotech and capital market transactions. He currently serves as the Associate Investment Director at Beyond Ventures, a Hong Kong-based venture capital firm, where he focuses on biotech investment.
Prior to joining Beyond Ventures, James was a Transaction Manager in the capital markets team at Kirkland & Ellis LLP, a top-tier international law firm, advising biotech companies on global offerings and listing.
James graduated with First-class Honours from the University of Hong Kong and pursued doctoral studies in clinical medicine at Oxford. There, he trained as a cancer scientist under the supervision of 2019 Nobel Prize Laureate Prof. Sir Peter Ratcliffe and leading cancer scientist Prof. Xin Lu.

SPEAKERS - THEATER 2



Irene CHEN

Head of Global Business development, China, Chiesi

Dr. Irene Chen is Head of Global Business Development, China at Chiesi, leading the company's global business development activities in China. Embedded within Chiesi's global Business and Corporate Development organization, she serves as a key bridge between China's rapidly evolving biotech innovation ecosystem and Chiesi's global BD teams. She is responsible for identifying and evaluating innovative opportunities and advancing strategic partnerships from initial engagement and due diligence through deal structuring, negotiation, and execution. Irene brings nearly a decade of business development and strategic partnering experience across multinational pharma and biotech, with prior roles at UCB, Boehringer Ingelheim, Delonix Biowork, and Henlius. She has led and supported multiple cross-border licensing and research collaboration transactions. Irene holds a Ph.D. in Biochemical Engineering from ECUST, with doctoral research training at UC Berkeley.



Bo CHEN

Chief Scientific Officer, China Resources Pharmaceutical Group Limited

Dr. Bo Chen is a specially-appointed expert for overseas high-level talents . He is currently the Chief Scientific Officer at China Resources Pharmaceutical Group Limited. He has more than 20 years of international career in the biotechnology and pharmaceutical industries, including basic research and innovative drug R&D team leadership in top scientific research institutions and pharmaceutical companies such as the National Institutes of Health, AstraZeneca, etc.

He has R&D background in the entire R&D value chain from target discovery to clinical development and commercial operation. He received his PhD. degree from the Air Force Medical University (China), completed the postdoctoral fellowship at the National Institutes of Health in the United States, and later obtained an MBA degree from Hood College (U.S.A)

He has published dozens of academic papers, book chapters and patents in peer-reviewed journals, including papers published in top journals such as Annals of the Rheumatic Diseases, Nature Communication, Nature Immunology, Nature Medicine, PNAS, etc.

He has won the second prize of the Ministry of Health's Science and Technology Progress Award, the AstraZeneca Staff Platinum Award and Silver Award, the NIH Outstanding Researcher Award, Qilu Pharmaceutical Group's Outstanding Leadership Award, etc.

SPEAKERS - THEATER 2



Lei FANG

Co-Founder Chairman&CEO, Excalipoint Therapeutics

Dr. Lei Fang is a biotech entrepreneur, immunologist, and drug developer focused on advancing next-generation cancer immunotherapies. He is the Co-founder and Chairman of Excalipoint Therapeutics, where he leads the company's strategic vision, scientific direction, and the development of innovative T-cell engager (TCE) therapies designed to unlock the full potential of T-cell–mediated cancer treatment. Dr. Fang has more than a decade of experience in oncology drug development, translational medicine, and innovative biologics. His work focuses on translating advances in immunology into differentiated therapeutic platforms capable of delivering more precise, potent, and durable immune therapies for patients with cancer. Prior to founding Excalipoint Therapeutics, Dr. Fang served as Vice President of Lepu Biopharma and CEO of CtM Bio, where he led development strategy and early clinical programs for innovative oncology biologics, including TCE therapies. Previously, he was Co-founder of I-Mab (NASDAQ: IMAB), where he contributed to the advancement of multiple innovative biologics and supported the company's growth into a globally recognized biotechnology company. Earlier in his career, Dr. Fang worked at GSK (GlaxoSmithKline) R&D China as a scientist focused on autoimmune drug discovery and translational medicine. During this time, he gained extensive experience in global pharmaceutical research and development and the integration of basic science with clinical drug translation. Dr. Fang received his Ph.D. in Cell Biology from the Chinese Academy of Sciences. He is recognized for his expertise in T-cell engager biology, translational immunology, and early clinical development of innovative cancer therapies, and is committed to building global biotechnology platforms capable of delivering transformative medicines for patients worldwide.



Peter HAMES

Chief Corporate Development Officer, Pharmanovia

Peter is Chief Corporate Development Officer at Pharmanovia, where he leads business development, licensing, M&A and strategic partnerships. He has extensive experience executing international pharmaceutical transactions, with transactions valued at over $1 billion across acquisitions and licensing deals, including the recent licensing of Senaparib from Impact Therapeutics. His experience spans sourcing and partnering innovative medicines from China and the US for commercialisation across European and global markets.

SPEAKERS - THEATER 2



Ruchun JI

Partner, Sidley Austin LLP

Ruchun Ji focuses his practice on advising investors, strategic and private equity buyers, and high-growth companies in life sciences, healthcare, and technology industries globally. He counsels clients in a broad range of transactions, from company formation to venture capital financings, growth capital investments, joint ventures, strategic alliances, licensing and collaborations, mergers and acquisitions, initial public offerings, follow-ons and PIPEs. He also advises clients on regulatory matters involving the United States Committee on Foreign Investment in the United States (CFIUS) and disputes relating to licensing and collaboration transactions.



Chuen Yan LEUNG

Partner (Private Investments) at Value Partners Group

Dr. Chuen Yan LEUNG is Partner (Private Investments) at Value Partners Group, one of Asia's leading independent asset management firms, and Managing Partner of Silver Dart Capital, a boutique healthcare investment firm.
His experience spans private equity, biotechnology startups, and academia, including roles as an investment professional at EQT Group, a global top-tier private equity firm, and founding scientist at Procella Therapeutics, a Sweden-based stem cell therapeutics startup.

Dr. Leung serves as Non-Executive Director of Insilico Medicine (3696.HK), Non-Executive Director of Phase Scientific, and Vice President of the Hong Kong Biotechnology Organization.
He holds a PhD in Stem Cell Biology from the University of Cambridge and a BSc in Biochemistry from Imperial College London.

SPEAKERS - THEATER 2



Xinrui LI

Head of New Business Development, Nutraceutical & Wellness Division, Guyu Biotechnology Group Ltd.

Xinrui Li, Ph.D from Sun Yat-San University, majored in Nutrition and Food Hygiene, National Registered Dietitian and Advanced Sport Nutritionist. She is now the head of New Business Development, Nutraceutical & Wellness Division, Guyu Bio-technology Group Ltd. She leads product development from 0 to 1, including anti-aging supplements, and functional food, etc. She has more than 10 years product research experiences in Top 500 international companies, and focuses on chronic disease nutrition, digestive wellness and maternal and children nutrition categories. She adheres to an evidence-driven, science-based product development philosophy. By pushing the boundaries of nutritional innovation, she is committed to integrating therapeutic nutrition and preventive dietary strategies into everyday consumer products.



Xin LIU

Director of Healthcare Fund, Hony Capital

Professional experience:
Hony Capital | Director of Healthcare Fund
Joined in 2023; leading investments across innovative therapeutics, advanced therapies, medical devices, and healthcare services.
CCB PE | Founding Member, Biopharma Investment Team
Co- built CCB's healthcare investment platform in partnership with China Construction Bank.
Fosun International (New York Office)
Flagship Pioneering

Investment portfolio:
Innovative Therapeutics
Excalipoint Therapeutics · SKYEMED · Fosun Kite · Simnova · LaNova Medicines · IncTAC
Medical Devices & Advanced Supply Chain
Spirometrix · Intuitive Surgical · OptoMedic · Allyuos

Investment Focus:
Innovative drugs · Frontier therapies · Innovative diagnostics & devices · Healthcare services

Education:
Massachusetts Institute of Technology
Sloan School of Management · M.S. in Finance (Honors)
Washington University in St. Louis
B.S. with Honors · Biostatistics & Mathematics- Finance (double major)

SPEAKERS - THEATER 2



Yuk Lam LO

President of HK Bio-Med Innotech Association

Professor Lo has extensive experience in biotechnology industry, corporate management, academic research and community service.
Currently Professor Lo is serving as the President of HK Bio-Med Innotech Association, Strategic Advisor to the President and Adjunct Professor to the Division of Life Science of Hong Kong University of Science and Technology.
In the educational area, Professor Lo has been elected an Honorary Fellow of the Hong Kong University of Science and Technology. He is also the Honorary Professor of several universities in China.
Professor Lo was heavily involved in several committees of the HKSAR Government. He was the Chairman of the Advisory Council for Food Safety of the Food and Health Bureau of HKSAR government from April 2015 to March 2021, Director of the Hong Kong Applied R&D Fund Co. Ltd., Chairman of the Biotechnology Committee of the Hong Kong Industry & Technology Development Council, and Chairman of Biotechnology Projects Vetting Committee of the Innovation and Technology Fund of the HKSAR government.
In Mainland China, Professor Lo was a member of Chinese People's Political Consultative Conference in Jilin Province from 2007 to 2022. He was also a consultant of the Centre for Disease Control and Prevention of China. In recognition of his leadership in the community and dedication to his field, Professor Lo has received many awards, such as the "Pericles International Prize" in 2019. He is the second Asian and the first person from Hong Kong to be awarded the Prize since it was founded in 1986. In 2020, Professor Lo was awarded the Bronze Bauhinia Star from the HKSAR government for his outstanding services over the past decades.
In the business sector, Professor Lo had been served as the Chairman of Asia Pacific of PerkinElmer (NYSE: PKI) and the President of Asia Pacific of Bio-Rad Laboratories (NYSE: BIO). Currently he is the Chairman of GT Healthcare Capital Partners, and Partner & Investment Committee Member of Hongsen Investment Management Limited.



Francois MAISONROUGE

Senior Managing Director, Evercore Partners

Francois Maisonrouge is the chairman of Evercore's Global Healthcare Group.
At Evercore, among other transactions, Mr. Maisonrouge was involved in advising Star on its sale to Incyte, Apellis on its sale to Biogen, GSK on its acquisitions of Rapt and of Boston Pharma, Cidara on its sale to Merck, Regulus on its sale to Novartis, Novo Nordisk on its acquisition of manufacturing facilities from Catalent; Takeda on its acquisition of Nimbus; Arena Pharmaceuticals on its sale to Pfizer; Novo Nordisk on its acquisition of Dicerna Pharmaceuticals; Parexel on its sale to EQT; AstraZeneca on its acquisition of Alexion; Sanofi on its acquisition of Principia; Nestlé on its sale of Nestlé Skin Health to EQT and ADIA; Bristol-Myers Squibb on its acquisition of Celgene; Takeda on its acquisition of Shire; AstraZeneca on its defense across from Pfizer; and Sun Pharmaceutical Industries on its acquisition of Ranbaxy Laboratories from Daiichi-Sankyo.
In addition, Mr. Maisonrouge has advised on numerous IPOs (including most recently the IPO of Parabilis, the largest Biotech IPO of all time) and follow-on equity offerings, principally for biotech companies, as well as structured capital raising transactions.

Prior to joining Evercore, Mr. Maisonrouge was a managing director and chairman of life sciences at Credit Suisse.
He is a member of the Board of Advisors of the Harvard Business School Health Care Initiative, and the chairman of the Pasteur Foundation. In 2014, Mr. Maisonrouge was awarded the rank of Chevalier de la Légion d'Honneur.
Mr. Maisonrouge holds an M.S. in engineering from Ecole Centrale de Lyon and an MBA from Harvard Business School.

SPEAKERS - THEATER 2



Kim PNG

Partner, Novo Holdings Asia

Kim Png is a Partner at Novo Holdings, based in Singapore, where she focuses on biotech venture investments, with an emphasis on novel biology platforms and cross-border opportunities across Asia-Pacific.
Prior to joining Novo Holdings, Kim was with Polaris Partners, where she established the firm's Singapore office and managed a portfolio of biotech companies across the US, Europe, and Singapore. She was previously with Temasek's Life Sciences Investment Group, where she invested across private and public biotechnology companies globally and played a founding role in ClavystBio, Temasek's life sciences investment and venture-building platform.
Kim holds a PhD in Biomedical Sciences from Rockefeller University, a Master of Business Administration from Singapore Management University, and a BSE in Biomedical Engineering from Duke University.



Zhili RAO

Researcher, Shenzhen Winkey Technology Co., Ltd

Dr. Zhil Rao holds a Master's and Ph.D. in Biotechnology from Jeonbuk National University, South Korea. She previously served as a Postdoctoral Fellow and Assistant Researcher at the Institute of Biomedicine and Biotechnology, Shenzhen Institute of Advanced Technology (SIAT), Chinese Academy of Sciences, prior to joining winkey Technology in 2026.
With years of in-depth experience in molecular biology, structural biology, and synthetic biology, Dr. Rao has established comprehensive expertise across the entire technology chain—from gene cloning and protein expression/purification to advanced structural analysis and functional validation. She has participated in multiple high-impact research projects covering protein structure determination, signal transduction pathways, and vaccine development, with several publications in top international journals including Nature Biotechnology.

SPEAKERS - THEATER 2



Kenneth SUN

Senior Vice President & Head of Asia at Royalty Pharma

Kenneth Sun is Senior Vice President & Head of Asia at Royalty Pharma, based in Hong Kong, where he leads the company's royalty business across the region.
Prior to joining Royalty Pharma, Kenneth spent more than 18 years in investment banking, most recently as Managing Director and Head of Asia Pacific Healthcare Investment Banking at Morgan Stanley, where he built the bank's leadership position in China. He advised a broad range of strategic clients across biotech, medtech, CRO, pharmaceutical, and healthcare services companies, and led the origination and execution of numerous industry-defining transactions — including IPOs, M&A, and biotech licensing advisory — with a primary focus on Greater China. Earlier in his career, he held roles at China Renaissance and BNP Paribas.



Jialin SUN

General Manager, GTJA Investment Group

Master of International Economic Law, Soochow University. He serves as Director of the VC Special Committee of China Investment Association, Director of China Healthcare Industry Investment 50- People Forum (CH50), Vice Chairman of the Pharmaceutical Innovation Investment Special Committee of China Pharmaceutical Innovation and Promotion Association, and Vice President of Shenzhen Venture Capital Association.

With 18- years of in- depth experience in healthcare equity investment, he possesses profound understanding and insights into investment and financing across the broader health sector. He has extensive expertise in private equity investment & financing, capital strategy formulation, industrial resource integration, and corporate M&A transactions.

He has led and participated in investments in nearly 20 healthcare projects, among which multiple high- quality companies have achieved successful IPOs. Selected investment cases: Changfeng Pharmaceutical (02652), Zhijiang Biology (688317), ViaBio (01873), Sinobal Pharmaceutical (300294), Huahan Plastic Surgery (430335), Ark Pharmaceutical (002513), Weimou Bio, Luoyi Bio, Meihua Medical, etc.

Awards & Honors
- Top 50 Influential PE Investors in China, 2022- 2025
- Top 50 Best Private Equity Investors in China, 2022- 2025
- Top 30 Outstanding Healthcare Investors, 2025
- Top 30 Most Influential Healthcare Investors in Asia, 2022- 2023

SPEAKERS - THEATER 2



Jimmy TAO

Chairman of Federation of Hong Kong Industries (FHKI)

Prof. Jimmy Tao is a seasoned serial entrepreneur, angel investor, and a prominent leader in Hong Kong's innovation ecosystem. With over 20 years of experience founding, funding, and scaling technology companies, he brings profound expertise in deep-tech and life sciences, particularly in molecular biology, Alzheimer's drug discovery, and analytical chemistry.Currently serving as the Chairman of both the Hong Kong Biotechnology & Healthcare Council and the Hong Kong Startup Council at the Federation of Hong Kong Industries (FHKI), Prof. Tao is at the forefront of driving the local biotech ecosystem. His exceptional track record in technology transfer and commercialization is globally recognized; he is a World Economic Forum Technology Pioneer and a recipient of the Grand Prix at the International Exhibition of Inventions of Geneva and the WIPO Medal for Inventors.As an active angel investor in 20 companies and an Adjunct Professor at City University of Hong Kong, Prof. Tao excels at mentoring researchers to overcome translational barriers and build businesses with strong social missions. He holds a BSc in Materials Science from UMIST and an MPhil in Engineering from the University of Cambridge. Combining his robust academic foundation with extensive commercial acumen, he is passionate about guiding HKUMed innovators in refining their value propositions, securing investments, and transforming groundbreaking medical research into real-world impact.



Wen WANG

Founder & CEO, Skye Medicine

- Dr. Wen Wang is the Founder and CEO of Skye Medicine. He has over 10 years of experience in CAR-T cell therapy product development.
- He got M.D. degree from Tongji University/University of Würzburg, Germany, Ph.D. degree from University of Aberdeen, UK, and Postdoc training at University of Connecticut, US
- He led clinical development of China's first CAR-T new drug targeting CD19 and BCMA, respectively (relmacabtagene autoleucel, Carteyva® and equecabtagene autoleucel, Fucaso®)
- In 2023, "Outstanding British Alumnus" awarded by the British Council and the British Embassy in China for contributions in the field of biopharmaceuticals
- With 5+ years of experience as a surgical resident and attending physician in Shanghai, and 15+ years of experience in cell therapy.
- Previously served as CEO/CMO of IASO Bio, Head of Clin Sci in Simcere Pharmaceutical Group (HKEX: 02096), Head of Clin Dev in JW Therapeutics Co., Ltd (HKEX: 02126), Head of Medical Research in Cellular Biomedicine Group (Nasdaq: CBMG).

SPEAKERS - THEATER 2



Nicholas WONG

Co-Founder and Chief of Staff of Full-Life Technologies

Dr Nicholas Wong is Co-Founder and Chief of Staff of Full-Life Technologies, a global radiopharmaceutical company operating across China, Europe and US. He is a serial biotechnology entrepreneur with over a decade of experience in oncology drug development and technology commercialization. He has led multiple therapeutic and diagnostic radiopharmaceutical programs from early discovery to global clinical translation, including regulatory interactions and approval with agencies such as FDA, NMPA, MHRA and TGA.

Through out his career, Dr Wong has built and led multidisciplinary team across discovery, preclinical development, CMC, quality and early clinical development. He has also play key roles in technology licensing, strategic partnership, contributing to financing exceeding US$200 million. Dr Wong obtained his PhD from the Li Ka Shing Faculty of Medicine at The University of Hong Kong and is committed to accelerating the translation of biomedical innovations into transformative healthcare solutions that ultimately improving the lives of patients around the world.



Linda ZHANG

Founding Partner, Innokylin Capital

Linda is the founding partner of Innokylin Capital which primarily invests in healthcare industry and provide the relevant services. Linda has 20+ years leadership experience in leading financier (e.g. GE Capital) and big pharma (e.g. BMS) etc. before she co-founded Innokylin Capital with other ex-executives from big pharmas. Linda has led and participated in multiple signature investments, M&A and partnering projects, and managed the post-investment alliances and post-acquisition integrations across the Asia Pacific Region. She has been taking board seats at the relevant legal entities of big pharma, leading investors and currently sits at the advisory board of some globally leading PEs.

SPEAKERS - THEATER 2



Hongzhi CAO

Dean/School of Medicine and Pharmacy, Ocean University of China

Dr. Hongzhi Cao is the dean and a Professor of Pharmaceutical Science at the Ocean University of China. He received his Ph.D. in chemistry from Shanghai Institute of Organic Chemistry (SIOC), Chinese Academy of Science (CAS) under the supervision of Professor Biao Yu. He was a postdoc fellow in the laboratory of Professor Xi Chen at the University of California at Davis from 2005-2009. In 2010, He moved back to China as an associate professor at Shandong University and promoted to full professor in 2016. Since 2020, he took his current position as a distinguished professor at the School of Medicine and Pharmacy of Ocean University of China. His group develops novel strategy for the enzymatic or chemoenzymatic synthesis of complex carbohydrates. Dr. Cao received the BASF Young Innovation Award (2019) from Chinese Chemical Society, the research grant award (2020) from the Mizutani Foundation for Glycosicence.



Barbara CHAN

Au Chik Ko and Au Leung Shook Yin Professor of Biomedical Engineering

Prof. CHAN Pui Barbara （陳佩） obtained her Bachelor degree in Biochemistry and PhD degree in Surgical Science from the Chinese University of Hong Kong. She received Postdoctoral Fellowship in Laser Medicine from the Massachusetts General Hospital in US. Prof. Chan served the Biomedical Engineering programme of the University of Hong Kong since 2003. She joined the School of Biomedical Sciences, Department of Biomedical Engineering, and Institute of Tissue Engineering and Regenerative Medicine, of the Chinese University of Hong Kong since 2023.Prof. Chan established the Tissue Engineering Laboratory with the vision to improve the quality of life in patients through bioengineering biomaterials- and stem cell-based tissues for personalized therapies. Her research interests centered around tissue engineering and regenerative medicine, natural and biomimetic biomaterials, multi-cellular organoids and tumoroids, mechano-regulation, multiphoton microfabrication and micropatterning, cell niche engineering and laser medicine.Prof. Chan obtained her professional membership (Biomedical Engineering) and the status of Chartered Engineer and Chartered Scientist from the Institute of Materials, Minerals and Mining IMMM) since 2015. She has been a registered authorized person (AP) for advanced therapeutic products (ATPs) in Hong Kong since 2020. She has served the professional community in many areas, such as being an Associate Editor in Biomaterials since 2017, a panel member for the European Research Council since 2022, a member of the Task Force on Regulations of ATPs in Hong Kong. On knowledge exchange, together with her business partner, PhD students and Postdocs, she has co-founded a technology startup company in developing personalized tissue engineering therapies.

SPEAKERS - THEATER 2



Yoko FUJIMOTO

Managing Director and Chief Medical Officer (CMO), ROHTO Pharmaceutical Co., Ltd.

Dr. Fujimoto is an experienced neurologist, immunology researcher, and pharmaceutical executive. After serving as Neurology doctor at Tokyo Metropolitan Neurological Hospital, Tokyo Metropolitan Bokutoh Hospital, etc. from 1992, Dr. Fujimoto became a Research Fellow in the Department of Immunology at Duke University in 1997. In 2001, Dr. Fujimoto joined the Department of Neurology at Tokyo Medical and Dental University Hospital (now Institute Science of Tokyo). In 2002, Dr. Fujimoto joined Pharmacia (now Pfizer), holding leadership roles in R&D clinical development planning and medical affairs. In 2019, Dr. Fujimoto was appointed Director and Executive Officer, leading the vaccines division. Since June 2025, Dr. Fujimoto has served as Managing Director and Chief Medical Officer (CMO) of ROHTO Pharmaceutical.



Abby GAO

Director of Investment Research Deputy Head, DEFTA Partners (Hong Kong)

Dr. Abby Gao is the Deputy Head of DEFTA Partners Hong Kong and oversees the operation of the Hong Kong based activities. She works as an investor in a wide range of biotech areas in Hong Kong to identify the advanced technology with potential, work closely with researchers, and help the tech-based startup grow. Before DEFTA, she worked in Hong Kong Science and Technology Parks Corporation (HKSTP) promoting development and commercialization of innovative technology in therapeutic area and facilitating the business development of biotech companies in Hong Kong. Before moved to Hong Kong, Dr. Gao was trained as a scientist with Ph.D. in Chemistry and worked in Merck Sharp & Dohme focusing on drug discovery in the U.S..

SPEAKERS - THEATER 3



George HARA

Group Chairman and CEO, DEFTA Partners

Ambassador George Hara is an archaeologist, tech entrepreneur, and venture capitalist.

In private sector, he founded DEFTA Partners in 1985. He was considered one of the most prominent Silicon Valley venture capitalists in the 1990s. He led more than twenty tech companies to success in the U.S., Europe, UK, Israel, and Japan, including Borland, PictureTel, SCO, Tradex, Unify, Oplus Technolgies, Fortinet, CUORiPS. Mr. Hara also founded DEFTA Hong Kong Office, to invest and to foster next generation of entrepreneurs, to promote collaboration between Hong Kong and Japan, and to make Hong Kong China's international innovation and technology hub.

He has served several posts in public office, such as Special Adviser to the Cabinet Office of the Prime Minister of Japan, Special Adviser to the Ministry of Finance, and the Prime Minister's Special Commissioner on the Government Tax Panel. He is an advisor to the Ministry of Internal Affairs and Communications, and he used to be the Intergovernmental Ambassador Extraordinary and Plenipotentiary to United Nations.

Ambassador George Hara also serves as Chairman of the Alliance Forum Foundation, and endeavours to promote the cultivation of new industries for a new era and to foster global leadership around the development of a next-generation core industry.



Jimmy HUI

Scientist, ROHTO Pharmaceutical Co., Ltd.

Hui Chun Wai (Jimmy), Ph.D., is a Scientist at ROHTO Pharmaceutical Co., Ltd., where he works on regenerative medicine and extracellular vesicle-based development. Jimmy Hui's research focuses on MSC-derived extracellular vesicles technologies for their production and characterization. He is particularly interested in overcoming key challenges in EVs manufacturing and quality control to support the development of next-generation regenerative therapies.

SPEAKERS - THEATER 3



Aimin HUI

Founder, Chair and CEO, EnCureGen Pharma

Dr.Hui during the COVID-19 pandemic, in collaboration with Germany's BioNTech, actively participated in the development of the first mRNA product (mRNA COVID-19 vaccine Comirnaty) in human history, and led the research and development of the vaccine (Fubitai) in Greater China and its launch in Hong Kong, Macao and Taiwan; prompted the China's mRNA industry. During his career, Dr. Hui has driven the global development and market approval of several anti-tumor blockbusters, including Ixazomib, Isatuximab, et al. In 2013, Dr. Hui pioneered the clinical registration model of ' Chinese extension study of global Phase III clinical trial', substantially shorten the time span for innovative drugs in China. Dr. Hui published 100+ papers in prestigious journals including NEJM, Nature Med, Lancet Onco, Cancer Cell， and authored 8 scientific monographies. Dr. Hui is the recipient of the 2021 International Award of the 4th Translational Medicine Awards among 20+ other prestigious awards. Dr. Hui is the former Executive President, Chair of the Scientific Committee, President of Global R&D and Chief Medical Officer of Fosun Pharma. Former Global Vice President of Sanofi， Director of the Shanghai Key Laboratory for Stem Cell Therapy.



JiaYee LEE

Director, Strategy and Alliance, BioNTech Australia

Dr. JiaYee Lee is based at the BioNTech Australia Innovation Centre in Melbourne, where she leads and shapes strategic engagement and ecosystem development activities that accelerate innovation in mRNA therapeutics and vaccines. Working closely with researchers, clinicians, entrepreneurs, industry partners, and investors, she helps identify emerging scientific opportunities and fosters collaborations to enable the translation of mRNA-based innovation along the portfolio development pathway. Her career spans medical research, technology innovation, venture creation, commercialisation, and policy development, providing a unique end-to-end perspective on how scientific discoveries progress from the laboratory into products and technologies that deliver real-world impact. Prior to joining BioNTech, JiaYee was Professor of MedTech at the University of Melbourne, where she led multidisciplinary initiatives at the interface of academia, industry, healthcare, and government. She also served as Director of the Health and Life Sciences Business Team at National ICT Australia (NICTA), now CSIRO's Data61, where she drove research translation and commercialisation across diagnostic genomics, biomedical informatics, digital health, and assistive technologies. Earlier in her career, JiaYee led virology research programs funded by Australia's National Health and Medical Research Council at the Victorian Infectious Diseases Reference Laboratory and the Macfarlane Burnet Centre (now Burnet Institute for Medical Research and Public Health). Dr Lee has an Adjunct Professor appointment at La Trobe University and graduated with a BSc (Hons), PhD, and MBA from the University of Melbourne.

SPEAKERS - THEATER 3



Qiubin LIN

Founder and CEO, Delonix Bioworks

Dr. Qiubin Lin is the founder and CEO of Delonix Bioworks, where he spearheaded the establishment of multiple innovative synthetic biology-based vaccine technology platforms and pipelines. Notably, he led the design, development, and preclinical research of China's first engineered Group B Meningococcal OMV vaccine. He brings over 15 years of dedicated expertise to synthetic biology and vaccine R&D.
A recognized industry leader, Dr. LIN serves on committees for both the China Vaccine Industry Association and the Chinese Pharmaceutical Biotechnology Association. His contributions have earned him several prestigious honors, including being named a 36Kr "36Under36" Young Entrepreneur, a "Pearl Program" Elite Talent, and one of the "Top Ten Rising Figures" in the Zhangjiang Life and Health Industry. Dr. LIN holds a bachelor's degree in bioengineering from Tianjin University and a doctorate degree in biomedical sciences from The University of Hong Kong.



Xin LIU

Director of Healthcare Fund, Hony Capital

Professional experience:
Hony Capital | Director of Healthcare Fund
Joined in 2023; leading investments across innovative therapeutics, advanced therapies, medical devices, and healthcare services.
CCB PE | Founding Member, Biopharma Investment Team
Co- built CCB's healthcare investment platform in partnership with China Construction Bank.
Fosun International (New York Office)
Flagship Pioneering

Investment portfolio:
Innovative Therapeutics
Excalipoint Therapeutics · SKYEMED · Fosun Kite · Simnova · LaNova Medicines · IncTAC
Medical Devices & Advanced Supply Chain
Spirometrix · Intuitive Surgical · OptoMedic · Allyuos

Investment Focus:
Innovative drugs · Frontier therapies · Innovative diagnostics & devices · Healthcare services

Education:
Massachusetts Institute of Technology
Sloan School of Management · M.S. in Finance (Honors)
Washington University in St. Louis
B.S. with Honors · Biostatistics & Mathematics- Finance (double major)

SPEAKERS - THEATER 3



Juncai MA

Director of WFCC-MIRCEN World Data Center for Microorganisms(WDCM) The Institute of Microbiology, Chinese Academy of Sciences

Dr. Juncai MA is the director of China National Microbiology Data Center, the director of World Data Center of Microorganisms (WDCM), vice chair of Asian Network of Research Resource Centers(ANRRC) and Board Member of World Federation of Culture Collections (WFCC), Deputy Secretary-General of the Chinese Society of Biotechnology.
Dr. Juncai MA is leading The China National Information Platform for Microorganisms, China Biotechnology Information Network, Global Catalogue of Microorganisms (GCM) and WDCM 10 K Type Strain Sequencing Project. Now 151 microbial culture collections from 51 countries joined GCM system.



Zhaoming SU

Principle Investigator, West China Hospital Sichuan University

Dr. Zhaoming Su is a Principal Investigator at West China Hospital of Sichuan University. He received his Ph.D. in Organic Chemistry at North Carolina State University in 2012, and subsequently conducted postdoctoral research at the Scripps Florida, Baylor College of Medicine, and Stanford University. In 2019, he established the SuLab and employs single-particle cryo-electron microscopy (cryo-EM) to investigate the structural and functional mechanisms of pathogenic RNA and RNA–protein complexes. The lab has identified various new intron sequences and elucidated their dynamic splicing mechanisms, as well as the oligomeric structures and assembly mechanisms of bacterial noncoding RNAs. Dr. Su has also developed HitSTARS, a modular framework to identify Hit Small molecules TArgeting RNA Structures as chemical probes and potential drug candidates. The lab has published over 70 research papers in journals such as Science, Nature, and Cell.

SPEAKERS - THEATER 3



Xiaotian TAN

Associate Professor, Shenzhen Institutes of Advanced Technology

Dr. Xiaotian Tan is an Associate Professor at the Shenzhen Institute of Advanced Technology, Chinese Academy of Sciences, specializing in microfluidic biosensing, minimally invasive blood testing, AI-enabled protein design, and optofluidic sensing. He received his B.S. from New York University and his Ph.D. in Biomedical Engineering from the University of Michigan, where he also conducted postdoctoral research. His work integrates engineered molecular probes, microreactors, optical transduction, and data-driven analysis, including tubular immunoassays for microlitre-scale fingertip blood testing, the TRACE platform for antibody fingerprinting from dried blood spots, and next-generation bio-laser and resonant optofluidic biosensors.



Zhou TONG

Associate Professor, Institute of Microbiology, Chinese Academy of Sciences (CAS); Deputy Director, Division of Scientific Strategic Planning and Major Programs; Deputy Secretary-General, Chinese Society of Biotechnology;

Zhou Tong's research focuses on the mechanism of broad-spectrum antibody generation and in vitro antibody engineering. He established a microbial surface antibody display and screening platform based on phages, yeasts, and bacteria, and further integrating microfluidic systems, developed a high-throughput protein genotyping and rapid functional labeling system via microdroplet reactions, enabling high-throughput screening of multi-species antibody libraries and solving the microbial antibody display system's low reproducibility.

He co-founded a rare antibody discovery platform based on the "human distant-source immune animal model" with Ocean University of China, addressing the inability to generate antibodies against low-immunogenicity targets in humans and traditional mammalian models. He also collaborated with the National Microbial Data Center to build an antibody digital database (covering human, cotton rat, shark, etc.) and a modification hotspot prediction algorithm system, and further developed an AI-assisted antibody interpretation and prediction system based on antibody generation rules.

These platforms strongly supported monoclonal identification and reshaping of multiple detection/therapeutic antibodies. He has co-authored 27 SCI papers, with 6 published as first/corresponding author in PNAS, Cell Reports, Nature Communications, and Nucleic Acids Research in recent five years, and holds 18 authorized national invention patents. His "Dia-19 bispecific antibody" for broad-spectrum COVID-19 prevention obtained national clinical trial approval in February 2024 (2024LP00386).

SPEAKERS - THEATER 3



Hung Fat TSE

Chairperson of the Department of Medicine, School of Clinical Medicine, Li Ka Shing Faculty of Medicine, the University of Hong Kong

Prof. Tse Hung-Fat, MBBS, MD, PhD, FACC, FRCP, FESC
Prof. Hung-Fat Tse is Chair Professor of Cardiovascular Medicine, and William MW Mong Professor in Cardiology; Chairpersons and Chief of Service of the Department of Medicine; Chief in the Cardiology Division, Department of Medicine, Queen Mary Hospital; Co director, Cardiac & Vascular Center, The University of Hong Kong - Shenzhen Hospital. He is also the academic lead, HKUMed Laboratory of Cellular Therapeutics, The University of Hong Kong.
He is a clinician scientist and an international expert in cardiovascular medicine, including cardiac pacing, clinical electrophysiology, and cardiovascular regeneration. Prof. Tse is one of the pioneers for novel therapies, including stem cell and devices for treatment of cardiovascular diseases. He has established the large animal laboratory for cardiovascular research as well the "Good Manufacturing Practice" laboratory for human stem cells and biological therapies in the University of Hong Kong. He has been awarded multiple major local grants (including the Theme Based Research Grant, Research Impact Fund and Innohealth) as well as national research grants (National Natural Science Foundation of China and 973 grants) for his researches. He has been participated into many international and regional clinical trials and studies, and is currently the Associate Editors for several international journals, including Cardiovascular Diabetology, Frontier in Cardiovascular Medicine, Journal of Cardiovascular Electrophysiology, Pacing and Clinical Electrophysiology and Journal of Arrhythmia. He has published over 730 scientific publications in international top-ranking scientific journals, including New England Journal of Medicine, Lancet, Nature Medicine, Nature Cell Biology, Nature Genetic, Nature Protocol, Nature Communication, Nature Biomedical Engineering, Nature Disease Primer, Cell Stem Cell, Circulation, Journal of American College of Cardiology, and European Heart Journal.



Aimee WANG

Co-Founder & CEO, CATUG Biotechnology

Dr. Xiao (Aimee) Wang is the Co-Founder, Chairman, and CEO of CATUG Biotechnology, a next-generation CRDMO platform focused on RNA, lipid nanoparticle (LNP), and advanced nucleic acid therapeutics. Founded in 2021, CATUG has rapidly grown into the leading RNA-LNP CRDMO platform in China and is expanding globally, serving more than 400 biotechnology and pharmaceutical clients across the US, Europe, and Asia.
Under Dr. Wang's leadership, CATUG has completed multiple rounds of financing totaling over USD 60 million and delivered more than 1,000 RNA-related projects, with a strong focus on in vivo CAR and other next-generation therapeutic applications, including oncology, gene editing, and protein replacement. The company has established an integrated one-stop platform spanning plasmid DNA, RNA drug substance, LNP formulation, analytical development, and GMP drug product manufacturing, positioning CATUG as a key enabler in the global advanced therapeutics ecosystem.
Prior to founding CATUG, Dr. Wang held senior management roles at Henlius Biotech and Neurophth. She has extensive experience in corporate strategy, operations, project management, fundraising, cross-border business development, and capital markets, including Hong Kong IPO execution.
Dr. Wang received her Ph.D. in Molecular Genetics from Stockholm University and a Master's degree in Cellular and Molecular Biology from Uppsala University. Her academic research focused on viral vector-based gene therapy, viral small RNA mechanisms, and immune regulation in infectious diseases.
She has been recognized with multiple honors, including Hurun China Under 35s (2024), Hurun China Medical Young Entrepreneurs, Pioneers in Science & Innovation – SHE POWER, Key Industrial Talent of Suzhou, and China Finance Summit – Healthcare Innovation Entrepreneur. She is also a member of YPO Greater China.

SPEAKERS - THEATER 3



Xiangxi WANG

Professor, Principal Investigator Institute of Biophysics, Chinese Academy of Sciences

Principal Investigator at the Institute of Biophysics, Chinese Academy of Sciences; New Cornerstone Investigator; Recipient of the National Outstanding Young Scientist Fund (National Science Foundation of China). His research primarily focuses on the structural and functional characterization of whole virions directly associated with major infectious diseases, as well as their complexes with neutralizing antibodies and key receptors. Based on these structural insights, He develops next-generation virus-like particle (VLP) vaccines and antiviral therapeutics. Utilizing cryo-electron microscopy (cryo-EM), He has elucidated the molecular mechanisms of herpesviruses, African swine fever virus (ASFV), and SARS-CoV-2, with landmark publications in Cell, Nature, Science, PNAS, and other leading international journals. He has been honored with the China Youth Science and Technology Award, the CAS Young Scientist Award, and the Tan Jiazhen Life Science Innovation Award, among other prestigious accolades.



Wei WEI

Professor/State Key Laboratory of Biopharmaceutical Preparation and Delivery, Institute of Process Engineering (IPE), Chinese Academy of Sciences (CAS)

Wei Wei, Ph.D., is a Professor and Doctoral Supervisor at the Institute of Process Engineering (IPE), Chinese Academy of Sciences (CAS), where he serves as Director of the Key Laboratory of Biopharmaceutical Preparation and Delivery. His research pioneers biomimetic formulation engineering, focusing on innovative preparation processes and the novel design of biomimetic carriers. Dr. Wei has published over 160 SCI papers, including three papers in Cell and Nature, and 22 in CNS sub-journals. He holds 22 authorized patents, with 7 formulations currently in Investigator-Initiated Trials (IIT). A recipient of the National Science Fund for Distinguished Young Scholars, his work has earned prestigious accolades, including the SCEJ Award for Outstanding Asian Researcher and the First Prize of the Beijing Natural Science Award, significantly advancing the field of biomimetic medicine.

SPEAKERS - THEATER 3



Jinghua YAN

Leading Scientist/Beijing Changping Laboratory

Dr. Yan is a Lead Scientist of Beijing Changping Laboratory, Chair of Antibody Professional Committee, Chinese Society of Biotechnology. She focuses on the development of the vaccines and antibody drugs. She had published over 100 papers, including Cell, Nature, Science, Sci. Transl. Medicine, and Nat. Microbiology, and filed over 50 patent applications. She co-developed the COVID-19 Recombinant Protein Vaccine with Zhifei Biological and the COVID-19 monoclonal antibody Etesevimab with Junshi Biosciences and Eli Lilly.



Linqi ZHANG

Professor and Director of Comprehensive AIDS Research Center /School of Basic Medical Sciences, Tsinghua University

Professor Linqi Zhang is a tenured professor at the School of Basic Medical Sciences, Tsinghua University, where he holds the Vanke and Bayer Endowed Chair Professorships. He is Director of the Comprehensive AIDS Research Center, China Director of the Indonesia–China Joint R&D Center on Vaccines and Genomics, and a founding member of the Pandemic Research Alliance.

Over the past 35 years, Professor Zhang has made pioneering contributions to HIV/AIDS, antibody immunity, vaccine development, and emerging infectious diseases. His team developed MabSeek, an AI-powered "Sample-in, Antibody-out" platform that integrates artificial intelligence, automation, and high-throughput screening to accelerate therapeutic antibody discovery. During the COVID-19 pandemic, he co-led the development of China's first approved anti-SARS-CoV-2 monoclonal antibody therapy and continues to advance next-generation mucosal vaccines and antibody therapeutics.

Professor Zhang received his Ph.D. from the University of Edinburgh and was an Associate Professor at the Aaron Diamond AIDS Research Center of Rockefeller University before joining Tsinghua in 2007. He has published over 200 peer-reviewed papers, received numerous national honors, including the National Science Fund for Distinguished Young Scholars and the Changjiang Distinguished Professorship, and was recently elected a Foreign Fellow of the African Academy of Sciences.

SPEAKERS - THEATER 3



Jie ZHANG

Institute Committee Member, Director of Division of Scientific Strategic Planning and Major Programs / Institute of Microbiology, Chinese Academy of Sciences

Jie ZHANG, Principal Investigator and Recipient of the Excellent Young Scientists Fund from the National Natural Science Foundation of China. His research mainly focuses on the mechanisms of microbial pathogenesis and environmental adaptation. He has elucidated the biochemical functions of multiple regulatory factors governing microbial environmental adaptation, as well as their molecular mechanisms in manipulating plant immune signaling pathways. He has led a series of research projects, including the Strategic Priority Research Program of the Chinese Academy of Sciences, sub-projects of the National Key R&D Program, and programs funded by the National Natural Science Foundation of China. He is also a member of the Youth Innovation Promotion Association, Chinese Academy of Sciences. His research has been published in top international journals, such as Cell Host & Microbe, Developmental Cell, The Plant Cell, Molecular Plant, and FEMS Microbiology Reviews.



Diwei ZHENG

Researcher, Beijing Institute of Process, Chinese Academy of Sciences

Dr. Diwei Zheng is a researcher working at the interface of biomaterials, microbiology, and translational medicine. His research focuses on developing next-generation live biotherapeutic products and biomaterial-enabled strategies for precise modulation of bacteria and complex microbial communities.
He has established multidisciplinary bacterial engineering approaches that integrate materials science, chemistry, and physics to regulate bacterial structure, function, in vivo distribution, and therapeutic activity across subcellular, single-cell, and microbial-community scales. His work has advanced the understanding of biomaterial–bacteria interactions and introduced new concepts for spatiotemporal control of bacterial behavior in vivo.
Dr. Zheng is particularly interested in applying engineered bacteria–biomaterial systems to major diseases, including gastrointestinal cancers, metabolic disorders, and renal failure. His current efforts focus on intratumoral microbiota remodeling, metabolic cascade regulation, biomimetic retention, and long-term mucosal adhesion to improve the safety, persistence, and therapeutic efficacy of bacterial therapeutics. Through these studies, he aims to accelerate the clinical translation of innovative microbial therapies for unmet medical needs.

SPEAKERS - THEATER 3



Xi ZHOU

Deputy Director-General, Wuhan Institute of Virology, CAS

Xi Zhou is a Professor and Deputy Director of Wuhan Institute of Virology, Chinese Academy of Sciences. He also serves as Deputy Director of State Key Laboratory of Virology and Biosafety, and recipient of the National Science Fund for Distinguished Young Scholars. He focuses on virus-host interactions, viral replication, pathogenesis, and AI-driven biomedicine (AI4Biomed). He has published over 50 papers in journals including Immunity and Nature Microbiology, with two cover articles, and holds more than 10 granted patents.



Julie ZHU

Executive Director of the FIC Program, College of Future Technology, Peking University

FIC Program leveraging in-depth collaboration with top-tier institutions and industrial partners both domestically and internationally, the FIC Program brings together over 100 authoritative experts spanning the entire value chain of innovative drug R&D. It has established a proprietary expert knowledge base and developed industry decision-making intelligence. The Program serves the core decision-makers of domestic innovative pharmaceutical enterprises and fosters a high-value industry ecosystem.

About the College of Future Technology, Peking University

Founded in 2020, the College of Future Technology is a newly established college at Peking University dedicated to the future life and health field. It focuses on cutting-edge areas including biomedical engineering, molecular medicine, and cell and gene therapies.

SPEAKERS - THEATER 4



Bashar BADRAN

Gestala, VP, Head of Clinical and Science

Dr. Bashar Badran is a neuroscientist and neurotechnology executive working at the frontier of brain-computer interfaces, neuromodulation, and human-machine interaction. He currently serves as Vice President and Head of Clinical & Science at Gestala, where he leads the clinical and scientific development of non-invasive ultrasound technologies designed to interface with the human brain with increasing precision and scale.
Previously, he was Clinical Partnerships Lead at Neuralink and Founding Director of the Neuro-X Lab and Computational Brain Imaging Core at the Medical University of South Carolina. His work spans focused ultrasound, neural decoding, brain stimulation, neuroimaging, and clinical translation. He has contributed to more than 150 scientific publications, abstracts, patents, and other scholarly works.
Across academia and industry, Dr. Badran's work is driven by a central goal: building technologies that can safely and precisely communicate with the human brain to restore neurological function, treat disease, and ultimately transform the interface between humans and machines.



Jonathan BERENT

Chief Executive Officer, NextSense, Inc

Jonathan Berent "JB" is the Founder and CEO of NextSense, Inc., a spinoff of X, Google's Moonshot Factory, building EEG-powered earbuds that enhance sleep and unlock brain health at scale. After a decade leading sales and partnerships at Google and Oracle, JB pivoted in 2016 to pursue a lifelong belief that unlocking the mind is the key to human potential. His work at X grew into the lab's largest funded early-pipeline project by 2020. JB co-authors peer-reviewed sleep research, lectures regularly at Stanford and UCSF, and was featured on the cover of Wired in June 2022. He holds a BA with Honors in Philosophy & Religious Studies from Stanford University.

SPEAKERS - THEATER 4



Paddy Kwok Leung CHAN

Founder, Brainsmart Technology Limited Associate Professor, Department of Mechanical Engineering, Faculty of Engineering, The University of Hong Kong Centre Co-Director, Advanced Biomedical Instrumentation Centre

Prof. Chan is the Founder of Brainsmart Technology Limited, an Associate Professor in the Department of Mechanical Engineering at the Faculty of Engineering, The University of Hong Kong, and Co-Director of the Advanced Biomedical Instrumentation Centre. He has long been engaged in research on micro/nano fabrication, flexible electronic components, and brain–computer interfaces, and possesses combined expertise in academic research, research management, and technology translation. He has received the Outstanding Young Researcher Award and the Research Output Award from the University of Hong Kong, and was also honoured with the Emerging Investigator Lectureship from the Royal Society of Chemistry's Physical Chemistry Chemical Physics (PCCP). He currently serves as a non-official member of the Committee on Artificial Intelligence plus (AI+) and Industrial Development Strategy, contributing his professional expertise to policy and strategic planning for AI- driven industrial transformation in Hong Kong.



Christoph GUGER

CEO/ g.tec medical engineering GmbH

Christoph Guger studied electrical and biomedical engineering at the University of Technology Graz in Austria and Johns Hopkins University in the USA and received his PhD in 1999. In 1999 he started the company g.tec which has now branches in Austria, Spain, the USA, Canada and Hong Kong and India. g.tec produces high-quality neurotechnology and real-time brain computer interfaces for the research, medical and consumer market. The company is active in many international research projects about brain-computer interfacing, neuromodulation, stroke rehabilitation, assessment and communication with patients with disorders of consciousness and high-gamma mapping in epilepsy and tumor patients.

SPEAKERS - THEATER 4



Steven JIANG

General Manager, Zhongwan International Finance Co., Ltd

Master's degree from Columbia University in the United States, MBA from the University of Hong Kong. Holds Hong Kong SFC Type 1, 4, 9 licenses. Member of the Hong Kong Digital Asset Association. Member of the Shanghai Yangtze River Delta Science and Technology Innovation Investment Promotion Association. Co-founding member of the China Robot Industry Alliance. Has participated in investment and financing projects worth over RMB 20 billion at multiple leading financial institutions, and led investments in several high-tech sectors, including BrainCo, Biren Technology, Zhipu AI, and Xiwang.



Ka Kit Gilberto LEUNG

Director, School of Clinical Medicine, HKU; Tsang Wing-Hing Professor in Clinical Neuroscience, HKU; Co-Director, Centre for Medical Ethics and Law, HKU.

Professor Gilberto Leung is Tsang Wing-Hing Professors in Clinical Neuroscience at the University of Hong Kong (HKU). He graduated from the University of London with M.B.B.S. in 1992 and completed postgraduate training with the Hallett Gold Medal from the Royal College of Surgeons of England and the J. Douglas Miller Medal from the Royal College of Surgeons of Edinburgh. He joined HKU in 2005 where he obtained his MS, PhD, and MD degrees.

He is currently Director of the School of Clinical Medicine and Convenor of the Clinical Neuroscience Consortium at HKU; Immediate-Past President and Honorary Fellow of the Hong Kong Academy of Medicine; and Convenor of the Institute for Medical Advancement and Clinical Excellence (IMACE).

He holds an LLB from the University of London and an LLM in Medical Law and Ethics with Distinction from the University of Edinburgh. He is Co-Director of the Centre for Medical Ethics and Law at HKU and Chairperson of the Clinical Ethics Committee at Queen Mary Hospital, where he practises clinically as Honorary Consultant Neurosurgeon.

His research interests include endoscopic neurosurgery, neuro-oncology, and medical law and ethics, having published 231 peer-reviewed journal articles, three monographs, and 13 book chapters.

SPEAKERS - THEATER 4



Fred LI

Managing Director and Head of University Ventures, Gobi Partners

Fred Li
Managing Director and Head of University Ventures

Fred has over 15 years of experience in private market transactions, management operations, and turnarounds as both a deal maker and a former General Manager. Fred holds a Bachelor of Business Administration in Accounting and Finance from the University of Hong Kong and a Master of Science in Biotechnology from the Hong Kong University of Science and Technology. He is a Certified Public Accountant (CPA) of HKICPA and Certified ESG Analyst (CESGA).

Fred began his career as a restructuring advisory specialist at Deloitte. Later, he gained full-cycle deal experience and served on the board of directors of portfolio companies during his positions at VC and PE firms, including Senior Associate at Ocean Equity Partners (MFO), Vice President at CITIC CLSA Capital Partners, and Executive Director at Hywin International. He also gained practical experience in business management, successful turnarounds, and digital transformation as Group General Manager at Gaia Group, a 1,000-person task force company in his previous portfolio.

He has served as the lecturer, advisory committee, vetting panelist, trainer, and mentor for ecosystem partners such as Hong Kong's Universities, NUS, BIOHK, BIOCHINA, HKSTP and Cyberport. Fred has hybrid experience across technology and business strategy and operations, with a focus on university spin-offs, Healthcare & Biotechnology, AI+ and GreenTech.

Appointments
HKSTP Vetting Panel of Acceleration Programme and ELITE Programme
Lead Lecturer, MSc of Biopharmaceutical Company Development and Commercialisation, PolyU
Guest Trainer, HKU, HKUST, CUHK, POLYU, HKBU, CITYU, MTR Corp, GUIDE GBA
Vetting Panel, RAISe+ (HKU, HKUST, PolyU, HKBU, etc)
Founding Organising Committee & Chair of Angel Investment Committee, HKU Super Angel Network
Vetting Panel, TSSSU+ (HKU, HKUST, POLYU, HKBU, CITYU)
Advisory Committee to EIF IC Panel, PolyVentures, PolyU
Task Force on the Review of Graduate Attributes for RPg Students, HKBU
Regular Start-up Mentor and Independent Consultant, BLOCK71, NUS
Regular Start-up Mentor of HKU, HKUST, PolyU, HKBU, CUHK-Shenzhen research
Industry Advisor, HKFBS

SPEAKERS - THEATER 4



Hanna LU

Assistant Professor, The Chinese University of Hong Kong

Dr. LU Hanna works as Assistant Professor at the Department of Psychiatry, The Chinese University of Hong Kong (CUHK). Before joining in CUHK, Hanna was a registered Attending Psychiatrist in Guangzhou, China. From bedside to bench, Hanna was motivated by the strong interests in aging brain and started the journey of becoming a clinical neuroscientist.
Centred with ageing brain and disease-modifying therapy, Hanna's research interests include: (1) to apply novel neuromodulation techniques in preclinical populations; (2) based on imaging data, to construct computational models for guiding personalized interventions for cognitive decline and sleep disturbances; (3) to develop AI-driven biomarkers (e.g., brain age model) for predicting treatment response and disease progress at individual level. With the financial supports from GRF, HMRF, CUHK grants and generous donations, the findings of her studies were published on renowned medical and neuroscience journals. Some of her studies have received the Gold Awards on the Asian Oceanian Congress of Neurology (2021), Healthy Longevity Catalyst Award (Hong Kong) (2023) etc.



Steven LU

Founding Partner, HL Oriental Partners

Steven has spent more than 17 years in the financial industry, starting as an equity analyst at Chinese Investment Bank Haitong Securities. He later advanced the path as director of asset management at CCB International and managing director at GBA Development Fund (A PE firm in Hong Kong with an AUM of 2 Billion USD) before founding his ventures in 2023. Steven graduated from Xi'an Jiaotong University and University of Hong Kong, He also holds MBA degree from University of Cambridge.

In parallel, he pursued academic interests in mathematics and Artificial Intelligence, and has raised over £2m for Cambridge University and therefore been named as a fellow at Clare Hall Cambridge.

SPEAKERS - THEATER 4



Minmin LUO

Director and Distinguished Investigator, Chinese Institute for Brain Research, Beijing

Minmin Luo is the Director of the Chinese Institute for Brain Research, Beijing, and a New Cornerstone Investigator. He has long been dedicated to studying the neural mechanisms of reward and punishment and conducting translational research on related brain disorders. He has published over 100 high-impact papers, including more than 30 in top-tier journals such as Nature (2), Science (3), Cell (1), and Neuron (14), with total citations exceeding 13K. He also holds 14 granted invention patents, and has led 16 investigator-initiated clinical trials, covering revolutionary gene therapies for vision restoration and refractory epilepsy that have received approval from China's National Medical Products Administration (NMPA) or the U.S. FDA for clinical trials, as well as a world-leading wireless high-throughput invasive brain-computer interface system..



Phoenix PENG

Founder and CEO of Gestala; Distinguished Researcher at Tianfu Jincheng Laboratory

Phoenix Peng is the Founder and CEO of Gestala, China's first ultrasound BCI company, as well as a Distinguished Researcher at Tianfu Jincheng Laboratory.
Gestala has recently raised CN¥150 million(US$21 million) in an Angel Round, setting a new record for the largest early-stage financing in China's BCI industry.
Peng holds a Bachelor's degree from the University of Science and Technology of China (USTC) and a Master's degree from The Hong Kong Polytechnic University. He earned his Ph.D. from the Institute of Science and Technology for Brain-Inspired Intelligence (ISTBI) at Fudan University.
A seasoned serial entrepreneur, Peng founded Keruyun in 2012, which was acquired by Alibaba Local Services in 2019 for RMB 1 billion. In 2021, he co-founded NeuroXess. As a tech entrepreneur with a background in Internet and AI, he successfully pivoted into life sciences, leading NeuroXess to become China's premier invasive BCI company in under four years. He is widely regarded in the industry as one of the "entrepreneurs who best understands science."

SPEAKERS - THEATER 4



Zhihai QIU

Principal Investigator, Guangdong Institute of Intelligence Science and Technology

Dr. Zhihai Qiu received a Ph.D. in Biomedical Engineering from The Hong Kong Polytechnic University in 2019. From 2019 to 2022, Dr. Zhihai Qiu conducted postdoctoral research at Stanford University School of Medicine. Dr. Zhihai Qiu has received multiple awards at leading international conferences in neuroscience, biophysics, biomedical engineering, and optical engineering.
Their research has been published in prominent journals, including Proceedings of the National Academy of Sciences (PNAS), Cell Reports, iScience, Advanced Science, Brain Stimulation, Advanced Photonics Research, IEEE Transactions on Ultrasonics, Ferroelectrics, and Frequency Control, and STAR Protocols. Dr. Zhihai Qiu is the principal investigator of a General Program funded by the National Natural Science Foundation of China and has filed six Chinese invention patent applications and four U.S. patent applications.
Dr. Zhihai Qiu was invited to contribute a chapter on ultrasound neuromodulation to an Oxford University handbook on transcranial brain modulation and currently serves as an Advisory Board Member of STAR Protocols.



Philip SABES

CEO, Forest Neurotech; Prof. Emeritus, UCSF

Prof. Sabes studied Physics as undergradute at Washington University and then completed a second bachelors degree in Mathematics at Cambridge University (Trinity College) as a Marshall Scholar. Dr. Sabes then went to MIT, where obtained his PhD in Brain and Cognitive Sciences, in Michael I. Jordan's lab, focusing on machine learning and human motor control. He then did his postdoctoral research in neurophysiology at Caltech and the Salk Institute, working with both Richard Andersen and Terry Sejnowski, before joining the UCSF Department of Physiology in 2000.

Prof. Sabes was asked to help build the founding team of Neuralinkexternal site (opens in a new window), and in 2017 he retired from UCSF in order to work full time on this groundbreaking company. While he was at Neuralink, the company refined the sewing-machine approach to brain interfacing started in his lab, demonstrating 1000+ channels of robotically-inserted, micron-scale thin-film electrodes with a fully implanted, wireless interface. Since leaving Neuralink, Philip has focused on brain interfacing for Neuromodulation. In 2020 he co-founded Starfish Neuroscience, which is working on non-invasive Neuromodulation as well as advanced implantable brain interfaces. He is currently working on a new startup, Integral Neurotechnologies, with the goal of treating psychiatric and neurological disorders and advancing human neuroscience.

SPEAKERS - THEATER 4



Ludovic SEREX

CTO, Neurosoft Bioelectronics

Ludovic is a Medtech entrepreneur and microengineering specialist dedicated to transforming healthcare through advanced neurotechnology. With a PhD in microsystems and microelectronics and many years of experience spanning the biotech and medtech sectors, he is the Co-founder of Neurosoft Bioelectronics. Driven by a mission to help patients with debilitating neurological disorders, his company pioneers ultra-soft, bio-integrable neural implants.
Unlike many other technologies, these minimally invasive implants can safely interface with large brain areas. This unique capability overcomes the limitations and risks of traditional rigid devices, making Neurosoft's technology specially positioned to create more precise and deliberate Brain-Computer Interfaces (BCIs). By capturing high-fidelity, large-scale neural data across the full cortex, this innovation also provides the essential data layer for Neurosoft's brain AI. It enables the training of advanced cortical foundation models that dramatically improve brain decoding, unlocking new frontiers for scalable therapeutics and bringing tangible hope to patients.



Lei SUN

Director of Non-invasive Brain Computer Interface, Professor of Biomedical Engineering, The Hong Kong Polytechnic University

Prof. Lei SUN, Professor in the Department of Biomedical Engineering, the Hong Kong Polytechnic University. Prof. Lei SUN has 25 years of research and development experience in medical ultrasound technology, including system development, signal/image processing and biomedical applications. He holds more than ten US and Chinese patents, either granted or filed. As a Principal Investigator, he has led research projects in Hong Kong and Mainland China with a total funding of over HK$80 million HK dollars, including CRF, GRF, HMRF, ITF, MOST, NSFC, etc. He is a Senior Research Fellow of the Hong Kong Research Grants Council, director of research center of Non-invasive Brain Computer Interface, Deputy Director of the Centralized Animal Facility, member of the University Council, member of Staffing Committee and Research Committee of the Faculty of Engineering. He has published more than 250 peer-reviewed journal articles and international conference proceedings, including Nature Communications, PNAS, Advanced Science, Research, Biomaterials, Cell Reports, Molecular Psychiatry, Brain Stimulations, etc. He is the general chair of the Focused Ultrasound Neuromodulation 2025 (FUN25), has hosted scientific sessions at various conferences. He has won Merit Award in Research and Scholarly Activity, Research Grant Achievement Awards, Faculty of Engineering, the Hong Kong Polytechnic University.

SPEAKERS - THEATER 4



Shouyan WANG

Deputy Dean, Institute of Science and Technology for Brain-inspired Intelligence, Director, Neuromodulation and Brain-machine-interface Centre, Fudan University

Professor Shouyan Wang is the Director of Brain-computer Interface Innovation Accelerator at Neurospace of Shanghai, Vice Dean Institute of Science and Technology for Brain-Inspired Intelligence, Director of Neuromodulation and Brain-machine-interface Centre, Fudan University. He is the Chairman of Neuromodulation Branch of Chinese Neuroscience Society. Vice Board Chairman of Brain Computer Interface Alliance of China. He had conducted research on neural information decoding and brain stimulation at University of Oxford (2002-2007), University of Southampton (2007-2012) and Chinese Academic of Sciences (2012-2017) before he joined Fudan University. He has developed research platform for neuromodulation, which include research facilities for invasive neuromodulation, non-invasive neuromodulation, advanced technology development of intelligent neuromodulation and neuroimaging as well. His research interests are intelligent neuromodulation, digital healthcare and translational research into clinical applications.



Xufeng WEI

Chairman, Medphoenix Group, General Manager, GoldenWing (Suzhou) Medical Technology, Industry Professor, Nanjing Medical University

I've been in medicine for over 20 years and founded Jiangsu Medphoenix Group, focusing on innovative medical device evaluation. I used to be a cardiovascular surgeon at Xijing Hospital of the Fourth Military Medical University and an assistant professor at the University of Maryland in the U.S. I've completed over 4,000 heart surgeries and have been recognized multiple times as an outstanding medical professional and teaching achiever. I participated in China's first biological heart valve project, published 33 key SCI research papers, 21 related to high-end medical device R&D, and hold 14 patents. I studied in the U.S. for four years, overseeing preclinical large animal experiments for devices like artificial hearts and submitted several preclinical research reports for artificial hearts and heart valves to the U.S. FDA.

SPEAKERS - THEATER 4



Jinsong WU

Chief of Shanghai Key Laboratory of Clinical and Translational Brain-Computer Interface Research； Vice-chair (research), Neurosurgery, Huashan Hospital

•Professor, Doctoral Supervisor, Fudan University
•Distinguished Professor, ShanghaiTech University
•Chief of Shanghai Key Laboratory of Clinical and Translational Brain-Computer Interface Research
•Chief Physician of Neurosurgery
•Vice-Chair (Research), Department of Neurosurgery, Huashan Hospital
•Deputy Director, Neurosurgical Institute of Fudan University
•Head of the Glioma Division, National Center of Neurological Disorders
•Director, Brain Function Laboratory
•Director of BioBank, Huashan Hospital
•Vice-Chair of Chinese Society of Neuro-oncology (CSNO), CACA
•Asso editor of Brain Research



Frank YANG

Founding Partner&CEO

Mr. Yang Feng has over 25 years of experience in venture capital, private equity, and life sciences investment, with more than US$1 billion in cumulative investment track record and multiple award-winning healthcare transactions.
Before founding BOCG, Mr.Yang served as Managing Director of China Construction Bank International (CCBI), leading healthcare investments across USD and RMB funds. Prior to that, he was responsible for strategic investments in China at PPF Group and participated in the establishment of Home Credit China. He also worked at Texas Pacific Group (TPG).
Mr. Yang focuses on biotechnology innovation, brain science, brain-computer interface (BCI), and cross-border healthcare investment and collaboration. Under his leadership, BOCG became one of the first healthcare-focused investment institutions in China to join the United Nations-supported Principles for Responsible Investment (UN PRI), promoting ESG and sustainable development.
Mr. Yang holds an MBA from HKUST and completed exchange studies at Columbia Business School and HHL Leipzig Graduate School of Management.

SPEAKERS - THEATER 4



Dongdong ZHANG

BCI BU Director, OYMotion

Director of the BCI BU at OYMotion. He holds a PhD in Brain Science from Fudan University and previously served as Head of Product at NeuroXess. With more than 10 years of experience in brain computer interface research and development, he has held key positions at several AI and BCI start-ups.
He has led the development of multiple invasive and non-invasive products, including medical-grade devices and smart wearable products. These products span both neural monitoring and neuromodulation and have been applied across rehabilitation, assessment, and clinical treatment scenarios. Products developed under his leadership have received honors including the Shanghai Magnolia Award and Shanghai Design 100+.

SPEAKERS - THEATER 5



Stephen Lam CHAN

Clinical Professor in the Department of Clinical Oncology at the Chinese University of Hong Kong

Stephen L. Chan
MD (CUHK), FRCP (Edin., Lond.), FHKCP, FHKAM (Medicine)

Stephen Lam CHAN is a Clinical Professor in the Department of Clinical Oncology at the Chinese University of Hong Kong (CUHK). He is renowned for his clinical and translational research on hepatobiliary and pancreatic cancers. Prof. Chan has authored over 270 papers published in peer-reviewed journals. Internationally, he has served on the scientific committees of ASCO and ESMO conferences, and is currently the President of the International Liver Cancer Association (ILCA). Prof. Chan is an associate editor for journals such as the Journal of Hepatology. Locally, he is a board director of the CUHK Medical Centre and the Assistant Dean (External Affairs) of the Faculty of Medicine at CUHK. He also established the Hand in Hand Cancer Foundation, a charity dedicated to serving patients in need.



Bobo DANG (Presented by Tian LI)

Associate Professor, School of Life Sciences, Westlake University; Principal Investigator, Laboratory of Protein Engineering and Protein Therapeutics; Program Associate Director, Chemical Biology

Dr. Bobo Dang is an Associate Professor at the School of Life Sciences, Westlake University, and Principal Investigator of the Laboratory of Protein Engineering and Protein Therapeutics. He also serves as Program Associate Director of Chemical Biology. He received his B.S. from Nanjing University, Ph.D. from the University of Chicago, and completed postdoctoral research at UCSF. His research focuses on chemical protein synthesis, site-specific protein modification, protein design, high-throughput screening, and protein therapeutics.

SPEAKERS - THEATER 5



Xiaofei GAO

Professor, Westlake University

Dr. Xiaofei Gao is a Professor at Westlake University, where he leads the Laboratory of Cellular Medicine and Delivery Technology. He received his Ph.D. from the University of Kansas and completed postdoctoral training at the Whitehead Institute for Biomedical Research / Massachusetts Institute of Technology. His research focuses on developing next-generation cell therapeutics and delivery systems by harnessing the intrinsic biological properties of mammalian cells. He pioneered the concept of red blood cell (RBC) medicines by revealing the previously underappreciated interactions between RBCs and the immune system, and established innovative platforms for immune modulation, in vivo immune cell engineering, and targeted RNA delivery. Building on these discoveries, he founded Westlake Therapeutics, a biotechnology company dedicated to translating RBC-based medicines into clinical applications for cancer, autoimmune diseases, and other immune-related disorders. The company's lead RBC-based immunotherapy programs have entered clinical trials and have demonstrated encouraging preliminary clinical activity and a favorable safety profile in patients with advanced solid tumors. Dr. Gao's research has been published in leading journals including Nature, Nature Cancer, Science Translational Medicine, and Cell Host & Microbe, and has received multiple national and international awards.



Bosun HAU

Managing Partner, Tybourne Strategic Opportunities Fund

Bosun Hau is Managing Partner and Co-Founder of Tybourne Strategic Opportunities Fund (TSOF), a family of investment vehicles managing approximately US$1.2 billion in net asset value, focused on global private growth equity through Tybourne Capital Management in Hong Kong. He has more than 20 years of investment experience across the United States, Asia, Europe, and Israel, spanning public and private markets.

Previously, Bosun was a Partner at Sailing Capital in Shanghai and Hong Kong and at MVM Partners in London and Boston. Earlier, he held roles at JPMorgan Chase & Co. in New York, S.R. One, the venture capital arm of GSK, in Philadelphia, and McKinsey & Company in Singapore. He began his career at Eli Lilly and Company.

Bosun has served as a board director or observer for more than 25 public and private companies across healthcare, technology, fintech, and consumer sectors. He is also an active angel investor and advisor to early-stage ventures.

He holds an MBA from Wharton, an M.Sc. in Biotechnology from Johns Hopkins University, and three bachelor's degrees from the University of Arizona. He also serves as a Board Advisor to Johns Hopkins Technology Ventures and a Board Overseer at Beth Israel Deaconess Medical Center.

SPEAKERS - THEATER 5



Susan KONG

VP Regulatory & Strategic Development, Caidya

Yunxia (Susan) Kong, VP of Regulatory & Strategic Development at Caidya, has over 20 years in pharma and biotech, with deep focus on China regulatory strategy. She held senior roles at Caidya, Roche, GSK, and Sanofi. Her expertise covers regulatory strategy, IND/NDA filings, and agency consultations across intensive therapeutic areas. With comprehensive knowledge of US FDA and China NMPA regulations, Susan bridges cross-border requirements. She integrates China's clinical capabilities into global programs from the start to accelerate proof- of- concept, optimize dose and indication decisions, and build globally credible development packages that support licensing, M&A, and IPOs. She also addresses regulatory harmonization and cross- border governance challenges to drive strategic value creation.



Minh LE

Associate Professor and Graduate Program Director, Department of Pharmacology; Principal Investigator, Institute for Digital Medicine, Yong Loo Lin School of Medicine, National University of Singapore

Minh Le received a Ph.D. degree in Computational and Systems Biology from the Singapore-MIT Alliance and further trained as a postdoctoral fellow at Boston Children's Hospital. She started her lab at City University of Hong Kong in 2015 and moved to the National University of Singapore in 2019. Her group has developed strategies to harness EVs from red blood cells and engineer EVs for targeted delivery (lelabnus.wordpress.com). Minh is a recipient of the L'Oreal Singapore for Women in Science Fellowship, the Graduate Mentor of the Year Award as well as multiple national grants from the Singapore government. She was ranked among the top 2% scientists by citations in 2025. She currently serves a deputy editor of the Journal of Extracellular Biology and an associate editor of the Journal of Extracellular Vesicles. Besides, she is also a scientific cofounder of Carmine Therapeutics and EVCertis, and the leader of the EVANTICA industry alignment program in Singapore.

SPEAKERS - THEATER 5



Miron LILA

Chief Corporate Development Officer, Caidya

Based in Hong Kong, Miron Lila is Chief Corporate Development Officer at Caidya, where he is responsible for M&A, key financing and strategic initiatives, identifying partnership opportunities to accelerate the company's global growth, and investor and biopharma ecosystem collaboration efforts. With over eighteen years of healthcare-focused corporate finance, capital markets, and mergers and acquisitions experience, Miron brings a wealth of expertise to his role.
Prior to joining Caidya, he served as Co-Head of Asia Healthcare Investment Banking at Citi, where he played a key role in establishing Citi's healthcare franchise in Asia. During his time in banking, Miron successfully completed over 30 transactions across all investment banking products, amounting to a total deal value of US$15 billion.
Miron is also a member of the Hong Kong Stock Exchange Listing Committee, where he was appointed in July 2022, and serves as an Independent Board member of Vitaccess, a UK-based real-world evidence company. Miron holds a BSc. from the London School of Economics and Political Science.



Dan LIU

Associate Professor, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology

Dr. Liu earned a Ph.D. in Obstetrics and Gynecology from Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology in 2014. His primary research focuses on ovarian cancer and therapeutic resistance. He is a recipient of the Distinguished Young Scholar Program of the Hubei Provincial Natural Science Foundation, has served as Principal Investigator of one Youth Project and three General Projects funded by the National Natural Science Foundation of China, and is a key member of a project under the National Key R&D Program of China during the "14th Five-Year Plan" period. Research findings have been published as first or corresponding author in prestigious journals including Sci Transl Med, Cell, Lancet Oncology, J Clin Invest, Nature Communications, and Cancer Research. His research achievements have been recognized with the First Prize of the Natural Science Award at the National Maternal and Child Health Science and Technology Award (2019), the First Prize of the Chinese Medical Science and Technology Award (2020), and the First Prize of the Ministry of Education Award for Outstanding Research Achievements (2025).

SPEAKERS - THEATER 5



Shoupeng LIU

Associate Director, Outreach and Strategic Partnerships, Asia Science/AAAS

Dr. Shoupeng Liu received a B.Sc. Degree in Physics from Beijing Normal University, and a master's degree from the Institute of Physics, Chinese Academy of Sciences (CAS). She then went to the University of Konstanze, Germany, where she earned her Ph.D. in Physics. After her postdoctoral research at the University of Notre Dame, U.S.A., she returned to China to join the Suzhou Institute of Biomedical Engineering and Technology (SIBET), CAS, in 2014. She was a professor in the Medical Electronics Laboratory and one of the founders of the Science partner journal BMEF. She is now working in the Science Beijing office and responsible for outreach and training activities in Asia.



Eva ROHDE

Chair, Department of Transfusion Medicine, University Hospital Salzburg, Paracelsus Medical University Salzburg; Director, GMP Unit, Paracelsus Medical University, Salzburg; Research Progeram Lead (Medical Science Liaison), Ludwig Boltzmann Institute for Nanovesicular Precision Medicine (LBI-NVPM), Salzburg, Austria; Co-Founder, Small New World Laboratories GmbH, a spin off of the Paracelsus Medical University Salzburg; Co-Chair, ISEV-Task Force on Regulatory Affairs and Clinical Use of EV-based Therapeutics; Member, ISCT Exosome Committee (chaired by Sai Kiang Lim, Singapore

Eva Rohde, MD, is Head of the Clinical Department of Transfusion Medicine at the Paracelsus Medical University in Salzburg, Austria. She is Director and Qualified Person of the GMP Unit in Salzburg, which has achieved the pharmaceutical manufacturing authorization for mesenchymal stromal cells (MSC and MSC-EVs) in 2015 and participated a clinical trial testing MSCs in Multiple Sclerosis. Recently, the first-in-human clinical trial "Extracellular Vesicle-enriched Secretome Fraction (VSF1.01) for the Reduction of Cochlear Implant Surgery Related Trauma (ESCRT) started: An open-label monocentric phase I/IIa pilot study to investigate the safety of intracochlear application of VSF1.01 enriched with hUC-MSC-EVs in patients receiving cochlear implantation" https://euclinicaltrials.eu/search-for-clinical-trials/?lang=en&EUCT=2024-512498-29-00 or NCT06545175.
Another phase I/IIa prospective, multicenter, double-blinded, randomized, controlled trial to assess local injection of VSF for the treatment of mid-portion Achilles tendinopathy (AT) in more than 100 patients is currently prepared.
Since 2019, Eva Rohde chairs the ISEV - Task Force on Regulatory Affairs and Clinical Use of EV-based Therapeutics https://www.isev.org/rigor-standardization.
In 2024, she joined the Ludwig Boltzmann Institute for Nanovesicular Precision Medicine (LBI NVPM) in Salzburg (https://nvpm.lbg.ac.at/) promoting the clinical evaluation of Nanovesicular Therapeutics (NVT) by bridging patients' needs, the opportunities and challenges of clinical research with legal requirements.
https://orcid.org/0000-0001-8692-886X
Recently, Eva Rohde was awarded together with Mario Gimona, Salzburg with the ISEV2026 Special Achievement Award of the International Society of Extracellular Vesicles.

SPEAKERS - THEATER 5



Wei Seong TOH

Research Director, Associate Professor, Department of Orthopaedic Surgery, Yong Loo Lin School of Medicine, National University of Singapore

Wei Seong Toh, PhD, is an Associate Professor with tenure and Research Director at the Department of Orthopaedic Surgery, Yong Loo Lin School of Medicine, National University of Singapore (NUS). He is also a Principal Investigator at the NUS Tissue Engineering Program. His research focuses on understanding the mechanisms for degeneration and developing strategies for regeneration of tissues of the musculoskeletal system. His team first reported that the small extracellular vesicles, popularly known as exosomes, underpin the therapeutic efficacy of mesenchymal stem cells in joint repair. He is currently the Secretary of SOCRATES, Society for Clinical Research and Translation of Extracellular Vesicles Singapore. He is also an executive committee member of APSEV, Asia-Pacific Societies for Extracellular Vesicles, and a member of ISEV, International Society for Extracellular Vesicles Task Force on Regulatory Affairs and Clinical Use of EV-based Therapeutics. He is an active member of several meetings and workshops on mesenchymal stem cell-derived extracellular vesicles.



Yajie WANG

Assistant professor, Westlake University

Dr. Yajie Wang received her B.S. in Chemical and Biomolecular Engineering from Nanyang Technological University, Singapore, in 2012, and her Ph.D. in Chemical Engineering from the University of Illinois Urbana-Champaign, USA, in 2018. She was named one of MIT Technology Review's Innovators Under 35 China in 2022 and received the "Future Chemical Engineering Scholar" Award from the Global Chinese Chemical Engineers Society in 2025. Her research focuses on the discovery and characterization of sequence-divergent homologous enzymes, the development of catalytic systems for new-to-nature reactions, and the construction of efficient enzymatic cascade networks for active compound synthesis. Her work has been published in Science, Nature, Nature Catalysis (2), Nature Communications (2), Advanced Science, Chemical Reviews etc.

SPEAKERS - THEATER 5



Hang Hubert YIN

Distinguished Professor at Beijing Normal University, Executive Dean of the Advanced Research Institute, Director of the Frontier Biotechnology Center, Director of the Key Laboratory of Radiopharmaceuticals, Ministry of Education

Professor Hang Hubert Yin is a Distinguished Distinguished Professor at Beijing Normal University, Executive Dean of the Advanced Research Institute, Director of the Frontier Biotechnology Center, and Director of the Key Laboratory of Radiopharmaceuticals, Ministry of Education. He serves concurrently as the Editor-in-Chief of Journal of Extracellular Vesicle and Bioorganic & Medicinal Chemistry Letters, as well as an editorial board member of journals including Cell Chemical Biology.
Professor Yin has successively been selected as the National Distinguished Expert by the Central Organization Department and Distinguished Expert of the Overseas Talent Program of China Association for Science and Technology. He has received numerous honors, including the National Science Fund for Distinguished Young Scholars, Beijing Outstanding Young Scientist Award, Wu Jieping-Paul Janssen Medical & Pharmaceutical Award, Distinguished Contribution Award of China Pharmaceutical Development Award, First-Class Science and Technology Award of Chinese Pharmaceutical Association, and the American Chemical Society David W. Robertson Award for Excellence in Medicinal Chemistry.

SPEAKERS - THEATER 6



Jasna CANADI

Senior Bioanalytical Consultant

Jasna Canadi Semadeni is a senior bioanalytical consultant providing specialist consulting to biotechnology and pharmaceutical organizations, supporting the development and delivery of bioanalytical strategies for complex biologic programmes. She advises partners on biologics and multispecific therapeutics, developing and optimizing analytical strategies across PK, PD, immunogenicity and biomarker assays, with particular expertise in ligand-binding methods. Jasna guides assay development and GLP/GCP method validation aligned with regulatory expectations and scientific best practice and collaborates with cross-functional teams to ensure methods are fit-for-purpose for programme milestones and regulatory decision-making. She has led outsourced bioanalysis with CRO partners worldwide, including strategic partnerships in China, directing sample analysis for preclinical and clinical studies and ensuring high data quality across global vendor networks.
Previously, Jasna held bioanalytical leadership positions at Roche as Head of Regulated Large Molecules Bioanalytics and various scientific roles at Novartis in Basel, Switzerland. Over more than 20 years, she has supported drug development across various stages and diverse therapeutic modalities through robust bioanalytical assessments.



Dong DONG

Associate Professor, JC School of Public Health and Primary Care, Faculty of Medicine, The Chinese University of Hong Kong

Prof. Dong Dong (PhD, MBE, MPhil, BA) is an interdisciplinary public health researcher and bioethicist at the JC School of Public Health and Primary Care, The Chinese University of Hong Kong. Grounded in community-academic partnerships, her work focuses on structurally marginalized populations in Hong Kong, mainland China, and other Asian contexts, spanning rare diseases, migrant and refugee health, reproductive and genomic technologies, empirical ethics, and community health. In 2019, Prof. Dong founded the Rare Disease Real-world Data Lab at the CUHK Shenzhen Research Institute, where she works closely with patient organizations to study the lived experiences, quality of life, healthcare access, and patient journeys of people living with rare diseases. Her broader community-engaged work involves migrant and refugee communities and other underserved populations, with an emphasis on generating evidence to inform healthcare delivery, policy, and community action. Prof. Dong is a Cheng-Dzau NAM-CUHK International Policy Fellow (2026–2028) and an Atlantic Fellow for Health Equity supported by the China Medical Board and The Atlantic Philanthropies (2023–present).

SPEAKERS - THEATER 6



Jian FRANSEN

Physician and Researcher; Representative, Swedish Society for Prevention and Longevity Medicine (SSPLM); Affiliated Researcher, Karolinska Institutet

Jian Fransén is a physician and researcher affiliated with Karolinska Institutet and a representative of the Swedish Society for Prevention and Longevity Medicine (SSPLM). He holds a medical degree from Karolinska Institutet and a PhD from Uppsala University.

His current research includes clinical biomarkers of ageing to improve cancer-risk prediction, innovative clinical-trial design and precision-medicine approaches involving the PI3K/AKT/mTOR pathway in ageing, oncology and vascular malformations. He is also involved in surgical research and the development of pan-European federated registries.

Through SSPLM, Jian contributes to the development of evidence-based prevention and clinically grounded longevity medicine. His work connects clinical practice, research and data-driven approaches to healthy ageing, with a focus on translating emerging science into responsible and meaningful improvements in healthcare.



Philippe GERWILL

Founder & Managing Director, PGEA Ltd (Abu Dhabi, UAE)

Philippe Gerwill is a Global Digital Healthcare Humanist, Futurist, International Keynote Speaker, Executive Advisor and Innovation Key Opinion Leader. With more than 30 years of global leadership experience in the pharmaceutical and specialty chemicals industries, including senior roles at Novartis, Ciba and Lonza, he brings a unique perspective at the intersection of healthcare, technology, innovation and human-centered transformation.
He advises companies and organizations across Europe, the Middle East, Asia, Africa and the Americas, with a strong focus on artificial intelligence in healthcare, digital health, longevity, healthcare in the metaverse, precision medicine, innovation ecosystems and the future of preventive health.
Philippe is also an Adjunct Professor at Rome Business School, a LinkedIn Top AI Voice, and a globally recognized speaker regularly invited to international conferences and executive forums. His work emphasizes that technology should never be the final objective, but a powerful enabler to improve human lives, strengthen healthcare systems and create more inclusive, ethical and sustainable futures.

SPEAKERS - THEATER 6



Jin LEE

Founder, Cure NDD; Founder, IMIDeology; Visiting Scholar, Stanford University

Dr. Jin Lee is the Founder of the Consortium for Understanding, Research, and Education in X- linked Neurodevelopmental Disorders (Cure NDD). She's also the founder of IMIDeology, a clinical trial site network for autoimmune diseases. Dr. Lee is currently a visiting scholar at Stanford University, an investor in multiple funds, and an advisor across multiple startup accelerators. She held leadership roles across biopharma, health insurance, and major hospital systems in innovation and ventures, and currently serves on multiple startup and nonprofit boards. A Presidential Leadership Scholar nominated by four American Presidential Centers, she has been recognized as one of the 100 Most Impactful Women and Allies Shaping the Future of Biopharma, Healthcare, and Life Sciences. Dr. Lee holds a Ph.D. in Experimental Psychology from the University of Oxford and a B.A. from the University of Pennsylvania.



Da LIU

Managing Director, China Resources CP Life Science Fund

Mr. Liu currently serves as the Managing Director of the CR-CP Life Science Fund, whose shareholders, China Resources Group and Charoen Pokphand Group, are both ranked among the Fortune Global 500.Previously, Mr. Liu served as Business Director of the Strategic Management Department at China Resources Group, where he was responsible for strategic research and project investment in the life sciences sector. He also served as a Senior Director at China Resources Pharmaceutical Group Limited (HK: 03320), overseeing business development and international cooperation.In addition, Mr. Liu held the positions of Senior Director at China Resources Pharmaceutical Business Group, General Manager of China Resources Pharmaceutical Airport (Beijing) International Trading Co., Ltd., Deputy General Manager of Beijing Pharmaceutical Co., Ltd., and Chief Operating Officer (COO) of Zhoulin Biospectrum Technology Co., Ltd.Prior to 2004, Mr. Liu served as a Pharmacy Manager at CVS Health Corporation (USA) and worked as a Clinical Pharmacist at the New York Healthcare Group.

SPEAKERS - THEATER 6



Chris LLOYD

Co-Founder at Healthcare Dialogues

Chris leads Healthcare Dialogues, the largest healthcare business networking community in the region, bringing together professionals all across the sector to make connections, deals and grow their organisations



Peter MARTIN

Founder and CEO, Funmed Group

Peter Martin, MD, PhD, is the founder and CEO of Funmed Group and a leading Nordic voice in precision health and functional medicine. Before founding Funmed in 2014, he spent approximately 15 years working in medical and pharmacological research.

Through Funmed, Peter has helped develop a more personalised and preventive approach to healthcare, combining advanced testing, clinical assessment, nutrition and lifestyle interventions to identify factors contributing to chronic ill health. His work focuses on moving healthcare beyond symptom management towards earlier intervention, improved healthspan and individually tailored care.

SPEAKERS - THEATER 6



Norazli Mohamad NOR

Venture Partner, Xeraya Capital

Norazli Mohamad Nor (“Azli”) is a Venture a Partner and a founding member of Xeraya Capital, having spearheaded its preparatory aspects leading to its establishment while in Khazanah Nasional (“Khazanah”). Within Xeraya, Azli held a dual role in Investments deal-making as well as a corporate function managing a strategic fund, Mudharabah Innovation Fund (“MIF”).
Azli has a background that merges engineering and finance, gaining accreditation as a Professional Engineer with the Board of Engineers Malaysia while holding a Bachelor of Engineering (Electrical and Electronics) from Imperial College, London, United Kingdom, and an MBA with Finance specialisation from International Islamic University Malaysia.



Frances PLATT

Head of Department of Pharmacology, University of Oxford

Professor Frances Platt obtained her BSc in Zoology from Imperial College London and her PhD from the University of Bath, UK. She undertook postdoctoral training at Washington University School of Medicine in St. Louis, USA. She was a Lister Institute Senior Research Fellow and is currently Professor of Biochemistry and Pharmacology at the University of Oxford.
Her research focuses on the biology and pathobiology of glycosphingolipids and lysosomal disorders. This work has led to the development of miglustat and Aqneursa for the treatment of glycosphingolipid lysosomal storage diseases.
Professor Platt was elected a Fellow of the Academy of Medical Sciences in 2011, appointed Head of the Department of Pharmacology in 2020, and elected a Fellow of the Royal Society in 2021. She was elected a foreign member of the Royal Swedish Academy of Sciences in 2025.

SPEAKERS - THEATER 6



Pharima PONGPAIROJ

Co-founder, Tisrop (Thailand) Co.,ltd

Pharima Pongpairoj (DPhil, MEng) is an engineer who applies systems- thinking frameworks to healthcare and complex health challenges. Drawing from observations across veterinary and human healthcare, she advocates understanding health as an interconnected holistic system, rather than focusing on isolated symptoms.

She argues that effective care goes beyond symptom management. It should address underlying contributing factors and subsequent care stages during intervention, with the objective to restore and maintain overall bodily function.

Her work sits at the intersection of engineering, healthcare, environment and systems thinking. She explores ways to decipher complex health problems, identify prevention opportunities, and design healthier environments as well as sustainable approaches to wellbeing.



Lucy ROBERTSHAW

Board Member and Project Lead, Life Science, Hong Kong Chamber of Commerce in Sweden (HKCCSE); Founder, Connecting Life Sciences

Lucy Robertshaw is a life-science business leader with more than 25 years of experience across pharmaceuticals, biotechnology, medical devices, healthcare and international market development. She is a Board Member and Project Lead for Life Science at the Hong Kong Chamber of Commerce in Sweden and Founder of Connecting Life Sciences.

Lucy leads the Nordic Future Health Pavilion and Nordic-Hong Kong Life Science Delegation at BIOHK2026, connecting Nordic companies with healthcare organisations, investors, universities and strategic partners in Hong Kong and the Greater Bay Area. Her work focuses on translating innovation into commercial and clinical opportunities through cross-border partnerships, market-entry strategy, investor engagement and programme development. She is an experienced moderator and advocate for open international collaboration in life science and healthcare.

SPEAKERS - THEATER 6



Kathryn S.E. CHEAH

Emerita Chair of Biochemistry and Professor at The University of Hong Kong

Professor Kathryn S.E. Cheah (https://www.sbms.hku.hk/staff/kathryn-cheah) is Emerita Chair of Biochemistry and Professor at The University of Hong Kong. She obtained her BSc Hons and PhD from London University and Cambridge University respectively. After postdoctoral training in the UK, she joined the University of Hong Kong in 1983 and was appointed Chair Professor in 1997.

As a developmental geneticist and stem cell biologist, her research focuses on genomic and regenerative medicine, particularly in ageing, skeletal system disorders, and the inner ear. She has published in leading international journals such as Nature, Nature Genetics, eLife, Proceedings of the National Academy of Sciences (USA), Journal of Clinical Investigation etc. . Professor Cheah's discoveries provide a regulatory framework underpinning the complex development and physiology of healthy bone and mechanisms of associated congenital and degenerative disorders. She also discovered master regulators of inner ear development with significance for understanding hearing loss. Her goal is to translate fundamental discoveries into treatments for conditions like osteoarthritis and osteoporosis.

Professor Cheah is active in various scientific leadership roles, including panel memberships for the Hong Kong Health and Medical Research Fund, Hong Kong Science and Technology Park Biomedical Tech Incubation Programme and the Hong Kong University Grants Council Research Assessment Biology panel. She is Senior Editor for the journal eLife, and is on the Advisory Board of Natural Sciences. She serves on the USA Gordon Research Conferences (GRC) Board of Trustees Conference Evaluation Committee.

Passionate about science communication, over the years she organised several Advanced Study Institutes on Genetics, Stem Cells and Technology, the Future Science Prize Life Science Symposium 2024 "Transformative Science for Human Biology and Health", contributing to advancing Hong Kong's international scientific profile. She led the bid to bring the 2025 Annual Meeting of the International Society for Stem Cell Research (ISSCR) " Illuminating the Future" to Hong Kong (https://www.isscr2025.org/) and was co-Programme Chair with Eugenia Piddini (Bristol University) of the ISSCR 2025 meeting. She also co-Chaired the ISSCR 2025 one-day public outreach symposium entitled "Innovating the Future: The Power of Stem Cells for Medicine and Biotechnology" on Stem Cells. She is co-Vice-Chair and Co-Chair of the GRC on Developmental Biology for 2025 and 2027 respectively and is leading the organization of the Asia Pacific Symposium on Stem Cells & Regenerative Medicine: From Discovery to Therapy in 2027.



Jiawei TANG

COO, GlobalBioPharmaPartnershipsLLC.

Jiawei Tang is the Co-founder and COO of Global Biopharma Partnerships. She holds a Master's degree in Digital Transformation in Healthcare Management and brings over 15 years of extensive experience in the healthcare and life sciences industry, with a proven track record in sales, corporate strategy, and marketing.

Her professional background includes 12 years in management roles at Pfizer, a global pharmaceutical leader, and one year as Commercial Strategy Director at Resolian, a renowned contract research organization (CRO). She has successfully led and implemented numerous brand transformation, corporate strategy, integrated marketing communications, and business innovation projects across major markets, including the United States, the United Kingdom, Australia, and China.

In addition to her professional work, Jiawei serves in volunteer leadership roles at several non-profit healthcare organizations, including as a Geographic Expansion Leadership Member at the Healthcare Business Association, as an Advisory Board member of One Patient One Cure, and as Vice President of the Chinese Biopharmaceutical Association Greater Philadelphia.

SPEAKERS - THEATER 6



Anna TENSTAM

Angel Investor, Board Chair, Global Life-Science Executive

Anna Tenstam is an angel investor, board chair and global life-science executive with more than 35 years of leadership experience across pharmaceuticals, biotechnology, diagnostics, medical devices and medical aesthetics. She has held senior executive and board positions in international life-science companies and has managed global companies and boards towards successful partnerships and exits.

Her experience includes angel investment, strategic company development, international commercialisation, market expansion, fundraising, licensing, exit transactions, corporate governance and global partnership development. Anna combines an investor's perspective with hands-on operational experience, helping companies assess commercial potential, build credible growth strategies and develop the relationships required to enter international markets.

Her cross-border network and extensive industry experience make her a valuable bridge between Nordic life-science companies and investors, strategic partners and market opportunities in Hong Kong, the Greater Bay Area and beyond.



Nathan TIRTANA

CEO, Etana Biotechnologies Indonesia

- Nathan Tirtana is the President Director and CEO of PT Etana Biotechnologies Indonesia (Etana), an Indonesian biopharmaceutical enterprise he co-founded in 2014 to advance domestic vaccine manufacturing and affordable biological therapies.

SPEAKERS - THEATER 6



Simon TSOI

Senior Manager, BD & Alliance Management DCH Auriga

Simon Tsoi serves as Senior Manager, BD & Alliance Management at DCH Auriga. He has over 20 years of commercialization and market expansion experience across pharmaceuticals, medical devices, nutrition and consumer healthcare in Asia Pacific region. He has extensive experience in building regional operations and taking products from scratch to full market traction across Southeast countries for China Enterprises and Hong Kong Listed Companies. Prior to his Business Development roles, he took various regional and local commercial management roles with Global 500 companies including Nestle, Alcon, Roche and J&J in multiple Asia Pacific markets.
Simon holds a Master of Laws and a Master of Social Sciences from City University of Hong Kong, a Master of Business Administration from The University of Melbourne and an Optometry Degree from The Hong Kong Polytechnic University.



Ofra Castro WERSÄLL

Gynaecologist; Women's Health & Longevity Specialist; Founder, EndoHealth

Dr Ofra Castro Wersall is an MD, PhD, gynaecologist and women's health and longevity specialist with twenty years of clinical experience. She began her career at Karolinska University Hospital and later founded EndoGyn, a gynaecology clinic created to improve women's healthcare.

She is the founder of EndoHealth, a doctor-led women's longevity centre in Stockholm. EndoHealth combines advanced health mapping, individualised treatment and personalised prevention protocols designed around female biology. Its multidisciplinary approach considers the hormonal, metabolic, cardiovascular, cognitive and physical factors that shape how women age.

Ofra advocates for earlier intervention and a stronger medical evidence base for preventive women's health. Her work aims to improve care for individual patients while contributing research and clinical data that can support wider healthcare-system change.

SPEAKERS - THEATER 6



Lihan ZHOU

Executive Director, Co-founder & Chief Executive Officer, Mirxes

Dr. Zhou Lihan is the Co-founder and Chief Executive Officer of Mirxes (2629.HK). Founded in Singapore, Mirxes is an RNA biotechnology company dedicated to developing and delivering early cancer detection and precision health solutions, with the mission of saving lives and reducing healthcare costs. Dr. Zhou oversees the company's business operations and management across Singapore, China, the United States, and Japan, leading a team of over 350 professionals. He served as a Board Member of Enterprise Singapore from 2022 to 2025, and has been a member of the Future Economy Advisory Panel since 2024.

AGENDA+ SPEAKERS BIOGRAPHIES

DAY FOUR

12 September, Sat



09:00 – 11:30 Main Stage

Life Science Masterclass: From Butterfly Wings to the Nobel Stage

09:00 – 18:00 Theater 1

HKBIO Life & Health Festival: Healthy Futures — Where East Meets West

09:00 – 18:00 Theater 2

Biotech Investment Summit 5: Future Science Competition

09:00 – 18:00 Theater 5

BIOHK2026 Spotlight: Breakthroughs Shaping the Future of Biomedicine

09:00 – 18:00 Theater 6

Global AI Biotech Investment and RWA Summit

09:30 – 11:00 Theater 4

Global Cooperation Forum 6:
From Global Governance to the Hong Kong Opportunity:
Mapping the Future of AI, Health and Biomedicine

10:00 – 12:00 Theater 3

Living Longer, Living Better — Chronic Disease Management in the Big Health Era
(Co-organized by Hua Medicine)

11:00 – 12:30 Theater 4

The Global Moat: Biotech IP Strategy and Cross-Border Compliance

12:00 – 18:00 Main Stage

Junior Scientists: Biotech STEAM Discovery Day & Junior Science Awards

14:00 – 18:00 Theater 3

Cross-Border Healthcare Forum

09:00 - 11:30 (MAIN STAGE)

Life Science Masterclass: From Butterfly Wings to the Nobel Stage

Speakers:

Erling NORRBY
Former Permanent Secretary of The Royal Swedish Academy of Sciences, Sweden
Speech Title: Developments of Life on Earth

Pak-chin CHOW
Honorary Associate Professor, The University of Hong Kong
Speech Title: Common Eye Diseases --their Prevention and Treatment

Tim HUNT
2001 Nobel Prize in Physiology or Medicine, the Francis Crick Institute
Speech Title: Lessons From A Life In Science

Wei ZHANG
Professor, School of Life Sciences, Peking-Tsinghua Center for Life Sciences, Peking University
Speech Title: Evolution and diversification of mimicry and masquerade in butterflies

09:00 - 18:00 (THEATER 1)

HKBIO Life & Health Festival: Healthy Futures — Where East Meets West

Chair:

Lucy ROBERTSHAW
Board Member and Project Lead, Life Science, Hong Kong Chamber of Commerce in Sweden (HKCCSE); Founder, Connecting Life Sciences

Speakers:

Bent U. FRANDSEN
CEO of ExpreS2ion Biotechnologies

Bo PENG
Professor, Hong Kong Baptist University School of Chinese Medicine

Dicky CHOW
Assistant Research Director and Head of Healthcare & Social Innovation, Our Hong Kong Foundation

Emir NEZIROVIĆ
Founder and Chief Executive Officer, Uveo Sverige AB

Glenn BILBY
Founding Chief Executive Officer, Qinematic

Hoi Shan KWAN
Emeritus Professor, School of Life Sciences, The Chinese University of Hong Kong; Chairman, HSK GeneTech Limited

Hubiao CHEN
Professor and Associate Director of Teaching and Research Division, School of Chinese Medicine, Hong Kong Baptist University

Jing Yan HAN
Director of the Institute of Integrated Traditional Chinese and Western Medicine, Peking University Health Science Center

Mathias SVAHN
Chief Executive Officer and Co-founder, NextCell Pharma AB

Ofra Castro WERSÄLL
Gynaecologist; Women's Health & Longevity Specialist; Founder, EndoHealth

Philippe GERWILL
Founder & Managing Director, PGEA Ltd (Abu Dhabi, UAE)

Qianqian WANG
Associate Chief Physician, Peking University School and Hospital of Stomatology

Qinghua LIU
Investigator，National Institute of Biological Sciences, Beijing

Shahram LAVASANI
Founder and Chief Executive Officer, ImmuneBiotech AB

Stina LUNDGREN
Chief Executive Officer, Veltio Pharma AB

Thomas VARGOCZKY
Managing Director, Herbaferm Pte Ltd

Wing CHENG
Senior Business Developer, Life Science, Uppsala Innovation Centre (UIC)

09:00 - 18:00 (THEATER 2)

Biotech Investment Summit 5: Future Science Competition

Speakers:

Crystal JIN
Co-Founder & CEO/Bound Therapeutics

09:00 - 18:00 (THEATER 5)

BIOHK2026 Spotlight: Breakthroughs Shaping the Future of Biomedicine

Speakers:

Jialing LIU
Principal Investigator, Women's Hospital, Zhejiang University
Speech Title: HES1 is a mechanosensing extravasation suppressor activated by microvascular constriction of circulating tumor cells

Nikolay SERGEEV
CSO, ThriveBiome AI
Speech Title: A Multi-Modal Precision Medicine Platform for Predicting Individual Response to GLP-1/GIPR Therapies

ZhiCheng DU
CEO, CNK THERAPEUTICS
Speech Title: A Novel Non-Viral Manufacturing Platform for Scalable and Cost-Effective CAR Immune Cell Production

Sarah HO
Founder and CTO, AGeM Bio
Speech Title: Manufacturing MSC 2.0 Using a Non-Viral Gene Delivery Platform: From Cell Engineering to a First-in-Human Trial in Recurrent Glioblastoma

Yuanjun HU
Neurosurgery attending physician, The First Affiliated Hospital of Jinan University
Speech Title: A Cross-Body Closed-Loop Peripheral Nerve Interface System for Post-Stroke Upper Limb Rehabilitation: From Patent to Proof-of-Concept

09:00 - 18:00 (THEATER 6)

Global AI Biotech Investment and RWA Summit

09:30 - 11:00 (THEATER 4)

Global Cooperation Forum 6: From Global Governance to the Hong Kong Opportunity: Mapping the Future of AI, Health and Biomedicine

Speakers: **Brian WONG**
HKU-100 Assistant Professor, University of Hong Kong
Speech Title: On China's Global Governance Vision - How AI and Health Governance Go Hand-in-Hand

Panel: Hong Kong: From Financial Capital to Innovation Powerhouse

Panelists: Chuen Yan LEUNG, Donglei MAO, Eric SHAO, Hua ZHANG, Junyi MA

10:00 - 12:00 (THEATER 3)

Living Longer, Living Better — Chronic Disease Management in the Big Health Era (Co-organized by Hua Medicine)

Moderator: **Donne CHOY**
Founder & CEO, MedGo Group Limited

Speakers: **Elaine CHOW**
Associate Professor (Clinical), Department of Medicine and Therapeutics; Deputy Medical Director (Non-oncology), Phase 1 Clinical Trial Centre; Faculty of Medicine, The Chinese University of Hong Kong
Speech Title: Diabetes Medication Management

Mengchen ZOU
Vice Director, Department of Endocrinology and Metabolism, Nanfang Hospital, Southern Medical University; Professor, Chief Physician, PhD Supervisor and Postdoctoral Mentor
Speech Title: Prediabetes Identification and Reversal

Russell CHAN
Co-founder and CEO, E-SENSE Innovation & Technology; Honorary Assistant Professor, School of Biomedical Engineering, The University of Hong Kong
Speech Title: AI and Digital Health Management

Shaoling ZHANG
PhD (France), Chief Physician (Grade II), Master's and Doctoral Supervisor; Director, Pituitary and Adrenal Subspecialty, Department of Endocrinology; Member, Adrenal Study Group, Chinese Society of Endocrinology, Chinese Medical Association; Vice Chair, Diabetes Branch, Guangdong Medical Association; Corresponding Editorial Board Member, Chinese Journal of Endocrinology and Metabolism
Speech Title: Diet and Weight Management for Diabetes

11:00 - 12:30 (THEATER 4)

The Global Moat: Biotech IP Strategy and Cross-Border Compliance

Speakers: **Ken NG**
Senior Patent Examiner (Electricity), Intellectual Property Department
Speech Title: Latest Development of HK Patent System

Panel: Protect & Resolve: The Biotech IP Playbook for Going Global

Moderator: Yolanda Wang
Panelists: Benny LO, Janet XIAO, Luke SONG

12:00 - 18:00 (MAIN STAGE)

Junior Scientists: Biotech STEAM Discovery Day & Junior Science Awards

14:00 - 18:00 (THEATER 3)

Cross-Border Healthcare Forum

Speakers Part 1: **Benjamin LAU**
Chairman, Greater Bay Area Medical and Life Sciences (Hong Kong) Innovation Think Tank

Peggy FUNG
General Manager, Pfizer Hong Kong & Macau

Kin-Chung CHAN
Founder, HealthMutual Group

Speakers Part 2: **Loletta Kit-Ying SO**
Director, Greater Bay Area Hong Kong Doctors Association

Connie LO
Co-Founder, Greater Bay Area Health Information

Panel: Corporate Leaders Roundtable

Moderator: Benjamin LAU
Panelists: Connie LO, Jasper CHING, Loletta Kit-Ying SO, William LAM

SPEAKERS - MAINSTAGE



Pak-chin CHOW

Honorary Associate Professor, The University of Hong Kong

Dr. CHOW Pak Chin graduated from the University of Hong Kong and received his specialist training in ophthalmology at the Hong Kong government's ophthalmology department, the University of Edinburgh and the Moorfields Eye Hospital in London.

He has obtained fellowships from:
Edinburgh, the United Kingdom, Hong Kong, Singapore, and Malaysia.

Dr. Chow currently holds the following positions:

· Member of the Expert Group of the Chief Executive's Policy Unit, Hong Kong Special Administrative Region.
· Member of the Court of Hong Kong Metropolitan University.
· Honorary Associate Professor at the University of Hong Kong.
· Honorary Clinical Assistant Professor at the Chinese University of Hong Kong.
· Founding President and Current President of the Eye Care Charity Foundation.
· Patron of the Hong Kong Medical Association Charitable Foundation.
· Patron of the Asian Foundation for the Prevention of Blindness.
· Vice Chairman of Project Vision.
· "Honorary Ophthalmologist Ambassador" of "Sight First China Action."

Through these voluntary services, he has contributed to the completion of around 6 million charitable cataract surgeries in Chinese Mainland.

In recognition of his outstanding contributions, Dr. Chow has received:
· The National Ethnic Unity and Progress Award from the State Council of China。
· The Justice of the Peace and the Bronze Bauhinia Star from the Hong Kong Special Administrative Region Government.
· The Distinguished Service Award, Prevention of Blindness Award, and Susruta Lecturer Award from the Asia-Pacific Academy of Ophthalmology.



Tim HUNT

2001 Nobel Prize in Physiology or Medicine, the Francis Crick Institute

Tim Hunt grew up in Oxford, where he became fascinated by science at the Dragon School. At 14, he entered Magdalen College School, where his interest in biology grew. Tim entered Clare College, Cambridge in 1961 to read Natural Sciences. He joined the Department of Biochemistry in 1964 as a graduate student working on the control of haemoglobin synthesis. In 1968 he moved to the Albert Einstein College of Medicine in New York as a postdoctoral Fellow with Irving London.
Tim returned to the Department of Biochemistry in Cambridge in 1971 where he continued to work on translational control throughout the 1970s. He taught summer courses at the Marine Biological Laboratory, Woods Hole, Massachusetts from 1977 to 1983, looking at changes in protein synthesis in sea urchin and clam eggs after fertilisation. In 1979, he helped Joan Ruderman and Eric Rosenthal with experiments on the translational control of maternal mRNA in clam eggs, where two of the major mRNAs concerned later turned out to be the A and B-type cyclins. By 1982, Tim had almost exhausted the potential of sea urchin eggs, but it was then that he performed the experiment that led to the discovery of cyclins and subsequent research on the control of the cell cycle. In 1990, Tim joined ICRF (subsequently Cancer Research UK) in London. He became a fellow of the Royal Society in 1991, a foreign associate of the US National Academy of Sciences in 1999 and shared the Nobel Prize for Physiology or Medicine with Lee Hartwell and Paul Nurse in 2001. He enjoys cooking, photography and making up problems for Molecular Biology of the Cell with his friend John Wilson. In 2016, he and his wife Mary Collins moved to Okinawa, where Mary was the Provost of OIST (Okinawa Institute of Science and Technology). In 2022, Mary was appointed Director of the Blizard Institute of QMUL and they returned to London, where Tim holds an emeritus position at the Francis Crick Institute.

SPEAKERS - MAINSTAGE



Erling NORRBY

Former Permanent Secretary of The Royal Swedish Academy of Sciences, Sweden

Erling Norrby has an MD and PhD from the Karolinska Institute, the School of Medicine, Stockholm. He was the professor of virology and chairman at the Institute for 25 years. During that time he also served as Dean of the Faculty of Medicine for 6 years and was deeply involved in the work on Nobel prizes in physiology or medicine for 20 years. After leaving the Institute he became Permanent Secretary of the Royal Swedish Academy of Sciences for six years. During this time he had overriding responsibility for the Nobel Prizes in physics and chemistry and was a member of the Board of the Nobel Foundation. Presently he is at the Center for the History of Sciences at the Academy. In 2010 he published the book Nobel Prizes and Life Sciences, in 2013 a second book Nobel Prizes and Nature's Surprises, in 2016 a third book Nobel Prizes and Notable Discoveries, in 2019 a fourth book entitled Nobel Prizes – Cancer, Vision and the Genetic Code and finally in 2022 a fifth book with the title Nobel Prizes – Genes, Viruses and Cellular Signaling. He has had one of the leading functions at the Royal Swedish Court as Lord Chamberlain-in-Waiting.



Wei ZHANG

Professor, School of Life Sciences, Peking-Tsinghua Center for Life Sciences, Peking University

Wei Zhang is a Boya Distinguished Professor at the School of Life Sciences and the Peking-Tsinghua Center for Life Science at Peking University. She received her Ph.D. in Botany from the School of Life Sciences at Peking University in 2011. From 2012 to 2017, she conducted postdoctoral research at the Department of Ecology and Evolution at the University of Chicago. Since 2018, she has been affiliated with the School of Life Sciences at Peking University and the Peking-Tsinghua Center for Life Sciences, serving successively as Assistant Professor (tenure-track), Associate Professor (tenured), and Full Professor (tenured). The research group integrates experimental and computational biology methods to explore the theoretical foundations and molecular mechanisms of key evolutionary questions, such as studying the evolution of animal diversity and adaptive mechanisms using mimicry butterflies as a model system.

SPEAKERS - MAINSTAGE



Maki WAN

Former President, Rotary Club Kowloon Golden Mile

Dr. Maki Wan is a seasoned professional in corporate strategic planning and business development, with over 20 years of service at Mitsubishi Corporation, the largest Japanese conglomerate. Her extensive experience includes a pivotal role at Mitsubishi's headquarters in Tokyo from 2011 to 2015, when she managed the Group Chairman's external relations. In this capacity, Dr. Wan enhanced the company's international presence by supporting Mitsubishi at high-profile global conferences, including the World Economic Forum, and facilitating meetings between senior executives and national leaders. Currently serving as Mitsubishi Deputy General Manager in Hong Kong, Dr. Wan oversees strategic planning and business development. Born in China and raised in Japan, Dr. Wan has a rich multicultural background. She pursued her academic journey in Japan, France, and Hong Kong, ultimately earning a Ph.D. in French Literature and Cultural Studies from the Chinese University of Hong Kong. Beyond her corporate achievements, Dr. Wan is involved in philanthropy. As the Past President of the Rotary Club Kowloon Golden Mile, the largest Rotary Club in Hong Kong, she has led numerous fundraising initiatives. Additionally, she serves as an advisory board member for the Asian Fund for Cancer Research and is Vice President of BIOHK.

SPEAKERS - THEATER 1



Philippe GERWILL

Founder & Managing Director, PGEA Ltd (Abu Dhabi, UAE)

Philippe Gerwill is a Global Digital Healthcare Humanist, Futurist, International Keynote Speaker, Executive Advisor and Innovation Key Opinion Leader. With more than 30 years of global leadership experience in the pharmaceutical and specialty chemicals industries, including senior roles at Novartis, Ciba and Lonza, he brings a unique perspective at the intersection of healthcare, technology, innovation and human-centered transformation.
He advises companies and organizations across Europe, the Middle East, Asia, Africa and the Americas, with a strong focus on artificial intelligence in healthcare, digital health, longevity, healthcare in the metaverse, precision medicine, innovation ecosystems and the future of preventive health.
Philippe is also an Adjunct Professor at Rome Business School, a LinkedIn Top AI Voice, and a globally recognized speaker regularly invited to international conferences and executive forums. His work emphasizes that technology should never be the final objective, but a powerful enabler to improve human lives, strengthen healthcare systems and create more inclusive, ethical and sustainable futures.



Jing Yan HAN

Director of the Institute of Integrated Traditional Chinese and Western Medicine, Peking University Health Science Center

Graduated from the Department of Traditional Chinese Medicine at Liaoning University of Traditional Chinese Medicine; obtained a doctoral degree in Internal Medicine from the Medical School, Keio University, Japan; has served as Professor at the Peking University Health Science Center; Director of the Department of Integrated Traditional Chinese and Western Medicine; Head of the Department of Integrated Traditional Chinese and Western Medicine; Director of the Institute of Integrated Traditional Chinese and Western Medicine; Director of the Microcirculation Research Center; and Director of the Key Research Laboratory on Phlegm-Stasis at the National Administration of Traditional Chinese Medicine; concurrently holds the positions of Vice Chairman of the Chinese Society of Microcirculation; managing Director of the Chinese Association of Integrative Medicine (Chairman of its Microcirculation Professional Committee); Vice Chairman of the Board of Supervisors of the World Federation of Chinese Medicine Societies (President of its Qi and Blood Professional Committee); Executive Committee Member of the International Microcirculation Alliance; and Vice Chairman of the Japanese Society for Clinical Traditional Chinese Medicine.

SPEAKERS - THEATER 1



Hoi Shan KWAN

Emeritus Professor, School of Life Sciences, The Chinese University of Hong Kong; Chairman, HSK GeneTech Limited

Professor Hoi Shan Kwan is a distinguished Hong Kong life scientist and research entrepreneur with over 40 years of experience in education, research, and public service. He served as the Founding Chairman of Hong Kong's Expert Committee on Food Safety and is currently Chairman of HSK GeneTech and ProBioLife. His work focuses on translating research in the gut microbiome, probiotics, precision nutrition, and health technology into practical solutions. Professor Kwan is committed to fostering collaboration among academia, industry, and the community to advance science-driven health and wellness.



Bo PENG

Professor, Hong Kong Baptist University School of Chinese Medicine

09/1994 – 07/1999 | Bachelor of Medicine (MBBS) in Traditional Chinese Medicine, Anhui College of Traditional Chinese Medicine
09/2001 – 07/2004 | Master of Medicine (MMed) in Clinical Internal Medicine of Traditional Chinese Medicine, Anhui College of Traditional Chinese Medicine
09/2007 – 07/2010 | Doctor of Medicine (MD) in Integrated Traditional Chinese and Western Medicine (Clinical Internal Medicine), Nanjing University of Chinese Medicine
Deputy Head of the Clinical Division, School of Chinese Medicine, Hong Kong Baptist University
Professor of Clinical Division, School of Chinese Medicine, Hong Kong Baptist University
Henry H.K. Wong Professor of Chinese Medicine (Geriatrics), Hong Kong Baptist University
Chairman of the Respiratory Diseases Professional Committee, Hong Kong Registered Chinese Medicine Practitioners Association
Editorial Board Member, Hong Kong Journal of Chinese Medicine
Supervisor of the Hong Kong and Macau Alumni Association, Nanjing University of Chinese Medicine
Executive Committee Member, Hong Kong Registered Chinese Medicine Practitioners Association; Council Member, Hong Kong Tea Therapy Society
Specialist Leader in Chinese Medicine Pulmonary Diseases, School of Chinese Medicine, Hong Kong Baptist University

SPEAKERS - THEATER 1



Thomas VARGOCZKY

Managing Director, Herbaferm Pte Ltd

Thomas Vargoczky received his MD from Semmelweis University Hungary, MSc from The University of Sydney, MBA from LSE (London) and Design Thinking from Harvard University. Currently he is enrolled at NUS (Singapore) at the Medical Faculty in the Graduate Certificate Longevity course. He worked at Prince of Wales Hospital (Sydney), then as Consultant to Hewlett Packard Co in Singapore, Siemens Healthcare (Healthineers) in the USA and Germany. Until 2025 worked in London at King's College LIHE Incubator for Medtech startups. Started Herbaferm Pte Ltd with original Founders in 2023 in Singapore to build on European herbal medicine experience for Asia Pacific collaboration and research of novel solutions. Special interest in microbiome testing and building supplements from both TCM and European herbal extracts.



Qianqian WANG

Associate Chief Physician, Peking University School and Hospital of Stomatology

Associate Chief Physician , M.D of Stomatology, Peking University
Research focuses on the development of bioactive materials their applications in oral hard tissue repair and regeneration, and related clinical studies.

SPEAKERS - THEATER 3



Russell CHAN

Co-founder and CEO, E-SENSE Innovation & Technology; Honorary Assistant Professor, School of Biomedical Engineering, The University of Hong Kong

Dr. Russell Chan is the co-founder and CEO of E-SENSE Innovation & Technology, and an Honorary Assistant Professor at The University of Hong Kong School of Biomedical Engineering. He obtained his B.Eng. in biomedical engineering and Ph.D. in electrical and electronic engineering from The University of Hong Kong (HKU). He was a post-doctoral research fellow at Stanford University in Neurology and Neurological Sciences, and New York University in Neuroscience, Tech4Health, and Ophthalmology. Previously CTO of a Forbes Asia 100 to Watch startup, he was named REVIVE 2023 CTO of the Year and received the HKEST award in 2022. Under his leadership, E-SENSE has received the 2025 HK Tech Fest – Tech Impact Company of the Year, and Gold Medal with Jury Congratulations at the 2025 Geneva Inventions Exhibition. Recently, he was named HK Tech Fest 2026 Founder of the Year. Dr. Chan is an elected Junior Fellow of International Society of Magnetic Resonance in Medicine (ISMRM), a prestigious and highly selective award for young scientists from the leading global MRI society. He is the Chair of the Young Member Section at the Hong Kong Academy of Engineering (HKAE). He is the ex-co member and R&D focus group lead of the Hong Kong Institute of Engineers (HKIE) Biomedical Division. His focus is the research, development, application, and commercialization of state-of-the-art multi-modal and multi-scale biomedical imaging devices to improve quality of life.



Elaine CHOW

Associate Professor (Clinical), Department of Medicine and Therapeutics; Deputy Medical Director (Non-oncology), Phase 1 Clinical Trial Centre; Faculty of Medicine, The Chinese University of Hong Kong

Prof. Elaine Chow is Clinical Associate Professor in the Department of Medicine and Therapeutics, and Deputy Medical Director (Non- oncology) of the Phase 1 Clinical Trial Centre, Faculty of Medicine, The Chinese University of Hong Kong. She is also Honorary Associate Consultant at Prince of Wales Hospital, Hospital Authority.
She received her medical training in the UK and obtained her PhD from the University of Sheffield in 2015, focusing on cardiovascular impacts of hypoglycaemia in type 2 diabetes. At CUHK, she established research platforms for glucose clamp and CGM sensor evaluation. She has secured multiple grants for early- phase drug and device assessment, and leads investigator- initiated studies on prediabetes, diabetes and advanced chronic kidney disease. She has served as principal or co- investigator in over 100 phase I- IV cardiometabolic drug trials, with more than 130 peer- reviewed publications. She holds journal editorial roles and has received several academic awards. She provides expert advisory support on drug selection and utilisation for the Hospital Authority.

SPEAKERS - THEATER 3



Shaoling ZHANG

PhD (France), Chief Physician (Grade II), Master's and Doctoral Supervisor; Director, Pituitary and Adrenal Subspecialty, Department of Endocrinology; Member, Adrenal Study Group, Chinese Society of Endocrinology, Chinese Medical Association; Vice Chair, Diabetes Branch, Guangdong Medical Association; Corresponding Editorial Board Member, Chinese Journal of Endocrinology and Metabolism

Shaoling Zhang, MD, PhD, is Professor and Chief Physician in the Department of Endocrinology at Sun Yat-sen Memorial Hospital, Sun Yat-sen University, and Director of the Adrenal Specialty Program, member of the Adrenal Study Group, Chinese Society of Endocrinology, Chinese Medical Association; ViceChairman of the Diabetes Society, Guangdong Medical Association; Corresponding Editorial Board Member of Chinese Journal of Endocrinology and Metabolism. She has long been engaged in clinical diagnosis, treatment and basic research of diabetes mellitus, thyroid diseases, secondary hypertension and adrenal diseases. She has presided over and participated in multiple national and provincialministeriallevel research projects, boasting rich clinical experience and significant academic influence in the field of endocrine and metabolic disorders.



Mengchen ZOU

Vice Director, Department of Endocrinology and Metabolism, Nanfang Hospital, Southern Medical University; Professor, Chief Physician, PhD Supervisor and Postdoctoral Mentor

Mengchen Zou, MD, PhD, is Vice Director of the Department of Endocrinology and Metabolism at Nanfang Hospital, Southern Medical University. She is a Professor, Chief Physician, PhD Supervisor, and Postdoctoral Mentor. Following postdoctoral training at the Keck School of Medicine of the University of Southern California, Prof. Zou has focused on diabetes, diabetic foot disease, obesity, metabolic syndrome, and vascular complications of diabetes. She has led multiple national and provincial research projects, including grants from the National Natural Science Foundation of China. Her research findings have been published in leading journals such as Diabetes, JCEM, Oncogene, and Advanced Science. She is actively involved in several national and provincial academic societies in endocrinology and diabetes.

SPEAKERS - THEATER 4



Chuen Yan LEUNG

Co-founder, Silver Dart Capital; Partner, Healthcare Investments, Value Partners Group

Dr. Chuen Yan Leung is currently Partner (Healthcare Investments) at Value Partners Group, one of Asia's largest independent asset management firms offering world-class investment services and products for institutional and individual clients globally. He has 14 years of experience in the healthcare ecosystem from R&D, biotechnology start-ups, venture capital, and private equity. Previously Dr. Leung was a co-founder of Silver Dart Capital, a boutique healthcare private equity firm and a private equity vice president at EQT Group, a Swedish global investment organization with EUR 210bn assets under management as of 2023. He has previously held roles such as Vice President at Aeneas Capital and Lead Scientist at Procella Therapeutics. Dr. Leung is currently the Vice President of the Hong Kong Biotechnology Organization, and a member of the Shanghai Pudong Chinese People's Political Consultative Conference. Dr. Leung received his PhD in Stem Cell Biology from the University of Cambridge, and BSc in Biochemistry from Imperial College London.



Benny LO

Barrister & Chartered Arbitrator, Des Voeux Chambers, Hong Kong

Dr Benny Lo is a Barrister and Chartered Arbitrator in Hong Kong and has also been called to the English Bar. His legal practice focuses on commercial, shareholders, healthcare, pharmaceutical and intellectual property disputes. Apart from acting as counsel, Benny also sits as an international arbitrator and has been ranked by Chambers and Partners as one of the "Most-in-Demand Arbitrators " in Hong Kong. Before becoming a barrister, Benny worked as a scientist in pharmaceuticals and biotechnology research, including serving as Croucher Foundation Fellow under Nobel Laureate Sir Gregory Winter at the Medical Research Council in Cambridge.

SPEAKERS - THEATER 4



Junyi MA

General Manager of GBA, Hilink

Ma Junyi, General Manager of GBA, Hilink. He is dedicated to the commercialization of Chinese innovative medicines in Hong Kong, and conducts research on drug review and approval systems, medical insurance systems and pharmaceutical innovation policies in the Chinese Mainland and Hong Kong. He has participated in a number of relevant research projects commissioned by Chinese government authorities and industry organizations. He currently serves as the HKSAR Liaison Representative of PhIRDA and a member of the Medicinal Policy Specialty Committee of PhIRDA.

Mr. Ma has taken part in the preparation and execution of a series of nationally influential and authoritative flagship events, including the *China Biomed Innovation and Investment Conference*, *China Conference of Rare Diseases*, and the *China International Fair For Trade In Services – Hygiene and Health Special Session*. In recent years, he has been deeply engaged in the Greater Bay Area. He founded BridgeUs, a youth community for life sciences in the Guangdong-Hong Kong-Macao Greater Bay Area, and organized numerous industrial exchange events within the Bay Area.



Donglei MAO

Editor-in-Chief and Co-founder of PharmaDJ, Deputy Chief Editor of Asia Bio Inc., Columnist of Biotechgazine, Strategic Advisor of BIOHK, Strategic Advisor of GBAAPI

Donglei Mao holds an MSc in Drug Regulatory Affairs and Policy (DRAP) from The Hong Kong University of Science and Technology. She began her career in 2000 at the Southern Institute of Pharmaceutical Economics (under the National Medical Products Administration), writing for Pharmaceutical Economics News. She was one of the earliest journalists to provide sustained, in-depth coverage of China's drug regulatory reform, and has interviewed multiple NMPA officials and directors of the Center for Drug Evaluation (CDE).
In 2014, she co-founded PharmaDJ, which has since grown into a well-respected and influential media platform in the pharmaceutical industry. She closely follows drug regulatory trends in China and abroad, covering regulatory science, clinical trials, and biopharmaceutical innovation, and is proficient in both Chinese and English professional writing.
PharmaDJ serves as a media partner to the China Pharmaceutical Innovation Association (PhIRDA), DIA, and the Hong Kong Association of the Pharmaceutical Industry. Donglei also holds advisory and editorial roles, including Strategic Advisor to the Greater Bay Area Biomedical Innovation Alliance, Columnist for the Hong Kong Biotechnology Association, and Deputy Editor-in-Chief of Asia Bio Inc.

SPEAKERS - THEATER 4



Ken NG

Senior Patent Examiner (Electricity), Intellectual Property Department
Managing Director, GIPAC

Ken Ng is a Senior Patent Examiner at the Intellectual Property Department of the HKSAR Government, specializing in the substantive examination of OGP applications in the electrical engineering field. But what sets Ken apart is his rare, dual perspective on the patent lifecycle: he has sat on both sides of the table.
Prior to joining the government, Ken managed IP portfolios and evaluated inventions at the University of Hong Kong and the Hong Kong University of Science and Technology. In those roles, he worked closely with researchers to translate cutting-edge lab discoveries into commercially viable assets. He also served as a patent agent, where he handled worldwide patent drafting and prosecution for a diverse range of clients.

Ken received his Bachelor's degree in Information Engineering from the University of Hong Kong. He got the qualification of Chinese patent agent in 2013.



Eric SHAO

Managing Director, GIPAC

Eric Shao is the Managing Director of GIPAC. In this role, he leads advocacy on behalf of the multinational pharmaceutical companies GIPAC serves, facilitating dialogue between the industry and key government and policy stakeholders.

SPEAKERS - THEATER 4



Luke SONG

Of-Counsel, Jones Day

Luke Song is an intellectual property expert at Jones Day's Hong Kong office with over two decades of experience advising multinational companies on patent prosecution, litigation, invalidation, and trade secret matters. His practice focuses on high-technology and life sciences related innovations, drawing on a strong technical background in electrical engineering and extensive experience handling complex patent disputes across China. Luke has represented leading global companies in sectors including semiconductors, telecommunications, medical technology, and advanced manufacturing.



Yolanda Wang

Senior Vice President, Eagle IP Limited

Yolanda Wang holds the title of Principal at Eagle IP Limited, serving as the head of the firm's China Practice Group. She is a dual-qualified Chinese Patent Attorney and Patent Litigator with over 17 years of experience in the intellectual property sector.

SPEAKERS - THEATER 4



Brian WONG

HKU-100 Assistant Professor, University of Hong Kong

Dr. Brian Wong is a HKU-100 Assistant Professor at the University of Hong Kong. His research examines the ethics and dynamics of authoritarian regimes and their foreign policies, historical and colonial injustices, and the intersection of geopolitics, political and moral philosophy, and technology. At HKU, he serves as a Fellow at the Centre on Contemporary China and the World, sits on the Steering Committee for the Hong Kong Ethics Lab, and advises the Interdisciplinary Dynamics: Ethics, AI, and Society at the Institute of Data Science. As a seasoned geopolitical strategist, Brian briefs prominent MNCs, hedge funds, family offices, and investors on macro risks in the Global South, with a particular focus on Asia. His writings have appeared on Fortune, TIME, Foreign Policy, Nikkei, and South China Morning Post, and his comments have been featured on outlets such as CNN, Al Jazeera, Financial Times, and BBC, where he most recently spoke alongside the former National Security Advisor to the British Prime Minister and former Deputy National Security Advisor to the US President.

Brian currently serves as a Non-resident Honorary Fellow at the Asia Society Center for China Analysis, as well as a Fellow and Advisor on Strategy at the Oxford Global Society, an independent Oxford-based think-tank. He previously served as a Founding Fellow and then Board Member of Governance Partners Yangon (Asia) and the Founding Secretary of a youth think-tank based in Hong Kong. He is also the Chief Strategy Officer to the HK-ASEAN Foundation, Advisor on Asia-Pacific for Global Counsel, a UK-headquartered geopolitical advisory firm, and Advisor on Geopolitics to Blue Pool Capital, a Hong Kong-based family office. A Rhodes Scholar, Brian holds a DPhil in Politics from Balliol College; MPhil in Political Theory (Distinction) from Wolfson College, and an MA in Philosophy, Politics, and Economics (Double First Class, 9th out of 240) from Pembroke College, University of Oxford. Brian has taught modules in politics to students at Oxford and Stanford Universities.

Brian has published six books, two in Chinese, and four in English. His latest publications are Geopolitics of Artificial Intelligence (Cambridge University Press, 2026 - forthcoming) and Reparative Justice in Authoritarian States (Routledge, 2025).



Janet XIAO

Partner, Morrison Foerster

Dr. Janet Xiao is the Head of China Life Sciences at Morrison Foerster. She is a leading patent attorney specializing in global patent procurement, patent portfolio management, and IP strategic planning for life sciences and biopharmaceutical companies. Recognized by Chambers as a top-ranked intellectual property lawyer, Janet is highly sought after by biotech and pharmaceutical innovators worldwide for patent prosecution, patent strategy, and life sciences IP counsel. Janet is among the very few IP attorneys in the world who are both equipped with solid skills in global strategic IP management and knowledgeable about IP issues unique to China, and she has been the go-to counsel for IP issues in U.S./China cross-border transactions and operations in China. Janet holds a master's degree from the Chinese Academy of Sciences, a Ph.D. in biological chemistry from UCLA, and a J.D. from UC Berkeley.

SPEAKERS - THEATER 4



Hua ZHANG

Vice President and Chief Scientific Officer, SPH Biotherapeutics

Dr. Hua Zhang is an experienced immuno-oncologist whose fingerprints are on some of the most exciting advances in cell and gene therapy. He brings over four decades of experience spanning academia, global research, and biopharmaceutical innovation. After serving nearly 20 years as a senior scientist at the National Cancer Institute, where he helped pioneer CAR-T therapies for leukemia and solid tumors, he transitioned to industry leadership. Since 2018, he has served as Vice President and Chief Scientific Officer at SPH Biotherapeutics, spearheading groundbreaking work in oncolytic virus vaccines, logic-gated CAR-T cells, and multi-antibody platforms—garnering over 20 international patents and multi-million dollars in grant funding.

SPEAKERS - THEATER 5



Nikolay SERGEEV

CSO, ThriveBiome AI

Nikolay Sergeev, PhD, is Chief Science Officer of ThriveBiome.ai, where he leads development of multi-modal AI platforms for biomarker-guided precision medicine. He has held senior scientific/R&D leadership roles at Guardant Health, Amazon, Natera, Exact Sciences, and Applied Biosystems, spanning liquid biopsy, cell-free DNA screening, reproductive genetics, and PCR-based diagnostic platforms — over 20 years translating molecular assays into commercial and near-point-of-care products. His current work integrates genomic, metabolomic, microbiome, and digital-biomarker data to model individual therapeutic response, including a deployed Pace of Aging Analyzer that quantifies biological aging rate from clinical biomarker panels. At BIOHK 2026 he presents an AI-enabled framework for predicting efficacy and side-effect risk in GLP-1/GIPR metabolic therapies.



ZhiCheng DU

CEO, CNK THERAPEUTICS

Dr. Du obtained his PhD and completed postdoctoral research at the Department of Biological Sciences, National University of Singapore. He is a Zhejiang Provincial Leading Young Talent and Industry Appointed Expert of The Fourth Affiliated Hospital, Zhejiang University. He holds dual appointed researcher qualification at Liangzhu Laboratory, Zhejiang University. He previously worked at TESSA Therapeutics (Singapore) and Nasdaq listed CytoMed Therapeutics (GDTC, Singapore). He has led multiple national and provincial key R&D projects in China, and participated in major research programs in Singapore. Focusing on cell therapy, he has published 16 high impact papers, with over 400 citations and an h index of 12.

SPEAKERS - THEATER 5



Sarah HO

Founder and CTO, AGeM Bio

Dr. Sarah Ho is the Founder and CTO of AGeM Bio, a biotechnology company developing next-generation cell therapies for oncology and regenerative medicine. She is also an Adjunct Senior Research Fellow at the National University of Singapore (NUS). Her work focuses on engineering mesenchymal stem cells (MSCs) as targeted delivery vehicles for therapeutic payloads, with a strong emphasis on non-viral gene modification technologies. Dr. Ho leads the development of AGeM-102, an allogeneic MSC therapy engineered to express CD::UPRT and IFNβ for localized cancer treatment. Her research integrates cell engineering, translational medicine, and scalable manufacturing strategies to enable clinically viable and cost-effective cell therapy products.



Yuanjun HU

Neurosurgery attending physician, The First Affiliated Hospital of Jinan University

Doctor and Chief Physician of Functional Neurosurgery at the First Affiliated Hospital of Jinan University

SPEAKERS - THEATER 5



Jialing LIU

Principal Investigator, Women's Hospital, Zhejiang University

Dr. Jialing Liu is a Principal Investigator at the Women's Hospital, Zhejiang University School of Medicine. She received her Ph.D. in Nephrology from Guangzhou University of Chinese Medicine, with joint training at Harvard Medical School (Brigham and Women's Hospital), where she studied vascular repair mechanisms. Prior to joining Zhejiang University in October 2025, she served as a postdoctoral fellow and later as a Research Assistant Professor at Southern University of Science and Technology (2020–2025). Her research focuses on leveraging single- cell multi- omics and microfluidic technologies for circulating tumor cell (CTC) analysis, as well as elucidating the molecular mechanisms underlying CTC metastasis and advancing liquid biopsy development. She has published multiple SCI-indexed papers as first/co- first author in journals including J Am Soc Nephrol and Am J Pathol, and holds two patents. Dr. Liu has led three funded grants, including the NSFC Youth Program and the SMART Youth Program, with total research funding exceeding ¥1.2 million. She is also a recipient of the Shenzhen Overseas High- Caliber Peacock Talent Award (Class C).

中信证券
CITIC SECURITIES

Connecting Healthcare Innovation with Capital Markets

Insight ▸ **Industry** ▸ **Capital** ▸ **Wealth**

From industry insight to growth, capital formation and wealth creation



CITICS Platform

Leveraging CITIC Securities's integrated ecosystem to connect innovation, industry and capital

Investment Banking

Advisory and execution across IPOs, refinancing, M&A and strategic transactions

Wealth Management

Serving entrepreneurs and investors through diversified wealth solutions and connectivity

Research

Deep sector insight and institutional research support for the healthcare industry

Disclaimers: This advertisement is produced by CITIC Securities. This advertisement has not been reviewed by the Securities and Futures Commission ("SFC") or any other regulatory authority in Hong Kong.

Connect with CITICS Healthcare


企业概况 Company Profile

中信医疗健康产业集团有限公司是中国中信集团有限公司的一级全资子公司，是从事大健康产业的专属平台。主营业务涉及以**辅助生殖、医疗整形美容、康复**为主的特色专科以及综合性医院医疗服务，医康养结合的健康管理，医管分离非临床业务、医药和器械配送等。

医疗服务围绕以“**预防-治疗-康复**”为特征的全生命周期纵向发展。医药器械围绕以“**研发-制造-销售**”为特征的产业链横向发展，新形成“**一纵一横**”、“**双轮驱动**”“**长短互补**”的大健康发展新格局，打造“**医疗服务+药械制造**”的健康产业新业态。

中信医疗下属主营业务单位包括综合医院、专科医院、医药器械供应链管理及销售配送公司、医院非临床服务公司、基金公司、创投公司等。

中信医疗致力成为大健康领域具有市场影响力和良好口碑的优秀品牌企业，成为具有国际视野、国内一流的医疗健康产业资源整合平台，成为卓越的医疗健康产业的投资商和运营商。



未来发展展望 Future Development Prospects

发 展

践行实业“星链”，助力健康中国

愿 景

迈入国内医疗健康央企第一阵营---成为国内医疗健康领域强核突出、特色专科领先的一流企业

跻身集团实业“星链”第一梯队---成为集团践行国家战略、创新健康服务模式、实现价值贡献的重点企业

发展定位

成为建设生育友好型社会的践行者和支撑我国人口高质量发展的行动者

通过整合资本、产业、运营、技术、人才等核心要素，成为**国内医疗健康领域中具有特色的资源整合平台**

中信银行
CHINA CITIC BANK

中信银行成立于1987年，是中国改革开放中最早成立的新兴商业银行之一，是中国最早参与国内外金融市场融资的商业银行，并以屡创中国现代金融史上多个第一而蜚声海内外，为中国经济建设做出了积极贡献。2007年4月，在上海证券交易所和香港联合交易所A+H股同步上市。

经过30余年的发展，已成为一家总资产规模突破10万亿元、员工人数超6.7万名，具有强大综合实力和品牌竞争力的金融集团。

中信银行一级资本在英国《银行家》杂志“世界1000家银行排名”中位列第18位；荣膺英国《银行家》杂志“2025年中国年度银行”大奖。





全球化服务网络



全球协同服务

截至2025年末，中信银行在境内153个大中城市设有1484家营业网点，在境内外下设中信国金、信银投资、中信金租、信银理财、百信银行等8家附属机构。

境外设立伦敦分行、香港分行和悉尼代表处，收购哈萨克斯坦阿尔金银行，中信银行(国际)在香港、澳门、纽约、洛杉矶、新加坡等地设有营业网点。

领先的跨境服务银行·中信跨境金融中心

中信大外汇

不止于外汇 而是基于外汇业务的全景金融服务

本币+外币　在岸+离岸　境内+境外　线上+线下

Specialist:专业
Speed:快捷

全球价值链

专注于价值 更是基于价值链接的出海无限可能

业务+服务　资金+资源　行业+产业

Slim:灵活
Safe:安全




中信银行(国际)

经营百年 市场主流

中信银行(国际)在港经营跨越百年，前身可追溯至1922年成立的嘉华银号。1986年由中信集团注资3.5亿港元，由此正式成为中信一员。

作为中信集团在港部署的重要金融机构，以及中信银行国际化发展主要境外平台，中信银行(国际)深度融入中信生态，把握跨境金融机遇，为境内外客户提供一体化的中信服务。



中信建投证券
CHINA SECURITIES

公司介绍

中信建投证券成立于2005年11月2日，是经中国证监会批准设立的大型综合证券公司。公司总部位于北京，注册资本77.57亿元。2016年12月9日，公司在香港联交所上市，股票代码6066.HK；2018年6月20日，公司在上海证券交易所主板上市，股票代码601066.SH。公司在中国境内设有300余家证券分支机构，并设有中信建投期货有限公司、中信建投资本管理有限公司、中信建投（国际）金融控股有限公司、中信建投基金管理有限公司和中信建投投资有限公司等5家全资子公司。公司是国内证券行业首批6家并表监管试点企业之一，也是首批监管白名单企业之一。

加速国际化业务布局

中信建投（国际）金融控股有限公司作为中信建投证券国际化战略的桥头堡和主阵地，于2012年7月在香港注册成立，注册资本55亿港元，可为各类企业、机构和财富管理客户提供证券全牌照产品和服务，已成为港交所5年期中国国债期货首批流动性提供商，以及香港黄金期货、HAU香港金首批参与机构。

主营业务

中信建投证券业务涵盖：证券承销与保荐、证券经纪、与证券交易和证券投资活动有关的财务顾问、证券投资咨询、证券自营、证券资产管理、证券投资基金代销、为期货公司提供中间介绍业务、融资融券业务、代销金融产品业务、股票期权做市业务、证券投资基金托管业务、上市证券做市交易业务、销售贵金属制品以及有关监管机构批准的其它业务。

发展战略

公司核心战略是 **“三 ZHI 一新一化”**——打造价值投行、新质投行、数智投行，建立客户驱动新发展模式，着力提升国际化水平。到2030年，全面达到与行业优质头部机构相称的引领水平；到2035年，力争全面达到国内一流水平，努力成为具备国际竞争力和市场引领力的一流投资银行和投资机构。

中信建投国际荣获主要奖项

Highly Recognized by the Market and Received Numerous Awards

- MarketAxess — China Cross-Border Fixed Income Trading Leader Institution; Global Fixed Income E-Trading Excellence — Year 2026
- The Asset 25 — “Best G3 Bond Investment Institution” Top Place Among Securities Firms in Hong Kong — Year 2024 & 2025
- 债券通 Bond Connect — Innovative Institution for Primary Market – Underwriter — Year 2023 & 2024
- Win.d — Best IPO Sponsor; Best IPO Global Coordinator for H Shares — Year 2023
- SGX — Currency Futures Broker Partner Award — Year 2022
- HKEX 香港交易所 — Top Breakthrough Participant Currency Futures — Year 2021

发挥“四投联动”独特优势，助力生物医药企业发展壮大

中信建投证券在行业内率先构建“投研+投资+投行+投顾”四投联动机制，
为企业提供全生命周期综合金融服务方案，助力资本市场和实体经济高质量发展。



投行业务优势突出、市场领先

中信建投证券投行业务建立股权、债权、并购重组、跨境投融资的一体化服务体系，各项业务指标均位居行业绝对领先。投行委医疗健康行业部门实现生物科技细分领域服务全覆盖，先后服务数十家知名生物科技企业境内外IPO上市、再融资和并购重组，累计服务融资金额数千亿元。



中信建投国际独家保荐中国双抗行业先行者及引领者——武汉友芝友生物于港交所主板成功上市

投资业务聚焦重点、成效显著

中信建投证券聚焦战略性新兴产业和未来产业，完善私募股权投资业务和另类投资业务布局，有力服务了各类创新型企业发展壮大。在生物科技投资领域重点布局创新药、创新医疗器械、合成生物等领域，先后投资睿健医药、清普生物、宁丹新药等众多细分领域领先企业。



中信建投资本投资“AI+化学诱导”细胞治疗平台型企业睿健医药

投研业务实力雄厚、口碑卓越

中信建投证券建立研究发展部与未来产业和政策研究院“双轮驱动”的证券投资研究、智库研究体系。其中，研究发展部医药及大健康研究团队集行业经验、产业经验和海外研究于一体，全面覆盖生物医药产业链及海内外优质公司，连续多年在行业权威评选中名列前茅。



中信建投证券未来产业和政策研究院正式揭牌成立

投顾业务产品体系健全助力客户基业长青

中信建投证券加速财富管理转型，努力满足各类型客户多样化财富管理与投融资需求。公司于2023年正式推出“建投·柏年”企业家办公室，构建了市场领先的一站式“人、家、企、社”综合服务体系，并先后服务康泰生物、维立志博等企业的员工战略配售、股权激励等项目。



中信建投证券企业家办公室举办“跨境新航图，全球博弈下的产业并购与出海”活动

雲南白藥 YUNNAN BAIYAO | 雲白國際 YNBY INTERNATIONAL

聚焦主業·守正創新·穩健增長

雲南白藥為我國著名中成藥，具有止血癒傷、活血散瘀、消腫止痛、排膿去毒之功效。自 1902 年問世以來，以神奇的功效、顯著的治療效果馳名中外、經久不衰。

雲南白藥 1971 年建廠，1993 年上市成為「雲南第一股」。雲南白藥始終致力於推動傳統中醫藥融入現代生活，持續深挖傳統醫學產品的內生潛力，以產品創新回應現代生活需求，不斷為傳統品牌及傳統中醫藥產品注入新的生命力。企業始終秉承「守護生命與健康」的使命，圍繞藥品、中藥資源、健康、醫藥新流通四大業務基本盤持續深耕、穩健增長，已建立起包括天然藥物、中藥材飲片、特色藥、醫療器械、健康日化產品、保健食品等多個領域的業務佈局。

雲南白藥集團目前產品達 40 個品類 416 個品種，雲南白藥氣霧劑、創可貼、雲南白藥牙膏等多個產品在中國細分領域排名穩居第一。企業先後榮獲國家科學技術進步一等獎、中國工業大獎，並連續入榜最具價值中國品牌榜單，建成全球首座中醫藥健康品燈塔工廠。

Yunnan Baiyao is one of China' s most renowned Chinese patent medicines, celebrated for its efficacy in stopping bleeding, promoting wound healing, invigorating blood circulation, dissipating blood stasis, reducing swelling, relieving pain, and draining pus and toxins. Since its introduction in 1902, it has maintained an enduring reputation at home and abroad for its remarkable therapeutic effects.

Yunnan Baiyao was established as a manufacturing facility in 1971 and became the "first listed company in Yunnan Province" in 1993. The Company has consistently focused on integrating the traditional Chinese medicine (TCM) into modern life, explored the endogenous potential of traditional medical products, and responded to the needs of modern life with product innovation, thereby infusing traditional brands and TCM products with renewed vitality. Guided by its mission of "To safeguard life and health," the Company has built steady growth across four principal businesses: pharmaceuticals, TCM resources, health products, and pharmaceutical distribution. The Company has also expanded its business footprint into various domains, including natural medicine, TCM decoction pieces, special medicines, medical devices, personal care products, and healthcare food.


Today, Yunnan Baiyao Group offers 416 varieties across 40 categories. Several of its products—including Yunnan Baiyao Aerosol, Woundplast, and Yunnan Baiyao Toothpaste—rank first in their respective segments in China. The Company has been honored with the First Prize of the State Scientific and Technological Progress Award and the China Grand Awards for Industry. It has also been consecutively named among the Most Valuable Chinese Brands list, and operates the world' s first lighthouse factory for TCM health products.

發展歷程 DEVELOPMENT HISTORY

弘揚民族醫藥瑰寶
傳承中華文化精粹

持續、穩健、快速增長

40個品類 | 416個品種 | 16個上億單品





Navigating Opportunties
把握先机
CHALLENGE ACCEPTED
迎难而上
With insight, agility and collaboration,
we steward business growth to make
quality care more accessible.
以洞察把握市场，以应变赢得先机，以协作共创价值。
我们助力企业拓展业务，让优质健康生活触手可及。
DCH
AURIGA
COLLABORATIVE HEALTH SOLUTIONS

Airdoc鹰瞳

广告

眼底一张照
健康早知道

眼底是人体能直接观测到血管和神经的部位，
可以反映全身的健康状况，在疾病早期发出预警。





我国每年猝死人数76万，
而心血管病在居民疾病死亡构成比中占主因[1]
每7.5秒就有1人死于心血管病[2]
每1分钟就有1人失明[3]

青少年

近视率达80%[4]，
日后致盲隐患多。



中年人

心脑血管疾病患者3.3亿，占总死亡人数40%以上[5]，熬夜、劳累、996、经常应酬、有三高的40岁以上人群建议每年2次以上眼底检查。



老年人

60岁以上人群，老年痴呆症患者超1500万[6]，女性患病率约为男性的1.8倍，女性死亡率是男性的2倍以上[7]。



早发现，早干预，早获益！

70% 的心血管患病风险和死亡风险可以被预防[8]

80% 的失明可以被预防和治疗[9]



鹰瞳Airdoc 人工智能视网膜健康评估
通过视网膜照片评估55种健康风险

[1]《中国卫生健康统计年鉴2022》
[2]《中国心血管健康与疾病报告》编写组.《中国心血管健康与疾病报告2020》要点解读[J].中国心血管杂志,26(3):10.
[3] Yan L. Comparative study on preventing avoidable blindness in China and in Nepal[J]. Chinese medical journal, 2007120(4):280-283.
[4]国家卫生健康委员会官网
[5]国家心血管病中心《中国心血管健康与疾病报告2023》
[6]中国老龄协会《认知症老年人照护服务现状与发展报告》
[7]中国阿尔茨海默病报告2024
[8] Yusuf S, Joseph P, Rangarajan S, et al. Modifiable risk factors, cardiovascular disease, and mortality in 155 722 individuals from 21 high-income, middle-income, and low-income countries (PURE): a prospective cohort study [published correction appears in Lancet. 2020 Mar 7;395(10226):784]. Lancet. 2020;395(10226):795-808.
[9] Wei w B , Zhu R L , Yang L . Situation of low vision and blindness in China and their prevention [J]. Chinese medical journal, 2011,124(8):1123-1127.

www.airdoc.com

鹰瞳Airdoc官方微信

400-100-3999

EVER Neuro Pharma GmbH

EVER Pharma is an Austrian specialty pharmaceuticals company focused on the research, development, manufacturing, and commercialization of innovative products in neurology and specialty injectables, including oncology, intensive care, and hormone therapeutics, with EU GMP-certified production facilities in Austria and Germany and a commercial presence in more than 80 countries worldwide.

g-tec Medical Engineering GmbH

g.tec medical engineering GmbH is an Austrian neurotechnology leader with over 20 years of experience developing advanced brain-computer interface (BCI) systems and CE-certified/FDA-cleared medical devices for clinical and research applications, serving the Asia-Pacific region through its Hong Kong office and seeking collaborations with healthcare professionals, neurosurgeons, and researchers in neurorehabilitation, brain mapping, and BCI technologies.

MacroArray Diagnostics GmbH

Developed by Austrian company MADx (Macro Array Diagnostics), the ALEX³ test is an advanced molecular allergy diagnostic solution that uses multiplex technology to provide a highly comprehensive allergy profile from a single blood sample, covering 82 allergen extracts and 218 molecular allergens, and is used by healthcare providers in more than 90 countries.

ADVANTAGE AUSTRIA - Austrian Trade Commission
Contact Person:
Ms Monica NG & Yvonne CHOI
T +852 2522 2388
E hongkong@advantageaustria.org
W www.advantageaustria.org/cn

baidao data | Google Cloud

Google Cloud PREMIER Co-sell Partner

Google Cloud PREMIER Services Partner



AIMRx 智能研究矩阵
新一代 AI 驱动的医药研发新范式

百道数据倾力构建 AIMRx 智能研究矩阵，基于 Gemini Enterprise Agent Platform 与 ADK 框架，打造具备自主推理能力的多智能体系统。该解决方案通过统一调度架构与专业模型协同，重新定义了药物研发与临床研究的智能化工作流程，为医药创新提供端到端的 AI 赋能。

Medical Research Agent
医学智能路由的中枢系统

采用先进的查询路由机制，本系统智能识别用户意图并调度相应专业模型。覆盖从通用医学知识到专业化合物分析的多元场景，为研究人员提供精准的信息服务，奠定未来扩展至蛋白质组学、临床数据分析的架构基础。



Agentic-Tx
新一代药物发现智能引擎

作为 AIMRx 矩阵的核心组件，Agentic-Tx 重塑了早期药物发现范式。系统由 Gemini 2.5 Pro统一协调，整合研究员与分析师双专业智能体，依托 TxGemma 专业模型与权威数据库，实现从靶点识别到安全性评估的完整研究闭环。

Clinical Research Synthesizer
临床开发流程的智能革命

本系统通过智能任务分解与动态编排，将复杂临床查询转化为可执行的研究计划。其突破性的多源数据整合能力，无缝对接科学文献与临床试验数据库，显著提升临床开发效率。模块化架构为后续扩展提供坚实基础，支持基因组学、真实世界数据等多元数据接入。

AIMRx 矩阵价值：通过三大系统的有机协同，为医药研发机构提供覆盖早期发现、临床开发到专业医学研究的全流程智能解决方案，显著提升研发效率与决策质量。

合作咨询：contact@baidaodata.com

携手百道数据，赋能全球业务

EXSHINE
BIOPHARM
昕卓越生物医药



北京昕卓越生物医药

关于我们 About Us

- 公司成立于 2024 年 12 月，总部位于北京大兴国际生物医药园，是一家专注于多能干细胞来源的通用型细胞药物、类器官药物开发的创新型生物技术企业，致力于打造世界一流生物制药企业。公司核心布局“基因编辑平台”“工艺开发平台”“质量研究平台”三大通用平台技术，用于开发治疗肝纤维化、肝硬化、实体瘤等难治性疾病的 ATMP 类产品，力争 2030 年推动多项核心管线进入 IND 阶段。
- 目前已与中国科学院动物研究所、北京干细胞与再生医学研究院等国内顶尖干细胞科研机构建立深度合作，构建协同创新的研发体系。
- 自建 5500㎡ GMP 标准研发中心，涵盖研发、质检、工艺三大功能区，为细胞药物研发与临床转化提供国际化高标准支撑。

Founded in December 2024 and headquartered in Beijing Daxing Airport International Bio-medical Park, Beijing Exshine Biopharm is an innovative biotech company specializing in the development of universal cell therapies and organoid therapies derived from pluripotent stem cells, dedicated to building a world-class biopharmaceutical enterprise.





We have established three universal technology platforms — Gene Editing Platform, Process Development Platform, and Quality Research Platform — to support the development of ATMP products for refractory diseases including liver fibrosis, liver cirrhosis and solid tumors. We aim to advance core pipelines to the IND stage by 2030.

We have built in-depth collaborations with leading stem cell research institutions, including the Institute of Zoology, Chinese Academy of Sciences and Beijing Institute of Stem Cell and Regenerative Medicine, to foster a collaborative, innovation-driven R&D ecosystem.

Our 5,500㎡ GMP-compliant R&D center, comprising R&D, quality control and process development divisions, providing international-standard support for cell therapy R&D and clinical translation.

联系我们 Contact Us

+86 136 8108 9984 xzy.contact@exshine-bio.com

官方微信
Official Wechat

Highthink
海金格医药

专业临床研究CRO 服务

双重认证体系，助力您的新药研发成功

Professional Contract Research Organization Services for Clinical Research

海金格医药科技（香港）有限公司是母公司北京海金格医药科技股份有限公司的国际业务运营平台。海金格医药于2006年成立，专注创新药 Ⅰ-Ⅳ 期全流程临床 CRO 服务，公司具备中美双报、eCTD 电子申报实操能力，严格遵循 ICH 国际质量体系，携手全球 CRO 合作伙伴，助力新药全球临床开发。海金格（香港）依托母公司全维度技术与资源赋能，两地联动，为全球客户提供一站式临床研究解决方案。

Highthink Medical Technology (HK) Limited serves as the international business platform of its parent company, Beijing Highthink Pharmaceutical Technology Co., Ltd. Founded in 2006, Beijing Highthink specializes in phase I–IV clinical CRO services for innovative drugs. Equipped with practical capabilities in US-China simultaneous filing and eCTD submissions, we comply strictly with ICH guidelines and cooperate with global CRO partners to advance global clinical development of new drugs.With technical support from the parent company, Highthink (HK) adopts a Hong Kong-mainland dual-location collaboration model to offer one-stop clinical research solutions globally.

关于我们 / About Us

企业员工 EMPLOYEES	项目经验 PROJECTS	合作客户 CLIENTS	覆盖城市 CITIES	治疗领域 AREAS
1400+	1000+	700+	150+	30+

IEC27001 信息安全管理体系国际认证 ISMS International Certification

ISO9001 质量管理体系认证 QMS-Certified

我们的服务 / Our Services

- 临床项目运营 Clinical Trial Operation
- 数据管理与统计 Data Management & Biostatistics
- SMO 现场管理 Site Management Organization
- 医学事务 Medical Affairs
- 药物警戒 PV Pharmacovigilance
- 质量稽查 Quality Audit
- 海内外注册申报 Domestic & International Regulatory Affairs

海金格医药科技（香港）有限公司

Highthink Medical Technology (HK) Limited

Tel: 010-8369-2660 Web: www.highthinkmed.com

扫描二维码 了解更多资讯 / Scan QR Code for More Info >>

北科生物 Beike Biotechnology

海南自由贸易港 博鳌乐城国际医疗旅游先行区 HAINAN FREE TRADE PORT BOAO HOPE CITY

企业介绍

北科生物创建于2005年，公司总部坐落于中国深圳。北科生物是我国专业从事战略性新兴产业生物治疗技术临床转化及技术服务的国家高新技术企业，拥有在细胞领域成果卓越的多位专家级国内外学者领衔的专业技术研发团队。

2025年5月，琼海北科生物正式落户海南博鳌乐城先行区，采用“技术产业化+市场规模化”运营模式，分两期投资5500万元，依托自动化产线夯实产能基础，重点开展干细胞治疗2型糖尿病、系统性红斑狼疮等核心病种的生物医学新技术的临床转化应用。





国家技术发明奖


获批国家药监局
新药临床试验(IND)


干细胞临床研究项目
国家备案


连续14年通过
AABB认证


连续多批次通过
中国药品检定研究院检定


北科生物主导的
国家级项目(部分)


全国首发：博鳌乐城干细胞治疗临床转化


2026年3月，“引领干细胞治疗2型糖尿病新范式技术暨临床应用项目发布会”盛大举行



琼海北科生物受邀参加琼海市2026年"5·18"项目签约仪式，代表乐城先行区已投产企业发言


琼海北科生物接受《海南新闻联播》专访，介绍在乐城先行区生物医学新技术临床转化的应用情况


海南博鳌乐城国际医疗旅游先行区医疗药品监督管理局

乐医药监〔2025〕113号


乐城医疗药品监管局
关于同意“2型糖尿病的人脐带间充质干细胞治疗技术”项目转化应用的批复

慈铭博鳌国际医院：

你院关于“2型糖尿病的人脐带间充质干细胞治疗技术”项目的转化应用申请收悉。根据《海南自由贸易港博鳌乐城国际医疗旅游先行区生物医学新技术促进规定》（以下简称《促进规定》）、《海南自由贸易港博鳌乐城国际医疗旅游先行区生物医学新技术转化应用实施办法（暂行）》（以下简称《实施办法（暂行）》），经审查，批复如下：

一、同意你院内分泌科开展该项目转化应用，适应证为“基于现有的联合使用至少3种降糖药（包括胰岛素在内）血糖控制不佳的2型糖尿病患者”，制剂生产商为深圳市北科生物科技有限公司，制剂规格：1×10^7个细胞/1ml/支，2×10^7个细胞/1ml/支，5×10^7个细胞/2.5ml/支，输注途径：静脉回输，用法用量：1×10^6个细胞/kg/次，每周1次，连续3次。

— 1 —


海南博鳌乐城国际医疗旅游先行区医疗药品监督管理局

乐医药监〔2026〕77号

乐城医疗药品监管局
关于附条件同意“缓解系统性红斑狼疮的人脐带间充质干细胞治疗技术”项目转化应用的批复

海南海控乐城医院（四川大学华西乐城医院）：

你院关于“缓解系统性红斑狼疮的人脐带间充质干细胞治疗技术”项目的转化应用申请收悉。根据《海南自由贸易港博鳌乐城国际医疗旅游先行区生物医学新技术促进规定》（以下简称《促进规定》）、《海南自由贸易港博鳌乐城国际医疗旅游先行区生物医学新技术转化应用实施办法（暂行）》（以下简称《实施办法（暂行）》），经审查，批复如下：

一、同意你院风湿免疫科开展该项目转化应用，适应证为“系统性红斑狼疮”，制剂制备企业为深圳市北科生物科技有限公司，剂型规格：注射剂，1×10^8个细胞/袋，50ml/袋；用法用量：1个疗程1次治疗，每次治疗静脉注射1袋50ml干细胞制剂，含

— 1 —

·2型糖尿病的人脐带间充质干细胞治疗技术·
·缓解系统性红斑狼疮的人脐带间充质干细胞治疗技术·

个人微信号

马也 北科生物科技（琼海）有限公司 执行董事
海南博鳌乐城先行区 科普传播大使
Tel.+86 18926074577

400-0904-999
海南博鳌乐城国际医疗旅游先行区·北科生物

扫码关注视频号

BGI·Tech

Leveraging Multi-Omics to Accelerate Discovery

As a globally influential life-science research service platform, BGI Tech has deepened its roots in the research services sector for nearly 20 years, remaining dedicated to delivering end-to-end multi-omics big data solutions to scientists worldwide.

Headquarter: Shenzhen (China)
Laboratories: Warsaw (Poland), Wuhan (China) and Hong Kong (China)

100+ Countries & Regions

7,000+ Collaborating Partners

40,000+ Clients Served

Sequencing Services

- Single-Cell Sequencing
- Spatial Transcriptome
- Whole Genome Resequencing
- *De Novo* Sequencing
- Metagenome
- Transcriptome
- Whole Genome Bisulfite Sequencing
- ……

Mass Spectrometry Services

- Quantitative Proteome
- Nanoproteome
- Metaproteome
- PTM Proteome
- Untargeted Metabolome
- High-Throughput Targeted Metabolome
- Lipidome
- ……

Multi-Omics & Synthesis Services

- Spatial Transcriptome+ scRNA-seq
- Bulk RNA-seq+scRNA-seq
- Transcriptome+Proteome+ Metabolome
- Metagenome/16S+Metabolome
- Dr. Tom Visualization System
- Gene Synthesis
- ……

Contact Us

info@bgi.com
www.bgi.com/global

For research use only. Not for use in diagnostic procedures.
Copyright© 2026 BGI Tech. All rights reserved.

百奥赛图 BIOCYTOGEN | RenSuper BIOLOGICS

biocytogen.com.cn

RenMice全人抗体与TCR发现平台

7+ RENMICE平台 | **80+** 临床前候选资产 | **1M** 全人抗体序列库 | **350+** 全人抗体合作项目

全人单抗

RenMab®

基于RenMab小鼠进行多样性好、亲和力高的全人单抗开发

全人双抗

RenLite®

基于RenLite小鼠的共轻链双抗药物开发，避免轻重链错配

双抗ADC

RenLite®

基于RenLite小鼠的双抗ADC药物研发，多种TAA靶点组合

全人纳米抗体

RenNano®

基于RenNano小鼠的纳米抗体开发，跨越血脑屏障、浸润肿瘤，易于组装双/多抗、CAR-T等

全人TCR



RenTCR™

基于RenTCR小鼠开发高亲和力抗原特异性全人TCR，拥有优异的T细胞免疫应答，助力新表位的发现

类TCR抗体

RenTCR-mimic™

基于RenTCR-mimic™筛选出针对胞内抗原的抗体，比TCR有更好的亲和力和特异性

GPCR抗体

RenMice® KO

针对多次跨膜蛋白等困难靶点，利用RenMice KO小鼠进行规模开发

BIOMICE

- 动物&细胞模型
- 药理药效服务
- 基因编辑服务
- 动物中心相关服务

与全部TOP10药企成为合作伙伴　　创新动物模型已销往 20+国家/地区

2000+货架型靶点人源化动物/细胞模型

700+ Antibodies (mAbs, BsAbs)

PD-1	4-1BB	CD3E	CD16A
CCR8	NKG2A	NKG2D	IL4R
TSLP	IL17A/F	TL1A	IL23

50+ CAR-T Cell Therapy

B-NDG	B-NDG hIL15
B-NDG GL3	B-NDG MHC I/II DKO
B-NDG Kit W41 mice	B-NDG FCγRKO mice

100+ Nucleic Acid Drugs

ANGPTL3	PCSK9	LPA
AGT	APOC3	CFB
GLP1R	HSD17B3	INHBE

200+ Antibody-drug Conjugate (ADC)

HER2	TROP2	EGFR	B7-H3
CD20	CD19	DLL3	NEFTIN4
GPC3	5T4	CDH17	EPCAM



50+ Vaccine

HLA-2.1	HLA-11.1	HLA-24.2
HLA-3.1	HLA-B35.1	HLA-B7.2
HLA-DR1	HLA-DR4	

5000+现货动物模型，用于新药研发

为评估药物药效、安全性和机制研究提供可靠的解决方案


BioMetas
A world leading biotechnology-focused preclinical CRO
Target Validation
Recombinant Protein Expression
Antibody Production
In vitro Assays
Cell-based Assays
In vivo Pharmacology
DMPK/Exploratory Toxicology
GLP-Compliant Safety Assessment
Find out more at biometasgroup.com



high-dose selenium
for survival

selenase®





Next Generation
Immune Anticancer

IMMUCOTHEL®

biosyn Arzneimittel GmbH
Schorndorfer Straße 32
70734 Fellbach, Germany
Phone: +49 711 57532-00

RM1208,12FL.,299QRC,No.299 Queen's Road
Biosyn (HongKong) Company Ltd.,
Central, Hong Kong
Tel:+852-35868878

wir
forschen.

biosyn

澳門大學
UNIVERSIDADE DE MACAU
UNIVERSITY OF MACAU

澳門大學
University of Macau (UM)

澳門大學，是一所國際化研究型綜合公立大學。澳大推行“四位一體”協同育人教育模式，融合專業教育、通識教育、研習教育與社群教育，並以住宿式書院系統為核心平台，實踐全人教育。作為首間延伸至橫琴粵澳深度合作區辦學的澳門高校，澳大正積極建設合作區校區 ，進一步強化澳大在粵港澳大灣區的角色。

UM Official Website

The University of Macau (UM) is a comprehensive research-oriented public university of international standing. UM adopts a distinctive '4-in-1' collaborative education model that integrates discipline-specific, general, research and internship, and community and peer education, with the residential college system as its core platform for whole-person education. As the first higher education institution in Macao to extend operation into the Guangdong-Macao In-Depth Cooperation Zone in Hengqin, UM is actively developing its new campus in Cooperation Zone to further strengthen its role in the Guangdong-Hong Kong-Macao Greater Bay Area.

澳門大學 UNIVERSIDADE DE MACAU UNIVERSITY OF MACAU | 協同創新研究院 Instituto de Inovação Colaborativa Institute of Collaborative Innovation | 創新創業中心 | 大健康+加速器 Health+

澳門大學創新創業中心
Centre for Innovation and Entrepreneurship (CIE)



CIE Official Website

澳門大學創新創業中心(CIE)連結政府、學校、企業、孵化器、投資機構及導師，協助師生、校友和教職員將具商業潛力的創意轉化為創業項目。中心於2019年獲批為國家級眾創空間，致力構建科技成果轉化與創新創業生態。中心於2025年獲澳門科學技術發展基金資助，設立澳大“大健康+”加速器。聚焦保健、醫藥及醫療器械，推動優質科研成果轉化，協助項目跨越研究至商業化的“死亡之谷”。

WeChat Official Account

'Health+' Accelerator Official Website

CIE connects government, universities, enterprises, incubators, investors and mentors to assist students, alumni, faculty and staff in transforming innovative ideas with commercial potential into entrepreneurial projects. Approved in 2019 as part of China's national framework of co-working spaces, CIE is dedicated to building an ecosystem for technology transfer and innovation & entrepreneurship. In 2025, with funding from the Macao Science and Technology Development Fund, CIE established the 'Health+' Accelerator. Focusing on health and wellness products, pharmaceuticals and medical devices, it promotes the translation of high-quality research outcomes and helps projects cross the 'Valley of Death' from research to commercialization.

CHINA PHARMACEUTICAL INNOVATION AND RESEARCH DEVELOPMENT ASSOCIATION

PhIRDA has long served as a strategic architect of China's pharmaceutical policy environment, advancing pharmaceutical innovation through policy research, proactive advocacy and industry collaboration. Dedicated to building a more open, innovation-driven and globally interconnected pharmaceutical ecosystem, PhIRDA connects policy, science and capital to accelerate the future of healthcare.

1988
Founded

160 Members
Leading pharmaceutical R&D enterprises, research institutions, clinical institutions, R&D services companies and investment institutions across China.

41% of China's Innovative Drug Approvals
PhIRDA members accounted for 31 of the 76 innovative drugs approved by the NMPA in 2025.

12 Specialty Committees
Covering the entire pharmaceutical innovation value chain-from R&D and manufacturing to clinical application, investment and capital markets.

2 International Organization Memberships
International Federation of Pharmaceutical Manufacturers & Associations, IFPMA
Asia Partnership Conference of Pharmaceutical Associations, APAC

2026 CHINA BIOMED INNOVATION AND INVESTMENT CONFERENCE (CBIIC)

CBIIC as a premier platform fostering high-level dialogue between the pharmaceutical and investment industries, was established and initiated by PhIRDA in 2016. The CBIIC focuses on China's latest policies in the pharmaceutical industry, explores the new trends of global pharmaceutical R&D, and trends in the investment and financing circle. The CBIIC is built as an authoritative, comprehensive, professional, and international high-level platform for industry leaders, experts, scholars, domestic and foreign pharmaceutical innovation enterprises, and investors to discuss current trends of innovation and new strategies for investment and cooperation. It has become the most influential pharmaceutical investment platform in Asia-Pacific region.

Yangtze River International Conference Center, Nanjing, China

October 24-25, 2026

Host:

China Pharmaceutical Innovation and Research Development Association (PhIRDA)

Hong Kong Exchanges Clearing Limited (HKEX)

Agenda of 2026 China BioMed Innovation and Investment Conference

10.24 Morning	Opening Ceremony of 2026 CBIIC					
10.24 Afternoon	Parallel Session 1 Digital and Smart Biotechnology Forum	Parallel Session 2 SSE STAR Market Forum	Parallel Session 3 Clinical Research Forum	Parallel Session 4 Clinical Trial Data Release	Parallel Session 5 International Projects Roadshow	Parallel Session 6 License-in/out & Commercialization Forum
10.25 Morning	Parallel Session 1 Advanced Technologies Forum	Parallel Session 2 HK Capital Markets Forum	Parallel Session 3 Innovative Projects in Early Stage Roadshow	Parallel Session 4 Weight Loss & Metabolism Forum	Parallel Session 5 Listed Company Roadshow	Parallel Session 6 International Regulatory Forum
10.25 Afternoon	Parallel Session 1 Oncology Drugs Clinical Research Forum	Parallel Session 2 Global Expansion & Internationalization Forum	Parallel Session 3 Non-Listed Company Roadshow	Parallel Session 4 Investors Forum	Parallel Session 5 Technology Commercialization Forum	Parallel Session 6 Pharmaceutical Policy Sharing Forum

Conference Contact: MA Mingyao, mamy@phirda.com
Partnership Contact: YAN Dixi, yandx@phirda.com

PhIRDA Official Website

PhIRDA WeChat Official Account

CBIIC Wechat Official Account

Join us in Nanjing on October 24-25,2026, to shape the future of biomedical innovation, forge cross-border alliances, and accelerate the translation of science into life-changing therapies. CBIIC 2026 – where vision meets capital, and partnership knows no borders.

CHINESE PEPTIDE
A MEDTIDE COMPANY



中肽生化有限公司

多肽/寡核苷酸CRDMO合作伙伴

公司概况

中肽生化，泰德医药 (03880.HK) 旗下全资子公司，是一家专注于多肽和寡核苷酸的合约研究、开发及生产机构 (CRDMO)，为全球客户提供从早期发现、临床前研究及临床开发到商业化生产的全周期服务。公司成立于2001年，总部位于中国杭州，国际总部位于美国加州，在中国和美国均设有商业化生产基地和办事处。

满足全球供应的大规模药品GMP生产能力

批量可达
50kg

API年产量
1000公斤以上



合成仪

- 灵活的方法：固相、液相、杂化/连接、Fmoc、t-Boc、Cbz
- SPPS反应器：20L、50L、100L、150L、500L、1000L、3000L





纯化柱

- 可变流速制备高效液相色谱法
- 纯化柱: 8", 12", 20" , 30", 50"
- 多个隔离处理区

冻干机

- 工业搅拌机和浓缩器
- 多歧管冷冻干燥机
- 冻干机: 20-50L, 150L, 200L, 500L, 1000L



浙江省杭州市钱塘区12号大街69号，31800
sales@chinesepeptide.com
+86-57186737011
www.chinesepeptide.com

HK Tech 300
Venture Beyond Boundaries

香港城市大學
City University of Hong Kong

HK TECH 300



(Incubated by HK Tech 300)
(HK Tech 300 培育的初創企業)

Sponsored Training Programme
資助訓練課程

2,100+
Participants
參加者

HK$100,000 Seed Fund
10萬港元種子基金

860+
Start-up Teams
初創團隊

HK$1,000,000 Angel Fund
100萬港元天使基金

220+
Start-up Companies
初創企業

Strategic Partners, Co-investors & Supporting Organisations
策略合作夥伴、共同投資夥伴和支持機構

110+

Mentorships
師友配對

300+

(Data as of Aug 2026)

HK Tech 300 - a large-scale flagship innovation and entrepreneurship programme from CityUHK, aiming to provide development opportunities and entrepreneurial experience for young people. The programme focuses on translating CityUHK's research achievements, intellectual property and technology into practical applications through the establishment of tech start-ups.

HK Tech 300 - 香港城市大學大型旗艦創新創業計劃，旨在為年輕人提供發展機會和創業經驗，通過成立科技初創，將城大的研究成果、知識產權及技術轉化為實際應用。

HK Tech 300
CityU_Innovation
cityu.edu.hk/hktech300

NATURAL PLANT POWER
Synergy of traditional herbs and natural fermentation.

herbaferm®
VITALITY & BALANCE

HERBAFERM DROPS

NATURAL SUPPORT FROM PLANTS AND LACTOBACILLUS COMMUNITIES

LACTOBACILLUS COMMUNITIES
A diverse and active community that supports natural balance.

Herbaferm Drops is a herbal extract made by natural fermentation, containing a carefully selected blend of 7 medicinal plants and a complex community of Lactobacillus strains.

1. **CHAMOMILE FLOWER**
Matricaria chamomilla



Soothing and gentle support for the digestive and immune systems.

2. **YARROW FLOWERING HERB**
Achillea millefolium



Traditionally used to support digestion and maintain normal gut function.

3. **ELDERFLOWER**
Sambucus nigra



Supports natural defences and contributes to overall well-being.

4. **ROSEHIP**
Rosa canina



Rich in natural vitamin C, supports immunity and antioxidant protection.

5. **PROPOLIS**
Propolis




A natural bee product, traditionally used to support the immune system.

6. **OAK BARK**
Quercus robur



Contains tannins, supports normal digestive comfort and gut balance.

7. **WHITE WORMWOOD FLOWERING HERB**
Artemisia absinthium



Traditionally used to support digestion and maintain a healthy balance.



IMMUNE SUPPORT
The carefully selected plant extracts and Lactobacillus communities help support your natural defences.

DIGESTIVE BALANCE
Supports digestion and helps maintain a healthy balance of gut flora for overall well-being.

NATURAL & FERMENTED
Made by natural fermentation from herbal extracts. No artificial additives, preservatives or colours.

CONCENTRATED FORMULA
High potency with maximum nutrients in every drop.

EASY TO USE
Simple and convenient dosage for everyday use.

THE POWER OF LACTOBACILLUS COMMUNITIES



Our unique fermentation process cultivates a diverse community of *Lactobacillus* strains, which contribute to a balanced intestinal microflora and support natural fermentation in the gut.

THE JOURNEY OF NATURAL FERMENTATION

1 CAREFULLY SELECTED HERBS
High-quality herbs chosen with care.



2 NATURAL FERMENTATION
Herbs are gently fermented using a traditional method.

3 LACTOBACILLUS COMMUNITIES
Fermentation cultivates a diverse community of beneficial lactobacillus strains.



4 HERBAFERM DROPS
Concentrated, fermented herbal extract with Lactobacillus communities.



BENEFITS OF OUR COMPLEX FORMULA

- Natural plant extracts
- Fermented with Lactobacillus
- High quality ingredients
- Made in Germany

RECOMMENDED DOSAGE



5–15 DROPS
per a glass of water (200ml)
Use daily.
Shake before use.

herbaferm® VITALITY & BALANCE

Herbaferm combines the power of nature with the benefits of fermentation to support your health – naturally.

www.herbaferm.co.uk

Booth No. 3E-S02

The Republic of Belarus and the China – Belarus Industrial Park «Great Stone» – your gateway to new markets of modern and Traditional Chinese Medicine!



The Republic of Belarus is Eastern European country and active supporter of **Belt & Road Initiative**. Is Founding Member of the **Eurasian Economic Union**, which market has population of 186 million people.

Great Stone Industrial Park allows providing of medical services with the use of medicines, medical devices, and treatment methods that are not registered in Belarus, **provides simplification and shorter timelines for registration of medical devices**.

We are open to your projects!

the Consulate General's of the Republic of Belarus in Hong Kong SAR resources

LinkedIn Telegram Website

the China–Belarus Industrial Park «Great Stone» resources

Telegram Website

Uruguay

BUSINESS & INNOVATION HUB #1 IN LATAM

DECISION PROCESS

LANDING

AFTERCARE

- CUSTOMISED INFORMATION AND ASSESSMENT
- AGENDA PREPARATION
- INTRODUCTION TO PUBLIC AND PRIVATE ACTORS
- SUPPORT AND TALENT DEVELOPMENT
- POLICY ADVOCACY
- CLUSTER DEVELOPMENT
- ACCESS TO INVESTMENT PROMOTION TOOLS

CONTACT US

Consulate-General of Uruguay in Hong Kong

Consulate-General of Uruguay in Hong Kong
cghongkong@mrree.gub.uy

Uruguay XXI
INVESTMENT, EXPORT AND COUNTRY BRAND PROMOTION AGENCY

invest@uruguayxxi.gub.uy
investinuruguay.uy

DELONIX BIOWORKS

Next-Generation Genetically Engineered Bacterial Vaccines

Delonix Bioworks is a clinical-stage biotech at the forefront of developing next-generation genetically engineered bacterial vaccines. Leveraging its proprietary OMV Plus platform, the company is dedicated to advancing a robust pipeline of first-in-class and best-in-class programs addressing critical unmet needs, including vaccines for *Neisseria meningitidis* serogroup B, *Bordetella pertussis*, *Neisseria gonorrhoeae*, and *Klebsiella pneumoniae*.

Shanghai, China

BD@delonixbio.com


www.delonixbio.com

Scan this QR code

to visit our official website for more information!

OMV Plus

Next-generation engineered OMV vaccine



- **All-in-one OMV design**
  No additional recombinant proteins or adjuvants
- **Precise pathogen genome editing**
  Multi-gene edits ensure improved safety, coverage, and yield simultaneously
- **Scalable production**
  100L GMP manufacturing yields 1M+ doses per batch
- **Rapid development for versatile applications**
  18 months to IND application of OMV vaccines for 10+ pathogens

License-out & NewCo Opportunities

MenB OMV vaccine

- $2+ billion global market
- Potential best-in-class MenB vaccine with high coverage for China & global, on-going Phase I trials in both China and Australia

Pertussis OMV vaccine

- $2Bn market potential as of adult / adolescent pertussis vaccines
- Next generation vaccine against immune escape strains and prevents transmission

N. gonorrhoeae OMV vaccine

- Urgent global AMR problem with $1Bn+ market potential
- utilizes a novel heterologous approach (Nm OMV chassis + Ng antigens) to bypass the immune escape mechanisms of native Ng

S. aureus vaccine

- $5Bn+ global market, no launched product worldwide
- Leverage first-in-class MoA bacterial immnue checkpoint to improve immune protection efficacy

We also welcome OMV-based vaccine co-development, potential target pathogens include *Pseudomonas aeruginosa*, *Klebsiella pneumoniae*, Salmonella, and *Shigella flexneri*.



我们是谁

深度智耀DIP成立于2017年，由具有跨国药企研发与AI技术背景的团队创立，是一家以多智能体技术推动医药研发与科学创新的平台型企业。

在生命科学领域，DIP聚焦临床试验全链路，通过专业智能体、临床数据系统、质量体系与专家团队协作，将模型能力转化为可追溯、可审计、可交付的临床研发服务，推动AI从单点辅助走向端到端临床试验整包交付。根据Frost & Sullivan研究，DIP在全球 LLM+MAS 临床 CRO 市场份额 No. 1，位居全球第一，累计服务逾1,500家客户，客户覆盖多家全球领先制药企业及创新型Biotech。

在物质科学领域，DIP致力于以AI FOR SCIENCE（AI4S）的研究新范式赋能千行百业，将AI多智能体平台能力延伸至农药化工、新能源材料、半导体材料、功能食品及保健品等物质科学行业研发，推动研发从"发现"走向"创造"。

目前，深度智耀已实现商业化持续盈利，并成长为数十亿美元估值的AI制药独角兽企业，并在中国、日本、美国、新加坡及澳大利亚设有10余个功能性总部及区域中心。

关于我们

No. 1
全球 LLM+MAS
临床 CRO 市场份额 No. 1

2017
公司成立
深耕临床试验服务垂直领域

1500+
服务客户
药企、Biotech、医院、研究院、高校

FIMAN | FILLDERM 弗缦™
B\OYONCE 碧妍思

直补·涂抹·食补
胶原三态 全链抗老*



55+ 胶原专利　10+ 药研提取专利　2000+ 医美机构入住

*肌肤的老化简述，如淡化细纹等
*三抗小紫瓶为产品昵称，产品注册名为胶原蛋白肽透明质酸钠饮品
*四修小蓝瓶为产品昵称，产品注册名为胶原蛋白肽角子酱液态饮品

弗缦公众号

碧妍思公众号



FOUNTON CAPITAL

HONG KONG

凝聚東西智慧

Converging Minds

Creating Tomorrow

創新醫療未來

大灣區醫療及生命科學創新智庫，2022年創立，以香港為起點，凝聚政、產、學、研，聚焦灣區醫療創新。我們以跨領域政策研究，連結東西方智慧，為區域健康未來提供戰略藍圖。

Founded in 2022 with Hong Kong as our base, we unite government, industry, academia, and research to advance healthcare innovation across the Greater Bay Area. Through cross-disciplinary policy research, we bridge East and West — delivering the strategic blueprint for our region's health future.



智庫先後發表
Our policy proposals —

《香港特別行政區作為大灣區醫療創新樞紐 推動下一波經濟成長》（2025年7月）
Hong Kong SAR as a GBA Healthcare Innovation Hub Driving the Next Wave of Economic Growth (July 2025)

《香港作為「一帶一路」個人醫療服務樞紐倡議書》（2026年7月）
Hong Kong as a "Belt and Road" Personal Medical Service Hub (July 2026)

大灣區醫療及生命科學（香港）創新智庫
GBA(HK) Medicine & Life Science Innovation Think Tank




FASTASeq™ S

CE



FASTASeq™ 300

CE NMPA



GenoLab™ M

CE NMPA



SURFSeq™ 5000

CE NMPA



SURFSeq™ Q

CE



T2400

CE

SURFSeq 5000

CMS™ Sequencing Kit V1.0

CMS™ (Cross Mountains and Seas) is GeneMind' s proprietary sequencing chemistry.Featuring engineered polymerase variants, it dramatically improves performance in difficult genomic regions, enhances coverage uniformity, and delivers unbiased, global Q50 (99.999%) accuracy data.

CMS

Breaking Sequencing Barriers

- Conquering challenging regions
- Delivering uniform genome-wide coverage

Q50

Unmatched Precision

Q40>95% | Q50>70%

Maximum Efficiency

Over 1500 Gb per day
PE150 in as fast as 16 hours



CE NMPA



GeneMind combines CMS™ and Lightning Chemistry Plus™ in the SURFSeq 5000 CMS™ Kit V1.0 to accelerate scientific discovery and industrial-scale sequencing.


GSK
Ahead Together
We unite science, technology and talent to get ahead of disease together.
gsk.com

高特佳投资
GIG GTJA INVESTMENT GROUP

高特佳简介
ABOUT GIG

230亿+管理规模 | 100+大健康企业 | 30家大健康企业IPO

2001年高特佳投资在深圳成立，率先在业内提出“主题行业投资”的投资模式，专注医疗健康产业投资，以战略性股权投资为主导，覆盖VC、PE、Pre-IPO以及并购的全投资阶段，拥有国内为数不多的深度聚焦医疗健康赛道的专业投资团队，致力于成为具有全球影响力的医疗健康投资机构。资产管理规模超230亿元，先后投资100余家医疗健康企业，并推动了30家企业成功上市。高特佳投资业务立足中国，面向全球，在深圳、上海、北京、香港等地建立运营中心。

投资案例 OUR PORTFOLIO

博雅生物 300294 | 迈瑞医疗 300760 | 联影医疗 688271 | 康方生物 09926 | 热景生物 688068 | 圣湘生物 688289

之江生物 688317 | 安必平 688393 | 长风药业 02652 | 复宏汉霖 02696 | 和铂医药 02142 | 维亚生物 08173

中慧生物 02627 | 加科思 01167 | 博安生物 06955 | 拨康视云 02592 | 汇宇制药 688553 | 心泰医疗 02291

方舟健客 06086 | 睿昂基因 688217 | 英派药业 07630 | 丹诺医药 06872 | 天广实 874070 | 华韩整形 430335

新元素医药 | 联影智能 | 维眸生物 | 韬略生物 | 鑫康合生物 | 科望医药

罗森博特 | 图湃医疗 | 清湃科技 | 思康睿奇 | 津渡生科 | 铖联科技

普瑞基准 | 鼎科医疗 | 桥济生物 | 无限医疗 | 四星玻璃 | 先衍生物

昌郁医药 | 时迈药业 | 麦科田 | 达歌生物 | 子瞻生物 | 安诺优达

DEDICATED EXPERT IN HEALTHCARE INVESTMENT

广州
Guangzhou

全球生物医药与健康产业高地
Global Hub for Biomedicine and Health Industry

广州市生物医药发展现状
Current Status of Biomedicine Industry in Guangzhou

广州正全力打造全球生物医药与健康产业高地，具有战略性新兴产业集群，已构建起基础研究-临床转化-中试生产-市场应用完整产业生态，具备产业集群、临床资源、科技平台、创新产出、政策服务、空间载体六大坚实基础。
产业生态健全。广州汇集了6500多家生物医药与健康领域的企业，其中12家世界500强企业、30家上市公司、超1000家高新技术企业。
医疗资源丰富。拥有医疗卫生机构超7600家，其中50家三甲医院，年总诊疗量达1.94亿人次。
科技创新活跃。拥有"人体蛋白质组导航"国际大科学计划、广州国家实验室、中科院健康院、全国高校技术转移转化分中心（细胞和基因治疗、AI制药）等重大平台。
创新产出丰富。成功完成全球首例远程机器人视网膜手术、全国首例地中海贫血基因治疗、全国首例异体干细胞治疗肝衰竭临床应用。盖伦奖中国分支机构正式落户广州。
政策优势明显。广州深入实施"港澳药械通"政策，2025年全市20家指定医疗机构的44种、146批次药品，以及56种、119批次医疗器械取得粤港澳大湾区内地临床急需进口港澳药械批件。出台支持创新药械高质量发展、医保商保多元支付、伦理审查互认等多项生物医药领域配套措施，加快创新药械入院使用与多元支付落地。
产业承载充足."一核两极"高端生物医药产业空间格局逐渐成型（即一核：广州生物岛，两极：中新广州知识城、南沙科学城）

Guangzhou is striving to build a global highland for biomedicine and health industries, home to strategic emerging industrial clusters. It has established a complete industrial ecosystem spanning basic research-clinical translation-pilot-scale production-market application, underpinned by six solid foundations: industrial clusters, clinical resources, science and technology platforms, innovation outputs, policy services and spatial carriers.
Sound Industrial Ecosystem. Guangzhou gathers more than 6,500 enterprises in the biomedicine and health sector, including 12 Fortune Global 500 companies, 30 listed companies and over 1,000 high-tech enterprises.
Abundant Medical Resources.The city has more than 7,600 medical and health institutions, among which are 50 Grade-A Tertiary Hospitals. Its total annual patient visits reach 194 million
Vibrant Scientific and Technological Innovation. It hosts major platforms including the International Human Proteome Navigation Project, Guangzhou National Laboratory, the Institute of Health of the Chinese Academy of Sciences (CAS), and the National University Technology Transfer Sub-Center (Cell and Gene Therapy, AI-powered Pharmaceutical R&D).
Rich Innovation Outputs. Guangzhou has delivered milestone medical achievements, including the world's first remote-robotic retinal surgery, China's first clinical gene-therapy for thalassemia, and China's first clinical application of allogeneic stem-cell therapy for liver failure. The Chinese branch of the Prix Galien has officially settled in Guangzhou.
Distinct Policy Advantages. Guangzhou fully implements the 'Hong Kong-Macao Medicines and Medical Devices Access Scheme'. In 2025, 20 designated medical institutions in the city obtained mainland approval for 44 medicines (146 batches) and 56 medical devices (119 batches) that are urgently needed for clinical use in the Guangdong-Hong Kong-Macao Greater Bay Area, A series of supporting measures for biomedicine have been issued, covering high-quality development of innovative medicines and devices, diversified payment by medical insurance and commercial insurance, and mutual recognition of ethical reviews. These measures accelerate the hospital adoption of innovative medicines and devices and the implementation of multi-payment mechanisms.
Sufficient Industrial Carrying Capacity. The spatial pattern of 'One Core, Two Poles' for high-end biomedicine industries is taking shape, namely: One Core — Guangzhou International Bio Island; Two Poles — China-Singapore Guangzhou Knowledge City and Nansha Science City.



广州国际生物岛
Guangzhou International Bio Island

广州国际生物岛1.83平方公里集聚超700家生物医药企业和10余家省级以上重点实验室，全国高校区域技术转移转化中心生物医药分中心已在此落地。

Covering an area of 1.83 square kilometers hosts more than 700 biomedicine enterprises and over 10 key laboratories at or above the provincial level. The Biomedicine Sub-center of the National University Regional Technology Transfer and Transformation Center has been established here.

中新广州知识城
China-Singapore Guangzhou Knowledge City

中新广州知识城作为粤港澳大湾区唯一的国家级双边合作项目，全球首个PD-1双抗在此诞生，是本土创新药出海标杆；13.6万升的生物药原液产能，打造规模领先的生物制药基地；规划5平方公里国际医疗健康产业园，携手新加坡共建国际肿瘤诊疗平台，聚力打造国际化医疗康养高地。

As the only national-level bilateral cooperation project in the Guangdong-Hong Kong-Macao Greater Bay Area, China-Singapore Guangzhou Knowledge City witnessed the birth of the world's first PD-1 bispecific antibody, making it a benchmark for local innovative medicines going global. Boasting a biologic drug substance production capacity of 136,000 liters, it has built a biopharmaceutical base with leading scale. An international medical and health industrial park covering 5 square kilometers is planned. In partnership with Singapore, an international oncology diagnosis and treatment platform will be constructed to forge an international highland for medical care and health-wellness.

南沙科学城
Nansha Science City

南沙以"一城三谷六园"产业布局为骨架，打造超220万平方米专业化载体，集聚超500家生物医药与健康产业"四上"企业。

ANansha has developed over 2.2 million square meters of specialized industrial carriers and gathered more than 500 industrial enterprises above designated size in the biomedicine and health sector.

中新广州知识城 · 国际医疗健康园

China-Singapore Guangzhou Knowledge City · International Health Park

粤港澳大湾区国际医疗健康与产业创新中心

Greater Bay Area International Medical Health & Industry Innovation Center

知识城区位

Location of Knowledge City

中新广州知识城位于广州市的地理几何中心，规划面积232平方公里，规划人口100万，是中国-新加坡国家级双边合作项目、粤港澳大湾区高水平科创载体。

The Knowledge City is located at the geographical and geometric center of Guangzhou. With a planned area of 232 square kilometers and a planned population of 1 million, it is a national-level bilateral cooperation project between China and Singapore and a high-level scientific and technological innovation platform for Greater Bay Area.




知识城20个组团

20 Industrial Clusters

知识城按照“一核两芯三带多组团”的空间格局，划分为约20个功能组团。本项目位于08单元——国际医疗健康园，地处中部核心区域，毗邻九龙湖田园生态CBD，紧邻迳下美丽乡村、莲塘古村等生态文旅资源。周边已集聚中山六院知识城院区、中山大学附属肿瘤医院、皇家丽肿瘤医院等多家高端医疗机构，是知识城生命科学临床转化与国际医康养服务的关键枢纽。

Located in Unit 08 (International Health Park) at the core of Knowledge City, this project neighbors Jiulong Lake Ecological CBD and cultural sites like Jingxia Village. Surrounded by premium hospitals including Sun Yat-sen University Sixth Hospital, Sun Yat-sen University Cancer Center and Guangzhou Royal Lee Cancer Hospital, it serves as a key hub for life science translation and international medical care.



项目定位

Project Positioning

规划总面积约 5 平方公里。依托生物医药产业优势和生态环境优势，打造**"国际医康养融合服务、前沿生命科技临床转化"**的健康生态圈与产业创新高地。

An area of approximately 5 square kilometers.
Leveraging the advantages of the biomedicine industry and the environment, it aims to create a health ecosystem and an industrial innovation hub featuring "International Medical Care, Health Care Integration Services & Cutting-edge Life Science Clinical Transformation".

医疗开放“试验田”	产业发展“新空间”	广州城市“新名片”
Medical Reform Testbed	Industrial New Space	Guangzhou 's New Icon

五业融合

Five-industry Integrated Ecosystem

打造“药、械、医、养、险”五业融合生态，构建“创新供给—临床验证—健康服务—支付保障”闭环，把研发制造优势转化为临床价值、消费价值和产业价值。

Build an integrated ecosystem of pharmaceuticals, medical devices, healthcare, elderly care, and insurance; establish a closed loop of “innovative supply – clinical validation – health services – payment coverage”; and transform R&D and manufacturing advantages into clinical value, consumer value, and industrial value.

药 Drug

前沿药物转化

- 细胞与基因治疗(CGT)
- 放射性药物
- 专科创新药

- Cell and gene therapy (CGT) products
- Radioactive drugs
- Other specialized innovative drugs

械 Equipment

器械验证应用

- 精准诊疗影像设备
- 前沿药物制备装备
- 专科治疗手术器械
- 康复照护监测设备

- Precision diagnosis imaging
- Frontier drug preparation
- Specialized treatment surgical
- Rehabilitation care monitoring

医 Treatment

国际特色诊疗

市域医疗协同联动
"1+X"特色诊疗专科集群

Urban medical collaborative linkage "1+X" distinctive diagnosis and treatment specialty cluster

养 Wellness

全周期康养

- 循证长寿与健康管理
- 术后康复与医养照护
- 生态康养与旅居度假

- Longevity & Health management
- Postoperative rehabilitation and medical care
- Ecological healthcare and resort living

险 Insurance

国际商保支付

构建患者端和企业端
高端保险服务体系

Build an advanced insurance service system for patients and enterprises

联系方式 | Contact Us

中新广州知识城合作事务办公室 / 中新广州知识城开发建设办公室

China-Singapore Guangzhou Knowledge City Development and Construction Office

地址：广东省广州市黄埔区中新广州知识城亿创街1号人才大厦32楼

Address: 32F, Talent Building, No.1 Yichuang Street, China-Singapore Guangzhou Knowledge City, Huangpu District, Guangzhou



华津医药 | 专注细菌创新药 CRO/CDMO 赋能创新细菌药物高效产业化

Sinogen Pharmaceutical | Specialized CRO/CDMO for Innovative Bacterial Medicines Enabling Efficient Industrialization of Innovative Bacterial Therapeutics

公司简介
Company Profile

广州华津医药是国内少数专注细菌类创新药、专攻细菌药物研发与产业化难题的平台型企业。公司不做泛生物药服务，深耕减毒沙门氏菌溶瘤细菌赛道十余年，依托自研临床II期核心产品 SGN1（桑美威克®）实战经验、国内首个细菌类专属 cGMP 生产基地与药品生产资质，打造细菌类药物专属 CRO+分析方法验证+CDMO+中美双报全链条服务，精准解决行业技术卡点，高效赋能项目从实验室走向临床与商业化。广州华津医药科技有限公司，不做泛生物药 CRO/ CDMO，只做细菌类药物。

Guangzhou Sinogen Pharmaceutical is one of the few platform-oriented enterprises in China focusing on innovative bacterial medicines, dedicated to solving R&D and industrialization challenges for bacterial-based therapeutics. Instead of providing general biopharma services, the company has over ten-year expertise in attenuated-Salmonella-based oncolytic bacteria. Leveraging hands-on experience from its self-developed Phase II clinical lead product SGN1 (SalMet-Vec®), China's first bacterial-dedicated cGMP manufacturing site and drug production license, Sinogen delivers a full-suite service covering bacterial-drug-specific CRO, analytical method validation, CDMO, and Sino-US dual regulatory filing. It addresses key technical bottlenecks and accelerates programs from lab-scale research to clinical trials and commercialization. Guangzhou Sinogen Pharmaceutical Technology Co., Ltd.—We do not provide general biologic CRO/CDMO services; we focus exclusively on bacterial therapeutics.



华津拥有国内首个细菌类药物专属cGMP生产基地，已取得药品生产许可A证，通过药监部门现场核查。
Sinogen owns China's first cGMP-compliant production site dedicated to bacterial therapeutics. It has obtained the Drug Production License and passed on-site inspection by pharmaceutical regulatory authorities.



服务简介
Service Introduction

一、核心差异化：只做细菌赛道，专攻细菌类药物难题
1.Core Differentiation: Focus exclusively on the bacterial-therapeutic segment, tackling technical challenges for bacterial-based medicines

二、全链条专属服务（细菌类药物定制化）
2.End-to-End Dedicated Services (Customized development for bacterial therapeutics)

三、四大技术平台，筑牢细菌药物产业化壁垒
3. Four Major Technology Platforms, building solid foundations for industrialization of bacterial medicines.

四、安全等级：BSL-2 实验室
4.Biosafety Level: BSL-2 Laboratory

联系我们
电话：020-89853002
邮箱：sinogen@sinogen.cc
地址：广州市黄埔区开源大道11号C5栋101室

Contact Us
Tel: +86-020-89853002
Email: sinogen@sinogen.cc
Address: Room 101, Building C5, No.11 Kaiyuan Avenue, Huangpu District, Guangzhou

商务合作咨询 Business Cooperation Inquiry

项目经理 Project Manager

广东大光控股集团有限公司

广东大光控股集团有限公司是一家现代化医药企业，其主营业务覆盖医药研发、药品生产、互联网医疗及大健康产业。集团旗下拥有广东中科药物研究有限公司、广州大光制药有限公司、吉林省中晟制药有限公司、大光药业有限公司、大光惠世医疗科技有限公司等子公司。



创新药管线

产品代码	治疗领域	临床前	I 期	II 期	III 期	NDA
ZONK018	术后疼痛					
ZONK1103	脑卒中					
DGYF68	脑卒中					
DGYF08	眼部炎症					
ZONK2301	肝脏和肺纤维化					
ZONK1901	前列腺癌					

脑卒中全球1类创新药DGYF68

[redacted]

- 动物试验药效学研究结果表明：DGYF68 对 MCAO 小鼠的行为学、脑梗死面积、脑水肿等方面均表现出明显药效作用，优于阳性药依达拉奉，均表现出统计学显著性差异（p<0.01 vs. Edaravone）。

DGYF68（灌胃）	VS	依达拉奉注射（注射）
52.04%	梗死改善率	27.66%
27.11%	脑血流差	33.13%
0.371ml	脑体积	0.385ml

- 本项目即将获得国内IND批件，计划2026年年底开展 I 期临床。
- 专利情况

（1）国内专利：本项目的化合物专利已在中国授权。
专利名称：《一种杂环化合物及其制备方法与应用》
专利号：ZL 202211368240.8

（2）国际PCT专利

[redacted]

中国·广东省广州市黄埔区瑞泰路 号

Akesobio 康方生物

肿瘤免疫治疗2.0时代开创者
A PIONEER OF THE IMMUNO-ONCOLOGY 2.0 ERA

康方生物（9926.HK）成立于2012年3月，是中国原创生物药物研发的先行者，也是中国极少数拥有完善全链条独立自主新药开发体系、生产体系和商业化体系的公司。

自成立以来，公司始终以患者为中心，以临床价值为导向，打造了独有的端对端康方全方位新药研究开发平台，构建了AI制药研发技术赋能、覆盖双抗/多抗、ADC、TCE、siRNA技术、细胞治疗及mRNA等全球生物医药前沿开发技术的研发创新体系，建立了国际化标准的GMP生产体系和运作模式先进的商业化体系，成为了全球范围内具有竞争力的生物医药创新公司。

Akeso, Inc. (9926.HK) established in 2012, is a biopharmaceutical company founded by a team of scientists with extensive experience in global drug development. Since its inception, Akeso has established the unique end-to-end Akeso Comprehensive Exploration Platform (ACE Platform), building an AI-powered R&D innovation system centered on core technologies including BsAb/MsAb, ADC, TCE, siRNA, Cell Therapy, and mRNA. The company has also built an internationally standardized GMP-compliant manufacturing system and a commercialization system with advanced operational models. Akeso has emerged as a globally competitive biopharmaceutical innovation company.

肿瘤 Oncology
自身免疫 Autoimmune diseases
炎症 Inflammation
代谢 Metabolic diseases
呼吸 Respiratory disease
神经中枢系统 Neurological diseases

聚焦前沿，源头高质量创新：具有全球创新价值的高潜力管线科学推进

Independent and globally leading technology: Akeso is devoted to FIC/BIC drugs with vast market potential and strategically focuses on core and cutting edge areas in biopharmaceuticals

50+ 独立自主研发的创新候选药物
in-house-developed innovative candidate drugs

8 商业化销售新药
marketed products

30 新药进入临床研究阶段
drug candidates at clinical stage

160+ 临床项目在中美澳等国开展
ongoing clinical trials worldwide

全球双抗开发领导者：强势引领全球双抗新药的发展新浪潮

A global leader in bispecific antibody drug development: Driving a new wave of global bispecific antibody innovation

2 商业化全球首创双抗
commercial - stage FIC BsAbs

15 潜在FIC、BIC双抗/多抗/双抗ADC
potential FIC and BIC BsAb/MsAb/BsAb ADC drugs

全球第一个
肿瘤免疫治疗双抗
WORLD'S FIRST DUAL IMMUNE CHECKPOINT INHIBITOR BISPECIFIC ANTIBODY
中国专利金奖 China Patent Gold Award

全球第一个
肿瘤免疫+抗血管机制双抗
WORLD'S FIRST IMMUNE CHECKPOINT INHIBITOR+ ANTI ANGIOGENESIS BISPECIFIC ANTIBODY
全球首个头对头战胜“药王”帕博利珠单抗 The First Drug to Beat Pembrolizumab in a Phase III Head-to-Head Monotherapy Trial

胃癌 Gastric cancer
宫颈癌 Cervical cancer
肺癌 Lung cancer
肝细胞癌 Hepatocellular carcinoma
胰腺癌 Pancreatic cancer
结肠癌 Colon cancer
食管鳞癌 Esophageal squamous-cell carcinoma



肺癌 Lung cancer
胰腺癌 Pancreatic cancer
结直肠癌 Colorectal cancer
头颈鳞癌 Head and neck squamous-cell carcinoma
胆道癌 Biliary tract cancer
乳腺癌 Breast cancer
肝细胞癌 Hepatocellular carcinoma

康方在广州、中山等地建立了国际GMP标准、规模化的商业生产基地，具备自主生产高质量药物的能力及成本优势。

Backed by large-scale, world-class GMP manufacturing facilities in Guangzhou, Zhongshan and other production sites, Akeso supports robust in-house manufacturing capabilities for high-quality drug production with strong cost-competitiveness.



康方生物
网址： www.akesobio.com

版权所有 © 2012-2026 康方生物
Copyright 2012-2026 Akeso, Inc.

Biosyngen
百吉生物医药

百吉生物医药 | 中新合作標杆 免疫治療領域的國際領先企業

| 聯系方式

地址:中國廣州：廣州市黃埔區中新知識城粵港澳大灣區創新產業集聚區6號樓B座1-4層
新加坡：Taiseng Exchange, 5 TaiSeng Avenue, #08-51/52/53/54, Tower C, Singapore 536671
網址:www.biosyngen.com
電話:+86 6231 1128 (CHINA) +65 6908 0398 (SINGAPORE)
郵箱:info@biosg.com

扫码关注微信公众号



公司簡介

百吉生物（Biosyngen）是一家深度布局中國與新加坡的國際化生物技術公司，專注于開發針對實體瘤的突破性T細胞免疫療法。公司于2016年在新加坡成立，2017年入駐廣州黃埔，現已成長為免疫細胞治療領域的國際領先者。在中國華南地區和新加坡，公司分別建有當地最大的私立GMP細胞生產基地，成為中新兩國生物技術合作的典範。

公司匯聚了全球頂尖科學家團隊，成員包括法國科學院院士、前FDA審評專家等。產品管綫精準聚焦鼻咽癌、肝癌等目前缺乏有效治療手段的實體瘤。核心產品BRG01（鼻咽癌CAR-T）和BST02（肝癌TIL療法）均為全球首創，已獲美國FDA快速通道或孤兒藥資格，臨床數據展現出強勁的國際競爭力。所有核心產品均實現中美雙報，目前已累計獲得8項中美I期臨床試驗批件和2項II期臨床試驗批件，為產品同步進入全球主要市場奠定基礎。此外，有兩項新技術依據中國《818號令》獲得備案資質。百吉生物還與多家國內外頂級科研及醫療機構建立了長期緊密的合作關系，包括新加坡科技研究局（A*STAR）、德國慕尼黑赫姆霍茲中心、德國漢諾威醫學院、澳洲昆士蘭醫學研究所、美國斯坦福大學醫學院、法國古斯塔夫·魯西癌症中心（歐洲最大、全球排名第四的癌症中心）、中山大學腫瘤防治中心、復旦大學附屬腫瘤醫院等，豐富的科研及臨床資源覆蓋全球。





First-in-Class產品管綫 擁有全球權益技術與資源 具備拓展潛力

擁有自主知識產權的多技術路徑
First-in-Class抗腫瘤細胞治療產品管綫，能够實現全球授權





產品管綫同時覆蓋三大前沿T細胞療法CAR-T、TCR-T、TIL，并均已進入臨床階段

已獲得8個中美注册臨床IND批件及2個中美II期臨床批准，1條管綫已進入II期

療法/技術	適應症	產品	首個適應症	權利	臨床前	概念驗證臨床IIT	I 期	II 期	NDA/BLA
CAR-T/TCR-T	EBV陽性腫瘤	BRG01	鼻咽癌	全球	臨床I期已完成，臨床II期進行中				
		BRL03	EBV陽性腫瘤	全球	臨床I期進行中				
條件式激活裝甲CAR-T	腸胃道腫瘤	BGT007	結直腸癌、胰腺癌等	全球	IIT進行中				
TIL	肝癌	BST02	肝癌	全球	臨床I期進行中				
TIL	肺癌	BST08	多種實體瘤，包括非小細胞肺癌等	全球	IIT進行中				
通用型CAR-T	泛腫瘤	通用型雙靶點CAR-T細胞，低剂量强投傷	多種實體瘤	全球	臨床前研究				

快速通道資格認定
孤兒藥資格認定

東源药业

| ORIPLAMACY |



廣州市東源藥業科技有限公司

Guang Zhou Oriplamacy Technology Co., Ltd

一家專注于天然植物藥研發的高新技術企業

公司簡介 Company Profile

廣州市東源藥業科技有限公司是一家以前沿物理化學驅動天然藥物與新材料創新的生物醫藥研發企業，總投資7億元。公司專注于天然植物來源新原料及新原料前體的研發與生產，應用方向覆蓋藥品、醫療器械與化妝品，致力於篩選並開發安全、具有明確生物學功能的天然分子，下設蔚析藥研中心、GMP標準生產中心、致構醫學檢測中心、穗港澳華僑糖尿病創新研究院臨床中心四大中心。先後獲評省重點實驗室、國家高新技術企業等資質。

公司1.2類中藥創新藥已經獲得兩項臨床批件，聚焦糖尿病足潰瘍等慢性難愈創面。相關研究成果已在國際權威期刊發表多篇國SCI論文，並取得50多項發明專利。現已研發推出食、妝、械多個字號產品，入駐全國近百家連鎖藥店，覆蓋代謝調控、免疫調節、難愈創面修復、抗衰老等賽道，市場反響良好。

核心技術平臺

Core Technology Platform



發展前景 Development Prospects

戰略目標	打造以基礎科研、底層材料創新為核心的綜合性材料科學中心，持續為醫藥、醫療器械、化妝品行業輸出高品質天然新原料及原料前體。
研發佈局	依託現有技術平臺，推進活性茶多酚在心衰治療藥物方向的研發；將紅藻卡拉膠打造為可提升藥效、降低毒副作用的高端仿製藥藥用輔料。
發展願景	持續推動前沿物理化學技術產業化落地，以原創新材料、新技術助力中藥現代化發展，賦能國內製藥產業轉型升級。

廣州市東源藥業科技有限公司

Guang Zhou Oriplamacy Technology Co., Ltd

服務熱綫：020-8759-7282 182-4494-0851

地址：廣州市天河區廣州大道中918號8樓

掃碼關注公衆號　客服微信

一品红 ApicHope | 股票代码 300723.SZ

全球化發展　打造創新型生物醫藥企業

一品紅藥業集團股份有限公司（ApicHope，300723.SZ）創建於2002年，2017年在深交所掛牌上市，員工逾1,300人，是聚焦於兒童藥及慢病藥研發、生產的創新型醫藥企業，擁有國家企業技術中心、國家級企業博士（後）科研工作站等技術研發平台，榮獲「中國化藥研發綜合實力百強企業」「中國化藥百強企業」以及「廣州市生物醫藥及高端醫療器械產業鏈鏈主企業」稱號。

錨定「全球新」的核心研發戰略，公司組建由全球資深首席科學家領銜的創新研發團隊。2025年研發投入佔營收21.7%，連續5年每年新增藥品註冊批件位居廣東省第一。在研創新藥項目10多個，覆蓋痛風、糖尿病、肥胖及自免等多種疾病領域，搭建了PROTAC等多個創新技術平台。

21.7% 2025年研發投入佔營收比重	240人 創新研發團隊
10餘項 在研全球創新藥	221個 藥品註冊批件

- 兒童藥領域
  - 30個 兒童藥註冊批件
  - 7個 在研兒童藥項目
- 慢病藥領域
  - 78個 慢性藥註冊批件
  - 17個 在研慢病藥項目

綠色智能製造基地　構築全球化供應能力

Green Intelligent Manufacturing Base: Building Global Supply Capabilities

一品紅藥業聯瑞智能製造基地專注全球創新藥、高端製劑、出口製劑的智慧化生產，嚴格按照中國、美國FDA及歐盟GMP標準建設，具備全球供應能力。現時已建成凍乾粉針、小容量注射劑、口服固體製劑、口服液、中藥提取等7個生產車間，並配備全自動化、智能化高架倉庫。廠區配備全球先進生產設備，部分車間實現「黑燈工廠」自動運行，並基於工業4.0理念，實現ERP、MES、DMS等全範圍信息化管理，讓產品更高效、更安全地送到患者手中。






全球痛風創新藥氘泊替諾雷(AR882)

A Global Innovative Gout Therapy: Pozdeutinurad (AR882)




效果展示圖
僅供醫學專業人士參考

- 目前全球唯一有效溶解痛風石的口服創新藥物，在研痛風、痛風石及慢性腎病三大適應症。
- 已完成全球多中心關鍵III期臨床REDUCE2研究，並取得積極頂線結果；中國多中心III期臨床實驗即將完成
- 獲得美國FDA快速通道審批資格
- 2023年，在美國風濕病學會(ACR)年會發表主題演講；2025年，在歐洲風濕病學會(EULAR)年會發表專題演講

已完成的全球多中心II b期臨床試驗數據顯示：

與現有療法相比，氘泊替諾雷(AR882)治療痛風患者的療效更顯著，安全性更高；除降低痛風患者的血清尿酸(sUA)，還能顯著減少痛風石、減輕尿酸結晶負擔及降低痛風急性發作率。

氘泊替諾雷(AR882)可有效溶解痛風石、緩解痛風性關節炎



OCUSUN 润尔眼科　全球首創白內障滴眼液

THE WORLD'S FIRST PHARMACOLOGIC THERAPY FOR CATARACT (EYE DROPS)



效果展示圖
僅供醫學專業人士參考

關於润尔眼科


廣州润尔眼科生物科技有限公司專注於眼科藥品全球化創新，在研10多個全球創新藥，涵蓋白內障、乾眼症、青光眼、眼科炎症和感染等眼科疾病領域。在研的白內障滴眼液是新靶點、新機制的原始創新First-in-class（全球首創）藥物，是全球處於註冊性臨床唯一的白內障治療藥物，解決白內障疾病只能通過手術治療的革命性技術，具有重大臨床意義。

公共衛生和社會價值

- 上市後，能有效為醫保和患者節約費用支出。
- 可加強“一帶一路”赤道國家和高原國家合作交流，助力國家戰略實施。

全球首創白內障滴眼液研發進展

- 即將開展國內III期臨床試驗及全球多中心III期臨床試驗。
- 前期研究成果發表在全球頂尖期刊《Nature》及《Science》。
- 全球申請專利100 + 篇，並已在40多個國家或地區獲得專利權。
- II期臨床試驗數據顯示，該藥物可有效提升患者視力，有望成為全球首款白內障非手術干預療法，填補目前藥物治療領域的空白，為全球6億白內障患者帶來光明的希望。
- 在CNBC全球科技大會作成果展示，被國家藥監局大灣區審評中心列為重點品種。



RoyalLee 廣州皇家麗腫瘤醫院

国际JCI认证医院
JCI Accredited Hospital

廣州皇家麗腫瘤醫院



廣州皇家麗腫瘤醫院為 JCI 國際認證三級腫瘤專科醫院，開放床位 400 餘張，具備國家藥物臨床試驗及醫保定點雙重資質，與海內外 40 餘家保險機構深度合作，嚴格遵循國際醫療標準，為跨境患者提供正規、可靠的高端醫療保障。

醫院立足多學科腫瘤治療體系，融貫傳統手術、放\化療、靶向與免疫治療，同時領航微創介入前沿 — 釔 90 微球治療、質子治療、冷凍消融、納米刀消融、粒子植入、微波消融、光動力療法等創新技術，資深腫瘤專家團隊為患者提供個體化、精準化的綜合治療方案。全程服务贯穿海内外患者，提供“从舱门到院门”的一站式服务。医院尊重不同的文化习俗。在腫瘤康復領域，醫院整合中醫學、營養學、心理學，以疼痛管理、睡眠管理為特色，切實減輕患者痛苦，延長生命，提升生活品質。

醫院以「敬佑生命」為宗旨，依托入住式體檢、提供「腫瘤早篩 — 慢病管理 — 機體抗衰」全週期健康服務。

Guangzhou Royal Lee Cancer Hospital is a JCI-accredited tertiary specialized oncology hospital with over 400 beds. Certified as a national drug clinical trial institution and designated medical insurance provider, it maintains deep partnerships with more than 40 insurance providers worldwide. Adhering strictly to international medical standards, the hospital delivers trustworthy, high-quality healthcare for cross-border patients.

Built on a comprehensive multidisciplinary oncology system, the hospital integrates surgery, radiotherapy, chemotherapy, targeted therapy and immunotherapy, while offering minimally invasive interventional treatments. The full range of advanced technologies includes Y-90 microsphere radioembolization, proton knife therapy, cryoablation, NanoKnife ablation (irreversible electroporation), radioactive seed brachytherapy, microwave ablation and photodynamic therapy. A senior expert team formulates precise, individualized comprehensive treatment plans for every patient, providing end-to-end, cabin-to-bedside one-stop services for patients worldwide. The hospital respects the diverse cultural customs and traditions of its patients.

For oncology rehabilitation, the hospital integrates traditional Chinese medicine, nutritional therapy and psychological intervention. Featuring professional pain and sleep management, it effectively alleviates patients' suffering, prolongs survival and improves quality of life.

Upholding the philosophy of *Reverence for Life*, the hospital offers on-site comprehensive health assessments and full-cycle health services covering early cancer screening, chronic disease management and anti-aging care.



熱綫電話：+86 186 1301 2387

醫院地址：中國廣東省廣州市黃埔區中新知識城慈濟路 1 號

Whats APP

We Chat

水木医疗-医疗器械全产业链一站式服务平台

工程化研发 + 动物实验 + 检验检测 + 临床试验 + 注册 + CDMO（含 IVD 标准品、质控品研发生产）+ 市场准入及医师培训

水木医疗
SHUIMU MEDICAL

ONE-STOP MEDICAL DEVICE FULL-INDUSTRY-CHAIN SERVICE PLATFORM

医疗器械全产业一站式服务平台

工程化研发 | 检验检测 | 临床试验 | 注册 | CDMO | 动物实验 | 市场准入



水木医疗科技服务集团
Shuimu Medical Technology Service Group

集团于2017年成立，总部位于北京经济技术开发区，本着致力于加快创新医疗器械产品注册上市进程的初心，以"让天下没有难做的医疗器械"为愿景，创建了全球首个医疗器械"工程化研发＋检验检测＋临床试验＋注册＋CDMO+应用推广"全产业链一站式服务平台，为医疗器械产品全生命周期提供"端到端"一体化创新服务。

Business Flow

Beijing Zhongguancun Shuimu Medical Technology Co., Ltd.

Functional R&D	Engineering R&D	Animal Experiment	Testing & Inspection	Clinical CRO	Registra-tion	CDMO	Market Access
Medical Device Manufacturers	Chengdu Shuimu Shuimu Jiheng	Shuimu Jingzhi	Shuimu Medical Laboratory	Shuimu Jingchuang	Shuimu Jingzhi	Active and Passive Devices / IVD → Chengdu Shuimu Shuimu Jinsheng	Medical Training → Shuimu Jingzhi

Enhancing product reliability and regulatory compliance

Addressing challenges of long timelines, high costs, and difficulties in hospital access

Efficiently enabling the transition from innovative concepts to product development and ultimately to commercialization


Information Flow




企业优势

所有核心技术成员均拥有超过15年在医疗器械行业技术检验领域的丰富经验，是医疗器械领域电气安全、电磁兼容性、 IVD 及医疗器械软件等领域的专家。此外，在质子与重离子大型核医学设备领域，该团队目前是中国唯一具备为医疗器械提供产业化设计与测试服务经验的团队。

拥有国内首家民营医疗器械第三方专业检验检测实验室，是国家高新技术企业，北京市"专精特新"中小企业。公司曾获北京市科学技术进步一等奖，获得众多国家级、北京市级重大科研项目支持，参与多项国家、行业、团体等标准制定。


电磁兼容实验室


可靠性实验室


软件实验室


机械实验室


电气安全通用实验室

水木医疗·粤港澳大湾区分中心

广东水木医疗科技有限公司成立于2025年6月，位于广州市黄埔区，一期已建3000方检测实验室，配有专业的检测团队和经验丰富的临床团队，二期9000方（预计2028年完工），将完善概念验证中心、CDMO、医师培训中心等其他链条。

作为水木医疗科技服务集团的粤港澳大湾区分中心，将复制水木医疗的全部服务功能，为客户提供高质量高效率的医疗器械全流程一站式服务。



广东省广州市黄埔区友谊路102号

186-2044-6068

让天下没有难做的医疗器械

Making medical devices easier to develop worldwide

Engineering R&D + Animal Studies + Testing & Inspection + Cinical Trials + Registration + CDMO (including research and production of IVD reference materials and quality controls) + Market Access and Physician Training

Shuimu Medical--One-stop service platform for the entire medical device industry chain

GHIC Guangzhou Hi-tech Investment Group Co.,Ltd



廣州高新區投資集團有限公司

致力於成為粵港澳大灣區世界級生物產業集群運營商

公司簡介

廣州高新區投資集團有限公司成立於 1984 年，總資產超 850 億元，擁有 AAA 主體信用評級，重點打造生物產業集聚發展、創新轉化、投資賦能 3 大核心平台，重點培育 CXO、生物製造、醫療健康、藥械流通 4 大重點領域，在腦機介面、AI + 製藥、核藥等前沿新賽道中積極佈局，打造引領區域產業發展的國際化生物產業集群運營商。


- 500+ 万㎡ 專業園區
- 4000+ 家 生態夥伴企業
- 3000+ 位 產業英才
- 200+ 亿 生物醫藥專項基金
- 一站式 CXO服務平台

投資領域

大分子藥 | 小分子藥 | CXO | 醫療器械 | 檢驗檢測

服務體系

高新區集團下設生物島生物產業服務中心 Bio Island Industry Service Center（BISC），作為集團超級聯絡人及統一服務視窗，BISC立足生物醫藥全產業鏈，統籌需求識別、智能分單與進度跟蹤，打通各類資源壁壘，同步提供註冊、金融、設備租賃等配套支撐服務。



地址：廣東省廣州市黃埔區科學大道映日路 1 號　　網址：http://www.gddidg.com

广州开发区
低空产业发展有限公司

企业背景

广州开发区交通投资集团全资子公司，粤港澳大湾区低空经济产业联盟理事单位。布局低空基建、无人飞行器产销、AI应用、保税物流等业务，拥有3项低空服务平台软著，配套800米试飞跑道，落地无人机跨境配送、保税物流、九龙湖无人航空器观光业务。



低空物流 | 医疗物资配送优势

·极速转运 抢出救治时间
不受地面拥堵制约，快速配送生物试剂、检验样本、急救物资，大幅压缩医疗物资流转时长。

·低损耗 保障物资品质
飞行路径稳定可控，颠簸少，货损率低，适配核酸样本、生物制剂等对运输条件敏感的医疗物资。

·全程可溯 满足医药物流合规
飞行轨迹、货物状态数据实时留存，源头到末端全链路溯源，契合医疗物资监管要求。

·场景灵活 覆盖复杂地域
可通达道路受限区域，兼顾城市、郊野场景，弥补地面运力短板，应急医疗补给响应更快。

现实项目成效

2025年4月起累计执行**511**单，飞行**857**架次，起降**2607**架次。打通物流与海关监管壁垒，打造安全高效合规绿色低空物流，形成可复制推广运营模式。

运送外资高保值医疗物资，常态化运行，时效较陆运提升**50%**，综合运输成本下降**30%**；货损率降至**0.3%**以下；电力驱动减碳**26.3**吨，实现飞行、货物、监管“三零”记录。

源瑞达®：中国唯一获批白血病，淋巴瘤两大适应症的CAR-T

纳入国家医疗保障局
《商业健康保险创新药品目录（2025）》

01 白血病、淋巴瘤双适应症

- 2023年11月，纳基奥仑赛获NMPA批准 中国第一，世界第二
- 2025年11月， r/r LBCL[2]

02 结构独特，疗效潜在最优

- 获国家发明专利
- ORR[5]85.4%，MRD[6] 100%
  ORR[5]92.4%，MRD[6] 97.8%

源瑞达®
Inaticabtagene Autoleucel Injection (Ina-cel)



03 国际领先的工艺水平

04 多适应症布局

- r/r B-ALL
- (SLE-ITP)IND (AIHA)IND、(SLE-LN)IND



广州市微米生物科技有限公司

公司简介

广州市微米生物科技有限公司2013年成立，坐落于联东U谷亿航智能科技园，为国家级高新技术IVD企业，集研产销一体化运营。公司坐拥七大主流诊断平台核心技术，搭建“一体两翼”技术发展体系，产品覆盖心脑血管、炎症、妇产、肿瘤、糖肾等多赛道检测项目，服务全国两千余家医疗机构。企业以“让检测更准、更快、更方便”为使命，秉持“一米之势始于微”文化，严守品质底线，矢志打造全球领先的体外诊断企业。

产品介绍

✦ 循环血小板活化状态监测

流式细胞术检测血小板膜糖蛋白（CD41/CD42a/CD42b/CD61）、血小板活化标志CD62P及血小板-白细胞聚集体（CD45/CD61/CD14），综合评估血小板黏附聚集功能、血栓风险，辅助血栓性疾病诊断、预后评估及炎症免疫状态监测。

✦ 抗板药（AA、ADP）药效监测

通过流式细胞术分析血小板在特定激动剂（如花生四烯酸AA和二磷酸腺苷ADP）刺激下表面P-选择素（CD62P）的表达水平，从而直接、灵敏地评估阿司匹林、氯吡格雷等常用抗血小板药物的生物学疗效。实现了对治疗方案的动态评估与个性化调整。

✦ 细胞因子检测

检测指标可包括IL-2/1L-4/IL-5/IL-6/IL-8/1L-10/IL-12p70/IL-17/IL-1β/TNF-a/IFN-α/IFN-γ。

细胞因子在炎症反应和免疫调节中起着重要作用，临床利用细胞因子谱判断炎症负荷，其升高或降低的情况往往反映了机体不同的病理生理状态，涉及感染、免疫疾病、肿瘤等多个领域。

✦ 淋巴亚群检测及绝对计数

评估细胞免疫与体液免疫水平，反映机体免疫状态及平衡，辅助诊断血液病、肿瘤、免疫缺陷、感染等疾病，用于发病机制分析、疗效监测及预后判断。

✦ 调节性T细胞检测

“免疫刹车”细胞，预警自身免疫病、肿瘤免疫逃逸及移植排斥风险，用于辅助临床判断免疫状态，指导个体化治疗策略。

✦ PD-1检测

PD-1是主要表达于T细胞上的免疫抑制分子，参与肿瘤免疫逃逸、病毒感染及自身免疫调节。用于辅助肿瘤进展评估、抗PD-1治疗疗效监测、手术预后判断，以及感染/自身免疫性疾病的病情进展评估。

✦ B族链球菌检测

B族链球菌（GBS）可致新生儿肺炎、败血症等严重感染。产前检测可及早发现阳性孕产妇，通过抗生素干预有效预防孕产妇并发症及新生儿垂直传播感染，降低母婴风险。

✦ IGFBP-1·fFN 双联检

胰岛素样生长因子结合蛋白-1(IGFBP-1)与胎儿纤维连接蛋白（fFN）双联检，可同时评估胎膜完整性及早产风险。IGFBP-1特异性诊断胎膜早破，fFN预测早产风险，联合检测能明确区分单纯早产或合并胎膜早破，为临床精准治疗提供依据。

✦ 血清淀粉样蛋白A测定

血清淀粉样蛋白A（SAA）水平是反映感染性疾病的灵敏指标，有助于感染的诊断、病情评估及转归预测。

广州市微米生物科技有限公司
地 址：广州市黄埔区大沙街道碧山大街29号联东U谷D1栋三楼D301房
电 话：020-82350856　020-31704194　　邮 编：510663
邮 箱：wmbio@weimijia.cn　　网 址：www.weimibio.com

长沙市微米生物科技有限公司
地 址：湖南省长沙市开福区沙坪街道中青路1048号山河医药健康产业园标准厂房3栋201房
电 话：0731-86200263　　邮 编：410003

©WM2026-07-02

广州知易生物科技股份有限公司

——活体生物药开发到申报一站式解决方案提供商

活体生物药合作开发

早期发现
Development Strategy

- 根据产品开发的不同阶段，制定合适的CMC开发策略
- 结合前期有效性数据，选择工艺规模及制定工艺开发策略

临床前
Preclinical

- 菌株安全性评价
- 药效评价
- 菌株特性鉴定
- 三级种子库建立及检定
- 菌粉工艺开发

临床期间
During the Clinical Period

- IIT/临床批样品制备
- 工艺放大研究与验证
- 稳定性考察

NDA
New Drug Application

- 商业化生产策略及技术转移
- 已上市产品CMC升级

微生态产品研发

01 功能性菌株评价

- 数据库：模型预测、功能预测
- 全基因测序及生物信息学分析：毒力基因分析，耐药基因分析
- 安全性：药敏、溶血、产毒
- 有效性：益生特性、生化特性
- 动物试验：毒性试验、肥胖模型、IBD模型、过敏性鼻炎模型……

02 消费品开发

- 拥有数万株自主分离益生菌菌种库
- 益生菌食品发酵、菌粉
- 益生菌日护品、保健品
- 宠物营养剂、奶粉、饲料、猫粮/狗粮、肥料、环保

03 现有人药管线在动保上的授权/合作

- 动物/宠物新药
- SK08（活菌型）：人药适应症4个、（UC/IBS/肿瘤/儿童腹泻），临床III期
- SK10（灭活型）：人药适应症1个（化疗腹泻），美国临床I期已完成
- AKK（活菌型/灭活型）：代谢，临床前已完成

菌株分离：样本采集 | 样本处理 | 菌株分离 | 物种锁定 | 保藏交付

发酵工艺优化及菌粉制备：发酵工艺优化 | 发酵过程控制 | 发酵放大 | 菌体收获 | 冻干工艺优化 | 菌粉交付

检测与质量研究：活菌数检测 | 微生物限度检测 | qPCR特异性分析 | 流式细胞术定量检测

地址：广州市黄埔区瑞泰路2号A栋301室

邮箱：service@zypharm.com.cn

电话：020-82258826/ 17328304717

ASTRI

Hong Kong Applied Science and Technology Research Institute
香港應用科技研究院

Hong Kong Applied Science and Technology Research Institute (ASTRI) was established in 2000 by the HKSAR Government. As Hong Kong's largest government-funded R&D centre, ASTRI serves as a key innovation driver and super-connector linking Hong Kong, the Greater Bay Area and the global ecosystem, strengthened by its merger with Nano and Advanced Materials Institute (NAMI).

7 Core Areas



Smart City


FinTech


Digital Health and Life Sciences


New Industrialisation and Intelligent Manufacturing


New Energy and Energy Storage


Application-Specific Integrated Circuits (ASIC) and Advanced Electronics


Green and ESG Technologies

9 Technology Divisions

ICT
- AI Platform and Solutions
- Communications Technologies
- Advanced Electronic Components and Systems
- Intelligent Sensing and Control Solutions

Materials
- Electronic Materials
- Battery Materials
- Construction Materials
- Biomaterials
- Functional Polymer

www.astri.org

Enquiry

LEADING INNOVATION • BREAKING BOUNDARIES

香港 檢測 | 認證
TESTED | CERTIFIED
IN HONG KONG

hkctc 香港檢測和認證局
The Hong Kong Council for Testing and Certification
www.hkctc.gov.hk

高度專業誠信
High Professional Integrity

完善的知識產權保障
Good Intellectual Property Protection

卓越技術水平
High Technical Competence

敏銳的市場觸覺
Quick Response to Market Needs

健全的認可制度，廣獲國際承認
Robust Accreditation System
Being Highly Regarded Internationally

擁有先進的物流支援
Excellent Logistics Support



使用獲香港認可處認可的機構所提供的檢測認證服務，可提高顧客對你的產品和服務的信心。
Using testing, certification and inspection services provided by Hong Kong Accreditation Service's accredited organisations could enhance customers' confidence in your products and services.

HKAS

想找合適的獲認可機構，請瀏覽香港認可處網站：
To find a suitable accredited organisation, please visit the website of Hong Kong Accreditation Service:

www.hkas.gov.hk



Hong Kong's Largest Life & Health Technology Ecosystem

ALL ROUND SUPPORT FROM BENCH TO BEDSIDE



- Biomedical Technology Support Centre
- Biobank & Histopathology Services
- Biological Resource Program
- Drug Safety Testing Center
- Medical Device Testing Lab
- Advanced Therapy Products GMP

Scan for more info

COMMUNAL LABORATORIES FOR EARLY STAGE STARTUPS

PHYSICAL LABS

- Biomedical Labs
- Chemical Labs
- Engineering Labs

SUPPORTS

- Clinical Translational Catalyst
- Medtech Co-Create Program
- Healthy Ageing Platform



A Hub for Pooling Global I&T Resources
全球創科資源匯聚點

HSITP 港深創科園

HSITP HSITP港深創科園 www.hsitp.org

弘毅投资
HONY CAPITAL

智汇资本 创造价值

1200亿+
资管规模

100+
被投领军企业

200万㎡+
一线城市商用物业

4个
控股上市平台

弘毅投资成立于2003年，是中国领先的投资管理集团，以“智汇资本，创造价值”为使命，拥有私募股权、不动产、证券基金、直管实控平台等业务板块。

弘毅投资管理资金总规模超1200亿人民币，聚焦数智科技、生命健康、新能源新材料、消费文娱等产业赛道，通过运营管理及科技创新全方位赋能打造100+行业领军企业。弘毅不动产管理一线城市商用物业资产规模超200万平方米，已投资产规模超400亿元。

弘毅投资致力于成为业绩优良、值得信赖、受人尊重的投资管理集团，持续引领行业，助力实体经济蓬勃发展！



北京 | 上海 | 深圳 | 香港
WWW.HONYCAPITAL.COM

人工智能
字节跳动 · 商汤 · 4Paradigm · 美图 · 创梦天地 · 晨鸿科技 · REBIRTH · 留形科技 · …

半导体/信息技术
紫光展锐 · 紫光国芯 · CVA芯华科技 · Aurasemi · IC Bench伴芯 · Geega · 影微创芯 · sicoya · …

新能源/新材料
ENN新奥 · 盈峰环境 · LINYANG · 国家电投 SPIC · 氢能公司 · SVOLT · 电管家集团 · SFCC · …

医疗健康
FibroGen · cutia · BIOSENSORS · 康臣药业 · 全亿健康 · LaNova · 清虹药业 · Neusoft · …

消费及服务
王府井集团 · 物美 · 明珠家居 · 九阳 · 芒果tv · 中粮资本 · 溪木源 · 粉笔 · 喜见小厨 · …

垂直布局 核心赛道

巨人网络 · 神州数码 Digital China · CIMC中集 · JUSHI · CNG中玻控股 · ZOOMLION · 石药集团 · Simcere · LI & FUNG

并购交易数 近30笔
并购交易规模 约250亿元
并购交易占比 25+%

并购积累 产业资源

華領醫藥

中華引領
醫藥創新



全球首創GKA，中國首發

降糖新藥葡萄糖激酶激活劑，現已於中國香港上市
修復感應 · 重塑穩態 · 從源頭治療2型糖尿病

華領醫藥

華領醫藥是總部位於中國上海的創新藥物研發、生產和商業化公司，在美國、中國香港設有子公司。公司匯聚全球醫藥行業高素質人才，融合全球創新技術，依托全球優勢資源，研發突破性概念技術與產品，引領全球代謝性疾病和神經退變性疾病醫療創新。

華領片® MYHOMSIS® (多格列艾汀片) Dorzagliatin Tablets



核心價值

- ◆改善胰島β細胞功能，降低胰島素抵抗
- ◆腎功能不全患者無需調整劑量
- ◆52週糖尿病緩解率65.2%[1]
- ◆平穩控糖，減少血糖波動[1]
- ◆納入《中國糖尿病防治指南》等多項權威指南共識[2]

1. Zeng J, et al. Diabetes Obes Metab. 2023 Oct;25(10):2878-2887
2. 中華醫學會糖尿病學分會.《中國糖尿病防治指引(2024版)》[J].《中華糖尿病雜誌》,2025,17(1):16-139 DOI:10.3760/cma.j.cn115791-20241203-00705.

良藥為民
行穩致遠



掃描二維碼
查看華領醫藥官網
瞭解更多企業資訊

地址:香港灣仔皇后大道東8號1701室
Suite 1701,8 Queen's Road East,
Wanchai, Hong Kong
電話:852-31903707

MEDPHOENIX
美凤力

PRECLINICAL STUDY CENTER FOR INNOVATIVE MEDICAL DEVICE

·Medphoenix Medical Group was founded by renowned Chinese doctors in 2018, committed to becoming **a global leading one-stop service provider** for innovative medical devices, providing specialized services including **medical research, preclinical large model studies, clinical trials, and global registration**.

·We have gathered **over 200 medical doctors with doctoral and/or Master's degrees** from hospitals both domestically and internationally.

·Our laboratories cover an area of **18,000 square meters**, equipped with a complete set of high-end **medical equipment including those named brands** such as Philips, Siemens, GE, Solin, Mindray, etc.

·The certification system covers OECD GLP, FDA GLP and CNAS GLP in GoldenWing Medical, a wholly-owned sub-company of Medphoenix Group.

·**We have served over 1,000 domestic and international clients as well as over 100 partner hospitals.** In the area of preclinical studies, Medphoenix has been ranked **No.1** in China.

GLP

1.OECD GLP
2.CNAS-CL06:2018(GB/T27416-2014)
3.US FDA GLP




200+ Employees	**18000 m²** Labs	**100+** Co-hospitals
1000+ Clients	**10000+** Procedures	**90%+** Success Rate

WHY CHOOSE US

01 Exceptional study success rates
02 Greatly reducing time to market
03 Attractive pricing strategy
04 The best reputation for independence and impartiality
05 Strict procedures ensure the confidentiality

FACILITY



Hybrid Operating Room

We have 3 hybrid operating rooms with: Philips Azurion 7 B20 (Double C type DSA)、Philips Azurion 3M15 、 Siemens Artis one.



CT Room

Philips 128 256 Slice CT Scanner



Ultrasound Equipment Philips EPIQ 7C



Electro-physiological Devices Abbott



Anesthesia Room



Surgical Operating Room

Contact: Manager Wei +86-17312606166 medphoenix@meifengli.com www.meifengli.com

金漫利醫藥
KingMYlab
金域醫學核心成員企業

立足香港 助力出海

Hong Kong Based, Global Focused

新藥臨床試驗首選中心實驗室

Your Central Laboratory of Choice for Clinical Trials



遵循CAP/CLIA/ISO 15189
國際質量管理體系
CAP/CLIA/ISO 15189
Accredited Central Laboratory

滿足中/美/歐
申報要求出海服務
NMPA/FDA/EMA
Compliant Quality System

積累>10個國家及地區
的樣本進口經驗
Proven Sample Transport Track
Record Across 10+ Jurisdictions

3 labs
穗、滬、港三大實驗室
Guangzhou/Shanghai/Hong Kong

4300+
中心實驗室檢測指標
Central Laboratory Tests

1000+
全球客戶
Local and Global Clients

4500+
承接註冊臨床項目
Clinical Trials

100+
助力藥物上市
Drugs Approval

180+
通過NMPA/FDA/EMA核查
NMPA/FDA/EMA Inspections

掃碼訂閱公眾號 | 查看視頻號
T:86-20-28330088
E:kingmylab@kingmylab.com
A:香港特別行政區觀塘區鴻圖道23號1樓
www.kingmylab.com

科學、合規、一站式臨床試驗實驗室服務平台
Providing Scientific, Compliant, and
Comprehensive Central Laboratory & Data Services

HKU Med
LKS Faculty of Medicine
The University of Hong Kong
香港大學李嘉誠醫學院

Driving the Next Era of Biomedical Innovation



WHAT TO EXPLORE AT BOOTH T17:

TOP 5
Innovative Projects

Discover HKUMedXelerate, our flagship innovation challenge, and the selected high-impact ventures

CHART
New Centre Launch

Centre for Health AI Research and Translation champions AI innovations that drive real-world medical breakthroughs for patients, carers, and the community.

Nurturing Future Talent

Empowering the next generation of biomedical leaders through world-class postgraduate programmes.

VISIT US AT BOOTH **T17**

Dates: 9–12 September 2026
Location: BIOHK2026, HKCEC

Scan the QR code to explore project details, CHART information, or view programme guides.

南京知和医药科技有限公司

NANJING CHIHEAL BIO MEDICINE TECHNOLOGY CO., LTD.

AI 驱动的全链条创新药研发企业

BOOTH 展位

3E-A09

Hall 3E · HKCEC

创新药 & 改良新药 一站式服务

One-Stop Services for NCEs & Improved-Formulation New Drugs

从立项评估到注册申报，为药物研发项目提供全链条支持

Full-Chain Support · From Project Evaluation to Registration Filing

01 立项评估 & 项目尽调
Project Evaluation & Due Diligence

靶点调研 / 竞品分析
技术风险预判
市场前景评估

Target & competitor
Tech risk assessment
Market outlook

02 分子设计
Molecular Design

新药分子设计定制
AI 驱动分子定制
靶向分子从头优化

Custom NCE design
AI-driven design
De-novo & optimization

03 沟通资料撰写
Communication Materials

Pre-IND / Pre-NDA
CDE 沟通会资料
项目汇报文档

Pre-IND / Pre-NDA
CDE meeting materials
Project briefing docs

04 注册服务
Registration Services

注册资料整理
合规审核
注册法规咨询

Dossier preparation
Compliance review
Regulatory consulting

05 药学研究服务
Pharmaceutical R&D

CMC 研究
处方工艺研究
质量研究

CMC research
Formulation & process
Quality research

06 非临床 & 临床服务
Non-Clinical & Clinical

非临床方案 & 管理
临床方案撰写审核
临床CRO服务

Preclinical & PM
Clinical protocol review
Clinical CRO Services

为什么选知和
Why Chiheal

资深审评专家+ 资深药学专家 + AI 算法工程师，三位一体

Senior reviewers + pharma experts + AI engineers — Three in One

01 资深审评专家领衔
Senior Reviewer Lead

- 核心团队 9 项国家药品指南起草人
  Co-drafter of 9 national drug guidelines
- 资深审评专家
  Senior Reviewer
- 北京大学 IPEM 客座教授挂帅
  PKU-IPEM visiting professor

02 AI + 资深药学专家
AI + Pharma Experts

- AI算法+分子设计专家双轮加速
  Dual-engine acceleration driven by AI algorithms and molecular design experts.
- 靶点发现 / 分子设计 / 优化
  Target ID · molecular design · opt.
- 从立项到 IND 全链条算法赋能
  Full-chain AI empowerment

03 已对外授权分子
Molecules Licensed Out

- 多款分子已授权给上市公司
  Licensed to listed pharma cos.
- 覆盖抗流感 / 抗支原体肺炎 / 抗失眠
  Anti-influenza / anti-mycoplasma / anti-insomnia
- 管线 DSC-8001 / CNS268 全球 FIC
  DSC-8001 / CNS268 global FIC

南京知和医药科技有限公司 · 侯雯 Ms. Wen Hou 总经理

NANJING CHIHEAL BIO MEDICINE TECHNOLOGY CO., LTD.

电话 / Tel: +86 130 5762 7553（微信同号 / WeChat）

地址:南京市鼓楼区幕府东路 199 号 A5 栋 N203 室

Web: https://chihealbio.com

扫码添加 / Scan

HONG KONG CHAMBER OF COMMERCE IN SWEDEN

LucyJRobertshaw
Connecting Life Sciences
Bridging ecosystems. Accelerating innovation. Improving lives.

THE NORDICS

Small region.
Global life-science impact.

The Nordic countries may be small in size, but we punch above our weight in life sciences. We combine world-class research, advanced healthcare systems, innovative companies and a culture of trust and collaboration to turn bold ideas into better outcomes for patients worldwide.

From Nordic science to global patient impact.

NORDIC STRENGTHS

World-class science
Leading universities and research institutions driving breakthroughs.

Advanced healthcare
Strong, equitable health systems and high-quality data enabling innovation.

Innovative companies
From early-stage biotech to global medtech and digital health leaders.

Collaborative by nature
A culture of openness, sustainability and cross-border partnerships.

Global outlook
Connecting the Nordics with the world to improve health and create value.



~27 MILLION people | **WORLD-CLASS** research | **HIGH-QUALITY** health systems | **THOUSANDS** of innovative companies | **A GLOBAL PARTNER** for better health



Connecting Nordic innovation with Hong Kong and the Greater Bay Area

Through the Nordic Future Health Pavilion at BIOHK 2026, we bring the best of Nordic life science to Asia – creating new connections, partnerships and opportunities for patients.

MEET US AT BIOHK 2026

9–12 SEPTEMBER 2026

HONG KONG CONVENTION AND EXHIBITION CENTRE

NORDIC FUTURE HEALTH PAVILION
Booth T13 – next to the Main Stage



NORDIC INNOVATION. HONG KONG CONNECTIONS. GREATER IMPACT FOR PATIENTS.

A meeting point for science, capital and market access

The Pavilion brings Nordic life-science companies into direct conversation with investors, healthcare leaders, researchers and strategic partners across Hong Kong and the Greater Bay Area.

01

SCIENTIFIC BREADTH

Cell and T-cell therapies, cancer immunotherapy, microbiome therapeutics, pharmaceutical formulation, digital health and infection prevention.

02

COMMERCIAL PURPOSE

Investor dialogue, strategic partnerships, clinical collaboration, distribution, licensing and pathways into Asian markets.

03

PATIENT IMPACT

Helping strong science translate faster into more personalised care, wider access and better health outcomes.

9–12 SEPTEMBER 2026

Hong Kong Convention and Exhibition Centre

BOOTH T13

Next to the Main Stage

NORDIC INNOVATION × ASIA

Lucy Robertshaw



HKCCSE Board Member & Project Lead

Life-Science Business Leader

Building the relationships that move Nordic life-science innovation into Hong Kong, the Greater Bay Area and beyond.

> **She does more than make introductions. She builds the structure that helps them become opportunities.**

More than 25 years across pharmaceuticals, healthcare, medical devices and international market development, combined with hands-on delivery and an instinct for bringing the right people together.

WHAT LUCY BRINGS

01	**Cross-border strategy**	Nordic–Hong Kong market access and ecosystem development
02	**Credible delivery**	Delegations, investor engagement and complex programme leadership
03	**Industry depth**	Commercial insight supported by MDR, ISO 13485 and quality experience

CONNECT

LucyJRobertshaw AB • Connecting Life Sciences

Supported by

Consulate General of Sweden
Hong Kong

AstraZeneca
阿斯利康

UPPSALA INNOVATION CENTRE

40 years
1986-2026
SWEDCHAM
Swedish Chamber of Commerce in Hong Kong



AstraZeneca

Connecting Nordic science with Hong Kong's healthcare innovation ecosystem

AstraZeneca is supporting the Nordic Future Health Pavilion at BIOHK 2026, strengthening connections between Nordic life-science innovation and Hong Kong's rapidly developing healthcare and biotechnology ecosystem.

Through collaboration across industry, research, healthcare and innovation, the partnership reflects a shared ambition to accelerate scientific innovation and ultimately improve outcomes for patients.

Science. Collaboration. Impact.
For patients today and tomorrow.



SCIENCE & INNOVATION

Connecting world-class research and emerging healthcare technologies to advance discovery and improve patient outcomes.

ECOSYSTEM COLLABORATION


Building bridges between Nordic innovators, Hong Kong and the Greater Bay Area across industry, academia, healthcare and government.

PATIENT IMPACT

Helping translate scientific advances into meaningful healthcare solutions that improve the lives of patients.

BIOHK 2026
Nordic Future Health Pavilion

Working together to advance innovation, strengthen ecosystems



anocca

130
Colleagues from **40+ nations** across six continent

60+
Patents in **5 technology** categories


10+
Pre-clinically validated products

8500
Size in sqm of R&D and cGMP manufacturing facility

200
Capital raised (in mnEUR) over 10 years from Nordic investors and EIB

>70%[1] of fatal diseases including cancer occur because the immune system fails to identify the diseased cells

1 **Cancer grows when immune cells (T cells) fail to detect/eliminate them**




T cells Cancer cells

2 **T cells detect cancer cells with an intricate molecular handshake**



T cells Cancer cells


3 **T cells use this handshake to identify and attack cancer**



T cells attacking cancer cells

Anocca recreates the intricate handshake in the lab, million of times over, to decipher how to target the cancer

10^{18}
Possible TCR in each person



1000s
HLA presenting different peptides

$>9^{20}$
Possible peptide combinations

Targeting system Cancer targets

We manufacture therapies on-site in Södertälje, with Europe's first "gensaxen" TCR-T therapy already dosed in patients

Pancreatic cancer
First cancer we are targeting, claimed **Sven-Göran Eriksson, Hans Rösling**

2000
Swedes succumb annually, **400k people globally**

8 top hospitals
Incl. **Karolinska Institutet** in 4 EU countries running first trial

1 Global statistic that includes both direct and indirect immune system failures contributing to fatal diseases, triangulated from data sources: WHO, IHME Global Burden of Disease, Nature Medicine, Cleveland Clinic

We possess the broadest TCR-T oncology pipeline in the industry

Because of the diversity of the immune system across humans, having a broad pipeline is imperative

19	12	11	1	
Discovery	Lead Optimization	IND Enabling	Early Clinical	Late Clinical

Solid cancers treatable :

- Lung
- Colorectal
- Pancreas
- Stomach
- Oesophageal
- Bladder
- Breast
- Brain
- Ovarian

Our tech can also be used for infectious diseases and autoimmunity

We are led by an experienced cross functional team

Experiences include

AstraZeneca, Karolinska Institutet, orexo, moderna, University of Oxford, Peter Mac, GE HealthCare, University of Cambridge, KIT, Roche, dkfz. German Cancer Research Center, GSK, University of Otago, McKinsey & Company, London School of Hygiene & Tropical Medicine

Guided by captains of industry

Experiences include

investor, Electrolux, SKF, Atlas Copco, Mannheimer Swartling, Lilly, storaenso, AstraZeneca, Roxtec, Richter Gedeon, BioInvent, Santen

Backed by leading Nordic institutions

Investors include

Melby Gård, AMF, Michano, Ramsbury, Swedbank Robur, European Investment Bank

We grow Sweden's talent pool

We hire talent from Sweden's universities and have our own BioStart training programme for other roles

June 2021

Arbetslösa Tilda, 21, fick en chans och tog den – upptäcktes av bioteknikföretaget: "Trodde jag aldrig i min vildaste fantasi"

LT



Feb 2025

From refugee to QA/QC: A journey of opportunity and growth

When Asad Edman arrived in Sweden from Afghanistan in 2015, he didn't expect to work in a biotechnology lab. His enrollment in Anocca's BioStart program changed his career path forever.

BioXconomy by informa





Find out more

The Anocca team

Former Moderna CSO Sweden
Former Roche Clinical Trials Director
Former CSO, Eli Lily
Former Chair, Nobel Assembly
Co-discoverer, NK Cells

Engineered Immunity
Built by nature, engineered by Anocca

Forskargatan 20C
151 36 Södertälje, Sweden

Registration number
556946-2384

CIRIO

Legal Expertise Across the Life-Science Journey

Strategic legal counsel for life sciences, healthcare and cross-border growth

Cirio is a leading Swedish business law firm with one of Sweden's largest dedicated Life Sciences practices, advising companies, investors and other stakeholders across the full life sciences lifecycle.

Supporting innovation from development to international growth

- Regulatory strategy & market access
- Intellectual property, licensing & technology transfer
- R&D, collaboration & commercial agreements
- Financing, capital markets & M&A
- Strategic partnerships & international expansion
- Data protection, digital health & AI

Connecting Nordic Expertise with International Opportunity

Cirio combines specialist Life Sciences expertise with a dedicated Asian Practice, supporting Nordic–China business, cross-border investment, collaboration and market entry.



Per Hedman

Partner | Head of Life Sciences

20+ years advising life sciences companies and investors on international M&A, licensing and collaborations.

per.hedman@cirio.se

+46 76 617 09 21



Hanna Yan Karlsson

Swedish Advokat & Chinese-qualified Lawyer

Bridging legal and cultural perspectives to support Chinese and Nordic clients in cross-border business.

hanna.yan.karlsson@cirio.se


+46 76 617 08 17

expreS2ion BIOTECH

NORDIC FUTURE HEALTH PAVILION
BIOHK 2026

ACTIVE IMMUNOTHERAPY FOR HER2-EXPRESSING CANCERS

A clinical-stage biotech company advancing ES2B-C001 (HER2-VLP) in Oncology, and other first-in-class pipeline assets in Infectious Diseases, while enabling complex protein development through the ExpreS2 platform



COMPANY AT A GLANCE

01 ExpreS2ion Biotechnologies develops active immunotherapies and vaccines using its proprietary ExpreS2 protein expression platform.

02 Our lead programme, ES2B-C001, is a first-in-class HER2-targeted active immunotherapy in Phase I for metastatic HER2-positive and HER2-low breast cancer.

03 It is designed to complement existing HER2-directed therapies and induce durable, polyclonal anti-HER2 immunity.

FOR PATIENTS

We are developing a new approach to help patients' own immune systems recognise and target HER2-expressing cancer — with the potential to complement existing HER2-directed treatments and improve outcomes.

PATIENT VISION

Harnessing the patient's own immune system

1. Stimulate durable, polyclonal anti-HER2 immunity
2. Potential to complement current and future HER2-directed therapies
3. Aiming to contribute to more durable, long-term treatment approaches.

MEET THE TEAM



Bent U. Frandsen
Chief Executive Officer



Claus von Arenstorf
Director, Business Development

KEY MESSAGES

01 **ES2B-C001**
Phase I HER2-targeted active immunotherapy with encouraging safety, immunogenicity and early clinical readouts.

02 **COMBINATION-AGNOSTIC STRATEGY**
Designed to complement current and future HER2-directed therapies across treatment modalities.

03 **DURABLE ANTI-HER2 IMMUNITY**
Designed to induce a broad, polyclonal anti-HER2 immune response with the potential for durable immune control.

04 **ExpreS2 PLATFORM**
Proprietary Drosophila S2 cell expression platform for scalable production of complex recombinant proteins.

PARTNERING OPPORTUNITY

<-> Seeking global or regional development and commercialisation partners for ES2B-C001.

OK **PHASE 3-TESTED** Platform validation

\+ **SCALABLE** Complex protein production

B2B **PARTNER-READY** Development + manufacturing

expres2ionbio.com partnering@expres2ionbio.com

NextCell

Seeking development, investment and commercial partners in Hong Kong

NXTCL-T1D: clinically validated stromal cell therapy for newly diagnosed type 1 diabetes



Selected for functional consistency

Clinically validated in type 1 diabetes

Designed for reproducible immunomodulation

Clinical development programme in type 1 diabetes

ProTrans-1
Phase I | n=9
Dose escalation and safety
Completed


ProTrans-2
Randomised Phase II | n=15
Clinical proof-of-concept
Completed

ProTrans-Repeat
Phase I/II | total n=15
Repeat-dose cohort n=9
Completed

ProTrans-Young
Ages 7–21 | n=66
Randomised efficacy cohorts
Follow-up

In randomised studies, NXTCL-T1D and placebo were administered on top of standard of care.

Durable clinical evidence after a single infusion



* p<0.05 ** p<0.01

Long-term follow-up of the randomised Phase II study

5 years
persistent separation

~3–4×
greater preserved insulin production at year 5

- Randomised Phase II proof-of-concept achieved
- Repeat dosing well tolerated; no de novo HLA sensitisation
- Programme in newly diagnosed patients aged 7–21 is in follow-up

Product profile

- Off-the-shelf, cryopreserved
- Fixed-dose IV; outpatient-compatible
- No post-thaw processing beyond dilution
- Shelf life beyond three years
- Functional selection and donor pooling reduce variability
- Designed for reproducible multi-site manufacturing

Fixed-dose outpatient treatment with low patient burden.

Late-stage development readiness

- Regulatory meetings with EMA, PMDA and NMPA
- FDA precedent in disease-modifying stage 2 T1D
- Existing European manufacturer with technology-transfer plan
- Advanced CDMO assessments in the US, Europe and Asia
- Site, process, equipment, cost and timeline assessments completed

Objective: partner-enabled Phase III development and commercialisation.

Hong Kong opportunity

What we know

- NextCell Hong Kong Ltd. Established
- Greater China rights intended to be contributed
- Existing clinical package supports regional development
- Local safety cohort expected before pivotal trial

What we seek

- Strategic investors and partners in Hong Kong / Greater China
- Flexible structures: equity, JV, licensing or co-development

NXTCL platform beyond T1D

Shared therapeutic logic: responsive multi-pathway immunomodulation of dysregulated or hyperactivated immune responses, with potential added pro-reparative support in selected settings.

NXTCL-VRD
Clinical experience

NXTCL-nRD
Preclinical

NXTCL-CNS
R&D exploration

NXTCL-T1D is an investigational medicinal product and has not received marketing authorisation.

One treatment. Multi-year biological effect.
Partnering to bring NXTCL-T1D to patients.

www.nextcellpharma.com/en/
NextCell Pharma AB (publ)
NextCell Hong Kong Ltd.
Scan for company and programme information

ImmuneBiotech

PRECISION MICROBIOME THERAPEUTICS

PRECISION MICROBIOME THERAPEUTICS

Clinically validated. Commercially proven.
Expanding in **Asia**.



- Clinically validated
- Commercially available in **EU, USA & China**
- Safe, well-tolerated & suitable for long-term daily use
- Designed for all ages & everyday health

OUR PRODUCTS



GutMagnific®

Our flagship precision probiotic formulations.

- **150 proprietary strains** sourced from healthy foods
- **5 precision-selected strains** in every product
- **Human clinical validation** and real-life efficacy data
- **High-quality manufacturing** with rigorous quality control
- **Commercially available** in **EU, USA and China**

COMMERCIAL TRACTION

EUROPE
- Established brand presence
- Strong distribution network
- Growing consumer demand

USA
- Market entry achieved
- Distribution partnerships
- Positive market response

CHINA
- Health food approval
- Approved health claim
- 6,000 units delivered
- Distribution partnerships
- Expansion underway

Clinically validated technology with commercial scale across three major markets.

WHY HONG KONG, WHY NOW?

Exploring Hong Kong as our Regional Hub for Asia.

- Strategic gateway to Asia's fast-growing health & wellness markets
- Explore GBA manufacturing for quality & efficiency
- Regional supply hub for Asia with efficient logistics
- Faster access to Asian markets and consumers
- Commercial partnerships & scalability

> "We believe precision microbiome science can transform everyday health. Hong Kong is the ideal platform to accelerate our impact across Asia."

ABOUT IMMUNEBIOTECH

A Swedish microbiome innovation company founded on more than 20 years of translational immunology research. We develop clinically validated precision microbiome products that improve everyday health.

HEADQUARTERED IN SWEDEN

Lund, Sweden
immunebiotech.com
info@immunebiotech.com

MEET US AT BIOHK 2026

Nordic Future Health Pavilion
9–12 September 2026
Hong Kong Convention & Exhibition Centre

BIOHK2026 HONG KONG

"Designed for everyday use, practical and reliable."

Softmed

NORDIC FUTURE HEALTH PAVILION

SOFTMED + KEEADA HEALTH

Digital health and mobile screening for a healthier future

SoftMed and Keeada Health bring together healthcare innovation, digital technology and mobile screening solutions – making preventive healthcare more accessible, earlier and easier to deliver.




OUR PROCESS – SAFE, SIMPLE AND SECURE


1. SCAN	2. THERMAL IMAGING	3. MEDICAL REVIEW	4. CONFIDENCE
Smart and radiation-free	Advanced AI technology	Analysis by a specialist	A complement to your breast health care

The method is not used for diagnosis and does not replace mammography.

1. SCREENING



2. AI ANALYSIS



AI-Powered Insights

WHY HONG KONG?

Hong Kong and the Greater Bay Area offer a dynamic ecosystem for innovation and collaboration in healthcare and digital health.

Healthcare providers · Strategic partners · Investors · Technology partners · Market-entry partners

OUR SOLUTIONS

Preventive care
Supporting a shift from reactive treatment to prevention and early detection.

Women's health
Addressing women's health needs across all life stages with accessible solutions.

Digital innovation
Mobile screening and digital tools that bring healthcare closer to people and communities.

LIVE AT BIOHK 2026

Experience our mobile health screening solutions at the Nordic Future Health Pavilion and the Life & Health Festival.

- Mobile health screening demonstrations
- Digital health and data insights
- Engagement with healthcare innovators
- Building partnerships for the future



BUILDING NORDIC–HONG KONG CONNECTIONS

We are committed to connecting Nordic expertise with the Hong Kong and Greater Bay Area ecosystems to create new opportunities for collaboration, innovation and improved health outcomes.



MEET SOFTMED + KEEADA HEALTH IN HONG KONG

NORDIC FUTURE HEALTH PAVILION
BIOHK 2026 | 9–12 SEPTEMBER 2026
HONG KONG CONVENTION & EXHIBITION CENTRE

CONNECTING NORDIC HEALTH INNOVATION WITH HONG KONG AND THE GREATER BAY AREA

uveo

Disinfecting light technology



A NEW STANDARD IN INFECTION PREVENTION

UVEO is a Swedish company delivering continuous disinfection for hospitals, clinics, and care homes — helping to make the care facilities safer for patients and medical staff.

The first patented technology that continuously reduces viruses, bacteria, and other pathogens in the air and on surfaces, without interrupting everyday care.

★★★★★

"Widely installed disinfecting light could maybe prevent the next pandemic or the next yearly influenza epidemic."



Prof. David Brenner
Ph.D. D.Sc.
Columbia University

"World-changing technology"
– FORTUNE MAGAZINE 2020

WHERE UVEO MAKES AN IMPACT

HOSPITALS & CLINICS
Supporting safer waiting rooms, operation theatres, and clinical environments.

ELDERLY CARE
Helping protect older and vulnerable populations in care facilities.

PUBLIC & HIGH-TRAFFIC ENVIRONMENTS
Creating healthier shared indoor spaces.

WHY HONG KONG?

Hong Kong offers a unique opportunity for infection prevention and indoor health technology: a dense metropolis, world-class healthcare, and a strong focus on healthy ageing.

SWEDEN ····· ✈ ····· HONG KONG

UVEO is joining the Nordic Future Health Pavilion at BIOHK 2026 to explore:

- Healthcare partnerships
- Distribution channels
- Pilot projects & references
- Strategic partners & investment

UVEO IS SEEKING

DISTRIBUTION PARTNERS
Enable access to the life-saving technology across Hong Kong and Greater Bay Area.

HEALTHCARE PARTNERS
Hospitals, clinics, and elderly care facilities for implementation, projects, and advanced pilots.

STRATEGIC PARTNERS
Collaborate to advance infection prevention and indoor environmental health.

INVESTORS
Support the growth of a science-backed, commercially proven technology in Hong Kong.



MEET UVEO IN HONG KONG

Emir Nezirović
CEO, UVEO
emir.nezirovic@uveo.se
uveo.se
linkedin.com/in/emirne

Nordic Future Health Pavilion
BIOHK 2026 | Hong Kong
9–12 September 2026

NORDIC FUTURE HEALTH PAVILION AT BIOHK 2026

CONNECTING NORDIC HEALTH INNOVATION WITH HONG KONG AND THE GREATER BAY AREA

BIOHK2026 HONG KONG

THE LIFE SCIENCES EVENT

veltio pharma

UNLOCK YOUR MOLECULE'S POTENTIAL.

We solve **solubility** and **bioavailability** challenges with our algae inspired cellulose technology, turning more molecules into **viable medicines.**





STINA LUNDGREN

Chief Executive Officer
Veltio Pharma

Life science leader with extensive experience from global pharmaceutical companies, bringing deep expertise in drug development, strategy and building high-performing teams.

MANY PROMISING MOLECULES STRUGGLE WITH:

- Poor solubility
- Low oral bioavailability
- Inconsistent absorption
- Dissolution limitations
- Commercialisation barriers

OUR SOLUTION: FROM ALGAE TO BETTER OUTCOMES

ALGAE → INNOVATIVE ALGAL CELLULOSE → BETTER DRUG ABSORPTION → BETTER OUTCOMES FOR PATIENTS

Our proprietary platform uses renewable porous algal cellulose to enhance the oral bioavailability of poorly soluble compounds.

WHY PARTNER WITH VELTIO?

Proven technology platform
Unique, sustainable and protected cellulose technology.

Science-driven collaboration
Deep formulation expertise and a collaborative mindset.

Broad therapeutic potential
Applicable across many drug classes and indications.

Sustainable by design
Using renewable materials for a healthier future.

LOOKING TO CONNECT IN HONG KONG

INVESTORS

- Life science and healthcare investors
- Venture capital and growth funds
- Family offices
- Strategic investors focused on formulation and drug delivery

STRATEGIC PARTNERS

- Pharmaceutical and biotech companies
- Co-development and licensing partners
- CDMOs and formulation specialists
- Market access and distribution partners

RESEARCH & CLINICAL PARTNERS

- Academic institutions and research centres
- Hospitals and clinical development partners
- Innovation hubs and public-private initiatives



EXPLORING HONG KONG & THE GREATER BAY AREA

We are exploring the Hong Kong and Greater Bay Area ecosystem to identify long-term partners and opportunities to advance our technology and bring better medicines to market in Asia.

- Meet strategic partners and pharma innovators
- Access to investors and capital for growth
- Explore market access and commercialisation opportunities
- Build collaborations across Asia and beyond

We welcome collaborations that overcome formulation challenges and accelerate better medicines to patients worldwide.

MEET US AT BIOHK 2026


9–12 September 2026
Hong Kong Convention & Exhibition Centre
Booth T13 – Next to the Main Stage

**SIMPLE SOLUTIONS.
BRILLIANT SCIENCE.
SUSTAINABLE IMPACT.**

LET'S SOLVE FORMULATION CHALLENGES TOGETHER.

UPPSALA, SWEDEN

Kripthonite Therapeutics



PIONEERING HYPOXIA-TARGETED CANCER THERAPY

Kripthonite Therapeutics is a Danish biotechnology company developing a new class of treatments targeting hypoxic tumour cells, the cancer cells that can survive conventional treatment and contribute to recurrence.

The company has developed and patented hypoxia-targeted macrocycles (HTMCs) designed to selectively eliminate hypoxic cancer cells in combination with established cancer treatments. In a preclinical animal model of solid tumours, the technology demonstrated strong antitumour efficacy when combined with radiotherapy.



Jan Stenvang
Chief Executive Officer

Kripthonite Therapeutics | Palle Juul-Jensens Boulevard 82, 8200 Aarhus N, Denmark
js@kripthonite.com | www.kripthonite.com

JIAN FRANSÉN

MD, PhD

SURGEON • PRECISION MEDICINE
HEALTHY AGEING • CLINICAL INNOVATION



BIOHK 2026
Nordic Future Health Pavilion
9–12 September 2026
Hong Kong Convention & Exhibition Centre
BOOTH T13 | MAIN STAGE

BRIDGING CLINICAL MEDICINE, RESEARCH AND TECHNOLOGY TO ADVANCE THE FUTURE OF HEALTHCARE

Jian Fransén is a Swedish physician, surgeon and researcher working at the intersection of precision medicine, healthy ageing, artifical intelligence and clinical innovation.

PROFILE SNAPSHOT

AFFILIATION	CLINICAL RESEARCH	RESEARCH TOOLS	TRANSLATION FOCUS
Karolinska Institutet	**40+ clinical trials**	**Biomarkers, AI & large datasets**	**Evidence into clinical practice**

FROM DATA TO CLINICAL IMPACT

Jian brings together frontline clinical experience with a strong understanding of how emerging technologies can be translated into real-world healthcare.

His PhD research investigated large clinical datasets and machine learning in diagnostics and clinical decision-making, including the development and evaluation of AI-based approaches for burn assessments.

WHY JIAN'S WORK MATTERS

✓ **Healthy ageing & healthspan**
Biomarkers and biological pathways linked with ageing, cancer and disease risk.

✓ **Precision medicine**
More individualised approaches to prevention, diagnosis and treatment.

✓ **AI-supported care**
Technology that can strengthen diagnostics and clinical decisions.

✓ **Clinical-trial innovation**
Rigorous evaluation connected with real-world implementation.

RESEARCH PRIORITIES

CLINICAL BIOMARKERS OF AGEING
Improving cancer-risk prediction and understanding healthspan.

PRECISION MEDICINE
Targeting the PI3K/AKT/mTOR pathway through more individualised approaches.

INNOVATIVE CLINICAL-TRIAL DESIGN
Connecting promising science with robust evidence and patient benefit.

CONNECTING SWEDEN WITH ASIA

Jian's combined expertise creates opportunities for collaboration between Nordic and East Asian healthcare ecosystems.

Potential areas include longevity research, precision medicine, clinical trials, digital health and next-generation diagnostics.

COLLABORATION • RESEARCH • CLINICAL TRANSLATION

TURNING SCIENTIFIC INNOVATION INTO BETTER, MORE PERSONALISED AND PREVENTIVE HEALTHCARE.

MEET JIAN FRANSÉN
Physician • Surgeon • Researcher • Clinical Innovator
Stockholm, Sweden | Karolinska Institutet

UPPSALA INNOVATION CENTRE

NORDIC FUTURE HEALTH PAVILION

BIOHK 2026

ACCELERATING SWEDISH INNOVATION

BUILDING GLOBAL CONNECTIONS

UIC supports innovative startups and growth companies as they develop, commercialise and scale their businesses.

FROM UPPSALA TO HONG KONG AND ASIA

- International market development
- Strategic partnerships
- Investment and access to capital
- Entry into Hong Kong, the Greater Bay Area and wider Asian markets



MEET WING CHENG, PhD, EMBA

Business Developer, Life Science

Regulatory affairs • Health economics • Entrepreneurship • Investment

BUILDING BRIDGES FOR INNOVATION

Sweden • Hong Kong • Greater Bay Area • Asia

wing.cheng@uic.se

www.uic.se

bluecell therapeutics

Scalable cell therapies.
Curative potential.

Off-the-shelf allogeneic cell therapies with the potential to transform outcomes for patients with serious conditions and significant unmet medical need.



Søren P. Sheikh
MD, PhD, HD
Founder & CEO

72%
of severe ED patients regained functional erections following treatment[1]

300M+
men worldwide affected by erectile dysfunction

Off-the-shelf
Allogeneic platform designed for scalability, access and global impact

75%
of target capital already secured

OUR PROGRAMMES

Severe erectile dysfunction (ED)
Lead programme addressing more than 300 million men worldwide.

Pulmonary arterial hypertension (PAH)
A serious, life-altering condition with high unmet need.

One platform. Broad potential.


CLINICAL READY. GLOBAL FOCUS.

- Clinical-ready allogeneic cell therapy platform
- Our human clinical data demonstrate proof-of-concept in severe ED
- International clinical programme across the UK, Australia and China
- Plans to run an Investigator-Initiated Trial (IIT) in China



SEEKING AT BIOHK
Partners for the next stage of growth

- Co-investors in the existing round
- Co-development partners to accelerate clinical development and market access in Asia
- China clinical & IIT partners
- Manufacturing / CMC partners
- Strategic partners



BII BioInnovation Institute

BASED AT BIOINNOVATION INSTITUTE
An international initiative supported by the Novo Nordisk Foundation.
Ole Maaløes Vej 3
2200 Copenhagen N, Denmark
CVR 39981610

GET IN TOUCH
Søren P. Sheikh
Founder & CEO
sheikh@blue-cell.com
blue-cell.com | +45 21 38 04 10

[1] Phase I study using autologous stem cells in severe ED patients.


NOVOTECH™
Biotech's Partner at Every Phase
Your science deserves a true CRO partner
Novotech partners with you to advance your science–every step of the way.
Scan to learn more

OPIS

A Science Driven Biotech Focused CRO

WHERE CLINICAL EXPERIENCE DRIVES TRIALS ON TIME



SCIENCE DRIVEN BIOTECH FOCUSED

27 YEARS OF LEADERSHIP

FULLSERVICE CRO (PHASEI-IV)



From Oncology to Rare Diseases

Advancing Medicine through Operational Excellence

Global Presence. Local Delivery.

Clinical Operations Across
USA | Europe | Asia-Pacific



EMPOWERING BIOTECHS GLOBALLY

ACCELERATE YOUR STUDY WITH SMART DATA SOLUTIONS

THEMADETOMEASURE EDCSystem



Built for speed. Designed for compliance

Request a Demo
Visit clinical.net

WEBBASED
Access your study data anytime, anywhere.

CUSTOMIZABLE
Tailored workflows and forms builtaroundyourprotocol needs.

USER FRIENDLY
Designed for simplicity. Intuitive for sites, monitors, and sponsors.

GCP, FDA & GDPR COMPLIANT
Validated, secure,and fullyaligned withglobal regulatory standards.

+19 YEARS ON THE MARKET
Atrustedplatformwith proven performance for nearly two decades

Original Cells Group | Regenerative Medicine Full-Chain Biomedicine Incubation Platform
>初源賽爾集團 | 再生醫學全鏈條生物醫藥孵化平台

Original Cells Group was founded in December 2020 with its headquarters in Xi'an. It is a National High-tech Enterprise and Shaanxi Provincial Specialized, Refined, Unique and Innovative Small and Medium-sized Enterprise. The Group acts as the supporting entity of the Xixian New Area Stem Cell Translational Medicine Engineering Technology Research Center. Leveraging Original Cells (HK) Biotechnology Research Institute Limited as its overseas operation entity, the Group develops a full-chain biomedicine incubation platform within the regenerative medicine sector.

初源賽爾集團成立於 2020 年 12 月，總部設立於西安，是國家高新技術企業、陝西省專精特新中小企業，是西咸新區幹細胞轉化醫學工程技術研究中心的依託單位，依託初源賽爾（香港）生物科技研究院有限公司作為海外運營主體，打造再生醫學領域全鏈條生物醫藥孵化平台。



Core Business Matrix >核心業務矩陣

Clinical-Grade Cell & Exosome Raw Materials	臨床級細胞／外泌體原料
Full Range of CD Culture Reagents by CellSource	中科培源全系列 CD 培養試劑
Laboratory EPC Construction	試驗室 EPC 建設
Process Technology Transfer	工藝技術轉移
Joint Incubation	聯合孵化

Core Differentiation >核心差異化

Dual Tracks:
Human-derived & Pet Fields
人源 + 寵物雙賽道

Integrated Services
一體化服務

Original Cells Industrialization Solutions
>初源賽爾產業化解決方案

Core Star Products >核心明星產品



Human-derived Stem Cell CD Medium
人源幹細胞 CD 培養基

Veterinary Stem Cell CD Medium
寵物幹細胞 CD 培養基



Stem Cell Exosome Derivatives
幹細胞外泌體衍生品



Automated Culture Equipment
自動化培養設備



MSC Exosomes
間充質幹細胞外泌體



Antler Stem Cell Exosomes
鹿茸幹細胞外泌體

Supply Advantages >供貨優勢

Spot warehouse established in Hong Kong to ensure stable delivery; free from export restrictions applicable to Japanese brands with controllable lead time.
香港設立現貨倉，穩定交付；無日系品牌出口限制，交期可控

Cost Advantages >成本優勢

Equivalent culture performance with significant price advantages compared with Japanese brands.
同等培養性能，對比日系品牌具備顯著價格優勢

Service Advantages >服務優勢

Supporting services including process optimization, laboratory construction and technical training.
可配套工藝優化、實驗室搭建、技術培訓

Cooperation Modes >合作模式

- ○ Raw Material & Consumable Procurement
  原料耗材採購
- ○ Integrated Laboratory Co-construction
  實驗室整體共建
- ○ Joint Incubation Projects
  聯合孵化項目

聯絡人 | Contact Person: Director Dou竇總監 聯絡電話 | Tel.: +852 6996 0739 電郵 | E-mail: originalcellcn@gmail.com

PJ LESTARI
SUSTAINABLE PJ
永续八打灵
நிலையான பிஜே

ALPHA HYGIENIC®

自家品牌系列產品均保證無防腐劑、無添加劑及不含糖，
孕婦及糖尿病人士均可安心食用。



時光膠原蛋白飲+
(15000mg德國專利膠原蛋白、不含糖、
孕婦及糖尿病人士可服)



倍效益生菌
(250億活性益生菌、不含滑石粉、甘油、蘆薈)



絡樂骨骼飲
(軟骨再生、強健骨骼、強韌筋腱、關節潤滑)



奇清淨血素
(速效溶栓、改善栓塞)

alphahygienic　alpha hygienic　+852 6556 6425　Alpha Hygienic

地址: 觀塘大業街21號嘉合發展中心11樓(全層)　網址: www.alphahygienic.com

CISION PR Newswire

UNMATCHED VISIBILITY. POWERFUL RESULTS.

325K
Releases Distributed Annually

170K+
Countries

40+
Languages

74K+
Media Outlets

12K+
Global Websites

440K+
Journalists & Influences

PR Newswire

UP TO **20%*** OFF
for your next order with us

*For selected circuits only.

www.cision.asia

PR Newswire APAC

apaccs@cision.com

Copyright © 2026 PR Newswire Asia Limited. All Rights Reserved

国药励展
Reed Sinopharm Exhibitions

构建共享无限商机的世界
SHARE A WORLD OF OPPORTUNITIES

www.reed-sinopharm.com
Tel：86+10-84556677



僅供備案
For Filing Purposes Only

善康醫藥
ScienCare Pharmaceutical



上善若水
康泽天下

超长效缓控释藥物遞送系统
LONG-ACTING SUSTAINED &
CONTROLLED RELEASE DRUG DELIVERY SYSTEMS

關於善康醫藥 ABOUT SCIENCARE

深圳善康醫藥科技股份有限公司主要從事以治療阿片類毒品/新型毒品復吸、酒精使用障礙為代表的成癮治療藥物的研發、生產和銷售，是一家擁有國際自主知識產權和全球視野的創新藥物研發企業，致力於打造成癮治療的「中国方案」。

Shenzhen ScienCare Pharmaceutical Co., Ltd. is an innovative pharmaceutical company dedicated to the research, production and commercialization of therapies for addiction treatment, including substance use disorders and alcohol use disorders. With international intellectual property rights and a global vision, we are committed to developing innovative therapies that address the unmet medical needs in addiction treatment.

公司自成立以来，就以解決精神活性物質成癮這一世界性難題為使命，通過多年的研發創新積累，公司已形成了以長效缓控釋植入劑技術為核心的藥物遞送系統創新研發平台，並專注於核心技術在成癮治療、中樞神經系統疾病、腫瘤治療、傳染病治療等多個疾病治療領域的創新性應用，致力於為患者提供更加安全、有效、可及的治療措施，踐行社會責任。

Since our establishment, we have been devoted to solving this global challenge through years of R&D and innovation. We have established a proprietary long-acting implant technology platform as our core drug delivery system innovation platform, focusing on multiple therapeutic areas such as addiction treatment, central nervous system diseases, oncology, and infectious diseases. Our mission is to provide patients with safer, more effective, and accessible treatment options, and to fulfill our social responsibility.

合作醫院
Collaborating Hospitals
200+

專利申請
Patent Applications
70+


携手醫療機構
共推成癮治療的規范化與可及性
Partnering with Medical Institutions to Advance Standardized and Accessible Addiction Care

深圳善康醫藥科技股份有限公司
Shenzhen ScienCare Pharmaceutical Co., Ltd.
中国廣東省深圳市坪山区坑梓街道
規劃四路長方集團園区C2棟
Building C2, Changfang Group Park,
Guihua 4th Road, Kengzi Subdistrict,
Pingshan District, Shenzhen, Guangdong, China
mkt.global@sciencare.cn
www.sciencare.cn
0755-84208896



PUT HUMAN HEALTH AT THE HEART OF YOUR RESEARCH?

Submit your research:
cts.ScienceMag.org



Science Translational Medicine
AAAS

Science.org/journal/stm

SELESTA.

Financial Clarity & Commercial Execution for Emerging Biotechs
為新興生物科技企業提供財務洞察與商業執行

Equity Research 股權研究 | Asset Valuation 資產估值 | Out-Licensing 對外授權

The Challenge 面臨的挑戰

Great science isn't enough to guarantee commercial success. Biotech leaders face three critical hurdles when scaling:
卓越的科學並不足以保證商業成功。生技領袖在擴張過程中面臨三大關鍵挑戰：

- **Communicating Value:** Translating complex clinical data into financial models that institutional investors trust.
  傳達價值：將複雜的臨床數據轉化為機構投資者信賴的財務模型。
- **Pricing Assets:** Establishing defensible, risk-adjusted valuations before entering deal negotiations.
  資產定價：在進入交易談判前，建立可靠且經風險調整的估值。
- **Monetizing Pipelines:** Reaching global pharma buyers who have the capital and capability to license your asset.
  管線變現：接觸具備資本與能力的全球製藥買家，授權您的資產。

> ***Selesta bridges the gap between lab innovation and global capital.***
> Selesta 架起實驗室創新與全球資本之間的橋樑。

Core Capabilities 核心服務能力

1 Institutional Equity Research
機構級股權研究

- **Wall Street Rigor:** Comprehensive, independent equity research reports tailored to institutional standards.
  華爾街嚴謹標準：符合機構標準的全面、獨立股權研究報告。
- **Investor Credibility:** Articulate clinical catalysts, market size (TAM), and risk profiles in clear financial language.
  投資者公信力：以清晰財務語言闡述臨床催化劑、市場規模與風險。
- **Capital Attraction:** Reach family offices, venture funds, and institutional healthcare investors.
  吸引資本：觸及家族辦公室、創投基金與機構醫療投資者。

2 Company & Asset Valuation
公司與資產估值

- **Defensible Modeling:** Advanced rNPV and DCF models built specifically for drug pipelines and medtech.
  可靠建模：專為藥物管線與醫療技術構建的 rNPV 與 DCF 模型。
- **Negotiation Power:** Know the true fair-market value of your assets before the deal table.
  談判優勢：在談判前掌握資產的真實公允市場價值。
- **Scenario Analysis:** Assess probability-of-success at every phase (Phase I to commercialization).
  情境分析：評估各階段（第一期至商業化）的成功機率。

3 Cross-Border Out-Licensing
跨境對外授權

- **Pipeline Monetization:** Target and pitch your assets to active deal-makers at global pharma and biotech.
  管線變現：向全球製藥及生技的活躍交易者推介您的資產。
- **Deal Structuring:** Guidance on upfronts, milestones, and royalties that maximize asset value.
  交易架構：就首付款、里程碑與權利金提供指導以最大化價值。
- **Global Access:** Connect Asia-originated innovations with Western and international markets.
  全球通路：將亞洲創新與西方及國際市場對接。

Why Partner with Selesta 為何選擇 Selesta

- **Biotech Expertise:** Deep understanding of clinical pathways combined with Wall Street financial mechanics.
  生技專業：深入理解臨床路徑，結合華爾街財務運作機制。
- **Unbiased & Independent:** Objective research and models that hold up under strict institutional due diligence.
  客觀獨立：經得起嚴格機構盡職調查的研究與估值模型。
- **Result-Oriented:** Active support through the full transaction lifecycle—from pitch to signed deal.
  成果導向：從推介到簽約，全程支援整個交易週期。

Let's Discuss Your Next Milestone
讓我們一同探討您的下一個里程碑

Web www.selesta.ai | **WeChat** cathybcc1106
Email dianaviola@selesta.ai · cathybi@selesta.ai

BOSTON · PARIS · HONG KONG

InnoStar (Stock Code: 688710) is a contract research organization (CRO) headquartered in China. We hold globally recognized accreditations,Pro vides One-stop Service From Nonclinical to Clinical Translation.

74,000+m²	1000+	1000+
Modern facilities	Professional	Clients

InnoStar Provides One-stop Service From Nonclinical to Clinical Translation



- Screening and Discovrey services
- Nonclinical Pharmacodynamics
- Nonclical Pharmacokinetics
- Nonclinical Safety Evaluation
- Clinical Biological Sample Testing
- Biomarkers and Translationl Research

Industry-leading Globalized Talent Team

4	2	3	17	11	1
NMPA CDE New Drug Evaluation Experts	NMPA & CNAS GLP Senior Inspectors	Member of NMPA CDE/ICH Guideline Expert Group	Diplomate of Chinese Society of Toxicology, DCST	China CSQA GLP-QA Certificates	CNAS Inspector
6	**3**	**3**	**2**	**1**	**1**
Diplomate of American Board of Toxicology, DABT	US SQA RQAP-GLP Certificates	AAALAC Inspection Specialists	Canadian Laboratory Animal Veterinary Qualification	Diplomate of the Japanese Society of Toxicologic Pathologists, JSTP	Diplomate of the Japanese College of Veterinary Pathologists, JCVP

Compliance with Global Regulatory Requirements

Shanghai InnoStar

NMPA GLP 2011/2015/2019/2022/2025	OECD GLP 2012/2015/2017/2019/2024
U.S.FDA GLP 2014/2018	AAALAC 2011/2014/2017/2020/2023
U.S. CAP 2015/2017/2019/2022/2025	

Nantong InnoStar

NMPA GLP 2019/2020/2021/2023/2024	OECD GLP 2024
U.S.FDA GLP 2025	AAALAC 2019/2023

Project Experiences

China		Overseas	
670+	28+	150+	3
INDs	NDA/BLAs	INDs	FDA NDA/BLAs

Data updated to: December 31, 2025

omics empower

Global Leaders in Single-Cell and Spatial

Hong Kong's First Commercial Xenium Platform at Omics Empower



Limited-Time Local Service Offer: HKD 150,000 / RUN

Spatial biology research depends on both data quality and workflow efficiency. For many teams, cross-border sample shipment, scheduling delays, and back-and-forth coordination can slow project progress and increase risk.

Omics Empower now introduces Hong Kong's first commercial Xenium platform, giving local researchers faster access to high-quality in situ spatial gene expression data with closer technical support.

Instead of sending samples abroad, you can now access a local Xenium workflow in Hong Kong with end-to-end support, including:

Sample Preparation → Sectioning → QC → Instrument Run → Data Delivery

Why Choose Local Xenium Service in Hong Kong?

- End-to-end Xenium service delivered in Hong Kong
- Shorter turnaround times to keep projects moving
- Lower risk from cross-border sample transport
- Faster local technical support and communication

Local Xenium Service for Precision Spatial Biology Research

Limited-Time Promotional Package

To support more researchers using Xenium for spatial transcriptomics research, we are offering a limited-time local service package:

Xenium Local Service Package (Hong Kong)	HKD 150,000 / RUN

- Species: **Human / Mouse**
- Eligibility: **First 30 customers only**

Contact us to secure this promotional offer.

Contact Us

Omics Empower Co., Limited
Email: info@omicsempower.com

Room 618, 6W, Hong Kong Science Park, New Territories



上海市浦东新区重点建设项目

金桥首个三线贯通的TOD项目

地处中国(上海)自由贸易试验区金桥片区，落位于浦东南北科创走廊，已纳入浦东新区“金色中环发展带”建设项目名录，总体量约100万方。

Located in China (Shanghai) Pilot Free Trade Zone's Jingiao Area in the Pudong North-South Science Innovation Corridor, this project is listed as part of the Jingiao Middle Ring Development Belt inPudong District and has an area of about 1 million square metres.



打造浦发未来医药城

依托TOD站点优势与科学家运营团队。倾力打造浦东未来医药、人工智能、信息技术主导的新兴科技产业承载区。聚焦AI制药、先进疗法、ICT、新材料等领先科技产业。

Bulds on TOD advantages and an operations team made up of scientists.Aims to become a new science and technologyindustry zone led by future medicine,artificial intelligence and information technology Focuses on advanced technologysectors such as AI pharmaceuticals, advanced therapies, ICT and new materials.

数药智能

400-666-0002
www.sdodt.com

微信扫一扫 了解更多

WhatsAPP

數藥智能

基於 AI 與腦機介面的腦健康數字藥物整體解決方案

集 研 發 / 設 計 / 個 性 化 訂 制 / 智 能 智 造 於 一 體



全球首個
腦電反饋
+
ADHD數字療法



專數達®**腦機版**
獲國內首張治療兒童 ADHD 的數字療法醫療器械證
(註冊證編號：湘械註準 20232210315)
精準腦電引導，多維科學干預多動
為ADHD注意力重建提供循證醫學方案

AI星河®**《孤獨症康復訓練與評估系統》**
國家級重點研發計劃重大科研轉化成果
國家衛健委全國數字健康創新應用大賽全國二等獎
(包含 VR 設備與訓練軟件 APP 支持平板電腦安裝)

——品牌簡介——

數藥智能成立於 2021 年，是一家以自主研發為核心的創新型數字藥物科技公司，系騰訊集團與世紀華通生態體系成員企業。公司依託兩大股東在互聯網科技、數字內容、人工智慧及雲計算等領域的深厚積累，聚焦腦科學、數字療法與智能醫療裝備研發，構建起覆蓋技術研發、臨床驗證到商業化落地的完整產業生態，致力成為國內領先的腦健康與智能診療科技企業。

公司始終秉持積極創新、銳意進取的精神，以臨床需求為牽引，發揮腦電生物資訊技術與核心演算法分析方面的優勢，研發適用於數字療法的技術、產品與平台，打造高效、便捷且具普適性的數字療法解決方案。同時，公司積極佈局腦機介面領域，依託在腦科學及腦機介面軟體開放服務平台方面的技術積澱，推動腦機介面研究與應用協同發展，促進成果轉化，為產業鏈融合創新與基礎合作搭建良好平台。

數藥智能匯聚了一支多領域、跨學科的優秀專家團隊，目前已形成覆蓋注意缺陷與多動障礙（ADHD）的《注意力強化訓練軟體》、孤獨症譜系障礙（ASD）的《孤獨症康復訓練軟體》、腦機介面產品《數眠》、兒童及成人認知康復的《多維互動訓練系統》以及助力特教精準評估的《VBMAPP 評估軟體》等在內的數字療法產品矩陣，為數字醫療技術的廣泛應用奠定了堅實基礎。

未來，公司將持續強化科研與技術研發能力，透過技術與產品的不斷創新，深入探索和理解人類大腦，助力精神健康改善，服務社會，為人類更美好的生活提供健康保障。



Tencent 腾讯　CHT·世纪华通

Email: jizhiyu@sdodt.com

泽德曼

THEDERMA SHANGHAI CO., LTD.

GLOBAL LEADER IN AHR-TARGETED THERAPEUTICS

Pioneering Novel Therapies for Inflammatory & Autoimmune Diseases

Proprietary AHRP Platform

Integrated drug discovery platform for topical and oral AhR-targeted therapeutics, iteratively built upon accumulated R&D insights to fuel the AhR-centric pipeline.

What is AhR

The Aryl Hydrocarbon Receptor (AhR) is a ligand-activated sensor widely expressed throughout human tissues. Best characterized for its role in maintaining barrier function and immune tolerance at the skin and gut interfaces, AhR also contributes meaningfully to respiratory, ocular, and systemic immune regulation.

Core Biological Functions

- Drives epithelial barrier repair & tissue regeneration
- Balances pro- and anti-inflammatory immune responses
- Regulates xenobiotic metabolism & tissue homeostasis
- Mediates host-microbiota crosstalk


Core Pipelines

Novel Mechanisms. Proven Science. A Pipeline That Keeps Redefining What's Possible with AhR.

Pipeline	Preclinical	IND	Phase I	Phase II	Phase III	Commercialization	Rights
Zedman Cream	Pediatric and Adult Atopic Dermatitis						
TAP-1502 Spray	Seborrheic Dermatitis						
TAP-1504 Gel	Acne						
TAN-118 Tablet	Dual IND Approval	Inflammatory Bowel Disease (IBD)					
TAN-219 Eye Drops	Dry Eyes						
TAN-1805 Nasal Spray	Allergic Rhinitis						

Zedman(Benvitimod/Tapinarof)Cream

First-in-class non-steroidal AhR topical drug for atopic dermatitis.



- Steroid-Free, Novel Target, Multi-pathway Mechanism.
- Significant Efficacy in Both Children (Aged 3 Month and Older) and Adults.
- Long Remission & Low Recurrence.
- Excellent Safety Profile；No Application Sites Restrictions.

TAN-118

Next-generation, colon-restricted oral AhR agonist for UC, combining a validated target with best-in-disease therapeutic potential and a best-in-class safety and colon-restriction profile. Phase 2a trial ongoing.

Official Website

WeChat Official Account

For informational purposes only, intended for scientific and business professionals only, not for patient use. Does not constitute medical advice.

辛顿人工智能科技有限公司

HintonAI

作为专注于AI+机器人技术研发与应用的科技企业，辛顿AI以AI决策引擎为核心、智能机器人集群为执行网络，致力于成为驱动从科研到产业效率革命的全域智能中枢，推动「研发→实验室→小试→中试→量产」的效率革命。自成立以来，我们坚持以产业需求为导向，在**生命科学**、**创新药**、**新材料**和**跨域科学**等垂直领域持续深耕，推出的移动智能复合机器人解决方案，已实现从核心控制器到系统软件的全链条自主可控，帮助客户显著提升科研与生产效率，也为行业智能化转型提供了可复制的实践路径。


Venus R 系列 智能复合移动机器人



VENUS 500S-R



VENUS 300S-R





深圳市生物医药产业联盟
Shenzhen Biopharmaceutical Industry Alliance

联盟简介

深圳市生物医药产业联盟是深圳市发改委落实深圳“20+8”战略性新兴产业集群布局、践行“一集群、一联盟”顶层工作体系的重要载体，于2024年3月14日正式成立。联盟在全市各产业主管部门指导支持下运营，立足深圳生物医药全产业链发展需求，面向本土上下游生态主体及意向落地深圳的域外生物医药企业，搭建垂直深耕、全域联动的综合资源对接与信息共享平台。目前联盟已集聚近300家会员单位，覆盖本土上市龙头、行业标杆、科创新锐企业，同时吸纳产业资本、产业园区、科研院所、高等院校等多元主体加入。联盟着力打通产业信息壁垒，构建高效顺畅的全链条政企协同沟通机制，激活产业创新源头动能，聚力探索政、企、医、校、投深度融合的可持续发展模式，搭建多层次、立体化的生物医药产业创新生态体系。



About the Alliance

Shenzhen Biopharmaceutical Industry Alliance (SZBio) serves as a key vehicle for the Development and Reform Commission of Shenzhen Municipality to implement Shenzhen’s "20+8" Strategic Emerging Industry Clusters initiative and materialize the top-level One-Cluster-One-Alliance working framework. It was officially inaugurated on March 14, 2024.

Operated under the guidance and support of municipal industrial competent authorities, SZBio responds to the full-industrial-chain development needs of Shenzhen’s biopharmaceutical sector. It builds a comprehensive platform for in-depth vertical resource matching and city-wide information sharing, serving local upstream-and-downstream ecosystem players as well as biopharmaceutical enterprises from outside Shenzhen intending to set-up operations in the city.

To date, SZBio has assembled nearly 300 member entities, including local listed leading enterprises, industry benchmarks and innovative startups. It also brings together diverse stakeholders such as industrial capital institutions, industrial parks, research institutes and higher-education institutions.

SZBio strives to break down industrial information silos and establish an efficient full-chain government-enterprise coordination mechanism. It unlocks original innovation momentum of the industry, explores a sustainable development model featuring deep integration of government bodies, enterprises, medical institutions, universities and investors, and fosters a multi-level, all-dimensional innovation ecosystem for the biopharmaceutical industry.

扫码了解·更多详情>>

Wedge万泽医药

万泽股份股票代码:000534

专注微生态，生命更精彩

Advancing Microecology, Enriching Lives



企业简介

万泽医药（股票代码：000534）历经三十载深耕，已构建起集研发、转化、制造、营销于一体的全产业链生态闭环，是国内目前唯一专注于消化和妇科两大微生态系统的微生态制剂国家级高新技术企业。公司专注于微生态药物的研发、生产和销售，在菌株筛选、发酵工艺、质量控制和临床应用方面拥有行业领先经验，主要产品为国家一类新药“金双歧”及独家妇科微生态制剂“定君生”。

Wedge Pharmaceuticals (SZSE: 000534) is a Shenzhen-based pharmaceutical company with more than three decades of experience in microecological products, building an integrated platform spanning R&D, technology translation, manufacturing and marketing. with a focus on digestive and gynecological microecology. It is currently China’ s only National High-Tech Enterprise specializing in microecological therapeutics for both digestive and gynecological field. The company specializes in integrating R&D, manufacturing and commercialization of microecological pharmaceuticals. It possesses industry-leading experience in strain screening, fermentation technology, quality control and clinical application. Two key products include the National Class I new drug "JINSHUANGQI" (Live Combined Bifidobacterium and Lactobacillus Tablets) and the exclusive gynecological microecological preparation "DINGJUNSHENG" (Live Lactobacillus Capsule for Vaginal Use).

核心产品 CORE PRODUCTS



国药准字：S19980004

Approval Number: National Drug Approval No. S19980004.

金双歧-双歧杆菌乳杆菌三联活菌片

JINSHUANGQI-Live Combined Bifidobacterium and Lactobacillus Tablets

适应症/功能：用于治疗肠道菌群失调引起的腹泻、慢性腹泻、抗生素治疗无效的腹泻及便秘。

This product is indicated for the treatment of diarrhea caused by intestinal dysbiosis, chronic diarrhea, diarrhea unresponsive to antibiotic treatment, and constipation.

1. 以双歧杆菌为主的原籍菌制剂，更适合人体肠道生理。
2. 所含三种菌株均纳入国家卫健委《可用于食品的菌种名单》，安全性更高。
3. 三联活菌，科学组合，协同增效。

1. A Bifidobacterium-dominant indigenous probiotic formulation that is better aligned with human intestinal physiology.
2. All three strains are included on the National Health Commission of China’ s "List of Strains Permitted for Use in Food", supporting a well-established safety profile.
3. A scientifically formulated three-strain live probiotic blend, designed to deliver synergistic benefits.



国药准字：S20030005

Approval Number: National Drug Approval No. S20030005.

定君生-阴道用乳杆菌活菌胶囊

DINGJUNSHENG-Live Lactobacillus Capsule for Vaginal Use

适应症/功能：用于由菌群紊乱而引起的细菌性阴道病的治疗。

This product is mainly used in the treatment of bacterial vaginitis which is caused by disordered bacteria group.

1. 全球首个国药准字（阴道用）乳杆菌活菌制剂
2. 优选阴道原籍菌株——德氏乳杆菌DM8909
3. 四大作用机制——抑菌、促菌、调节免疫、修复黏膜

1. The world’ s first NMPA-approved live Lactobacillus formulation for vaginal use.
2. Formulated with Lactobacillus delbrueckii DM8909, a selected indigenous vaginal strain.
3. Four key mechanisms of action:antimicrobial activity, microbiota support, immune modulation, and mucosal repair.



公司简介

Company Profile

华润三九医药股份有限公司是大型国有控股医药上市公司，主要从事医药产品的研发、生产、销售及相关健康服务。公司多次获评中国主板上市公司"金牛百强"、"价值百强"，被纳入深证成份指数、中证500和富时罗素指数股之列。

CR Hualan Sanjiu Pharmaceutical Co., Ltd. is a large state-controlled listed pharmaceutical company, primarily engaged in the research, development, production, and sales of pharmaceutical products, as well as related health services. The company has been repeatedly recognized as one of China's "Top 100 Golden Cows" and "Top 100 Value Leaders" among mainboard-listed companies, and is included in the Shenzhen Component Index, CSI 500, and FTSE Russell indices.

华润三九前身是1985年成立的深圳南方制药厂。1999年发起设立股份制公司;2000年3月9日在深圳证券交易所挂牌上市(000999)；2008年正式进入华润集团;2010年更名为"华润三九医药股份有限公司"。

China Resources Sanjiu was originally established as Shenzhen Southern Pharmaceutical Factory in 1985. In 1999, it initiated the formation of a joint-stock company and was listed on the Shenzhen Stock Exchange (000999) on March 9, 2000. In 2008, it officially joined China Resources Group and was renamed "China Resources Sanjiu Pharmaceutical Co., Ltd." in 2010.

华润三九主营核心业务定位于CHC健康消费品和处方药领域。CHC产品覆盖感冒、胃肠、皮肤、肝胆、儿科、骨科、妇科等品类，核心产品市场份额高;处方药覆盖心血管及代谢、肿瘤、呼吸神经/精神、消化、骨科、抗感染等，拥有复方丹参滴丸、血塞通系列、养血清脑颗粒、参附注射液、华蟾素、注射用重组人尿激酶原、示踪用盐酸米托蒽醌注射液、注射用头孢比罗酯钠等药品;中药配方颗粒及饮片打造"原质原味"的999配方颗粒和'三九本草悟'精致饮片。


China Resources Sanjiu's core business is positioned in the CHC health consumer goods and prescription drug fields. CHC products cover categories such as cold, gastrointestinal, skin, liver and gallbladder, pediatrics, orthopedics, gynecology, etc., with a high market share for core products; Prescription drugs cover cardiovascular and metabolic, tumor, respiratory nerve/psychiatric, digestive, orthopedic, anti infection, etc., including compound Danshen dripping pills, Xuesaitong series, Yangxue Qingnao granules, Shenfu injection, Huachansu, recombinant human urokinase for injection, tracer mitoxantrone hydrochloride injection, ceftriaxone sodium for injection, and other drugs; Traditional Chinese medicine formula granules and decoction pieces are used to create 999 formula granules with "original flavor" and exquisite decoction pieces of "Sanjiu Bencao Wu".

'999'品牌在消费者和医药行业中认可度高，构建"1+N"品牌矩阵。公司连续多年在中国非处方药协会综合排名中名列前茅，999感冒灵连续荣获感冒咳嗽类(中成药)第一名。

The "999" brand has a high recognition among consumers and the pharmaceutical industry, and a "1+N" brand matrix has been constructed. The company has been among the best in the comprehensive ranking of China Non prescription Drug Association for many consecutive years, and 999 Ganmaoling has won the first place in the category of cold and cough (traditional Chinese patent medicines and simple preparations).

同比增长 14.43%

营收收入



华润三九坚持"品牌+创新"双轮驱动，以创新引领高质量发展，聚焦高质量医药健康产品研发和智能制造，优化业务布局，强化品牌和渠道，构建中药全产业链竞争优势。2025年，公司实现营业收入316.03亿元，同比增长14.43%;归属于上市公司股东的净利润34.21亿元，同比增长1.58%。

China Resources Sanjiu adheres to the dual wheel drive of "brand+innovation", leading high-quality development with innovation, focusing on the research and development of high-quality pharmaceutical and health products and intelligent manufacturing, optimizing business layout, strengthening brand and channels, and building a competitive advantage in the entire traditional Chinese medicine industry chain. In 2025, the company will achieve a revenue of 31.603 billion yuan, a year-on-year increase of 14.43%; The net profit attributable to shareholders of the listed company was 3.421 billion yuan, a year-on-year increase of 1.58%.

华润三九高度重视研发创新和中药传承创新。公司产品"参附注射液"、红花注射液"参麦注射液"新泰林'999理血王牌血塞通三七软胶囊"青蒿系列"的科研项目先后荣获国家科学技术进步奖二等奖。公司设立六院三室:健康药物研究院、中医中药研究院、创新药物研究院、中药资源研究院、先进递送研究院、工艺技术研究院，以及深蓝实验室、伏羲实验室、水滴实验室，聚焦创新药、经典名方、中药资源、智能制造等研发。在中药传承创新方面，加快培育新质生产力，深耕中药全流程开发体系。

China Resources Sanjiu attaches great importance to research and development innovation and innovation in the inheritance of traditional Chinese medicine. The research projects of the company's products, including "Shenfu Injection", "Honghua Injection", "Shenmai Injection", "Xintailin", "999 Licong Ace Blood Seal Tong Sanqi Soft Capsules", and "Qinghao Series", have successively won the second prize of the National Science and Technology Progress Award. The company has established six institutes and three departments: Health Drug Research Institute, Traditional Chinese Medicine Research Institute, Innovative Drug Research Institute, Traditional Chinese Medicine Resources Research Institute, Advanced Delivery Research Institute, Process Technology Research Institute, as well as Deep Blue Laboratory, Fuxi Laboratory, Water Drop Laboratory, focusing on the research and development of innovative drugs, classic prescriptions, traditional Chinese medicine resources, intelligent manufacturing, etc. In terms of traditional Chinese medicine inheritance and innovation, it accelerates the cultivation of new quality productivity and deeply cultivates the full process development system of traditional Chinese medicine.

随着昆药、天士力的加入，华润三九形成了"一体两翼"的业务布局，3家上市公司将通过相互赋能，实现协同发展。其中华润三九以CHC为核心业务，争做行业头部企业；天士力以处方药为核心业务，创新驱动成为中国医药市场领先者；昆药集团以三七产品和精品国药为核心业务，争做银发健康产业引领者。

With the addition of Kunyao and Tianshili, China Resources Sanjiu has formed a "one body, two wings" business layout, and the three listed companies will achieve coordinated development through mutual empowerment. Among them, China Resources Sanjiu takes CHC as its core business and strives to become a leading enterprise in the industry; Tianshili focuses on prescription drugs as its core business and is driven by innovation to become a leader in the Chinese pharmaceutical market; Kunyao Group focuses on Sanqi products and high-quality Chinese medicine as its core business, striving to become a leader in the silver hair health industry.



面向未来，华润三九在"关爱大众健康，共创美好生活"使命引领下，朝着"成为大众医药健康产业的引领者"愿景砥砺前行，对标世界一流企业，专注高质量医药健康产品创新研发和智能制造，致力于成为中国医药健康第一品牌。

Facing the future, under the mission of "caring for public health and creating a better life together", China Resources Sanjiu is forging ahead towards the vision of "becoming a leader in the public pharmaceutical and health industry", benchmarking against world-class enterprises, focusing on innovative research and development of high-quality pharmaceutical and health products and intelligent manufacturing, and committed to becoming the first brand in China's pharmaceutical and health industry.

希格生科是全球首家基于"类器官+AI"技术平台进行癌症创新靶向药研发的公司，国家高新技术企业、深圳市专精特新企业。公司诞生于哈佛大学校园，于2020年底落地深圳，至今已完成近3亿元的融资及项目资助。

公司布局多条药物管线，其中基于"类器官+AI"这一全新范式自主研发出的全球首款弥漫性胃癌靶向药SIGX1094，已获得中美IND批件及美国FDA孤儿药资格认定与快速通道认定，并荣获有"医药界诺贝尔奖"之称的盖伦奖提名。该药物目前正在北京大学肿瘤医院进行临床 I 期试验，即将进入临床 II 期。

希格生科首创的"类器官+AI"药物研发平台既服务于自身管线，亦积极赋能大药企新药研发，致力以源头创新重塑药物研发格局。公司也获得了福布斯亚洲「100家值得关注企业」等多项荣誉与国家卫健委创新药物研发国家科技重大专项支持。

Signet Therapeutics (Shenzhen) Co., Ltd. is the world's first company to develop innovative targeted cancer drugs based on the "organoid + AI" technology platform. It is a national high-tech enterprise and a Shenzhen-based "Specialized and Sophisticated" enterprise. The company originated at Harvard University and was established in Shenzhen in late 2020. To date, it has raised nearly RMB 300 million in financing.

The company has built multiple therapeutic pipelines. Among its programs, SIGX1094, the world's first-in-class targeted drug for diffuse gastric cancer, was independently developed via this novel "organoid + AI" paradigm. It has received IND approvals in both China and the United States, as well as Orphan Drug Designation and Fast Track Designation from the FDA, and has been nominated for the Prix Galien, widely known as the "Nobel Prize of the pharmaceutical industry". The drug is currently in Phase I clinical trials at Peking University Cancer Hospital and is about to enter Phase II.

Signet Therapeutics' pioneering "organoid + AI" drug R&D platform not only supports its own pipeline but also actively empowers major pharmaceutical companies in new drug R&D. The company has won multiple accolades, including Forbes Asia's "100 Companies to Watch," and has received support from the National Science and Technology Major Project for New Drug Innovation.

5000m²
研发场地
R&D Facilities

500m²
实验动物房场地
Laboratory Animal Facilities

多条
first-in-class药物管线
First-in-class Drug Pipelines

5种
正常类器官模型
Normal Organoid Models

10+种
类器官疾病模型
Disease Organoid Models



全球分部：波士顿、深圳、上海、香港

类器官+AI：药物研发新范式
"Organoid + AI": A Novel Paradigm for Drug R&D

产品	靶点	治疗方式	适应症	药物发现 / pre-IND / IND / 临床一期	权益
SIGX1094	FAK (小分子)	单药	弥漫性胃癌,卵巢癌,三阴性乳腺癌等	Phase 1	
		联合KRAS抑制剂	KRAS突变耐药的非小细胞肺癌	IND Enabling	
		联合EGFR抑制剂	EGFR突变耐药的非小细胞肺癌	IND Enabling	
		单药(腹腔)	癌性腹水	IND Enabling	
SIGX2649	TEAD (小分子)	单药	间皮瘤,上皮样血管内皮瘤,肝癌等Hippo通路突变和激活的肿瘤	Phase 1	
		单药	肺癌等肿瘤	IND Enabling	
SIGX3	未披露 (小分子)	单药	暂未披露	LEAD-PCC	
SIGX4	未披露 (小分子)	单药	暂未披露	Hit-Lead	
SIGX5	未披露 (抗体)	单药	纤维化肿瘤	Hit-Lead	



SIGX1094是全球首个针对弥漫性胃癌的靶向药，同时也是首个基于类器官+AI开发的药物。
SIGX1094 is the world's first-in-class targeted drug for diffuse gastric cancer and the first therapy developed via the "organoid + AI" paradigm.

类器官+AI药物研发平台 "Organoid + AI" Drug R&D Platform

与晶泰科技(HK.2228)战略合作，整合AI分子设计+自动化合成+类器官验证，加速创新药开发，提升成功率。

The company has established a strategic partnership with XtalPi Inc. (HK.2228), integrating AI molecular design, automated synthesis, and organoid validation to accelerate innovative drug development and enhance clinical success rates.

正常类器官模型 Normal Organoid Models

希格生科自主研发的心脏类器官毒理测试模型，预测准确率可达约85%，助力药物安全性评估。

Signet Therapeutics has independently developed a proprietary cardiac organoid toxicity testing model with a predictive accuracy of approximately 85%, which facilitates preclinical drug safety evaluation.

疾病类器官模型 Disease Organoid Models

基于患者来源类器官(PDO)，已覆盖胃、肠、肝、肺等癌种，有效推动靶点发现与药效验证。

Based on patient-derived organoids (PDOs), these models cover multiple cancer types, including gastric, colorectal, liver, and lung cancers, effectively driving target discovery and preclinical efficacy validation.

Join Us: hr@signettx.com

Contact Us: contact@signettx.com

SALUBRIS 信立泰



深圳信立泰药业股份有限公司始创于1998年，2009年在深交所上市（股票代码：002294），是研产销一体化的创新国际化医药企业。公司深耕以心脑血管为主的CKM慢病治疗领域，持续创新突破，拓展医药边界，满足未被满足的临床需求。

Shenzhen Salubris Pharmaceuticals Co.,Ltd.,founded in1998,was listed on the Shenzhen Stock Exchange in 2009(Stock Code:002294).It is an innovative,international pharmaceutical enterprise integrating R&D,production,and sales.The company has long been dedicated to the CKM chronic disease therapeutic area,with a primary foocus on cardiovascular and cerebrovascular diseases.Through continuous innovation and breakthroughs,it strives to expand the boundaries of medicine to address unmet clinical needs.

信立泰坚持以患者为中心，布局创新药、高端医疗器械，拥有具全球竞争力的CKM慢病研发管线100+款，6款已上市创新药全部纳入国家医保目录。公司先后承担、参与国家重大专项及国家、省、市的重大科技项目70余项，3次获“中国专利金奖”。

Committed to a patient-centered approach,Salubris has strategically positioned itself in innovative drugs and high-end medical devices,boasting a globally competitive CKM chronic disease R&D pipeline of over 100 programs.The company has six innovative drugs already on the market.All of these products are included in the National Reimbursement Drug List(NRDL).Salubris has successively undertaken and participated in over 70 major national science and technology projects, including those under national mega-programs and at the provincial and municipal levels, and has been honored with the China Patent Gold Award on three occasions.

深圳信立泰药业股份有限公司
SHENZHEN SALUBRIS PHARMACEUTICALS CO.,LTD.
地址：深圳市福田区福保街道福保社区国际生物医药产业园2期4层A区
电话：(0755) 83867888　　邮编：518017
网址：www.salubris.com

BEOMING THE LEADER IN HIGH QUALITY BIOLOGICS

高品质生物药领导者



科兴制药(股票代码：688136)是一家专注于重组蛋白、多功能抗体、靶向递送疗法等研发、生产、销售一体化的创新型国际化生物制药企业，聚焦抗肿瘤、自身免疫、抗病毒等治疗领域，围绕未被满足的临床需求，打造新型蛋白、新型抗体等前沿生物技术平台，开发精准治疗及新型靶向递送药物，坚持"创新 + 国际化"双轮驱动的平台型发展模式，致力于成为高品质生物药领导者，服务全球患者。

Kexing Biopharm (Stock Code: 688136.SH) is an innovative and global biopharmaceutical company integrating the research and development, manufacturing, and commercialization of recombinant proteins, multifunctional antibodies, targeted delivery therapies, and other advanced biologics technologies.Focused on therapeutic areas including oncology, autoimmune diseases, and antiviral treatment, the company is committed to addressing unmet clinical needs through the development of cutting-edge technology platforms covering novel proteins, next-generation antibodies therapeutics. By advancing precision medicine and innovative targeted delivery therapies, the company adheres to a dual-driven strategy of "Innovation + Globalization" and is dedicated to becoming a global leader in high-quality biopharmaceuticals, serving patients worldwide.

全球商业化 GLOBAL COMMERCIALIZATION


20+年
海外商业化经验
20+ years of experience in global commercialization

70+个
国家和地区（含欧盟）
Sales network covers over 70 countries and regions (including the EU)

100%
覆盖人口超1亿的新兴市场
100% coverage of emerging markets with a population exceeding 100 million

100%
覆盖 GDP 排名前 30 的新兴市场
100% coverage of emerging markets ranked in the top 30 by GDP

约70家
国内已合作出海医药企业
About 70 domestic pharmaceutical enterprises have cooperated with us to go global



*科兴制药产品效果图，仅供参考，实际药品以上市销售产品为准
The product renderings from Kexing Biopharm are for reference only. The actual products sold on the market shall prevail.

康哲药业
CHINA MEDICAL SYSTEM



让每一款好药的价值充分实现

UNLOCK THE FULL VALUE OF EVERY QUALITY MEDICINE

康哲药业(股票代码:港交所867.HK,新交所8A8.SG)是一家专注于差异化专科医药产品的识别、构建与全生命周期管理的创新型医药企业,以自主研发与合作研发双轨并行,依托从零创建市场与品牌的能力,让每一款药品的临床价值和商业价值充分实现。

康哲药业聚焦心肾代谢、中枢神经、消化、眼科、皮肤健康等优势专科,以专业学术推广与多疾病领域学术资源,构建可持续的专科规模优势,皮肤健康业务已成为细分领域龙头。同时,持续推进国际化复制能力建设,在东南亚及中东等新兴市场验证商业模式的可迁移性,为集团高质量可持续发展注入长期动能。

康哲药业实施"产业国际化"战略,以新加坡为支点,通过研"CMSR&D"、产"PharmaGend"、销"Rxilient"全链生态,将经中国市场验证的全生命周期管理能力向亚太市场横向延伸。

CMS (Hong Kong Stock Code: 867, Singapore Stock Code: 8A8) is an innovative pharmaceutical company focused on the identification, building, and full lifecycle management of differentiated specialty pharmaceuticals. With a dual-engine approach of in-house R&D and collaborative R&D, and leveraging its core capability to build markets and brands from the ground up, the Group enables each medicine to fully realize both its clinical value and commercial value.

CMS focuses on advantaged specialties including cardiovascular-kidney-metabolic, central nervous system, gastroenterology, ophthalmology, and skin health. Through professional academic promotion and academic resources across multiple disease areas, CMS has built sustainable scale advantages in specialties, with its skin health business becoming a leading player in its segment. Meanwhile, CMS continues to strengthen its international replication capabilities, validating the transferability of its business model in emerging markets such as Southeast Asia and the Middle East, and injecting long-term momentum for the Group's high-quality, sustainable development.

CMS is implementing an "industrial internationalization" strategy, with Singapore as its pivot, extending its full-lifecycle management capabilities which have been validated in the China market horizontally across the Asia-Pacific (APAC) market through an end-to-end ecosystem spanning R&D ("CMS R&D"), manufacturing ("PharmaGend"), and commercialization ("Rxilient").

差异化专科医药产品的全生命周期管理者

Full-Lifecycle Manager of Differentiated Specialty Pharmaceuticals

双轨并行的创新体系
A Dual-Track Innovation System

识别 Identify
好产品的价值判断力
Quality Products Value Assessment

构建 Build
自研或合作研发最优路径选择
In-House or Collaborative R&D Optimal Path Selection

验证 Validate
临床快速推进注册高效执行
Rapid Clinical Advancement Efficient Registration Execution

学术引领的全域商业化体系
An Academically Led, Full-Spectrum Commercialization System

策略 Strategize
精准市场定位与差异化推广策略
Precise Market Positioning and Differentiated Promotion Strategy

创造 Create
专业学术推广品牌优势打造
Professional Academic Promotion and Brand Advantages Building

兑现 Realize
产品价值兑现(基础)国际化复制(延伸)
Product Value Realization (Foundation) International Replication (Extension)

9 款商业化创新药
9 Commercialized Innovative Drugs

40+ 独家药及其他产品
40+ Exclusive Drugs and Other Products

40+ 在研创新管线
40+ Innovative R&D Pipeline Projects

*销售网络覆盖 The sales network coverage

>60,000+ 医院及医疗机构
>60,000+ Hospitals and Healthcare Institutions

~320,000+ 家终端零售药店
~320,000+ Retail Pharmacies

7 主流电商及O2O平台
7 Major E-Commerce and O2O Platforms

*上述数据截至2026年6月30日 The above data are as at 30 June 2026

祥根生物- 聚焦环肽药物创新


SunCyclix™环肽研发平台

mRNA展示技术 DNA编码化合物库结构优化成药性优化工艺优化
超高通量虚拟筛选 生成式AI平台 AI分子动力学模拟 ADME预测

环肽药物

突破不可成药靶点
对靶蛋白亲和力高，靶点特异性高
识别靶点的浅表相互作用、绑定口袋结构

环形结构稳定且特异性强
对内源性蛋白酶的水解具有很强的抗性
可替代的构象较少，特异性强





深圳总部 2026年
AI+环肽创新药研发平台



深圳药化研发中心 2008年
药物化学合成
结构优化与工艺开发



香港临床商务中心 2025年
全球临床运营
海外BD 合作

祥根 AI+环肽创新药研发平台

靶点分析与验证平台

聚合分析靶点数据，生成证据可溯源 的报告
结合靶点结构、生物学证据以及虚拟对接的结果综合评判其环肽可药性

mRNA展示技术


建立定制环肽文库，库容10^{1}级
两款Myc靶点Hit可显著抑制三阴性乳腺癌细胞增殖，活性优于所有临床阶段药 物

DNA编码化合物库

引入高类药性砌块，非天 然氨基酸，杂 环等约500种化合物
单次同时筛选10^{3}-10^{4}个定向优化环肽

AI 全流程赋能

靶点结构预测	苗头化合物的超高通量虚拟筛选	药靶结合预测 ADME预测	基于自由能微扰的先导化合物优化



先导化合物的优化与临床前开发

结构优化	成药性优化	药效提升	工艺优化
环化方式 环大小/张力 侧链修饰 引入非天然氨基酸 精准调控立体构型 核心骨架修饰 官能团改造	优化相互作用力 安全性 优化ADME 物理化学性质 前药设计	构效关系研究 药代动力学 制剂开发 递送系统 生物学机制拓展 精准治疗	合成路线 纯化方式 成本控制 绿色溶剂 催化剂优化 连续化生产 一锅法反应

差异化重磅自研管线具备全球市场潜力

领域	分子	靶点	适应症	项目研发进展					下个里程碑
				立项	临床前	I期	II期	III期	
抗感染药物	SG1001片	DHODH抑制剂	真菌感染 曲霉及特殊菌种	中国					2026Q3 临床II期完成
				美国					2026Q3 临床I期完成
	SG5001针剂	超长效棘白菌素（环肽）	真菌感染 念珠菌及其他	全球					2027Q2 IND提交
	SG5001片	超长效棘白菌素（环肽）	真菌感染 皮肤及妇科	全球					2027Q3 IND提交
心血管药物	SG6001 片 SG7001片	PCSK9抑制剂（环肽） （环肽）	高血脂	全球					2026Q4 IND提交
			动脉粥样硬化	全球					2027Q2 PCC确认

SG1001（曲霉菌感染）

全新抗真菌靶点，解决真菌耐药问题
国内同靶点首款，全球同靶点药效最佳（BIC）
中国权益与丽珠完成交易，中国临床已进入II期
美国临床I期预计2026Q3完成 第十四届中国深圳创新创业大赛三等 奖

SG6001(高脂血症)

口服环肽，国内同靶点首款，解决他 汀临床 痛点
同靶点药效最佳（BIC）
降脂药市场超300亿美元，该靶点2024年超50亿美元，年增长率超40%
2025年第一批战略性新兴产业扶持计划资助项目

SG5001(念珠菌感染)

全球首款超长效棘白菌素，一天一针 优化为 两周一 针，解决患者依从性问题
口服制剂，是全球首款口服棘白菌素（FIC）
国内市场超30亿元，国外住院费用高，市场更广阔
第四届龙岗双创之星-创新创业大赛获生物医药组一等奖

For more information, please contact: Dr. Mengyao GUO (gmy@sungening.com)

LIYING BIOTECH



粒影生物 D²BTL循环

Shenzhen LiYing Biotechnology Co., Ltd. D²BTL cycle

粒影生物成立于 2022 年 4 月，坐落于深圳市光明区，是专注AI 驱动合成生物学领域的国家高新技术企业。公司深度融合人工智能与结构生物学技术，面向生物工程药物、医疗器械、化妆品、洗护日化等领域，提供重组胶原蛋白、酶、抗体、肿瘤标志物等蛋白分子的定制化设计与开发生产服务。

2025 年 12 月，公司正式发布 AI +生物制造公共服务“Proteincraft”平台，搭建“计算设计验证优化”全链路一站式技术服务体系，实现蛋白研发的智能化闭环赋能。

截至目前，公司累计申请中国发明专利 30 余项，其中授权 12 项，布局国际 PCT 及海外专利 5 项。企业先后获评专精特新、潜在独角兽等资质，斩获“华创杯”创业大赛一等奖、粤港澳大湾区高价值知识产权培育布局大赛金奖等多项行业荣誉。

Shenzhen LiYing Biotechnology Co., Ltd. (LiYing Bio) was founded in April 2022 in Shenzhen's Guangming District. A national high-tech enterprise, the company specializes in AI-driven synthetic biology, fusing artificial intelligence with structural biology to provide custom design and manufacturing of protein molecules—including recombinant collagen, enzymes, antibodies, and tumor biomarkers—for the biopharmaceutical, medical device, cosmetics, and personal care sectors.

In December 2025, LiYing Bio launched Proteincraft, an AI-powered bio-manufacturing service platform. Anchored by a "compute-design-validate-optimize" pipeline, it delivers a full-stack, one-stop technical ecosystem that enables an intelligent, closed-loop approach to protein R&D.

To date, the company has filed 30+ Chinese invention patents, with 12 granted, alongside 5 PCT and international patent applications. It has earned recognition as a Specialized, Refined, Unique and Innovative (SRUI) enterprise and a potential unicorn, and has won top honors including the First Prize in the Huachuang Cup Entrepreneurship Competition and the Gold Award in the Greater Bay Area High-Value Intellectual Property Development Competition.


实验设计 Design of Experiments



机器学习 Machine Learning







CFPS 蛋白表达 Protein Expression



数据分析 Data Analysis

晶泰科技 XtalPi | 2228.HK

构建自主科学发现新范式 *Building a New Paradigm for Autonomous Scientific Discovery*

XtalPi 晶泰科技

晶泰科技（2228.HK）是一家以量子物理为科学根基、以人工智能（AI）与机器人技术驱动创新的 AI for Science 平台型科技企业。公司由三位来自麻省理工学院（MIT）的物理学家创立，致力于构建面向全球的科学智能基础设施，加速创新药、新能源、新材料及化学化工等领域的研发进程。晶泰科技以XtalPi Science平台为统一技术底座，深度融合大语言模型、垂直科学模型、科学智能体与大规模机器人实验平台，形成贯通数字推理与物理实验的自进化AI研发闭环。在高质量实验数据积累和十余年真实产业项目经验的基础上，晶泰依托跨领域 Scientific AI（科学智能）科学模型、规模化部署的Physical AI（物理智能）实验体系及以 Genius Agent 为核心的多智能体系统，正通过智能体（Agent）调用、研发合作及智能自主实验室部署等模式，将领先的科学智能能力转化为可规模化的科学生产力，广泛赋能源头创新，加速科学构想向产业成果转化。

XtalPi (XtalPi Holdings Limited, 2228.HK) is an AI for Science company founded by three MIT physicists. Combining quantum-physics foundations with AI and robotics, we build platforms that accelerate R&D in innovative medicines, energy, materials, and chemicals. XtalPi Science is our core platform. It brings together large language models, domain-specific scientific models, scientific agents, and large-scale robotic labs in a closed loop—from computational reasoning to physical experiment—that improves with use. Drawing on more than ten years of industry projects and high-quality experimental data, we scale this capability through Scientific AI models, a deployed Physical AI laboratory system, and a multi-agent system built around Genius Agent. Partners work with us through Agent access, R&D collaboration, and autonomous lab deployment—to turn scientific ideas into results at scale.

全球布局 Global Locations

中国 深圳 Shenzhen, CN
中国 上海 Shanghai, CN
中国 北京 Beijing, CN
美国 波士顿 Boston, US
英国 利物浦 Liverpool, UK

技术基座 Technology

XtalPi Science 晶泰科技 科学发现智能平台

多智能体系统 Multi-Agent System

自主解析目标，自主编排任务，自主推进实验 Interprets research goals, orchestrates tasks, and advances experiments autonomously

Agentic System

Genius Agent

领域技能 Skills | 专家工具 Tools | 智能体生态 Agents Ecosystem

调度 Orchestrate

实验预测与指导 Experimental Prediction & Guidance

调度 Orchestrate

Scientific AI

专有科研数据训练的科学领域模型
Domain scientific models trained on proprietary research data
有持续验证和进化能力的领域科研超级专家
Continuously validated domain experts that improve over time



Physical AI

拥有自主发现能力的机器人实验室
Robotic laboratories with autonomous discovery capability
智能探索物理世界的高通量高精度科研基建
High-throughput, high-precision infrastructure for exploring the physical world

高质量数据收集反哺训练
High-Quality Data Feedback for Model Training

业务布局 Our Solutions

调度晶泰 AI4S 能力的智能中枢

Access our AI4S capabilities through the orchestration hub

Genius Agent



*Genius Agent 网页端目前正在内测当中。正式上线时间我们将通过晶泰科技官方网站及社交媒体平台另行发布。

The Genius Agent web app is currently in closed beta. General availability will be announced on XtalPi's official website and social channels.


共同推进新分子发现 加速领域科研

Advance Molecular Discovery, Accelerate Domain Research

药物发现 Drug Discovery	化学、材料与能源 Chemistry, Materials & Energy	更多行业 More Industries
小分子药物发现 Small-Molecule Drug Discovery	化学合成服务 Chemical Synthesis Services	个人护理品 Personal Care
分子胶药物发现 Molecular Glue Discovery	新材料领域研究 Advanced Materials Research	健康消费品 Consumer Health
抗体药物发现 Antibody Discovery	新能源领域研究 New Energy Research	……
药物固体形态研究 Solid-Form Research		
多肽药物发现 Peptide Drug Discovery		
小核酸药物发现 siRNA Drug Discovery		

部署未来科研基建 迈向自主发现

Deploy AI4S R&D Infra. for Autonomous Discovery



智能机器人实验室建设及实验工站定制
Intelligent Robotic Lab & Workstation Solutions



通用实验室机器人工作站产品
General-Purpose Laboratory Robotic Workstation




创新分子砌块供应
Innovative Building Blocks

TOTEM

AI驱动的下一代高速冷冻电镜

20000张/天 · L4级AI自动化工作流 · 更快更好更省心



全新4D STEM相机 | GraFuture 载网 | AI 超高速数据采集处理 | ESI 冷冻制样机

生命科学 · 材料科学 · 新能源 · 半导体 · 原子级制造

WEBSITE I www.shuimubio.com
EMAIL I hi@shuimubio.com

水木未来
AI + CryoEM,for Future



EMPOWERING LIFE SCIENCES INNOVATORS

ONLY FIRM RANKED BAND 1 FOR LIFE SCIENCES FOR 16 CONSECUTIVE YEARS

— *Chambers* Greater China Region

HIGHLY RANKED FOR LIFE SCIENCES

— *Chambers Global* 2026: Asia-Pacific Region, Europe-wide, Greater China, Multi-jurisdictional, UK-wide, and USA: Nationwide

Sidley's industry-recognized Global Life Sciences practice leverages integrated teams across regulatory, compliance, enforcement, litigation, corporate, and transactional practice groups to advise biotech innovators and investors throughout the lifecycle of their products and investments.

SIDLEY

sidley.com

Attorney Advertising - Sidley Austin LLP is a global law firm. Our addresses and contact information can be found at www.sidley.com/en/locations/offices. MN-30748

海口国家高新区概况

海口国家高新区于1991年经国务院批准成立，是我国第一批国家级高新区，是海南自贸港唯一的国家级高新区。海口国家高新区总规划面积85.42平方公里，以“一区七园”格局多元化发展，下辖美安生态科技新城、药谷工业园、狮子岭工业园、海马工业园、云龙产业园、海口观澜湖旅游园区、西海岸总部经济区。

海口国家高新区先后被评选为全国文明单位、国家知识产权示范园区、国家大众创业万众创新示范基地、国家中小企业公共服务示范平台、国家首批“双创”升级版项目单位。在产业发展尤其是生物医药领域，园区产业“向新”转型加速推进，不仅跻身国家中小企业特色产业集群行列，还承担起我国第二个重大新药创制国家科技成果转移转化试点建设任务；凭借着这项突出成效，园区荣获“2025年中国特色生物医药产业园区优秀案例”，在全国生物医药园区百强榜中排名第31位。

海南医药产业核心区

海口国家高新区是海南省医药产业发展的核心区，园区现有医药、医疗器械企业近800家，其中获得药械生产许可证企业153家，2025年完成医药工业产值189亿元，占全市医药产值的85.9%，占全省的80%。海口国家高新区聚焦医药产业链实施精准招商，引进晖致医药、瑞士雀巢、太阳药业、东亚制药、齐鲁药业、先声药业、赞邦药业、原子高科、华熙生物等一批行业龙头企业。当前，海口国家高新区正加速建设“海口药谷”国家级产业平台，全力打造“千亿级生物医药产业集群”。

产业定位

海口国家高新区是海南自贸港13个重点园区中唯一涵盖“旅游业、现代服务业、高新技术产业”三大主导产业的重点园区。





Hainan Huayan Collagen Technology Co., Ltd.
海南华研胶原科技股份有限公司

海南华研，2005 年成立于海口，隶属金意科技集团，是国内水解胶原蛋白肽生产先行者、首家鱼胶原蛋白肽生产许可企业，获评国家级高新技术企业等荣誉。

120 余项专利和年产超万吨的产能，掌握定向酶切、固相热环化等核心技术，产品通过16 项国际权威认证，远销 60 多个国家和地区，**是小分子肽领域全球领先的研发制造与全案供应商。**

引进战略投资人华熙生物及朗亚温氏投资助力企业发展。

Hainan Huayan, founded in Haikou in 2005 and part of the Jinyi Technology Group, is a pioneer in the domestic production of hydrolyzed collagen peptides and the first enterprise in China to obtain a production license for fish collagen peptides. It has been recognized as a national-level high-tech enterprise, among other honors.

With over 120 patents and an annual production capacity exceeding 10,000 tons, the company masters core technologies such as targeted enzymatic cleavage and solid-phase thermal cyclization. Its products have passed 16 major international certifications and are exported to more than 60 countries and regions, making it a globally leading R&D, manufacturing, and total-solution provider in the small-molecule peptide sector.

6 国内外大生产基地

6 Production Bases



Huayan · Haikou, Hainan Production Base | Huayan ·Wenchang, Hainan Production Base | Huayan·Bangkok, Thailand Production Base | Huayan · Liaocheng, Shandong Production Base | Huayan · Luyi, Henan Production Base | Huayan-Anhui Fuyang Production Base

创始于
2005年7月29日
Founded on
July 29, 2005

集研发、生产、销售一体
国家级高新技术企业
Integrated with R&D, Production And Sales
National-LevelHigh-Tech Enterprise

总部位于
海南海口
Headquartered in
Haikou, Hainan Province

公司人员
450人+
Nember
450+

海口 | 文昌 | 泰国曼谷 | 聊城 | 河南鹿邑 | 安徽
6大生产基地
HAIKOU WENCHANG THAILAND LIAOCHENG HENANLUYI ANHUI
6Production Bases

海口 | 广州 | 杭州 | 郑州 | 成都
5个客服中心
HAIKOU GUANGZHOU KANGZHOU CHENGDU
5Customer Service Centers

省级研发技术平台
3000m²
Provincial-level R&D Technology Platform
3000m²

发明专利
120+
Patents
120+

产品销售国家和地区
60+
Product sales countries and regions
60+

年产能超过
10000吨
Annual Production Capacity
over**10000** tons

出口占比
20%
Export share
20%

企业标准
150+
Enterprise Standards
150+

德镁 DERMAVON | Lumirix 百卢妥

始于医院 科学复色

白癜风全周期科学管理专家

百卢妥Lumirix隶属康哲药业(00867.HK)旗下德镁医药集团
是面向白癜风人群的全周期科学皮肤健康管理品牌



科学评估

百卢妥伍德灯

辅助观察皮肤白斑
状态变化，让干预
更有依据

居家光疗

百卢妥308光疗仪

结合居家光疗方式，
在不同阶段
推进科学干预

日常修饰

百卢妥遮盖系列

日常遮白肤色管理，
从容应对社交
与生活节奏

自信回归

百卢妥安心守护

在科学干预与日常
管理中，找回面对
生活的从容与自信

从发现到复色再到回归生活 百卢妥全程相伴

精准干预

观察-干预-护理
精准管理复色进程

循证医研

源自皮肤学研究与临床经验积累
结合用户反馈持续优化产品设计

长期守护

不止关注皮肤状态
更是专业又信赖的同行者

免责声明:本宣传资料所有内容仅供目标合作方及相关专业人士进行产品信息了解与市场参考之用，不构成任何形式的医疗建议、诊断或治疗方案承诺。本手册为产品市场推广资料，所载信息基于公司现有研究、数据及文献。所有表述均旨在说明产品设计的理论基础或部分研究观察，并非对最终使用效果的绝对保证。所有关于产品功效或潜在益处的描述，均以官方核准的注册证、说明书或备案凭证为准。本宣称资料若与前述核准文件不一致，应以核准文件为准。

WEITAI

微肽集团公司

WeiTai Group Co., Ltd.

·公司简介 COMPANY PROFILE·

微肽生物创立于 2012年，是国家高新技术企业。公司联合基因工程药物国家工程研究中共建基因工程暨南大学医药生物技术研究中心，深耕护肤前沿技术，坚持源头创新。企业拥有总面积超 110000m2的四大生产基地，具备消、械、妆生产资质，旗下设有多个自营品牌，专注问题肌肤修护。依托专业研发与临床验证，我们可为医美行业提供定制化美肤方案，助力产业高质量发展，致力打造行业领军企业。

Founded in 2012, Micropeptide Biotechnology is a nationalhigh-tech enterprise. The company collaborates with the National Engineering Research Institute for Genetic Engineering Drugs to establish theGene Engineering Jinan University Pharmaceutical Biotechnology Research Center, which is deeply rooted in cutting-edge skincare technol.ogies and adheres to source innovation. The enterprise has four majorproduction bases with a total area of over 110000 square meters, pos.sessing qualifications for the production of consumer goods, machinery, and cosmetics. It has multiple self operated brands under its um-brella, focusing on repairing problematic skin. Relying on professionaresearch and clinical verification, we can provide customized skin caresolutions for the medical beauty industry, help promote high-qualitydevelopment of the industry, and strive to build a leading enterprise inthe industry.

100+
已拥有发明专利

20+速度
每年以20+速度在申请

专利壁垒-难以复刻的核心竞争力
技术领先，让竞品难以模仿
Patent Barriers: Non-replicable Core Competitiveness
Leading technology, hard for competitors to copy



海康诺德 Hicanord®

COMPANY PROFILE
企业简介

Hainan Haikang Nuode Medical Devices Co., Ltd. specializes in the research, development, production, and sales of dental medical devices. Headquartered in the National High-tech Zone, Haikou, Hainan, China, the company is a nationally recognized high-tech enterprise. It operates a Class 10,000 dust-free purification workshop and has obtained ISO 13485 international medical device quality management system certification. Its main products include Perio Brown Bottle antibacterial gel, disposable oral examination kits, periodontal combination therapy units, and periodontal Er:YAG lasers, holding multiple utility model and design patents. The products are well-sold across Mainland China, Hong Kong, Macao, and Taiwan, and are also exported to Southeast Asia, the Middle East, and other regions. Committed to independent R&D-driven innovation, the company strives to provide high-quality solutions for global oral healthcare.

海南海康諾德醫療器械有限公司，專注於口腔醫療器械的研發、生產與銷售，總部設於中国海南海口國家高新區，係國家級高新技術企業。公司建有萬級無塵淨化車間，並通過ISO 13485國際醫療器械生產體系認證。主營產品有牙周小棕瓶抑菌凝膠、一次性口腔檢查包、牙周綜合治療機、牙周鉌激光等，擁有多項實用新型及外觀專利。產品暢銷中國大陸、港澳臺地區，並遠銷東南亞、中東等地區。公司堅持以自主研發驅動創新，致力於為全球口腔醫療提供高品質解決方案。

Utility Model Patent
實用新型專利
近 **20** 项

Design Patent
外觀設計專利
近 **10** 项

Computer Software Copyright
計算機軟著
1 项

The company headquarters is located in Meian High-tech Zone, Hainan Province, China, with a plant area of approximately 1,500㎡.
企業總部位於中國海南省美安高新區，廠房面積約1500㎡。



KBP 金熊药业 KING BEAR PHARMA

企业介绍

金熊药业是澳企中华金胆生物科技的全资子公司，2020年与澳门科技大学科研机构联合开发护肝大健康产品，2021年建成GMP生产车间，并成为横琴首批获得食品生产资质的企业，在澳门已申报生产九大系列产品，全网销售超300万盒，其中解酒护肝产品“金胆胶囊”销量领先。在守护肝脏健康的征程中，金熊药业携手老字号片仔癀开启全新篇章。与漳州片仔癀集团共研的“金胆护肝胶囊”，作为“澳门注册+横琴制造"典型产品，为琴澳中药大健康产业标准化、现代化和产业化发展探出新路。在海南海口的金熊药业专业深耕中药饮片，依托政策和产业标准，持续推动中医药产业融合、标准化升级。

COMPANY PROFIL

JinXiong Pharmaceutical is a wholly-owned subsidiary of China Golden Bile Biotechnology (an Australian-invested enterprise). In 2020, it jointly developed liver-protecting health products with research institutions of Macau University of Science and Technology. In 2021, it completed the construction of its GMP--compliant production workshop and became one of the first batch of enterprises in Hengqin to obtain food production qualifications. Nine series of its products have been filed for production registration in Macau. Its total online sales have exceeded 3million boxes, among which the anti-hangover and liver-protecting product Golden Bile Capsules takes the lead in sales.

On the journey of safeguarding liver health, JinXiong Pharmaceutical has turned a new page through its partnership with time-honored brand Pientzehuang. The co-developed Golden Bile Liver-Protecting Capsules, a typical product under the "Macau Registration + Hengqin Manufacturing" model, has blazed a new trail for the standardization, modernization and industrialization of the traditional Chinese medicine and health-care industry in the Guangdong-Macao In-depth Cooperation Zone of Hengqin.

Hainan Haikou-based JinXiong Pharmaceutical specializes in Chinese herbal decoction pieces. Leveraging supportive policies and industrial standards, it keeps advancing the integration and standardized upgrading of the traditional Chinese medicine industry.

主推产品



1、《Chinese Medicine》金胆粉解酒护肝研究：延长入醉时间8.8倍，加快醒酒 2.3 倍；
2、金胆粉消化吸收率吸收率98%；
3、提高乙醇脱氢酶活力62%，提高乙醛脱氢酶活力43%，并有效提高解酒酶含量；
4、3小时酒精浓度下降48.5%，缓解宿醉有效率100%；6小时宿醉感完全清零；
5、多次荣获抖音电商-保健食品类销量排行榜第一等；
6、线上线下销售超400万盒，累计销售额超1亿+。


金胆护肝胶囊臻品装



熊延堂解酒胶囊20粒装



熊延堂解酒胶囊6粒装


熊宝金胆护肝胶囊



中药饮片

苏生生物
SUSHENG BIOTECH

医疗科技促进大众健康
Promoting Health for All



海南苏生生物科技有限公司2019年12月自瑞士归国落地海口国家高新区，是由瑞士、法国、美国等名校海归博士领衔成立的高科技企业。公司先后荣获国家专精特新“小巨人”企业、国家高新技术企业等称号。



公司建立了一支90余人高学历人才队伍，其中全职海归博士和高级职称获得者10人，研究生以上学历超50%，包括自贸港B、C类高层次人才3人，D、E类5人，在多个国际国内学术组织中任职。



公司布局运动医学、生物材料以及创伤修复等多个产品管线，已上市20余款医疗器械产品。在研产品“软骨组织工程支架”、“个性化仿生颅骨修复材料”分别列入国家药监局第一、二批审评前置重点产品。



3D打印人工骨




聚酯胶原骨修复材料



软骨修复材料



锚钉系列




半月板缝合系统



界面螺钉



带袢钛板



一次性使用刨削刀头

聚焦前沿生物制造
志创全球头部品牌

企业简介

ENTERPRISE INTRODUCTION

新开利安生物科技（海南）有限公司是2023年10月海口产业招商大会重点招商项目，同年入驻海口国家高新区，2024年在海口市委市政府、海口国家高新区的大力帮助支持下，当年完成项目设计论证、设备安装调试并投产，真实体现了自贸港速度。

新开利安公司是国内唯一具有完全自主知识产权和完整体系认证，FDA注册的高端保健品还原型辅酶Q10的量产企业，是科伦药业成员单位，设计产能160吨每年，满产可实现5亿产值。

还原型辅酶Q10是全球健康产业的黄金原料，是人体可直接吸收利用的活性形态，它参与人体能量合成、抗氧化保护、养护心脑血管、延缓衰老、增强免疫、减少他汀类药物副作用等核心功效。

新开利安深耕还原型辅酶Q10系列产品核心技术攻关，依托合成生物学前沿技术，创新性打造基因工程菌构建——专利晶型优化、智能化、规模化全产业链技术闭环，截止2026年5月公司拥有四项国家发明专利、一项美国专利商标局授权专利，彻底打破国外专利垄断，为国家十五五大健康战略及全球高端保健品市场提供优质核心原料。

新开利安以“技术赋能、品质立足、合规先行”，为全球化发展战略，加速全球化布局，产品销往全球16个国家地区，是新西兰美大、丹麦法尔诺德、日本PEA、仙乐健康的全球供应商。

新开利安作为海口国家高新区重点培育的新型生物医药企业，在政策扶持、知识产权申报辅导、产业链资源对接等方面，提供全生命周期服务、助力我们快速完成产业突破，做到了保姆式服务，我们将不负众望为自贸港建设添砖加瓦。



TC4 钛合金耳内式数字助听器

YUE BEI FENG Brand TC4 Titanium Alloy ITE Digital Hearing Aid

您的智听伴侣

Your intelligent listening companion



TC4钛合金助听器，AI语音增强算法。

来自中科院声学所的核心团队，凝聚数十年积累精心打造，成就奢品级听觉典藏。

TC4 titanium alloy hearing aid, AI speech enhancement algorithm.

Powered by the core team of the Institute of Acoustics, CAS, this exquisite audio device fuses decades of groundbreaking research with meticulous artistry, creating a new standard in luxury sound.

- 佩戴舒适 钛合金金属外壳
- DNN语音增强专利技术
- 蓝牙便捷 一键切换
- 二类医疗器械 创新产品

- Titanium alloy, comfortable to wear
- DNN Speech Enhancement Patent Technology
- with one-click switch between BTM and HAM
- Innovative products Class II Medical Devices

厂家服务热线: 0898-68617716 / 400-8650-553/ 15308964565

厂家地址：海南省海口市国家高新技术产业开发区国科中心A701

经销:国药控股海南公司

ASYMCHEM

Integrated CDMO Solutions

Development to Commercial Supply

Since 1995
North Carolina, US


10,000+
Employees Worldwide

5,000+
R&D Scientists

100+
Successful Regulatory Inspections Worldwide

60+
Commercial Manufacturing Projects Annually





UK Sandwich Site

Asymchem's European Hub for Global Pre-clinical to Commercial API Development and Manufacturing



Learn more

Collaborative Client Partnership	Industry Leading High-Throughput-Experimentation Platformt	MHRA-certified multi-modular cGMP Pilot Plant
Experienced Pharma Industry Trained Workforce	Flow Chemistry & Biocatalysis Capabilities	Data-Centric Route and Process Design Workflows

Brochures

Linkedin

Contact Us

inquiry@asymchem.com

Meet us at

Booth #3E-C01



Proactive Partnership. Proven Impact.

At Syneos Health®, our deep experience gives us a clear understanding of the challenges involved in bringing new therapies to market. Our team of experts across clinical development and commercial delivery work together to reduce uncertainty and navigate the complexities of product development. Partnering with us means gaining a forward-thinking ally focused on accelerating progress, reducing risk and delivering therapies to patients faster.

Discover the impact of a proactive partnership—see how we can support you at syneoshealth.com.

Syneos® Health

© 2025 Syneos Health®. All rights reserved.

Taimei Intelligence

Booth: No. 3E-B12

A Technology-Enabled Clinical Development Partner



We help biopharmaceutical companies make better development decisions and accelerate the path to innovative therapies.

Rooted in China with a global footprint.

OUR CLINICAL DEVELOPMENT CAPABILITIES

Early Clinical Development	Clinical Strategy · FIH · Clinical Pharmacology · Cardiac Safety Assessment · Dose Optimization · PoC Planning · IIT
Pivotal Clinical Development	Regulatory Affairs · Study Design · Clinical Operations · Patient Recruitment · Medical Affairs · Data & Biostatistics · PV
Post-Approval & Evidence Generation	RWE · IRC

800+ Clinical Projects Supported

100+ Studies Supporting Regulatory Submissions

25+ Therapeutic Areas Covered

15+ Average Years of Core Team Experience

WHY TAIMEI INTELLIGENCE

Scientific Expertise | **Technology-Enabled** | **China Depth, Global Perspective**

Empowering Full-Life-Cycle Clinical Development

Preclinical — IND — **Clinical Development** (Phase I—III) — NDA — **Post-marketing**

FIH Clinical Studies | Full-Service Outsourcing for Phase I–IV Studies | Functional Service Provision | RWE / IIT / Others

Accelerate Your Clinical Development in China & Beyond.

Meet Taimei Intelligence at BIOHK 2026

WeChat LinkedIn

THE HONG KONG POLYTECHNIC UNIVERSITY
香港理工大學

THE HONG KONG POLYTECHNIC UNIVERSITY

The Hong Kong Polytechnic University (PolyU) aspires to be an innovative world-class university that pursues excellence in education, research and knowledge transfer for the benefit of Hong Kong, the Nation, and the world. Driven by its motto, "To learn and to apply, for the benefit of mankind", the University nurtures socially responsible professionals and leaders with a strong sense of national pride and a global perspective, and pursues world-leading research and innovation for societal benefits. The University's unwavering commitment to excellence has garnered international acclaim, with PolyU ranking 50th in the QS World University Rankings 2027. Five subjects were placed within the top 30 in the QS World University Rankings by Subject 2026. Furthermore, Hospitality & Leisure Management, Civil & Structural Engineering, Art & Design and Environmental Sciences were ranked first in Hong Kong. PolyU also strives to foster a University community in which all members are united with a strong sense of belonging and pride, empowering the University to scale new heights.

KTEO

The Knowledge Transfer and Entrepreneurship Office (KTEO) strives to create societal impact by advancing knowledge transfer and entrepreneurship. It provides a wide range of support and services to the PolyU community, from managing intellectual properties to translating research outcomes into impactful solutions through various models, promoting knowledge transfer, entrepreneurship and University-industry collaborations.



Knowledge Transfer and Entrepreneurship Office

Visit Us at 3E-B04

ABRAM Therapeutics Limited



ABRAM Therapeutics translates university discoveries into real-world impact. Our lead candidate ABarginase is designed to induce controlled transient amino acid starvation, helping reset the metabolic state to address obesity and related chronic conditions including diabetes and fatty liver.

Prof. Thomas LEUNG, Co-founder, ABRAM Therapeutics Limited
✉ thomas.yun-chung.leung@polyu.edu.hk

AIM Pharmaceutical International Limited



Founded in 2023 by Prof. Simon Lee of PolyU, AIM Pharmaceutical International develops natural product-based therapeutics and nutraceuticals for brain health. Its lead candidate, PD-001R, is a first-in-class oral disease-modifying therapy for Parkinson's disease, showing neuroprotective effects, blood-brain barrier penetration, favorable preclinical safety, with kilogram-scale synthesis, global patent filings and NMPA/CDE implied clinical trial approval.

Prof. Simon LEE, Founder & Chairman, AIM Pharmaceutical International Limited
✉ simon-my.lee@polyu.edu.hk / info@aimpharmaintl.com

InnoSentio Limited



InnoSentio Limited is a PolyU biotech start-up developing cutting-edge, low-cost sensing solutions for rapid, on-site detection of illicit substances. Our product, EtoChrom, detects etomidate in e-cigarette samples within one minute, designed for applications in public safety and regulatory enforcement.

Dr Achilles FUNG, Founder & CEO, InnoSentio Limited
✉ info@innosentio.com

PolyVentures

PolyU is committed to fostering innovation and entrepreneurship, cultivating next-generation entrepreneurs that are eager to tackle societal issues with innovative solutions. Via PolyVentures, our signature start-up ecosystem, the University supports PolyU start-ups in every stage of their entrepreneurial journeys - from education and ideation to incubation, acceleration, and fundraising. To equip them with necessary knowledge and skills for sustainable development and accelerated growth, a wide range of support, such as training, mentorship, shared office spaces, funding, and networking opportunities with business partners and investors, are available for our start-ups. PolyVentures serves as a super network that connects the academia, industry, and the capital market. It offers customised entrepreneurial support, incubates start-up projects, facilitates fundraising, and drives the translation of impactful research outcomes into real-world solutions, thereby bringing tangible benefits to society.

途深智合 TOURSYNBIO Toursynbio

Toursynbio

Toursynbio is an AI-native biopharmaceutical company dedicated to building an Autonomous AI Biopharma Foundry and transforming drug discovery into drug creation. By integrating artificial intelligence with automated experimentation, Toursynbio is redefining how biologic medicines are designed, validated, and developed.

2026 International Protein Design Competition (Binder × RBX1)



#1 in China **#2** in Globally

2/7	9/300	9.5x
Hit Rate 28.6%	Total Hit Rate	Above Overall Average


De novo Design

Claudin-18.2: Drug-like Molecules Generated in 1 Month



1	30	2	8 nM
Month Timeline	Designed Antibodies	Functional Hits	Best Binding Affinity

ToursynClaw



16 mAb PCC deliveries achieved within six months; 30 innovative molecule programs (mAbs, bispecific antibodies, ADCs, cyclic peptides, and beyond) targeted by the end of 2026.

CD3E	PSMA
DLL3	IL23
CD79	CD73
CEACAM5	FcRn
BAFF	APRIL
CD3 x CLDN18.2	CD3 x BCMA
CD3 x DLL3	EFGR x Cmet



Yu Guang Wang
Founder

PhD in Mathematics, UNSW
Associate Professor, Shanghai Jiao Tong University
Adjunct Professor, UNSW/ Monash University

S | CTO
PhD in AI for Healthcare, Johns Hopkins University

X | Drug Discovery Lead
Ph.D. in Biochemistry, Johns Hopkins University
Previously served as a Senior Scientist at Novartis

G | Senior Advisor
Former CSO of a U.S. listed company

Y | Head of R&D
PhD in Mathematics & Statistics, UNSW Postdoc in Molecular Biology, University of Cambridge

S | Sales Lead
Former executive & board director at a listed technology company

L | Chief AI Scientist
PhD in Computational Biology, UCL Postdoc, UCL CATH Group

contact@tsynbio.com | www.toursynbio.com

WALLONIA, BELGIUM
比利时瓦隆大区

欧洲中心的生物制药创新中心
EUROPEAN CENTER FOR BIOPHARMACEUTICAL INNOVATION CENTER





Wallonia.be

比利时瓦隆大区外贸与外国投资总署
Wallonia Export - Investment Agency

比利时瓦隆大区外贸与外国投资总署(AWEX)是比利时瓦隆大区负责经济贸易活动和投资事宜的政府机构，在世界各地设有92个经贸代表处，致力于促进瓦隆企业在国外开展商贸活动，同时推广瓦隆优良投资环境，吸引外国投资者落户瓦隆，促进瓦隆大区经济国际化。

生态系统——产学研紧密结合

世界级学术研究中心
5所大学，400多个研究中心

KU LEUVEN · Universiteit Antwerpen · LIFEBIO · imec · UCLouvain · UHASSELT · UNIVERSITEIT GENT · VUB VRIJE UNIVERSITEIT BRUSSEL · ULB UNIVERSITÉ LIBRE DE BRUXELLES · vito · VIB-UGENT CENTER FOR PLANT SYSTEMS BIOLOGY · UNIVERSITÉ DE NAMUR · LIÈGE université · UMONS

生物技术中小型企业
200多家生物制药企业

Ablynx · BIOCARTIS · eTheRNA · COMPLIX · DNAlytics · apitope · Bone Therapeutics · iTeos · Imcyse · PROMETHERA · mithra · Celyad Oncology · syndesi therapeutics · argenx · reMYND · TiGENIX · Galápagos · ASIT biotech

世界领先制药公司
总部/研发中心/制药基地

Chiesi · abbvie · NOVARTIS · AMGEN · Celgene · Shire · ucb · SERVIER · janssen · Pfizer · gsk

供应商/服务商
CDMO/物流/法律

ImmunXperts · Eurogentec · OVIZIO · Aepodia · MaSTherCell · UNIVERCELLS · Ncardia

产业集群

BIOWIN · BRIDGE 2 HEALTH · BRUSSELS SOUTH CHARLEROI BIOPARK · UI EUROPE · CBTC · essenscia

OVERSEAS RETURNEES TOWN
TRANSFAR INNOCITY

展位号/BOOTH
NO.T02

传化科技城·海归小镇

中国杭州
HANGZHOU CHINA



服务科学家创业成功
服务科创企业快速成长

ENABLE SCIENTISTS' ENTREPRENEURIAL SUCCESS
ACCELERATE TECH INNOVATION ENTERPRISES' GROWTH

官方微信二维码
Official WeChat QR Code

30000+	700+	20+	8000+	3.78KM²
职住人群	入驻企业	国家人群	科创人才	区域面积
Working&Living Population	Resident Enterprises	Nations	Sci-Tech Talents	Regional Area

传化科技城·海归小镇是由传化集团打造的国际都市产业新城，总规划面积3.78平方公里，是全国首批三个“海归小镇”之一，也是传化集团面向未来产业建设的重要战略载体。

依托传化集团近四十年的实业积淀、产业资源、应用场景和政企公信力，科技城聚焦人工智能与生物技术深度融合，重点布局前沿生命科学、生物制造及人工智能赋能，构建“孵化—中试—产业化”全链条创新体系，推动科技成果从实验室走向大市场。

传化科技城通过专业平台、精准服务、资本链接、场景开放和社群运营，为企业提供研发实验、中试放大、人才引育、融资对接、供应链协同和市场拓展等全生命周期服务，并链接传化集团及生态伙伴的产业资源，助力企业缩短从技术到产品、从产品到市场的转化路径。

目前，区域已汇聚一批创新平台和科技企业，超过30000人在这里工作与生活。面向未来，传化科技城将持续汇聚全球科学家、创业者和创新资源，服务科学家创业成功，服务科创企业快速成长，建设产业与城市共生、科技与人文交融的国际化产业创新生态。

Transfar Innocity · Overseas Returnees Town is an international urban industrial community developed by Transfar Group. Covering a planned area of 3.78 square kilometers, it is one of China's first three nationally recognized Overseas Returnees communities and a key platform for Transfar Group's future-oriented industries.

Building on nearly four decades of industrial experience and resources, Transfar Innocity focuses on the convergence of artificial intelligence and biotechnology, with priority areas including frontier life sciences, biomanufacturing, and AI-enabled innovation. Through professional platforms, capital connections, application scenarios, and full-lifecycle services, it supports technology ventures from incubation and pilot-scale production to commercialization.

Today, more than 30,000 people work and live here. Transfar Innocity is committed to connecting global innovation resources, helping scientists succeed as entrepreneurs, and enabling technology companies to grow faster.

四大国家级平台 The four national-level platforms



传化科技城
全国首批欧美同学会海归小镇



杭州合成生物产业中试(验证)中心
国家生物制造中试能力建设平台



传化国际科创园
国家级科技企业孵化器



谢径安·传化农创村
国家级和美乡村建设试点

展位号/BOOTH

NO.T02



TRANSFAR INNOCITY

OVERSEAS RETURNEES TOWN

传化科技城·海归小镇

中国杭州
HANGZHOU CHINA

30000+
职住人群
Working&Living Population

700+
入驻企业
Resident Enterprises


20+
国家人群
Nations

8000+
科创人才
Sci-Tech Talents

3.78KM²
区域面积
Regional Area



全球创业大赛
Global Entrepreneurship Competition



科创路演
Sci-Tech Innovation Pitch


科创生态大会
Sci-Tech Innovation Ecosystem Conference

服务科学家创业成功
服务科创企业快速成长

ENABLE SCIENTISTS' ENTREPRENEURIAL SUCCESS

ACCELERATE TECH INNOVATION ENTERPRISES' GROWTH

官方微信二维码

AnCode 動態健康智能化管理服務平台

讓健康科技觸手可及

AnCode

1. 關於我們 INTRODUCTION

AnCode 動態健康智能化管理服務平台以「讓健康科技觸手可及」為使命，透過 AnCode 品牌智能穿戴設備、AI 數據模型與區塊鏈加密技術，構建動態健康 AI 管理服務平台，為 B 端企業、政府、社區及康養機構提供全鏈條數碼化智能健康管理解決方案。



2. 核心服務

1. AI 健康報告
1.1 智能生成 AI 健康日報 / 週報 / 月報
1.2 直觀呈現健康數據變化與趨勢分析

2. 個人化養護方案
2.1 個人化食療調理方案
2.2 個性化運動計劃
2.3 科學作息養護建議

3. 家庭成員健康組
3.1 支持家庭成員健康數據互聯共享
3.2 一人佩戴，全家守護，隨時關注家人健康狀況

3. 聯絡我們 CONTACT US

郵箱：postmaster@hdfs.cloud
香港電話：00852 5957 2231
中國大陸電話：+86 133 4348 1688

香港安達生命科技有限公司
HONG KONG ANDA LIFE TECHNOLOGY LIMITED

WHO-Recommended First-in-Class MTB NPOC-NAAT



Accurate
PCR-level performance

Affordable
Low per-test cost

Simple
1–2 min hands-on time

Fast
Results available in as fast as **5 min**

Extensive
Single/Combo test support

Flexible
Cold-chain free

Same-Day Test & Treatment

Portable Power

Beyond TB

- MTB & Rifampicin Resistance
- HPV Multi-Type Genotyping
- Neglected Tropical Diseases
- Sexually Transmitted Infections (CT/NG/TV)



Additional assays in development

NEXA LONGEVITY
AI for Longevity. Insight for Life.

LaaC

Longevity-as-a-Choice

长寿，是一种持续的选择



CORE SERVICES 核心业务

SERVICE 01

INTERNATIONAL MEDICAL TRAVEL

国际医疗与跨境就医服务

SERVICE 02

AI-NATIVE LONGEVITY NAVIGATION

AI 原生长寿健康导航

FROM INSIGHT TO ACTION

从洞察到行动，贯穿健康与生活

01

SENSE & UNDERSTAND

SEE YOUR HEALTH IN CONTEXT.

在持续变化中，看见更完整的健康图景。

- SMART DEVICE INTEGRATION 智能设备连接
- LONGEVITY INTELLIGENCE 长寿算法
- AI HEALTH REPORT 智能健康报告

02

CONNECT & VERIFY

CONNECT DATA WITH GLOBAL EXPERTISE.

连接健康数据与全球专业资源。

- INTERNATIONAL SECOND OPINION 国际二诊
- GLOBAL SPECIALIST NETWORK 全球专家协作
- CROSS-BORDER CARE COORDINATION 跨境医疗协调

03

NAVIGATE & ACT

TURN INSIGHT INTO ADAPTIVE NEXT STEPS.

把洞察转化为可执行、可持续调整的行动路径。

- PERSONALIZED HEALTH PATHWAYS 个性化健康路径
- NUTRITION, SLEEP & RECOVERY 营养、睡眠与恢复
- CONTINUOUS FEEDBACK 持续反馈调整

PARTNER WITH NEXA

与 NEXA 合作

biz@nxlongevity.com

SCAN TO CONNECT

扫码联系

into.nxlongevity.com/biohk2026

LEARN MORE

LANDING PAGE

WHATSAPP

QR RESERVED

Development of Fully Human Anti-ACVR2A Antibodies with Enhanced Selectivity and Favorable Pharmacokinetics for Metabolic and Muscle Disorders

- **Authors:** YuxiangLiu,ShunZhou,YangWu,YihuaGao,ZhiFeng,ChengchengWang,XiaoliangLi,QiangWu,ZhengdongQin
- **Affiliation:** Cyagen Biosciences

Introduction

ACVR2A is a key type II transmembrane receptor in the TGF-β superfamily, regulating muscle growth, adiposity, and metabolic homeostasis. It is a promising therapeutic target for muscle atrophy, sarcopenia, obesity, and fatty liver disease. However, the human and mouse ACVR2A proteins share >99% sequence identity. This exceptionally high homology leads to immune tolerance in wild-type mice, making it extremely difficult to elicit a robust immune response against human ACVR2A using conventional immunization. Consequently, obtaining native antibody sequences targeting ACVR2A from immunized mice is also highly challenging. Existing approaches rely on ligand-trapping fusion proteins or non-fully human antibodies, which carry immunogenicity risks and suboptimal selectivity. Therefore, fully human, highly selective ACVR2A antibodies remain an unmet need for precision medicine.

Methods

Fully human anti-ACVR2A antibodies were generated from HUGO-Ab-eKO™ mice (humanized Ig, Acvr2a KO) immunized with human ACVR2A protein. Antigen-specific B cells were isolated by single-cell sequencing. Lead antibodies were validated for binding, selectivity, and functional blockade in vitro, and for PK and efficacy in vivo.






Figure 1. Workflow of the HUGO-Ab-eKO™ Homologous Rapid Knockout Technology Platform


Results



Antibody	Analyte	KD(nM)	KD fold (ACVR2B/ACVR2A)
A0009	ACVR2A	1.19	4908
	ACVR2B	5350	
A0040	ACVR2A	0.98	783
	ACVR2B	767	
Reference IgG1	ACVR2A	2.64	519
	ACVR2B	1370	

Figure 2. Kinetics and affinity analysis using Biacore
SPR sensorgrams showing concentration-dependent binding of antibodies to ACVR2A-His. Analyte concentrations (nM): 250, 125, 62.5, 31.25, 15.63. The association and dissociation phases were monitored to calculate kinetic parameters and equilibrium dissociation constants (KD). Compared to the Reference IgG1 (Phase 1 V-region), both A0009 IgG1 and A0040 IgG1 exhibited superior binding affinity and higher selectivity for ACVR2A over ACVR2B.





Receptor	Ligand	Ligand conc. (nM)	Luciferase assay IC50 (nM) A0040 IgG1	A0009 IgG1	Reference IgG1 (Phase 1 V-region)
ACVR2A-ALK4	GDF8	10nM	8.49	8.66	7.71
	ActivinA	1nM	42	32.82	34.25
ACVR2A-ALK7	ActivinB	50nM	50.89	50.15	51.62
	ActivinE	50nM	52.20	60.22	40.37

Figure 3. ACVR2A-SBE-LUC reporter gene assay across different ligands
Two pathways were reconstituted to mimic tissue-specific signaling: ACVR2A-ALK4-pSMAD2/3 (mimics signaling in muscle), regulating genes involved in myogenesis and growth. ACVR2A-ALK7-pSMAD2/3 (mimics signaling in adipocyte), regulating genes involved in lipid metabolism and adipogenesis. Upon ligand stimulation, both pathways lead to pSMAD2/3-dependent activation of the SBE-LUC reporter, resulting in luminescence. A0009 IgG1 and A0040 IgG1 efficiently blocked pathway activation in a concentration-dependent manner, thereby suppressing reporter expression in both muscle-like and adipocyte-like settings. Their blocking profiles were highly similar to that of the Reference IgG1 (Phase 1 V-region), indicating comparable inhibitory activity on ACVR2A-mediated signaling in these two cell-type contexts.




Figure 4. Serum PK parameters in wild-type C57BL/6N mice (anti-IgG detection)
Serum pharmacokinetic parameters ($t_{1/2}$, Cmax, AUC_{0-t}) of three antibodies were evaluated in wild-type C57BL/6N mice at a single dose of 20 mg/kg using an anti-IgG detection method. Compared with Reference IgG1 (Phase 1 V-region), both A0009 IgG1 and A0040 IgG1 exhibited superior PK profiles.A0009 IgG1 showed a half-life that was 2.4-fold longer than that of Reference IgG1, indicating markedly enhanced in vivo stability. Its peak concentration and total drug exposure reached 1.8-fold and 3.0-fold those of the Reference, respectively, demonstrating prolonged circulation and significantly higher systemic exposure. A0040 IgG1 also exhibited clear advantages: its half-life was modestly longer than that of Reference, while Cmax and AUC were 1.8-fold and 2.5-fold higher, respectively, indicating slower clearance and substantially improved exposure.

Test article	Route	Dose	Amount (mg)	Dose schedule
Semaglutide	SC	120ug/kg	10	QD
A0009 IgG1+Semaglutide		20mg/kg	35	weekly dose x 4 dose for Ab and QD for Semaglutide
A0040 IgG1+Semaglutide		20mg/kg	35	
Referennce IgG1+Semaglutide		20mg/kg	35	





Figure 5. Anti-ACVR2A alters body composition in DIO mice
In the DIO mouse model, we evaluated the effects of different antibodies on body weight and body composition. Among them, A0040 exhibited the strongest efficacy in reducing both total body weight and fat mass, significantly outperforming other tested antibodies. In terms of muscle gain (increase in lean mass), both A0009 and A0040 were significantly superior to the control antibody , suggesting that these two antibodies promote muscle preservation or accretion. In summary, A0040 combines potent weight loss, fat reduction, and muscle gain benefits, while A0009 stands out particularly for its muscle gain effect. Both are promising candidates for further development.



*one way ANOVA，compare to Vehicle group, * p<0.05, ** p<0.01*

Figure 6. ACVR2A blockade grip strength test in CB-17 SCID mice
In male CB-17 SCID mice (6–8 weeks old, n=8 per group), PBS (negative control), a reference antibody, or the test antibodies A0040 or A0009 were administered subcutaneously at 20 mg/kg once weekly for 4 weeks. Grip strength was assessed at the endpoint to evaluate muscle function. The results showed that, compared to the PBS control group, both A0040 and A0009 significantly improved grip strength (*p < 0.05, **p < 0.01), while the reference antibody had no significant effect. These findings demonstrate that A0040 and A0009 effectively enhance muscle function in CB-17 SCID mice and represent promising candidates for improving muscle atrophy-related endpoints.

Conclusions

We have successfully generated a panel of novel fully human anti-ACVR2A antibodies using the HUGO-Ab-eKO™ transgenic mouse platform. Lead antibodies A0009 and A0040 exhibit sub-nanomolar affinity, exceptional selectivity for ACVR2A over ACVR2B, and favorable pharmacokinetic profiles. In the DIO mouse model, A0040 demonstrates superior weight loss and fat reduction, while both A0009 and A0040 promote muscle preservation/gain. In CB-17 SCID mice, A0009 and A0040 significantly improve grip strength, indicating enhanced muscle function. These antibodies address key limitations of current therapies. Our findings support further development of A0009 and A0040 as promising therapeutic candidates for metabolic disorders and musculoskeletal conditions.

BIOHK2027

香港國際生物科技論壇暨展覽

SEPTEMBER 8 WED-11 SAT

HONG KONG CONVENTION AND EXHIBITION CENTRE

香港會議展覽中心

SAVE THE DATE FOR 2027



雲南白藥 YUNNAN BAIYAO | 雲白國際 YNBY INTERNATIONAL

聚焦主業·守正創新·穩健增長

雲南白藥為我國著名中成藥，具有止血癒傷、活血散瘀、消腫止痛、排膿去毒之功效。自 1902 年問世以來，以神奇的功效、顯著的治療效果馳名中外、經久不衰。

雲南白藥 1971 年建廠，1993 年上市成為「雲南第一股」。雲南白藥始終致力於推動傳統中醫藥融入現代生活，持續深挖傳統醫學產品的內生潛力，以產品創新回應現代生活需求，不斷為傳統品牌及傳統中醫藥產品注入新的生命力。企業始終秉承「守護生命與健康」的使命，圍繞藥品、中藥資源、健康、醫藥新流通四大業務基本盤持續深耕、穩健增長，已建立起包括天然藥物、中藥材飲片、特色藥、醫療器械、健康日化產品、保健食品等多個領域的業務佈局。

雲南白藥集團目前產品達 40 個品類 416 個品種，雲南白藥氣霧劑、創可貼、雲南白藥牙膏等多個產品在中國細分領域排名穩居第一。企業先後榮獲國家科學技術進步一等獎、中國工業大獎，並連續入榜最具價值中國品牌榜單，建成全球首座中醫藥健康品燈塔工廠。

Yunnan Baiyao is one of China’ s most renowned Chinese patent medicines, celebrated for its efficacy in stopping bleeding, promoting wound healing, invigorating blood circulation, dissipating blood stasis, reducing swelling, relieving pain, and draining pus and toxins. Since its introduction in 1902, it has maintained an enduring reputation at home and abroad for its remarkable therapeutic effects.

Yunnan Baiyao was established as a manufacturing facility in 1971 and became the “first listed company in Yunnan Province” in 1993. The Company has consistently focused on integrating the traditional Chinese medicine (TCM) into modern life, explored the endogenous potential of traditional medical products, and responded to the needs of modern life with product innovation, thereby infusing traditional brands and TCM products with renewed vitality. Guided by its mission of “To safeguard life and health,” the Company has built steady growth across four principal businesses: pharmaceuticals, TCM resources, health products, and pharmaceutical distribution. The Company has also expanded its business footprint into various domains, including natural medicine, TCM decoction pieces, special medicines, medical devices, personal care products, and healthcare food.


Today, Yunnan Baiyao Group offers 416 varieties across 40 categories. Several of its products—including Yunnan Baiyao Aerosol, Woundplast, and Yunnan Baiyao Toothpaste—rank first in their respective segments in China. The Company has been honored with the First Prize of the State Scientific and Technological Progress Award and the China Grand Awards for Industry. It has also been consecutively named among the Most Valuable Chinese Brands list, and operates the world’ s first lighthouse factory for TCM health products.

發展歷程 DEVELOPMENT HISTORY

弘揚民族醫藥瑰寶
傳承中華文化精粹

持續、穩健、快速增長

40個品類 | 416個品種 | 16個上億單品



ORGANIZERS AND SPONSORS

Academic Advisory Committee & Joint Organizers
學術指導委員會及聯合主辦

Organizers
主辦單位

Funding Organization
資助機構

Exclusive Strategic Partner
獨家戰略合作夥伴

Co-organizers
協辦單位

Dimond Sponsor
鑽石贊助

Platinum Sponsors
鉑金贊助

Gold Sponsors
黃金贊助

Silver Sponsors
白銀贊助

Media Partners
媒體合作夥伴

Official Press Release Distribution Partner
官方新聞稿發布合作夥伴

Supporting Organizations
支持單位